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Abstract 
 
By altering nucleosome positioning and composition, chromatin remodellers can 
modulate genomic accessibility, thereby regulating DNA metabolic processes. 
However, many remain poorly characterized, especially regarding the mechanisms 
underlying their regulation and genomic specificity. 
 
Some chromatin remodellers form multi-subunit complexes that change in subunit 
composition during development. It was reasoned that identifying tissue-specific 
subunits of chromatin remodellers would help elucidate their regulation. Thus, 
endogenous CHD1 and CHD5 were purified from mouse embryonic stem cells and 
brains respectively. However, detailed mass spectrometry analysis failed to reveal 
any novel tissue-specific complex subunits of either enzyme. 
 
The poorly characterized chromatin remodeller, SMARCAD1, is implicated in the 
maintenance of heterochromatin and double-stranded DNA break repair. 
SMARCAD1 constitutively forms a stoichiometric interaction with KAP1, a 
transcriptional co-repressor. The SMARCAD1-KAP1 complex was reconstituted in 
vitro with pure recombinant proteins. Although both SMARCAD1 and the 
SMARCAD1-KAP1 complex display nucleosome-stimulated ATPase activity, 
SMARCAD1 exhibits greater activity than the complex, suggesting that KAP1 is a 
negative regulator. 
 
Beyond a conserved SWI2/SNF2-like ATPase domain, SMARCAD1 features 
tandem CUE domains, which in other proteins, function as ubiquitin-binding 
domains. In cells, we find that point mutations affecting the SMARCAD1 CUE 
domains abrogate the SMARCAD1-KAP1 interaction. Significantly, using 
recombinant proteins that are not ubiquitylated, the SMARCAD1-KAP1 interaction 
was shown to be a direct, CUE domain-dependent, protein-protein interaction, 
involving the first SMARCAD1 CUE domain and the RBCC domain of KAP1. 
Unexpectedly, in silico approaches fail to identify a ubiquitin-homology domain 
within KAP1, suggesting either that KAP1 possesses an atypical ubiquitin-
homology domain or that the first SMARCAD1 CUE domain uniquely recognizes a 
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ligand structurally distinct from ubiquitin. An attempt to determine the co-crystal 
structure of the SMARCAD1-KAP1 interaction interface is described. Overall, the 
biochemical and structural characterization of the SMARCAD1-KAP1 complex offer 
mechanistic insight into the regulation of a chromatin remodeller with important 
roles in DNA metabolism. 
 
 
(300 words) 
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Chapter 1. Introduction 
The focus of this study was the biochemical characterization of the CHD1, CHD5, 
and SMARCAD1 chromatin remodellers, with the objective of elucidating upon their 
regulatory mechanisms. Thus, this introduction will present a general overview of 
chromatin – as befitting the setting in which chromatin remodellers exert their 
activity – and chromatin remodellers, before focusing on these three specific 
enzymes. Nonetheless, in keeping with the biochemical theme of this work, these 
topics will be approached with an emphasis on structural and in vitro studies that 
offer reductionistic insights into the fundamental properties of chromatin and into 
the basic mechanisms of chromatin remodelling. 
 
1.1 Chromatin 
1.1.1 Structural Organization of Chromatin 
Each human nucleus contains nearly two metres of linear DNA (Clapier and Cairns, 
2009). In the cell, this genetic material exists in the form of a complex of DNA and 
proteins, termed chromatin. The fundamental structural subunit of chromatin is the 
nucleosome, which is composed of 146 base pairs (bp) of DNA wrapped around a 
histone octamer core – itself comprised of two copies of each of the core histones, 
H2A, H2B, H3 and H4 – as approximately 1.7 superhelical turns (Figure 1.1) 
(Kornberg, 1974, Luger et al., 1997). Thus, a length of linear DNA can be wound 
into an 11nm fibre resembling beads on a string, with each nucleosome being 
separated by 20-75bp of linker DNA. Yet, by itself, this mode of packaging is 
insufficient to achieve, for instance, the 10,000-20,000-fold compaction that 
transforms linear DNA into chromosomes. Hence, a hierarchical organization akin 
to that of proteins has been proposed for chromatin, with the 11nm fibre being 
comparable to the primary structure of proteins, and the overall chromatin structure 
being dependent on higher order packaging (Woodcock and Ghosh, 2010). 
 
 
 
Figure 1.1 – Structure of the Nucleosome 
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A. The structure of the nucleosome core particle illustrates how 146bp of DNA is wound 
around a histone octamer in approximately 1.7 superhelical turns. The DNA backbone is 
coloured in brown and turquoise, histone H2A in yellow, H2B in red, H3 in green and H4 
in blue. The image on the left is the view of the nucleosome looking down the 
superhelical axis, while the image on the right is the view perpendicular to the 
superhelical axis. 
B. Half the nucleosome is shown here to illustrate the path of nucleosomal DNA. This is a 
view down the superhelical axis, and the colour scheme is the same as in A. The central 
base pair is denoted superhelix location (SHL) 0. Each SHL increment represents one 
complete turn of the DNA double helix from SHL0. The positions SHL 0-7 are labelled. 
The images were adapted from (Luger et al., 1997). 
 
Extending this analogy, the 30nm fibre that results from the formation of inter-
nucleosomal histone contacts is comparable to the secondary structure of proteins. 
This conformation – a compacted chromatin fibre 30nm in diameter – is adopted by 
polynucleosomal arrays in vitro when in the presence of buffers containing high 
concentrations of cations, which enables chromatin to overcome self-repulsion due 
to the polyanionic nature of DNA. While the 30nm fibre has long been described 
and is observed reproducibly, controversy abounds about its physiological 
relevance since it has yet to be directly observed in cells (Luger et al., 2012). 
Nonetheless, two plausible models have been proposed for the structure of 30nm 
fibre (Woodcock and Ghosh, 2010, Luger et al., 2012). The first, the “solenoid” or 
“one start” model, predicts that the 11nm fibre of nucleosome beads is coiled into a 
helix, whereby the linker DNA continues the helical trajectory of the nucleosomal 
DNA (Figures 1.2A and B). Thus, the nucleosomes are arranged such that inter-
nucleosomal histone contacts occur between consecutive nucleosomes (Robinson 
et al., 2006, Woodcock and Ghosh, 2010, Luger et al., 2012). The second, the 
“zigzag” or “two start” model, features nucleosomes arranged in a zigzag pattern, 
whereby alternating nucleosomes interact with each other (Figures 1.2C and D). 
 
 
Figure 1.2 – Model of the 30nm Fibre 
A. The “one-start” or “solenoid” model is based on inter-nucleosomal histone contacts 
between consecutive nucleosomes. 
B. This schematic representation of the “one-start” model shows the outcome of the 
intervening linker DNA continuing the helical trajectory of the nucleosomal DNA – 
namely, the 11nm fibre of nucleosome beads being coiled into a helix. 
C. The “two-start” or “zig-zag” model is based on inter-nucleosomal histone contacts 
between alternating nucleosomes (i.e. N1, N3, N5 etc). 
D. This schematic of the “two-start” model emphasizes how the two different models result 
in chromatin fibres that differ in width and in the trajectory of the linker DNA. 
The image was taken from (Luger et al., 2012). 
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The “two start” model is favoured by structural studies, such as the crystal structure 
of a reconstituted tetra-nucleosome, albeit one that lacks the H1 linker histone, has 
short linker DNA, and was obtained under non-physiological crystallization 
conditions (that included 90mM magnesium chloride) (Schalch et al., 2005). 
Crucially, however, this mode of structural organization was also observed in the 
recent cryogenic electron microscopy (cryo-EM) structure at ~11Å resolution of a 
30nm fibre reconstituted in vitro with recombinant Xenopus laevis histone octamers, 
histone H1, and a DNA fragment containing twelve 601 nucleosome-positioning 
sequences (Figure 1.3A). The 30nm fibre forms a left-handed double helix, 
comprised of repeating tetra-nucleosomal structural units, within which 
nucleosomes zigzag back and forth as a “two start” helix (Figure 1.3B). Thus, the 
tetra-nucleosomal unit is arranged into two stacks of nucleosomes joined by linear 
linker DNA. As the linker DNA is straight and extended, the diameter of the 30nm 
fibre increases as the length of linker DNA increases (Song et al., 2014). 
 
An important determinant of higher order chromatin packaging in metazoans is the 
H1 linker histone, which interacts with approximately 20bp of linker DNA. Through 
its lysine-rich carboxy-terminus, H1 binds strongly to DNA. Notably, nucleosomal 
arrays lacking histone H1 are refractory to the formation of 30nm fibres (Woodcock 
and Ghosh, 2010). The cryo-EM structure of the 30nm fibre reveals that the linker 
histone H1 associates with nucleosomes with a one to one stoichiometry, and that 
it is positioned asymmetrically towards the side of the nucleosome that contacts the 
next tetra-nucleosomal unit. This allows histone H1 to dictate that each tetra-
nucleosomal unit is rotated roughly 50° and translated by approximately 70Å along 
the stack axis relative to the preceding unit; these positional constraints by H1 
govern the spiral twisting of the 30nm fibre into a left-handed superhelix (Figure 
1.3C) (Song et al., 2014).  
 
 
Figure 1.3 – Cryo-EM Structure of the 30nm Chromatin Fibre 
A. This image is the cryo-EM reconstruction of the 30nm fibre. Each tetra-nucleosomal 
structural unit is highlighted in a different colour. In this figure, nucleosomes are labelled 
N1-N12. 
B. This schematic representation shows the straight linker DNA connecting the two stacks 
of nucleosomes, illustrated as discs. 
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C. This pseudo-atomic model of the 30nm fibre was built by docking 4 copies of the 12-
nucleosome structure, though the structure of histone H1 was not included here. This 
model illustrates the left-handed superhelix formed by the 30nm fibre. As in A, the tetra-
nucleosomal structural units are coloured in blue, orange or purple for clarity. The scale 
bar is 11nm in length 
The images were taken from (Song et al., 2014). 
 
Apart from unique exceptions such as metaphase chromosomes, our 
understanding of higher order chromatin structure beyond the 30nm fibre ventures 
largely into the realms of speculation. As investigation into this area relies 
disproportionately upon light microscopy, one main limitation is the inherent 
resolution limit of approximately 250nm imposed by the properties of light 
(Woodcock and Ghosh, 2010). Nonetheless, further evidence for non-random 
higher order chromatin organization is provided by the existence of long-range 
chromatin interactions that mediate regulatory functions. This phenomenon is 
arguably best illustrated by enhancers, which are DNA sequences that activate 
transcription from distant promoters separated by up to a hundred kilo base pairs 
(kb). This is possible as chromatin looping allows enhancers and their cognate 
promoters to be in close three-dimensional spatial proximity. Many enhancers are 
essential for developmental processes, emphasizing that chromatin organization is 
tightly regulated and represents much more than a means for DNA compaction 
(Kulaeva et al., 2012, Shlyueva et al., 2014). 
 
Initially a cytological description of areas of interphase chromatin that stain 
intensely with basic dyes, heterochromatin does not refer per se to a type of higher 
order chromatin structure, but instead describes an area of highly compacted 
chromatin with limited transcriptional activity that tends to adopt a peripheral 
location in the nucleus. Correspondingly, euchromatin is loosely compacted and 
has high transcriptional activity (Heitz, 1928, Woodcock and Ghosh, 2010). 
Constitutively heterochromatic regions always remain highly compacted and 
transcriptionally inactive; these tend to be gene-poor, late-replicating portions of the 
genome that are often marked by tri-methylation of lysine 9 of histone H3 
(H3K9me3). Alternatively, facultative heterochromatin may de-condense, allowing 
transcription in a context-specific manner, for example during specific 
developmental or cell cycle stages. Facultative heterochromatin is enriched in tri-
methylated lysine 27 of histone H3 (H3K27me3), a histone modification deposited 
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by the Polycomb Repressive Complexes (PRC). In contrast, however, 
transcriptionally competent euchromatin is characterized by “active” histone marks 
such as tri-methylation of lysine 4 of histone H3 (H3K4me3) and hyper-acetylation 
of the tails of histones H3 and H4 (Trojer and Reinberg, 2007). 
 
1.1.2 Modulation of Genomic Accessibility 
Packaging of DNA into higher order chromatin structures is intrinsically at odds with 
genome accessibility. Thus, the complex molecular machines that replicate, 
transcribe and repair DNA are obstructed from accessing regions of the genome 
that are compacted into chromatin (Clapier and Cairns, 2009). Even without 
contending with higher order chromatin structures, nucleosomes represent 
imposing obstacles for DNA metabolic enzymes. For example, RNA polymerase II 
(RNAPII) is inhibited from initiating transcription when the promoter sequence is 
wrapped around a nucleosome (Lorch et al., 1987). It is estimated that recognition 
sequences within nucleosome-occupied promoter regions are 10-20 fold less 
accessible to protein factors than identical regions of DNA lacking nucleosomes 
(Iyer and Struhl, 1995, Struhl and Segal, 2013). Therefore, the packaging DNA into 
chromatin represents an important level at which DNA metabolic processes may be 
regulated. 
 
Local modulation of genomic accessibility can be accomplished by dynamic and 
reversible alterations in chromatin structure mediated principally by two 
mechanisms – covalent modifications of histone tails and ATP-dependent 
chromatin remodelling (Clapier and Cairns, 2009, Tessarz and Kouzarides, 2014). 
Post-translational modifications of specific residues on the exposed tails of core 
histones may either act directly by altering the stability of nucleosomes, or indirectly 
by recruiting additional factors (Tessarz and Kouzarides, 2014). In contrast, 
SWI2/SNF2-like chromatin remodelling ATPases couple the energy released from 
ATP hydrolysis to repositioning, ejecting or modifying the composition of 
nucleosomes, for example by incorporating histone variants in place of the 
canonical core histones (Clapier and Cairns, 2009).  
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A characteristic feature of active chromatin is histone hyper-acetylation. Histone H3 
has been reported to be acetylated at specific lysine residues, including H3K56 that 
is located near the DNA entry and exit site on nucleosomes, and H3K122 that 
maps to the nucleosomal dyad axis. As acetylation neutralizes the positive charge 
of lysine residues, it is eminently conceivable that the histone-DNA interaction is 
weakened by these modifications (Tessarz and Kouzarides, 2014). While 
acetylation of H3K56 is probably insufficient to alter the overall nucleosome 
structure, by weakening histone-DNA contacts at the entry/exit point, it is capable 
of preventing oligomerization of sub-saturated nucleosomal arrays. Consequently, 
it has been proposed that acetylation of lysine 56 is a mechanism for the 
establishment of nucleosome-free regions (Watanabe et al., 2010). In contrast, as 
histone-DNA interactions are strongest at the nucleosomal dyad, interfering with 
these contacts through acetylation of H3K122 reduces nucleosome stability 
(Tessarz and Kouzarides, 2014). 
  
Another example of the ability of histone modifications to dramatically affect 
chromatin structure is citrullination of the linker histone H1 at arginine 54, a mark 
that has been recently identified as a modification specific to pluripotent cells. 
Citrullination describes the post-translational, enzymatic conversion of a positively 
charged arginine residue into citrulline, an uncharged, non-coded amino acid 
(Christophorou et al., 2014, Tessarz and Kouzarides, 2014). Due to charge 
neutralization, citrullination of arginine 54 interferes with the ability of histone H1 to 
bind DNA, thereby displacing the linker H1 from chromatin. As linker H1 is crucially 
important for the assembly of higher order chromatin structures, this histone 
modification contributes directly to the reduced chromatin condensation typical of 
the pluripotent cell state (Christophorou et al., 2014). 
 
It is generally believed that chromatin remodellers apply their ability to reposition or 
eject nucleosomes to expose specific DNA sequences, including transcription 
factor binding sites and gene promoters (Clapier and Cairns, 2009). Nucleosomes 
that occlude gene promoters are major impediments for transcriptional initiation 
and must be displaced by ejection or repositioning for productive transcription 
(Lorch et al., 1987). The ability of chromatin remodellers to specifically remodel 
promoter nucleosomes in an activator-dependent manner can be reconstituted in 
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vitro, for example with budding yeast Chd1 at the PHO5 gene promoter. Using a 
fully defined in vitro system, following multiple chromatographic steps, Chd1 was 
identified to be an essential factor for ejection of the promoter nucleosome at the 
repressed PHO5 gene locus in response to the Pho4 activator. Notably, 
nucleosome remodelling was specific to the promoter immediately upstream of the 
transcription start site (TSS) and did not affect nucleosomes over the gene body. 
Crucially, this study also proved that chromatin remodellers are capable of acting in 
isolation to remodel the chromatin structure of promoter regions into a transcription 
competent state, without any requirements for additional histone modifying 
enzymes or histone chaperones (Ehrensberger and Kornberg, 2011).  
 
Although histone modifications and chromatin remodelling are capable of 
independently manipulating chromatin structure, it is likely that they also act 
cooperatively. Indeed, many chromatin remodellers possess domains that 
recognize specific histone modifications, which may serve to recruit them to 
specific genes (Clapier and Cairns, 2009). For example, the pair of chromodomains 
in human CHD1 specifically recognizes the active H3K4me3 histone mark 
(Flanagan et al., 2005, Sims et al., 2005). Indeed, it has been observed that the 
recruitment of CHD1 to chromatin is enhanced by the H3K4me3 mark, thereby 
suggesting a plausible explanation for the localization of CHD1 at actively 
transcribed regions of the genome, including the de-condensed puff and interband 
regions of Drosophila polytene chromosomes (Stokes et al., 1996, Simic et al., 
2003, Lin et al., 2011). 
 
1.1.3 Determinants of Nucleosome Positioning 
At a genome wide level, nucleosome positioning assumes a generalizable pattern – 
the TSS is surrounded by a nucleosome-free region (NFR) and flanked by highly 
positioned nucleosomes immediately upstream (-1) and downstream (+1) of the 
TSS. Nucleosomes are positioned with a regular periodicity in arrays extending 
away from both the -1 the +1 nucleosomes, though each successive nucleosome is 
less well positioned than the preceding one. Similarly, the transcription termination 
site (TTS) is also depleted of nucleosomes, though in contrast, the TTS is not 
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flanked by highly positioned nucleosomes. Incredibly, this stereotyped pattern of 
nucleosome positioning is conserved across eukaryotes, though the means by 
which it is achieved have, in some cases, diverged (Segal et al., 2006, Valouev et 
al., 2011, Struhl and Segal, 2013, West et al., 2014). 
 
Reflecting the fact that histone-DNA nucleosomal contacts involve the DNA 
phosphate backbone, nucleosomes do not demonstrate traditional sequence 
specificity, such as that displayed by transcription factors (Luger et al., 1997, Struhl 
and Segal, 2013). Yet, the underlying DNA sequence can be a major determinant 
of nucleosome occupancy, arising from the requirement for nucleosomal DNA to 
bend around the histone octamer. Certain di-nucleotides, such as AA, AT or TA 
sequences, form a curvature in DNA; thus, the presence of such di-nucleotides at 
10bp intervals are optimal for nucleosome formation since achieve curvature of the 
DNA sequence as a whole (Segal et al., 2006, Struhl and Segal, 2013). 
 
Reconstitution of the nucleosomes in vitro with recombinant histones and yeast 
genomic DNA results in a pattern of nucleosome occupancy that correlates with the 
in vivo pattern. In fact, the DNA sequence alone ensures that up to 60% of genomic 
regions possess a nucleosome density comparable to that observed in the in vivo 
setting. Most notably, it is evident that the yeast DNA encodes for NFRs at the TSS 
and the TTS since these characteristic features are faithfully recapitulated in vitro 
(Kaplan et al., 2009, Zhang et al., 2009, Valouev et al., 2011, Zhang et al., 2011). 
This is probably due to the enrichment of homopolymeric poly(dA:dT) tracts at the 
promoters of yeast genes; due to their intrinsic stiffness, homopolymeric sequences 
prevent nucleosome occupancy (Iyer and Struhl, 1995, Struhl and Segal, 2013). 
Yet, by itself the DNA sequence is largely unable to specify the precise rotational 
positioning of nucleosomes; thus, a regular nucleosome periodicity extending into 
the gene body is not observed for nucleosomes reconstituted with yeast DNA and 
recombinant histone octamers (Kaplan et al., 2009, Zhang et al., 2009, Valouev et 
al., 2011, Zhang et al., 2011). However, incubation of the reconstituted chromatin 
with yeast extract in the presence of ATP is able to establish proper nucleosome 
positioning at the 5’ end of genes. As this process is strictly ATP dependent, it is 
probably mediated by ATP-dependent chromatin remodellers, though a role for 
enzymes such as kinases cannot be formally excluded (Zhang et al., 2011). Indeed, 
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genome-wide analyses of nucleosome occupancy and DNA accessibility in 
Drosophila following depletion of various chromatin remodellers suggest that 
chromatin remodelling enzymes actively reposition nucleosomes, overriding their 
intrinsic sequence preferences. In this manner, NuRD, (P)BAP and INO80 
complexes increase nucleosome density on sequences that are intrinsically 
unfavourable to nucleosomes; in contrast, ISWI reduces nucleosome occupancy at 
its target sites, which are generally intrinsically favourable to nucleosome formation 
(Moshkin et al., 2012). 
 
An integral role for chromatin remodellers in nucleosome positioning at a genome-
wide level is further supported by analyses of nucleosome positions in yeast strains 
lacking specific chromatin remodellers. For example, the chromatin remodellers 
ISW1b, INO80, CHD1 and SWI/SNF shift nucleosomes away from NFRs (i.e. 
nucleosomes downstream of the TSS are moved in the 5’ direction, whereas 
nucleosomes immediately upstream of the TTS are moved in the 3’ direction). In 
contrast, ISW1a and ISW2 move nucleosomes towards NFRs (Yen et al., 2012). 
Due to biological redundancy, the absence of individual chromatin remodellers 
does not result in significant alterations in nucleosome positioning; however, a 
budding yeast strain (isw1Δ, chd1Δ) lacking the CHD1 and ISW1 remodellers 
exhibits compromised nucleosome positioning in the gene body, though the +1 
promoter nucleosome remains unaffected (Gkikopoulos et al., 2011). This function 
appears to be highly conserved since the evolutionarily distant 
Schizosacchromyces pombe, which does not encode for any members of the ISWI 
family, relies upon its CHD1 homologues, Hrp1 and Hrp3, to maintain proper 
nucleosome positioning in the gene body (Flaus et al., 2006, Pointner et al., 2012, 
Shim et al., 2012). Curiously, however, depletion of Chd1 from mouse embryonic 
fibroblasts (MEFs) results in a global reduction in nucleosome occupancy, though 
most prominently upstream and downstream of the TSS, without affecting 
nucleosome positioning (Skene et al., 2014). Thus, while the overall principles of 
nucleosome positioning appear to be conserved across eukaryotes, it is probable 
that they differ at a precise, mechanistic level (Struhl and Segal, 2013). 
 
Indeed, much of our understanding of the determinants of nucleosome positioning 
is based on studies of Sacchromyces cerevisiae. Although many facets can 
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probably be extrapolated to higher eukaryotes, important inter-species differences 
must be recognized. Most importantly, HHO1p, the budding yeast homologue of 
histone H1, is present at very low levels, whereas the histone H1 is widely 
incorporated into the chromatin of higher eukaryotes, promoting the higher order 
packaging (Struhl and Segal, 2013). Additionally, the nucleosomal architecture 
around gene promoters differ slightly between budding yeast and metazoans – 
while the TSS is located within the +1 nucleosome in the former, it is typically 
situated in the nucleosome depleted region in metazoans. Likewise, the average 
spacing between nucleosomes displays inter-species variation (Segal et al., 2006, 
Mavrich et al., 2008, Schones et al., 2008, Lantermann et al., 2010, Li et al., 2011, 
Valouev et al., 2011, Skene et al., 2014). These idiosyncrasies probably reflect the 
specific complement of chromatin remodellers present within each organism in 
addition to differences in transcriptional activity (Struhl and Segal, 2013). 
 
1.1.4 Histone Modifications 
Besides targeting histone residues that contribute to histone-DNA contacts (as has 
been discussed previously – refer to subsection 1.1.2), post-translational 
modifications (PTMs) also frequently involve the tails of the core histones, which 
are accessible as they are disordered regions that extend away from the globular 
histone core. In general, covalent histone modifications can be regarded to perform 
one of two functions: 1) to directly affect the chromatin structure, for example by 
destabilizing nucleosomes, or 2) to act as signals for the recruitment of other 
protein factors. 
 
The ability of acetylation of specific residues of histone H3 (e.g. lysines 56 and 122) 
to affect chromatin structure has been mentioned. In brief, however, as the lysine 
residues targeted by acetylation are often important histone-DNA contacts, 
neutralization of the positive charges of lysine residues by acetylation contributes to 
the destabilization of nucleosomes and in some cases, prevents the formation of 
higher order chromatin structures (Watanabe et al., 2010, Tessarz and Kouzarides, 
2014). Although acetylation of lysine 16 of histone H4 (H4K16ac) does not appear 
to affect histone-DNA contacts, this histone modification reduces the propensity of 
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nucleosomal array to self-associate, thus compromising chromatin compaction 
(Shahbazian and Grunstein, 2007). Additionally, H4K16ac acts as a boundary 
element to prevent the spreading of heterochromatin (Suka et al., 2002). Thus, 
heterochromatin spreading requires that the Sir2 histone deacetylase – a 
component of the silent information regulator (Sir) complex that is a major 
constituent of heterochromatin – de-acetylates histone 4 at lysine 16, such as to 
promote the binding of additional molecules of the Sir complex, which has a higher 
affinity for hypo-acetylated histone H4 tails, to adjacent regions of chromatin 
(Shahbazian and Grunstein, 2007). (The other main occurrence of histone 
acetylation is on newly synthesized histones, though the acetyl moiety is rapidly 
removed by histone deacetylases shortly after deposition of these histones into 
chromatin. In many eukaryotes, the main sites of acetylation on histone H4 are 
lysines 5 and 12; acetylation sites on histone H3 are more variable – lysines 9 and 
14 in Tetrahymena and lysines 14 and 23 in Drosophila (Sobel et al., 1995, 
Shahbazian and Grunstein, 2007).) 
 
In contrast, PTMs that do not affect the net charge, such as lysine methylation for 
instance, are unlikely to directly affect nucleosome stability by interfering with 
histone-DNA contacts. Instead, these histone modifications are likely to act by 
coordinating the recruitment of a diverse set of factors to chromatin. This is feasible 
because histone mark-reading domains are capable of distinguishing between 
histone marks with a high degree of precision. In fact, it appears that each PTM 
can be recognized several classes of histone mark-reading domains. For example, 
an incomplete list of motifs that recognize methylated lysine residues includes plant 
homeodomain (PHD) fingers, bromo-adjacent homology domains and most 
prominently, “Royal family” motifs – a family that encompasses Tudor, PWWP 
domains and chromodomains (Patel and Wang, 2013). 
 
An example of canonical methyl-lysine recognition is the interaction between the 
chromodomain of heterochromatin protein 1 (HP1) and histone H3 tails modified by 
tri-methylation of lysine 9. The tail of histone H3 makes extensive β-sheet 
interactions with two β-strands of the HP1 chromodomain to form an antiparallel β-
barrel (Figure 1.4B). Crucially, the methyl-lysine side chain, occupies a surface 
groove pocket that culminates in a three-sided aromatic cage (Figure 1.4A). These 
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three conserved aromatic residues stabilize the methyl-lysine by cation-π 
interactions (Jacobs and Khorasanizadeh, 2002). Comparable aromatic cage 
architectures have adopted by other “Royal family” motifs to recognize methylation 
at other residues on the histone H3 tail, for example, by the chromodomain of 
Drosophila Polycomb to bind H3K27me3, and by the Tudor domain of PHF1 to 
recognize H3K36me3 (Min et al., 2003, Musselman et al., 2012a). 
 
 
Figure 1.4 – Recognition of the H3K9me3 Modification by the HP1 Chromodomain 
A. The crystal structure of the chromodomain of HP1 in complex with an H3K9me3 peptide 
reveals that the histone methyl-lysine side chain occupies a surface groove that has a 
three-sided aromatic cage at one end. These three conserved aromatic residues 
stabilize the methyl-lysine by cation-π interactions. 
B. The histone H3 tail also engage in extensive β-sheet interactions with two β-strands of 
the HP1 chromodomain to form an antiparallel β-barrel. 
The images were taken from (Patel and Wang, 2013). 
 
Recognition of the histone acetyl-lysine modification is mediated by bromodomains, 
which organize into anti-parallel four-helix bundles linked by variable loop regions 
(Figure 1.5A). The four helices establish a deep binding pocket that is primarily 
hydrophobic in character. Extending beyond the base of the helical bundle, the loop 
regions deepen the binding pocket, forming its rim. Due to the variable nature of 
the loop regions, they allow individual bromodomains to acquire unique surface 
characteristics that dictate binding specificities (Filippakopoulos et al., 2012, Patel 
and Wang, 2013). The acetyl-lysine side chain projects deep into the binding 
pocket, with the hydrophobic walls of the pocket packing against, and thus 
stabilizing, the aliphatic side chain. The specificity of bromodomains for acetyl-
lysine is heavily influenced by the electrostatic potential of binding pocket – without 
the charge-neutralizing acetyl PTM, an interaction between the positively charged 
lysine residue and the hydrophobic pocket is energetically unfavourable. A 
conserved asparagine residue is also a key determinant of bromodomain acetyl-
lysine recognition since the amide of the conserved asparagine forms a crucial 
hydrogen bond with the oxygen of the carbonyl group of the acetyl moiety (Owen et 
al., 2000, Patel and Wang, 2013). This intermolecular hydrogen bond is critically 
important as it serves to position the acetyl-lysine in the correct orientation. The 
bromodomain of the transcriptional co-repressor, KAP1, lacks this conserved 
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asparagine; correspondingly, it is unable to recognize the acetyl-lysine modification 
(Zeng et al., 2008).  
 
 
Figure 1.5 – Recognition of the H4K16ac Modification by the Gcn5p Bromodomain 
A. Bromodomains mediate histone acetyl-lysine recognition, as demonstrated in this 
structure of the Gcn5p bromodomain in complex with an H4K16ac peptide. A deep, 
largely hydrophobic binding pocket is created at one end of the four-helix bundle of the 
bromodomain. The acetyl-lysine side chain projects deep into the binding pocket. A 
conserved bromodomain asparagine residue forms a crucial hydrogen bond with the 
oxygen of the carbonyl group of the acetyl moiety. 
B. The hydrophobic walls of the binding pocket pack against, and thus stabilize, the 
aliphatic acetyl-lysine side chain. Additionally, the acetyl moiety is anchored to a 
bromodomain asparagine residue by hydrogen bonding. 
The images were taken from (Patel and Wang, 2013). 
 
Actively transcribed genes can typically be distinguished from repressed genes on 
the basis of their histone modifications. In addition to hyper-acetylation of histones 
H3 and H4, the promoters of active genes are typically associated with the 
H3K4me3 modification, which is deposited by members of the Trithorax family of 
lysine methyltransferases (Santos-Rosa et al., 2002, Kouzarides, 2007, Suganuma 
and Workman, 2011). Conversely, regions of constitutive heterochromatin that 
always remain highly compacted and transcriptionally inactive tend to be marked 
by H3K9me3. In contrast, facultative heterochromatin – repressed regions that can, 
nonetheless, be induced to decondense and permit transcription in a context-
specific manner – are enriched in H3K27me3 (Trojer and Reinberg, 2007, 
Suganuma and Workman, 2011). Hence, H3K4me3 could, simplistically, be 
regarded as an ‘active’ mark, in contradistinction to H3K9me3 and H3K27me3, 
which are prototypical ‘repressive’ marks. 
 
Although histone modifications probably do not represent a ‘code’ akin to the 
genetic code, there is emerging evidence that they can directly influence 
transcriptional activity. Most notably, H3K4me3 binds directly to the general 
transcription factor, TFIID, via the PHD domain of the TAF3 subunit (Vermeulen et 
al., 2007). Moreover, employing a cell-free transcription assay, it was demonstrated 
that the H3K4me3-TAF3 interaction directly recruits TFIID to promoters and 
facilitates the assembly of the transcription pre-initiation complex. Importantly, 
recruitment of TFIID by H3K4me3 is able to compensate for the absence of a 
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functional TATA box as assessed by activator-dependent transcriptional activity in 
vitro (Lauberth et al., 2013). Although the promoter typically resides in the NFR, it is 
possible that H3K4me3-TAF3 interaction promotes pre-initiation complex formation 
by recruiting TFIID to the peak of H3K4me3 just downstream of the TSS, thereby 
ensuring an accumulation of TFIID in the general vicinity of the promoter. 
 
H3K9me3 is essential for the maintenance of heterochromatin. Deletion of Clr4, the 
H3K9me3 lysine methyltransferase in fission yeast, or its two Suv39h homologues 
in mammals, results in defects in pericentric and telomeric heterochromatin, in 
addition to compromised gene silencing (Nakayama et al., 2001, Peters et al., 2003, 
Garcia-Cao et al., 2004). This histone mark achieves transcription repression 
through the recruitment of HP1 to chromatin, via a chromodomain-mediated 
interaction with H3K9me3 (Kouzarides, 2007). Indeed, enforced recruitment of HP1 
to euchromatic gene loci is sufficient to achieve transcriptional repression though a 
process that ultimately results in local chromatin compaction (Ayyanathan et al., 
2003). Moreover, it has been proposed that the H3K9me3 modification can be 
propagated – an initial H3K9me3 mark that serves as the nucleation site interacts 
with HP1, which in turn, causes the recruitment of a Suv39h methyltransferase to 
chromatin, such that the lysine 9 residue of neighbouring histone H3 tails is 
methylated, resulting in yet more HP1 binding sites (Hall et al., 2002, Grewal and 
Moazed, 2003, Muramatsu et al., 2013). Indeed, the dosage-dependent role of HP1 
in heterochromatic silencing might imply that such a self-amplifying positive 
feedback loop could be essential for the formation and maintenance of constitutive 
heterochromatin (Grewal and Moazed, 2003). 
The genes targeted by the H3K27me3 mark are frequently associated with 
differentiation and key developmental processes. Hence, in a developmental stage-
dependent and tissue-specific manner, regions of facultative chromatin 
decondense to permit transcription (Trojer and Reinberg, 2007, Schwartz and 
Pirrotta, 2013). The transcription repression of these Polycomb target genes 
involves the two PRC complexes. Containing the histone methyltransferase, Ezh2, 
the PRC2 complex tri-methylates histone H3 at lysine 27. It is suggested that PRC1 
is then recruited to chromatin through the chromodomains of its Cbx subunits, 
which display an affinity for H3K27me3. In this indirect manner, RING1 and RING2, 
the E3 ubiquitin ligase subunits of PRC1, are thereby brought into close proximity 
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to their target for mono-ubiquitylation, histone H2A (Schwartz and Pirrotta, 2013). 
Mono-ubiquitylated H2A (H2Aub) represses transcription by interfering with the 
recruitment of transcription elongation factors, such as the FACT complex (Zhou et 
al., 2008). Additionally, H2Aub mediates transcriptional repression at the level of 
higher order chromatin structure, as reconstituted nucleosomes bearing H2Aub 
interact more readily with the linker histone H1 than unmodified nucleosomes 
(Jason et al., 2005, Weake and Workman, 2008). Conversely, it is also suggested 
that de-ubiquitylation of H2A promotes dissociation of H1 from nucleosomes (Zhu 
et al., 2007, Weake and Workman, 2008). PRC1 may also mediate transcriptional 
repression in an H2A ubiquitylation-independent manner, perhaps by promoting 
chromatin compaction (Eskeland et al., 2010, Grau et al., 2011). 
 
In contrast to H2Aub, ubiquitylated H2B (H2Bub) is regarded as an active mark. 
Ubiquitylation of H2B is performed by the E2 ubiquitin conjugating enzyme, Rad6, 
and the E3 ubiquitin ligase, Bre1 (Weake and Workman, 2008). Requirements for 
ubiquitylation include active transcription and the presence of the PAF complex, a 
factor associated with RNAPII. Indeed, Rad6 directly interacts with elongating 
RNAPII (Wood et al., 2003, Xiao et al., 2005). Significantly, H2Bub is required for 
di- and tri-methylation of histone H3 at lysines 4 and 79, which are important active 
marks (as discussed earlier). Therefore, transcriptional repression is frequently 
associated de-ubiquitylation of histone H2B, which in budding yeast, is performed 
by Ubp8, a component of the SAGA complex, and Ubp10. Curiously, Ubp8 and 
Ubp10 are synergistic, and probably act on different pools of H2Bub (Weake and 
Workman, 2008). In Drosophila, biochemical and genetic evidence implicate the 
GMPS/USP7 complex as a transcriptional repressor as a result of its selective H2B 
de-ubiquitylation activity. The GMPS/USP7 complex participates not only in 
Polycomb silencing of homeotic genes – mutations in either protein result in 
homeotic transformations – but also in the repression of ecdysone target genes – 
hormonally-regulated genes that are essential for normal development (van der 
Knaap et al., 2005, van der Knaap et al., 2010). Histone ubiquitylation is also 
employed as a signaling mechanism for DNA repair. The E3 ubiquitin ligases RNF8 
and RNF168 ubiquitylate histone H2A around sites of damage enabling the 
ubiquitylation-dependent recruitment of DNA repair effectors, such as 53BP1 and 
RAP80, to chromatin (Panier and Durocher, 2013). 
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1.1.5 Differentiation as a Paradigm of Chromatin State Transitions 
The chromatin architecture not only reflects, but also abets the transcriptional 
activity of a cell. Thus, transitions in cellular state, which involve the adoption of 
distinct transcriptional programmes, correspondingly, are accompanied by 
significant and distinctive alterations in chromatin state. Characterized by the ability 
to differentiate into any cell arising from the three germ layers, pluripotency is 
indisputably one of the most unique of cell states. Regulated by a set of master 
regulators including the transcription factors, Oct4, Nanog and Sox2, the pluripotent 
cell state has been primarily studied in embryonic stem cells (ESCs), which are 
cells derived from the inner cell mass of blastocysts, exhibit indefinite self-renewal, 
and are amenable to ex vivo tissue culture (Boyer et al., 2005, Wang et al., 2006, 
Takahashi et al., 2007, Chen et al., 2008). Unsurprisingly, it has become apparent 
that the chromatin structure of ESCs is highly distinctive. 
 
ESCs are enriched in loosely packaged euchromatin and lack the abundant, 
punctate distribution of highly compact heterochromatic foci typical of differentiated 
cells (Meshorer et al., 2006). Supporting the notion of a globally open, 
transcriptionally permissive chromatin environment in ESCs are the observations 
that histones – both the core histones and the linker histone, H1 – associate less 
avidly with ESC chromatin and that histone exchange occurs at a faster rate in 
ESCs. Indeed, this permissive chromatin environment is reflected in a global 
increase in transcriptional activity; for example, higher levels of transcription at 
intronic and intergenic regions of the genome have been observed in ESCs (Efroni 
et al., 2008). 
 
Although approximately 80% of promoters in ESCs are marked by the active 
H3K4me3 histone modification, in the region of 22% of these concomitantly display 
the repressive H3K27me3 mark – a feature termed bivalency (Bernstein et al., 
2006, Mikkelsen et al., 2007). The genes that feature these bivalent marks are not 
actively transcribed in ESCs and are disproportionately over-represented by 
regulators of differentiation and developmental processes. Thus, it was postulated 
that bivalent marks keep genes encoding for important developmental regulators in 
a poised but nonetheless, transcriptionally repressed state (Azuara et al., 2006, 
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Bernstein et al., 2006). The vast majority of bivalent marks are resolved during 
differentiation by the loss of one of the two opposing histone modifications, and is 
accompanied by either transcriptional activation or persistent gene repression 
(Mikkelsen et al., 2007, Gifford et al., 2013, Xie et al., 2013). It is currently believed 
that bivalent marks serve to increase the precision with which gene expression is 
controlled during development – having more input sources enhances the 
robustness of the regulatory network controlling the transcription of important 
developmental genes and minimizes the possibility of inopportune gene expression 
(Voigt et al., 2013). 
 
In addition to the resolution of bivalent marks, differentiation of ESCs is associated 
with widespread deposition of the H3K27me3 mark across the genome (Figure 1.6) 
(Hawkins et al., 2010, Zhu et al., 2013). (A similar genome-wide increase in the 
H3K9me3 mark has subsequently been attributed to being an artifact of tissue 
culture rather than an effect of differentiation per se (Zhu et al., 2013).) Thus, the 
permissive chromatin state in ESCs is replaced during differentiation by a 
restrictive and compacted chromatin environment dominated by widespread 
Polycomb-mediated repression (Hawkins et al., 2010, Zhu et al., 2013). 
 
 
Figure 1.6 – Differentiation of ESCs is accompanied by a Chromatin State Transition 
This schematic depicts the changes in chromatin structure associated with the 
differentiation of pluripotent ESCs. Green flags represent the active H3K4me3 mark, while 
red flags denote the repressive H3K27me3 modification. ESC chromatin is uniquely open 
and many silent genes encoding for developmental regulators possess bivalent marks. 
Differentiation is associated with the resolution of bivalent marks, progressive chromatin 
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compaction, and widespread accumulation of the repressive, Polycomb-mediated 
H3K27me3 modification across the genome. 
 
In contrast to the large-scale changes in histone modifications, however, 
differentiation of ESCs does not result in widespread changes in nucleosome 
occupancy (Teif et al., 2012, West et al., 2014). Instead, most differences in 
nucleosomal occupancy between ESCs and their differentiated progeny involve 
small genomic regions the approximate size of mononucleosomes. Nonetheless, 
these regions of variable nucleosome occupancy are enriched for the DNA binding 
sites of factors involved in the regulation of pluripotency. Overall, however, in 
accordance with the notion of an increase in chromatin compaction upon 
differentiation, the majority of sites of variable nucleosome occupancy are 
associated with lower occupancy in ESCs than in their differentiated counterparts 
(West et al., 2014). Therefore, while various chromatin remodellers have been 
implicated as important determinants in the maintenance of pluripotency, it is 
unlikely that they function by mediating dramatic alterations in nucleosomal 
occupancy (Gaspar-Maia et al., 2009, Ho et al., 2009b). Instead, it is more 
probable that they act by regulating the transcription of key pluripotency or 
developmental genes. 
  
1.2 Chromatin Remodelling Enzymes 
As chromatin remodellers share many similar characteristics, a panoramic survey 
of these enzymes is of considerable utility. Nevertheless, where possible, general 
principles will be illustrated with examples pertaining to CHD proteins and the 
SMARCAD1-KAP1 complex, since they are the main focus of this study. 
 
1.2.1 Classification of Chromatin Remodellers 
Chromatin remodellers are enzymes that couple the energy released from ATP 
hydrolysis to repositioning, ejecting, or restructuring nucleosomes. Although a large 
and diverse group of proteins, members of the SWI2/SNF2-like family are unified in 
their shared possession of a helicase-like domain formed by a core of two recA-like 
domains (Durr et al., 2005, Clapier and Cairns, 2009). Multiple sequence alignment 
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of SWI2/SNF2-like family members identifies twenty-four distinct subfamilies that 
can be classified into six groups: 1) Snf2-like, 2) Swr1-like, 3) SSO1653-like, 4) 
Rad54-like, 5) Rad5/16-like and 6) distantly-related remodellers (Flaus et al., 2006). 
 
The Snf2-like group includes several notable subfamilies, including the SWI/SNF, 
ISWI, CHD1 and Mi2 (CHD3/CHD4) subfamilies (Flaus et al., 2006). Eukaryotes 
typically have at least two chromatin remodelling complexes that have at their 
cores, members of the SWI/SNF subfamily. For instance, Sacchromyces cerevisiae 
possesses the SWI/SNF and RSC complexes, whose ATPase activities are 
conferred by the paralogues Swi2/Snf2 and Sth1 respectively (Flaus et al., 2006, 
Clapier and Cairns, 2009). Typically, amongst the subunits of these complexes are 
nuclear actin-related proteins, which interact via a helicase-SANT-associated 
(HSA) domain on the core ATPase subunit (Szerlong et al., 2008, Clapier and 
Cairns, 2009). The presence of multiple bromodomains, which facilitate recognition 
of acetyl-lysine residues on histone tails, is another characteristic feature of 
SWI/SNF chromatin remodelling complexes – for instance, eight of the fifteen 
bromodomains encoded by budding yeast are distributed amongst the fifteen 
subunits of the RSC complex, including the catalytic Sth1 subunit (Cairns et al., 
1996, Clapier and Cairns, 2009). Biochemically, the essential RSC complex has 
3’5’ translocase activity, slides and ejects nucleosomes (Lorch et al., 1999, Saha 
et al., 2002, Lorch et al., 2006). 
 
C-terminal SANT and SLIDE domains, which contribute to DNA binding, are 
distinguishing features of ATPases of the ISWI subfamily (Grune et al., 2003, 
Clapier and Cairns, 2009, Yamada et al., 2011). (The SANT domain is related to 
Myb DNA-binding domain and its name reflects its frequent presence in proteins 
associated with chromatin, including Swi3, Ada2, N-CoR and TFIIB (SANT). The 
similar SLIDE domain stands for SANT-like ISWI domain (Grune et al., 2003, Boyer 
et al., 2004).) Many complexes of ISWI subfamily members, including budding 
yeast Isw1a and Drosophila ACF (ATP-utilizing chromatin assembly and 
remodelling factor), centre mononucleosomes reconstituted on short DNA 
fragments and mediate regulate spacing of nucleosomal arrays in vitro (Ito et al., 
1999, Tsukiyama et al., 1999, Stockdale et al., 2006). Indeed, supporting a general 
role in regulating nucleosome spacing, a S. cerevisiae strain (isw1Δ, chd1Δ) 
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lacking both the CHD1 and ISW1 remodellers experiences a genome-wide loss of 
proper nucleosome positioning in the gene body (Gkikopoulos et al., 2011). 
Likewise, in Drosophila, ISWI acts across the genome to reduce nucleosome 
density at sequences that are intrinsically favourable to nucleosome occupancy 
(Moshkin et al., 2012). 
 
As suggested by their name, chromodomain, helicase, DNA-binding (CHD) 
chromatin remodellers are characterized by an N-terminal tandem chromodomain. 
Although conserved from yeast to man, a single CHD protein in present in budding 
yeast, Chd1, as compared to the nine (CHD1-9) in mammals (Marfella and 
Imbalzano, 2007, Clapier and Cairns, 2009). CHD proteins can, however, be 
further sub-divided into three sub-families, Chd1 (the prototype of which is budding 
yeast Chd1, but which also includes mammalian CHD1 and CHD2), Mi2 (featuring 
CHD3-5), and CHD7 (a subfamily encompassing the relatively uncharacterized 
CHD7-9 proteins) (Flaus et al., 2006). The DNA-binding domain is actually specific 
to the Chd1 subfamily and is structurally homologous to the SANT and SLIDE 
domains of ISWI remodellers, though they share limited sequence homology (Ryan 
et al., 2011, Sharma et al., 2011). Indeed, it has become increasingly appreciated 
that Chd1 and remodellers of the ISWI subfamily share numerous similarities, not 
only in terms of their structural features, but also in their catalytic properties – Chd1 
also centres mononucleosomes and promotes the regular spacing of nucleosomal 
arrays (Lusser et al., 2005, Stockdale et al., 2006, Patel et al., 2011). Strikingly, 
Isw1 and Chd1 display functional redundancy in budding yeast – while strains 
bearing individual deletions display only mild phenotypes, double mutants exhibit 
synthetic phenotypes, including a defect in global nucleosome positioning 
(Gkikopoulos et al., 2011). 
 
Lacking SANT and SLIDE domains, remodellers of the Mi2 subfamily have tandem 
PHD domains in their N-termini instead. The tandem PHD domains mediate 
recognition of histone tails; for example, those of CHD4 bind the H3K9me3 
modification, whereas the CHD5 PHD domains are specific for unmodified H3 tails 
(Mansfield et al., 2011, Paul et al., 2013). CHD3 and CHD4 are the catalytic 
subunits of the multi-subunit nucleosome remodelling and histone deacetylation 
(NuRD) complex (Tong et al., 1998, Xue et al., 1998, Zhang et al., 1998, Wade et 
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al., 1999). As might be suggested from its ability to deacetylate histones, the role of 
the NuRD complex is that of a transcriptional repressor (Clapier and Cairns, 2009). 
 
The Swr1-like group is characterized by a “split” ATPase domain – an architecture 
that arises from the long insert separating the two recA-like lobes of the ATPase 
domain. The Swr1-like group of remodellers includes two sub-families of general 
importance, Ino80 and Swr1 (Flaus et al., 2006, Clapier and Cairns, 2009). The 
long insert serves as a platform to recruit regulatory subunits, such as the AAA+ 
ATPases, Rvb1 and Rvb2, to the catalytic subunit (Wu et al., 2005, Nguyen et al., 
2013, Tosi et al., 2013). In addition to nucleosome sliding, the SWR1 and the 
INO80 complexes catalyse histone exchange (Morrison and Shen, 2009). SWR1 
replaces conventional H2A/H2B dimers with free variant H2AZ/H2B dimers, while 
INO80 performs the converse reaction, exchanging incorporated H2AZ/H2B dimers 
for free H2A/H2B dimers (Mizuguchi et al., 2004, Papamichos-Chronakis et al., 
2011). 
 
1.2.2 General Mechanism of Chromatin Remodellers 
Related as they are to helicases, it is consequently unsurprising that SWI2/SNF2-
like chromatin remodelling ATPases are capable of processive translocation on 
DNA (Saha et al., 2002, Clapier and Cairns, 2012). It has been observed that 
ATPase domains of both ISWI and SWI/SNF remodellers bind nucleosomal DNA 
approximately 20bp, or two superhelical turns, away from the dyad axis (i.e. 
superhelix location (SHL) -2/+2) (Saha et al., 2005, Dang and Bartholomew, 2007). 
Thus, one popular model suggests that a chromatin remodeller would anchor itself 
to the nucleosome through its ATPase domain, which binds nucleosomal DNA at 
SHL +2 or -2. While the ATPase domain remains affixed to the nucleosome at that 
invariant position, its DNA-binding domain draws linker DNA into the nucleosome, 
creating a DNA loop on the nucleosome surface. The ATPase domain is believed 
to then pump the DNA along the nucleosome, towards the dyad. Presumably, each 
power stroke only breaks one or two DNA-histone contacts; however, by repeating 
this process, the transient DNA loop may be resolved by propagation around the 
nucleosome (Clapier and Cairns, 2009). While intuitive, it is unclear whether this 
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model of nucleosome sliding is compatible with chromatin remodellers that, for 
example, lack DNA-binding domains. 
 
 
Figure 1.7 – Model of Nucleosome Sliding by Addition of DNA 
Linker DNA is drawn into the nucleosome by a DNA-binding domain (annotated as DBD in 
the figure), creating a DNA loop on the nucleosome surface (State 2). The ATPase domain 
then pumps DNA towards the nucleosomal dyad by breaking DNA-histone contacts and 
allowing the DNA to propagate around the nucleosome, thus resolving the DNA loop (State 
3). If the DNA-binding domain rebinds to linker DNA, this cycle can then be repeated. This 
image was taken from (Clapier and Cairns, 2009). 
 
However, the aforementioned model is disfavoured by data from a recent study of 
ISWI proteins employing a single-molecule, fluorescence resonance energy 
transfer technique (FRET). It was observed that the first phase of the nucleosome 
sliding process was the exit of 7bp of nucleosomal DNA, accomplished by 
extruding DNA 1bp at a time. 3bp of DNA was then drawn into the nucleosome, 
presumably because the initial removal of 7bp of DNA generates tension at the 
DNA entry side. This cycle could then be repeated by extruding another 3bp of 
DNA in single base pair increments, such as to accumulate the 7bp deficit in 
nucleosomal DNA content required for triggering DNA entry (Figure 1.8) (Deindl et 
al., 2013). 
 
 
Figure 1.8 – Model of Nucleosome Sliding by Removal of DNA by ISWI  
The first step of the nucleosome sliding process by ISWI is the exit of 7bp of nucleosomal 
DNA, accomplished by the extrusion of DNA in 1bp steps. This generates tension at the 
DNA entry site, resulting in 3bp of DNA being drawn into the nucleosome. This cycle may 
then be repeated by extruding another 3bp of DNA in single base pair increments to 
accumulate the 7bp deficit in nucleosomal DNA content required to trigger DNA entry. The 
image was taken from (Deindl et al., 2013). 
This model, however, is perplexing since it implies that during the repositioning 
reaction, nucleosomes have to accommodate a deficit in DNA content of between 4 
to 7bp (Narlikar et al., 2013). Indeed, the crystal structure of the nucleosome does 
not suggest laxity in the way nucleosomal DNA is wound around the histone 
octamer (Luger et al., 1997). Although DNA could be underwound, for instance at 
SHL2 and SHL5, to cope with a 1bp reduction in nucleosomal DNA content, it 
remains difficult to conceive of the structural basis through which nucleosomes can 
accommodate a deficit of up to 7bp (Narlikar et al., 2013). 
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As these models are contradictory – one implies that DNA is first drawn into the 
nucleosome, while the other suggests that DNA is first extruded out of the 
nucleosome – it is likely that they are employed in a mutually exclusive manner by 
different chromatin remodellers. Thus, additional characterization of a diverse 
range of chromatin remodellers is required to determine which of the nucleosome 
sliding mechanisms is adopted by each specific remodeller. Much of the existing 
mechanistic characterization of chromatin remodellers has focused upon 
complexes with relatively few subunits, such as ISWI; thus, it would be informative 
to assess whether larger complexes, such as RSC, SWR1 or INO80, share a 
conserved mechanism for sliding nucleosomes. It is also remains unclear how 
chromatin remodellers couple ATP hydrolysis to the breaking of DNA-histone 
contacts. For Chd1, catalysis is associated with a conformational change in its 
ATPase domain; however, the ATPase motor is not linked to the DNA-binding 
SANT and SLIDE domains by a rigid connector through which force can be 
transmitted to push DNA out of the nucleosome (Nodelman and Bowman, 2013). 
Thus, further mechanistic studies are required to establish our understanding of 
nucleosome sliding by chromatin remodellers, and to elucidate the mechanisms 
behind other activities such as nucleosome ejection or histone dimer exchange. 
 
1.2.3 Regulation of Chromatin Remodellers 
Complementing the conserved ATPase domain, chromatin remodellers typically 
possess additional accessory domains. Through the recognition of substrates such 
as DNA and histone tails, these accessory domains act as both positive and 
negative regulators. Arguably the most highly characterized accessory domain is 
the HAND-SANT-SLIDE (HSS) domain that was first identified in the Drosophila 
ISWI protein and mediates binding of linker DNA (Grune et al., 2003, Dang and 
Bartholomew, 2007). Although the HSS domain significantly increases the affinity 
of the chromatin remodeller for nucleosomes, a fragment of the ISWI protein 
spanning only the core ATPase domain is nonetheless capable of sliding 
nucleosomes, albeit at a reaction rate an order of magnitude slower than that of the 
full-length protein (Grune et al., 2003, Mueller-Planitz et al., 2013). Within the 
context of the S. cerevisiae ISW2 complex in its entirety, however, deletion of the 
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SLIDE domain does not drastically reduce the remodeller’s affinity for either DNA 
or nucleosomes. Yet, disproportionately greater defects in nucleosome-stimulated 
ATPase and nucleosome sliding activities were associated with the ISW2 complex 
incorporating the Isw2 mutant lacking its SLIDE domain, suggesting that the LSIDE 
domains may contribute to processes beyond DNA binding (Hota et al., 2013). 
 
A role for the HSS domain as a positive regulator of nucleosome recognition and 
sliding is not solely confine to ISWI-type chromatin remodellers. A structurally 
homologous SANT and SLIDE domain has been identified in Chd1. 
Correspondingly, deletion of these domains in Chd1 compromises its affinity for 
nucleosomes and its ability to slide nucleosomes (Ryan et al., 2011, Sharma et al., 
2011). Moreover, the Chd1 SANT and SLIDE domains also appear to dictate the 
directionality of nucleosome sliding (McKnight et al., 2011). Other domains that 
modulate the nucleosome recognition capability of chromatin remodellers may 
have a comparable effect on catalysis. Indeed, the tandem PHD domains enhance 
the nucleosome sliding activity of CHD4, albeit when tested under the slightly non-
physiological setting of free CHD4 lacking additional subunits (Watson et al., 2012). 
 
Modular allostery – inhibition of the catalytic domain by another distinct structural 
domain of the same enzyme – is a strategy of negative regulation adopted by some 
chromatin remodellers. This mode of regulation is exemplified by the organization 
of the ATPase domain of Chd1 relative to its tandem chromodomains. The tandem 
Chd1 chromodomains are connected by two helices that pack against each other, 
forming a wedge-like structure. This ‘chromo-wedge’ occupies the central cleft 
separating the two RecA lobes of the ATPase domain, presumably stabilizing it in 
an open, inactive conformation (Figure 1.9). This form of conformational modular 
allostery is effective since the ‘chromo-wedge’ physically impedes the second 
ATPase lobe from rotating the fifty-two degrees required to adopt a closed, active 
configuration that permits ATP hydrolysis. Moreover, the ‘chromo-wedge’ has a 
highly acidic character that allows it to bind a basic surface on the second ATPase 
lobe that acts as a conserved DNA-binding interface. Thus, by inhibiting DNA and 
nucleosome recognition, the chromodomains also negatively regulate ATPase 
activity of Chd1 through steric modular allostery (Hauk et al., 2010). 
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Figure 1.9 – Modular Allostery by the CHD1 Chromodomains 
A. The chromodomains of CHD1 occupy the cleft between the two ATPase lobes, 
stabilizing them in an open, inactive configuration. Additionally, the chromo-wedge, 
consisting of the two helices that separate the chromodomains, packs against the DNA-
binding surface of the ATPase motor, thereby preventing nucleic acid binding. 
B. This schematic illustrates how the ATPase domain of CHD1 is arranged in an open 
state. The second lobe must undergo a 52° rotation for ATPase motor to assume the 
active, closed conformation seen in the ATPase motor of the Vasa helicase. 
The images were taken from (Hauk et al., 2010). 
The Drosophila ISWI protein is also highly regulated by modular allostery through 
two auto-inhibitory domains, AutoN and NegC. AutoN antagonizes ATPase activity 
by competing with the histone H4 tail for binding to a region on ISWI; 
correspondingly, deletion of AutoN relieves ISWI of its dependence on the H4 tail 
for ATPase activity. In contrast, NegC interferes with the coupling of ATPase 
activity with DNA translocation. It is believed that binding of the HSS domain to 
extranucleosomal DNA relieves the auto-inhibition of NegC, thereby ensuring that 
productive nucleosome sliding is limited to nucleosomes flanked by linker DNA of a 
sufficient length (Clapier and Cairns, 2012). Complementary single-molecule FRET 
analysis of human ACF, a chromatin remodelling complex of the ISWI subfamily, 
has confirmed the auto-inhibitory function of the AutoN domain of the Snf2h 
catalytic subunit. However, in the context of the entire ACF complex, NegC did not 
influence the relationship between linker DNA length and nucleosome sliding 
activity. Significantly, in addition to conferring H4 tail dependence on ACF ATPase 
activity, AutoN also serves as a sensor for the length of linker DNA – deletion of 
AutoN increases the rate at which ACF remodels nucleosomes with limited linker 
DNA. It is suggested that for nucleosomes with short linker DNA regions, the 
accessory subunit, Acf1, binds predominantly to the histone H4 tail, thereby 
preventing the H4 tail from relieving AutoN-mediated auto-inhibition. In contrast, in 
the context of increased linker DNA length, Acf1 instead binds preferentially to 
linker DNA, leaving the histone H4 tail free to displace AutoN from the ATPase 
domain, stimulating ATPase activity (Hwang et al., 2014).  
 
It is clear, therefore, that auto-inhibitory accessory domains are conserved features 
of Chd1-like and ISWI-like chromatin remodellers. Yet, as the relatively distant 
Rhp26 protein, the S. pombe homologue of CSB (an enzyme that is crucial for 
transcription-coupled nucleotide excision repair), also possesses a functionally 
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comparable repressive (leucine-latch) domain, it is likely that auto-inhibition by 
modular allostery is a common regulatory feature of chromatin remodellers (Wang 
et al., 2014a). 
  
Maintaining chromatin remodellers in an inactive state by default may be a general 
regulatory mechanism for cells for several reasons. First, as the human genome 
encodes for thirty-three proteins that possess a SWI2/SNF2-like helicase domain, it 
is likely that they are specialized for specific biological processes, with the majority 
not normally being required. Thus, maintaining a reserve of inactive chromatin 
remodellers that can be rapidly converted into an active conformation is a simple 
yet effective means by which cells can dynamically modify their chromatin structure 
in response to stimuli. Additionally, unregulated promiscuous ATPase activity from 
all of the many chromatin remodellers present in each cell may unnecessarily 
deplete cellular pools of ATP or disrupt normal chromatin structure (Flaus et al., 
2006, Narlikar et al., 2013). Indeed, overexpression of the Rhp26 chromatin 
remodeller in Schizosacchromyces pombe resulted in severe cellular toxicity in the 
absence of exogenous cellular stress. Strikingly, this phenotype was more severe 
when a hyperactive mutant was overexpressed, suggesting a casual correlation 
between ATPase hyperactivity and cellular toxicity (Wang et al., 2014a).  
 
1.2.4 Chromatin Remodellers as Multi-Subunit Protein Complexes 
Chromatin remodellers frequently manifest as large, multi-subunit protein 
complexes (Cairns et al., 1996, Tong et al., 1998, Xue et al., 1998, Zhang et al., 
1998, Wade et al., 1999, Clapier and Cairns, 2009). As accessory subunits may 
contribute unique histone mark-reading domains or protein-protein interaction 
surfaces, it is conceivable that they may drastically influence the function of the 
catalytic subunit, for instance, by modulating its genomic localization or its 
interaction partners (Mohrmann and Verrijzer, 2005). Hence, by associating with 
different sets of accessory subunits, the same catalytic subunit may be a 
component of multiple discrete complexes, with each complex being specialized for 
context-specific cellular functions. Although this phenomenon has been termed 
combinatorial assembly, it does not mean that all permutations of subunits are 
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functionally active or can be purified from cells as bona fide protein complexes. 
Instead, the current data suggests that in certain tissues, canonical subunits may 
be replaced in chromatin remodelling complexes by related homologues (Lickert et 
al., 2004, Lessard et al., 2007, Wu et al., 2007, Ho et al., 2009b). Thus, 
combinatorial subunit assembly may be particularly applicable for factors involved 
in development that act on different sets of target genes according to the specific 
developmental stage. Indeed, a multitude of variant-PRC2 complexes have been 
identified beyond the canonical PRC2 complex that are integral to H3K27me3-
mediated repression of developmental genes (Schwartz and Pirrotta, 2013). 
 
Combinatorial assembly in chromatin remodelling complexes has been best 
characterized for the BAF complex, the mammalian orthologue of S. cerevisiae 
SWI/SNF. Indeed, BAF complexes specific to ESCs, neural progenitor cells, post-
mitotic neurons and myocytes are essential for the maintenance of pluripotency, 
self-renewal of neural progenitors, dendrite growth, and cardiac development 
respectively (Lickert et al., 2004, Lessard et al., 2007, Wu et al., 2007, Ho et al., 
2009b). For instance, differentiation of neural progenitor cells into post-mitotic 
neurons is accompanied by replacement of the BAF45a and BAF53a subunits by 
BAF45b, BAF45c and BAF53b. Correspondingly, the neural progenitor cell-specific 
subunits BAF45a and BAF53a promote cell proliferation and self-renewal (Lessard 
et al., 2007). In contrast, BAF53b is required in post-mitotic neurons for proper 
activity-dependent dendritic development as it mediates recruitment of the BAF 
complex to the promoters of specific target genes (Wu et al., 2007). 
 
The capacity for small alterations in complex subunit composition to dramatically 
affect cellular phenotypes is illustrated by the potential for the mammalian 
SWI/SNF complex subunit, SNF5 (BAF47), to act as a tumour suppressor gene 
(Oruetxebarria et al., 2004, Vries et al., 2005, Kadoch and Crabtree, 2013). 
Deletion or mutation of SNF5 is observed in effectively all instances of malignant 
rhabdoid tumours (Versteege et al., 1998). However, re-expression of SNF5 in a 
malignant rhabdoid tumour cell line dramatically inhibits cell proliferation by 
inducing senescence. This dramatic reversal in phenotype is achieved by SNF5 
mediating recruitment of the SWI/SNF complex to the p16INK4a promoter, resulting 
in expression of the tumour suppressor p16INK4a (Oruetxebarria et al., 2004). 
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Strikingly, although the loss of SNF5 in malignant rhabdoid tumour cells is 
associated with polyploidy and chromosomal instability, these phenotypes can be 
reversed by re-expression of SNF5 (Vries et al., 2005). 
 
Curiously, cancers have evolved an alternative mechanism to inactivate SNF5 – 
through combinatorial subunit assembly, or more precisely, disassembly. Synovial 
sarcomas are characterized by the t(X;18)(p11.2;q11.2) chromosomal translocation 
that results in the expression of the SS18-SSX fusion protein, which competitively 
displaces SS18 and SNF5 from the BAF complex. This alteration in subunit 
composition causes aberrant localization of the mutant BAF complex at the SOX2 
locus, ultimately resulting in the transcriptional de-repression of the proto-oncogene, 
SOX2 (Kadoch and Crabtree, 2013).  
 
Another ubiquitous chromatin remodelling complex that undergoes combinatorial 
assembly is the NuRD complex that typically contains some combination of the 
following subunits: the ATPases CHD3 and CHD4, histone deacetylases 1 and 2 
(HDAC1 and HDAC2); methyl-CpG-binding domain 2 (MBD2) and MBD3; 
metastasis-associated 1 (MTA1), MTA2 and MTA3; the zinc-finger (ZNF) proteins 
GATAD2A (p66α) and GATAD2B (p66β); the histone-binding proteins 
retinoblastoma-binding protein 4 (RBBP4) and RBBP7; and the tumour suppressor 
deleted in oral cancer 1 (DOC1) (Tong et al., 1998, Xue et al., 1998, Zhang et al., 
1998, Wade et al., 1999, Le Guezennec et al., 2006). It has been observed that the 
presence of MBD2 and MBD3 in the NuRD complex is mutually exclusive (Le 
Guezennec et al., 2006). Yet, most cell types appear to express both MBD2 and 
MBD3, apart from ES cells, which specifically express MBD3 (Kaji et al., 2006, 
Gunther et al., 2013). In ES cells, MBD3 is necessary for the assembly of a stable 
NuRD complex. While ES cells generally need to be cultured in the presence of the 
cytokine, leukaemia inhibitory factor (LIF), for the maintenance of their pluripotent 
phenotype, ES cells lacking MBD3 (MBD3-/-) could be maintained in a pluripotent 
state despite culture in the absence of LIF. Conversely, however, MBD3-/- ES cells 
manifest defects in differentiation due to an inability to commit to developmental 
lineages (Kaji et al., 2006). These tissue-specific properties of MBD3 are consistent 
with the observation that MBD3-/- knockout mice experience embryonic lethality 
early in embryogenesis, in contrast to MBD2-/- knockout mice, which are viable and 
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fertile (Hendrich et al., 2001). At a biochemical level, while the MBD2/NuRD 
complex binds to methylated DNA, MBD3/NuRD is incapable of doing so (Zhang et 
al., 1999, Le Guezennec et al., 2006). Indeed, this observation is in accord with 
whole-genome studies characterizing the genomic localization of MBD2 and MBD3 
by chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq). 
Though CpG islands – regulatory regions of genes near the TSS containing a 
cytosine-guanine dinucleotide sequence – were the principal binding site of both 
proteins, a high proportion of the CpG islands bound by MBD2 were methylated, in 
contrast to MBD3 that primarily bound to un-methylated genes. Moreover, MBD2-
bound genes typically had low transcriptional activity, in contrast to the relatively 
high levels of transcription displayed by genes bound by MBD3. In fact, recruitment 
of MBD2-NuRD to a LacO array in cells is sufficient to mediate the conversion of 
open euchromatin into highly compacted heterochromatin bearing repressive 
marks (Gunther et al., 2013). Besides differences in genomic localization, MBD2 
and MBD3 also modulate NuRD function by mediating specific protein-protein 
interactions. For example, the arginine methyltransferase, PRMT5, has been 
described to be a specific interaction partner of the MBD2/NuRD complex, via an 
interaction with an N-terminal region of MBD2 rich in arginine and glycine residues. 
Indeed, PRMT5 is recruited to some CpG islands in an MBD2- and DNA-
methylation-dependent manner (Le Guezennec et al., 2006). 
 
All three homologues, MTA1, MTA2 and MTA3, have been identified to 
biochemically co-purify with the NuRD complex (Xue et al., 1998, Zhang et al., 
1998, Zhang et al., 1999, Fujita et al., 2003, Le Guezennec et al., 2006). However, 
immuno-affinity purification of the complex using an antibody specific to MTA2 
failed to recover either MTA1 or MTA3, and vice versa, arguing against the 
simultaneous presence of all three homologues in the same NuRD complex (Zhang 
et al., 1999, Fujita et al., 2003, Yao and Yang, 2003). Transiently over-expressed 
Gal4-MTA1 and Gal4-MTA2 fusion proteins functioned as potent transcriptional 
repressors of a luciferase reporter gene. In the same assay, however, Gal4-MTA3 
was a significantly less effective transcriptional repressor, suggesting that despite 
their sequence similarity, these homologues may mediate subtly different biological 
effects (Yao and Yang, 2003). This is exemplified in the context of breast cancer 
cells, where expression of MTA3 requires oestrogen receptor positivity; 
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correspondingly, therefore, incorporation of MTA3 into the NuRD complex is an 
oestrogen-dependent process. MTA3 – in contrast to MTA1, for example – 
mediates transcriptional repression of the transcriptional factor, Snail, probably in a 
direct manner as MTA3 can be detected on the Snail gene promoter by ChIP. As 
Snail inhibits expression of E-cadherin, an important cell-adhesion molecule 
specific to epithelial cells, it is unsurprising that the absence of MTA3 in breast 
cancer cells is associated with increased levels of Snail and down-regulation of E-
cadherin. The loss of expression of E-cadherin is believed to be a key contributor to 
an epithelial-to-mesenchymal cell transition, a process that is associated with the 
tumour invasion (Fujita et al., 2003). While the precise roles of the MTA proteins in 
the NuRD complex remain to be comprehensively elucidated, in an in vitro system, 
MTA2 facilitates the assembly of an enzymatically-active histone deacetylase 
complex – a core complex, containing HDAC1, HDAC2, RBBP4 and RBBP7, 
displayed considerably more histone deacetylase activity in the presence of MTA2 
than in its absence (Zhang et al., 1999). Nevertheless, it remains unclear whether 
its homologues MTA1 and MTA3 are similarly capable in this regard.  
 
Collectively, as illustrated by these observations, the ease with which the subunit 
composition of chromatin remodelling complexes can be manipulated to 
dramatically affect cellular phenotypes emphasizes the flexibility and power of 
combinatorial subunit assembly as a regulatory mechanism. 
 
1.3 CHD1 
1.3.1 Domain Architecture of CHD1 
CHD1 is a highly conserved chromatin remodeller. Indeed, the domain architecture 
of S. cerevisiae Chd1 is largely comparable to that of human CHD1 (Marfella and 
Imbalzano, 2007). The main features of CHD1 are a pair of N-terminal tandem 
chromodomains, a centrally located ATPase domain, and a C-terminal DNA-
binding domain that is structurally homologous to the SANT and SLIDE domains of 
ISWI-type chromatin remodellers (Figure 1.10) (Clapier and Cairns, 2009, Ryan et 
al., 2011, Sharma et al., 2011). 
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Figure 1.10 – Domain Architecture of Mouse CHD1 
This schematic of mouse CHD1 illustrates its annotated domains. 
Chromodomains typically function as histone methyl-lysine recognition modules (as 
discussed in subsection 1.1.4). While the chromodomains of human CHD1 behave 
predictably and specifically recognize the active H3K4me3 modification, the 
chromodomains of yeast Chd1 do not bind to (mono-, di-, or tri-) methylated H3K4 
(Flanagan et al., 2005, Sims et al., 2005). Nonetheless, the chromodomains of 
CHD1 do not recognize the methylated histone tail in the conventional manner 
since a helix-turn-helix motif connects the two chromodomains and positions them 
contiguously, forming a single, continuous surface for binding histone tails (Figure 
1.11). Rather than the conventional three-residue aromatic cage for methyl-lysine 
recognition, the CHD1 chromodomains use only two tryptophan residues (64 and 
67) – one contributed by each chromodomain. Thus, the methylammonium of 
lysine 4 is not encapsulated by a π-electron cage, as is typical for most 
chromodomain-methylated histone tail interactions. Instead, the interaction needs 
to be further stabilized by a cation-π interaction between tryptophan 67 and 
arginine 2 of the histone tail (Flanagan et al., 2005). Moreover, the surfaces 
employed by the tandem CHD1 chromodomains to interact with the H3K4me3 tail 
differ from that of canonical chromodomains, since many of the usual interaction 
interfaces are blocked in CHD1 by unique structural inserts (Patel and Wang, 2013). 
Therefore, structural studies clearly demonstrate that despite not being organized 
as canonical chromodomains, the tandem chromodomains of CHD1 nevertheless 
act as a bona fide H3K4me3-recognition module. 
 
In addition to recognizing the H3K4me3 histone modification, the tandem 
chromodomains of CHD1 probably also negative regulate the ATPase domain. 
Structural studies of budding yeast Chd1 reveal that the chromodomains are 
wedged between the two lobes of the ATPase domain, occupying its DNA-binding 
surface and also locking it into an inactive ‘open’ conformation (as previously 
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discussed in further detail in subsection 1.2.3) (Hauk et al., 2010). It is presumed 
that mammalian CHD1 proteins are similarly subjected to negative regulation by 
modular allostery of their chromodomains, though this assumption awaits formal 
validation. Moreover, it remains unclear how binding of the chromodomains to 
histone tails influence auto-inhibition of the ATPase domain. One conceptually 
attractive model is that recognition of the active H3K4me3 modification by the 
chromodomains relieves auto-inhibition, thereby allowing the chromodomains to 
restrict catalytic activity of the CHD1 chromatin remodeller to appropriate – actively 
transcribed – sites in the genome. 
 
 
Figure 1.11 – Recognition of the H3K4me3 Mark by the Tandem Chromodomains of 
Human CHD1 
The tandem chromodomains of human CHD1 act cooperatively to interact with the 
H3K4me3 mark by forming a single, continuous interaction surface. Instead of a 
conventional three-sided aromatic cage for methyl-lysine recognition, the CHD1 
chromodomains use only two tryptophan residues (64 and 67) – one contributed by each 
chromodomain. The interaction is further stabilized by a cation-π interaction between 
tryptophan 67 and arginine 2 of the histone tail. The image was taken from (Patel and 
Wang, 2013). 
 
The C-terminal DNA-binding domain of S. cerevisiae Chd1 bears structural 
homology to the SANT and SLIDE domains of ISWI-type chromatin remodellers 
despite sharing little sequence homology (Ryan et al., 2011, Sharma et al., 2011). 
The SANT and SLIDE domains are necessary and sufficient for binding to DNA 
and nucleosomes (Ryan et al., 2011). Curiously, however, though dispensable for 
Chd1 nucleosome sliding activity in vitro, the DNA-binding domain nonetheless 
dictates the directionality of sliding, which for Chd1 is to centre end-positioned 
nucleosomes (McKnight et al., 2011). 
 
In contrast to multi-subunit chromatin remodelling complexes, budding yeast and 
Drosophila CHD1 has been described to function in isolation without any accessory 
subunits (Tran et al., 2000, Lusser et al., 2005, Ehrensberger and Kornberg, 2011). 
Correspondingly, the structural and biochemical evidence described above clearly 
indicate that CHD1 intrinsically possesses all the necessary components to 
function as an autonomous chromatin remodeller (Flanagan et al., 2005, Hauk et 
al., 2010, Ryan et al., 2011). Yet, it is unclear how closely mammalian CHD1 
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proteins recapitulate the properties of their budding yeast homologue. Therefore, 
further biochemical characterization is required to elucidate the mechanistic basis 
for the developmental roles ascribed to CHD1 in higher eukaryotes. 
 
1.3.2 Functions of CHD1 
Biochemically, budding yeast Chd1 demonstrates nucleosome sliding activity in 
vitro. Chd1 shifts end-positioned nucleosomes to the centre of the DNA fragment, 
in a manner similar to ISWI-type enzymes (Stockdale et al., 2006). In addition, 
Drosophila CHD1 acts in concert with the histone chaperone, NAP1, to deposit 
histone octamers on DNA and to generate evenly spaced nucleosomal arrays in an 
ATP-dependent manner (Lusser et al., 2005). Due to the conservation of CHD1 
through evolution, it is likely that the CHD1 homologues of higher eukaryotes 
possess comparable biochemical activities. 
 
It was initially observed that CHD1 localizes to active regions of Drosophila 
polytene chromosomes, including puff and interband regions (Stokes et al., 1996). 
Genome-wide investigation of CHD1 localization at a molecular level by chromatin 
immunoprecipitation followed by DNA sequencing (ChIP-seq) in MEFs has 
revealed that CHD1 is enriched at promoters. Moreover, there is a high correlation 
between promoter occupancy of CHD1 and RNAPII, strongly suggesting that CHD1 
is recruited to the promoters of transcriptionally active genes (Skene et al., 2014). 
Further suggesting a role in transcription, proteomic and yeast two-hybrid screens 
indicate that Chd1 interacts with transcription elongation factors in budding yeast 
(Krogan et al., 2002, Simic et al., 2003). 
 
CHD1 has been implicated to influence various stages of the transcription cycle. In 
a fully defined in vitro system, S. cerevisiae Chd1 ejects the promoter nucleosome 
at the repressed PHO5 gene locus in a gene activator-dependent manner. 
Confirming a role in promoting transcriptional initiation, PHO5 gene expression was 
repressed in vivo in a chd1Δ, isw1Δ strain, lacking both the Chd1 and Isw1 
chromatin remodellers (Ehrensberger and Kornberg, 2011). A role as a termination 
factor was ascribed to Hrp1, a CHD1 homologue in S. pombe, by genetic screening. 
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Strikingly, this role in transcription termination is evolutionarily conserved since 
Chd1 also regulates termination at the CYC1 and ASC1 loci in S. cerevisiae, a 
distant yeast species, by modulating chromatin structure at the 3’ end of those 
genes, though the precise mechanism remains undefined (Alen et al., 2002). In 
contrast, CHD1 does not appear to facilitate pre-mRNA splicing through changes in 
chromatin structure. CHD1 stably associates with the SF3a subcomplex of the 
spliceosome, and directly promotes recruitment of the spliceosome to chromatin by 
physically bridging an interaction with histone tails bearing the H3K4me3 
modification (Sims et al., 2007). 
 
In budding yeast, Chd1 adopts a dominant role, albeit assisted by Isw1, in limiting 
histone exchange within the open reading frame of genes, especially towards their 
3’ ends (Smolle et al., 2012). This is probably a conserved role for CHD1, since it 
also limits nucleosome turnover within the gene body in MEFs (Skene et al., 2014). 
Considering its ability to catalyze nucleosome assembly in vitro, CHD1 probably 
promotes the nucleosome reassembly in the wake of transcription elongation 
(Lusser et al., 2005, Skene et al., 2014). Supporting a crucial role in maintaining 
global chromatin structure, increased cryptic transcription has been reported in a 
chd1Δ budding yeast strain (Smolle et al., 2012). One notable difference in the 
regulation of nucleosome dynamics by different CHD1 orthologues has, 
nevertheless, been noted – in MEFs (and presumably in most mammalian cells) 
but not in budding yeast, nucleosome turnover at the vast majority of promoters is 
controlled by CHD1 (Skene et al., 2014). 
 
In addition to regulating nucleosome occupancy, CHD1 also influences 
nucleosome positioning at a genome-wide level in several species. Although 
deletion of the chd1 gene by itself is insufficient for genome-wide changes in 
nucleosome positioning in S. cerevisiae, the combined absence of the CHD1 and 
ISW1 chromatin remodellers disrupts nucleosome positioning in the gene body, 
though without affecting the +1 promoter nucleosome (Gkikopoulos et al., 2011). 
Likewise, the S. pombe CHD1 homologues, Hrp1 and Hrp3, are required to 
maintain proper nucleosome positioning in the gene body (Pointner et al., 2012, 
Shim et al., 2012). However, evidence implicating CHD1 as a genome-wide 
determinant of nucleosome positioning in mammalian cells has not been 
Chapter 1. Introduction 
51 
 
forthcoming thus far – while depletion of CHD1 in MEFs reduces global 
nucleosome occupancy, nucleosome positioning is unaffected (Skene et al., 2014). 
Nevertheless, it is entirely plausible that akin to the situation in yeast, functional 
redundancy enables higher eukaryotes to compensate for the absence of CHD1 by 
relying on other chromatin remodellers to ensure proper nucleosome positioning. 
 
Given its importance for the regulation of transcription and the maintenance of 
chromatin organization, it would be unsurprising if the absence of CHD1 from cells 
were to manifest as striking cellular phenotypes. Indeed, mouse ESCs depleted of 
CHD1 display reduced self-renewal ability and compromised pluripotency, 
reflecting an inability to give rise to primitive endoderm (Gaspar-Maia et al., 2009). 
Notably, even mutations that are ostensibly minor can compromise normal 
differentiation – deletion of the first hundred amino acids from CHD1, which does 
not affect any of the annotated domains, is sufficient to skew in vitro differentiation 
of mouse ESCs in favour of the neuroectodermal lineage (Piatti et al., 2015). 
Additionally, depletion of CHD1 from mESCs causes an increase in 
heterochromatic foci marked by the H3K9me3 modification, suggesting that CHD1 
is an important regulator of the open chromatin state characteristic of pluripotency 
(Gaspar-Maia et al., 2009). Nevertheless, the role of CHD1 in pluripotency and 
development can still only be breached in descriptive terms, since mechanistic 
explanations for these fascinating observations remain elusive. Thus, the possibility 
of pluripotency-specific CHD1 complex subunits was investigated in this study 
(Chapter 3) by purification and mass spectrometry analysis of the endogenous 
CHD1 complex from mouse ESCs. 
 
1.4 CHD5 
1.4.1 CHD3, CHD4 and CHD5 are Homologues 
CHD5 is a homologue of CHD3 and CHD4, sharing 68% and 72% sequence 
identity with each protein respectively. Yet, one notable difference between them is 
their pattern of expression – CHD3 and CHD4 are ubiquitously expressed, whereas 
CHD5 is restricted to the nervous system and testis (Bergs et al., 2014, Zhuang et 
al., 2014). Indeed, the expression of CHD5 is mutually exclusive to that of CHD3 
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and CHD4 during spermatogenesis. CHD5 expression is undetectable in pre-
meiotic spermatogonia and spermatocytes, where CHD3 and CHD4 are highly 
abundant. In contrast, CHD5 expression reaches its zenith in post-meiotic late 
round spermatids, where CHD3 and CHD4 are restricted to low expression levels 
(Bergs et al., 2014). 
 
CHD3 and CHD4 are catalytic subunits of the NuRD complex. The NuRD complex 
may include the following components: histone deacetylases 1 and 2 (HDAC1 and 
HDAC2); methyl-CpG-binding domain 2 (MBD2) and MBD3; metastasis-associated 
1 (MTA1), MTA2 and MTA3; the zinc-finger (ZNF) proteins GATAD2A (p66α) and 
GATAD2B (p66β); the histone-binding proteins retinoblastoma-binding protein 4 
(RBBP4) and RBBP7; and the tumour suppressor deleted in oral cancer 1 (DOC1) 
(Tong et al., 1998, Xue et al., 1998, Zhang et al., 1998, Wade et al., 1999, Le 
Guezennec et al., 2006). The NuRD complex is unique in its possession of two 
distinct catalytic activities – nucleosome remodelling and histone deacetylation. 
Since histone acetylation is a mark of transcriptionally active genes, it is 
unsurprising that a major function of the NuRD complex is transcriptional 
repression (Lai and Wade, 2011).  
 
It has been observed that CHD5 co-immunoprecipitates with subunits of the NuRD 
complex, including HDAC2, RBBP7 and MTA3. Hence, it was speculated that 
CHD5 is a component of the NuRD complex in neuronal tissues (Potts et al., 2011). 
Nonetheless, this hypothesis has not been formally tested and it remains unclear 
whether CHD5 is stably associated in the NuRD complex. Due to the homology 
between these chromatin remodellers, CHD5 could conceivably either replace 
CHD3 and CHD4 in the NuRD complex, or be incorporated along with them. 
Further biochemical characterization is, consequently, integral to acquiring a 
detailed understanding of CHD5 and the complex in which it carries out its cellular 
functions. Moreover, it is not inconceivable that the NuRD complex displays 
combinatorial subunit assembly with regards to its catalytic subunit, since this 
phenomenon has already been documented for both its MBD and MTA subunits 
(as previously discussed in subsection 1.2.4) (Fujita et al., 2003, Le Guezennec et 
al., 2006). 
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1.4.2 Domain Architecture of CHD5 
A member of the Mi2 subfamily of chromatin remodellers, CHD5 contains four 
histone modification-reading domains in its N-terminus – a pair of tandem PHD 
domains followed by tandem chromodomains (Figure 1.12). The tandem PHD 
domains of CHD5 specifically recognize unmodified histone H3 tails (Paul et al., 
2013). Structural studies of DPF3b (also known as BAF45c; a subunit of the BAF 
complex in post-mitotic neurons) and the histone acetyltransferase MOZ reveal that 
their tandem PHD domains are positioned contiguously to form a single, continuous 
interaction surface to recognize histone H3 tails acetylated at lysine 14 (Zeng et al., 
2010, Qiu et al., 2012). In contrast, each PHD domain of CHD5 is capable of 
independently recognizing an unmodified histone H3 tail. Nevertheless, they work 
cooperatively to interact simultaneously with two histone H3 molecules; through 
this mode of bivalent interaction, the tandem PHD domains benefit from four- to 
eleven-fold greater affinity for unmodified H3 tails compared to either individual 
domain (Oliver et al., 2012). Indeed, the tandem PHD domains of the homologous 
CHD4 protein behave in a comparable manner to interact with two histone H3 tails 
marked by the H3K9me3 modification. It was also suggested that the tandem 
CHD4 PHD domains bind to the two H3 tails of a single nucleosome. This 
hypothesis arises from the inference (based on nuclear magnetic resonance (NMR) 
data indicating that the linker connecting the CHD4 PHD domains is largely 
unstructured) that the distance separating the two PHD domains is approximately 
70Å, which coincides with the distance between the two H3 tails of a single 
nucleosome (Musselman et al., 2012b). 
 
 
Figure 1.12 – Domain Architecture of Mouse CHD5 
This is a schematic representation of mouse CHD5, showing its annotated domain features. 
 
The tandem chromodomains also mediate histone mark recognition, specifically the 
H3K27me3 modification (Egan et al., 2013). Yet, in the absence of an atomic 
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structure, it remains unclear whether the CHD5 tandem chromodomains are 
independently capable of recognizing the H3K27me3 mark, or whether they form a 
single unified histone interaction surface comparable to that of the CHD1 
chromodomains (Flanagan et al., 2005). 
 
Considered as a whole, the N-terminal histone mark-binding region of CHD5 
displays highest affinity for the H3K27me3 modification, though it also interacts 
specifically with unmodified H3 tails (Egan et al., 2013). The dominance exerted by 
the chromodomains in ignoring the preference of the PHD domains for unmodified 
H3 tails is probably a simple reflection of their respective interaction affinities. 
Indeed, the dissociation constant (Kd) governing the interaction between the 
chromodomains and an H3K27me3 peptide is 1nM, whereas the PHD domains 
bind unmodified H3 tail peptides with a Kd of 9µM (Oliver et al., 2012, Egan et al., 
2013). 
 
The PHD and chromodomains of CHD4 are essential for the transcriptional 
repression of a model gene, mb-1 (Cd79a), in B-lymphocytes. As mutation of these 
histone mark-reading domains compromises the recruitment of CHD4 to the mb-1 
promoter, it is likely the PHD and chromodomains contribute to CHD4-mediated 
transcriptional repression partly by regulating the genomic localization of CHD4 
(Musselman et al., 2012b, Ramirez et al., 2012). However, the tandem PHD and 
chromodomains probably also influence the ATPase motor through allosteric 
regulation (Morra et al., 2012). Given the similarities between CHD4 and CHD5, it 
is likely that the tandem PHD and chromodomains also regulate the recruitment of 
CHD5 to chromatin. Yet, limited correlation was identified between the genomic 
localization of CHD5 and the H3K27me3 modification recognized by its tandem 
chromodomains (Egan et al., 2013). Thus, further work is required to understand 
the interplay between the PHD domains and chromodomains; specifically, it is 
unclear whether they function entirely independently of one another, or whether 
they bind histone tails cooperatively. Indeed, it must be clarified whether the 
histone mark recognition domains in CHD5 form an integrated interaction module, 
such as that of the PHD-bromodomain of TRIM24, which interacts with a histone 
tail that is unmodified at lysine 4, but acetylated at lysine 23 (Tsai et al., 2010). 
Ultimately, clarification of the structural basis for the interaction between CHD5 and 
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histone tails will be necessary to fully comprehend the determinants controlling the 
recruitment of CHD5 to chromatin and to reconcile biochemical and genome-wide 
ChIP-seq data. 
 
The ATPase domain and C-terminus of CHD5 have not been characterized 
biochemically. Indeed, a DNA-binding domain similar to the SANT and SLIDE 
domains of CHD1 and ISWI-type chromatin remodellers has not been identified in 
CHD5. Yet, pure recombinant CHD5 is able to interact with nucleosomes, 
suggesting that similar to other SWI2/SNF2 chromatin remodelling ATPases, the 
core ATPase motor of CHD5 is capable of binding DNA and thereby, nucleosomes 
(Durr et al., 2005, Mueller-Planitz et al., 2013, Quan and Yusufzai, 2014). 
 
1.4.3 Functions of CHD5 
Recombinant CHD5 is capable of increasing the accessibility of chromatinized 
templates and mononucleosomes to restriction enzymes in vitro (Quan and 
Yusufzai, 2014). However, this chromatin remodelling activity appears to be distinct 
from either the nucleosome sliding typical of most chromatin remodellers or the 
nucleosome ejection catalysed by the RSC complex (Lorch et al., 1999, Wang and 
Zhang, 2001, Stockdale et al., 2006). CHD5-remodelled chromatin was subjected 
to micrococcal nuclease digestion followed by glycerol gradient sedimentation, 
which separates according to molecular mass. Although the CHD5-remodelled 
sample contained mono- and di-nucleosomes that co-sedimented with canonical 
mono- and di-nucleosomes, the nucleosome fractions were associated with DNA of 
the expected length, along with shorter DNA fragments. This observation is 
inconsistent with nucleosome sliding, since repositioned nucleosomes would 
nonetheless protect the same length of DNA. Instead, CHD5-remodelling increases 
the accessibility of endonucleases to nucleosomal DNA that is usually protected by 
histone-DNA interactions. This was conceptualized to represent CHD5 stably 
unwrapping DNA from the histone octamer at an internal nucleosomal site, 
approximately 40-50bp from the entry or exit point, in an ATP-dependent manner. 
This form of chromatin remodelling appears to be unique to CHD5, as nucleosome 
unwrapping activity is not observed even with its close homologue, CHD4. Overall, 
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in terms of chromatin remodelling, CHD5 acts with low processivity and does not 
appear to affect nucleosome positioning (Quan and Yusufzai, 2014). 
 
The effect of CHD5 on chromatin organization in vivo is unknown. However, given 
the similarity between CHD5 and CHD4, and the link between both proteins and 
the NuRD complex, it is possible that they function similarly (Potts et al., 2011). 
Genome-wide DNase I hypersensitivity mapping has revealed that inhibition of 
CHD4 function by inducing over-expression of an ‘ATPase-dead’, dominant-
negative mutant, which presumably outcompetes endogenous CHD4 for genomic 
binding sites, increases chromatin accessibility at a large number of sites (4125 
sites) across the genome. In contrast, considerably fewer DNase I hypersensitive 
sites are lost (242 sites) in response to antagonism of CHD4. Thus, this data 
indicates a global role for CHD4 at maintaining a closed chromatin structure (Morris 
et al., 2014). Similarly, in Drosophila, the NuRD complex acts at its target sites 
primarily by increasing nucleosome density; notably, these sites generally possess 
sequence properties that discourage nucleosome occupancy (Moshkin et al., 2012). 
Collectively, these observations are entirely consistent with the prevailing paradigm 
of CHD4 as a transcriptional repressor (Lai and Wade, 2011). 
 
Extrapolating from the role of CHD4 as a transcriptional repressor, it might be 
expected for CHD5 to adopt a similar function. However, there is currently only 
limited data to support this notion. For instance, CHD5 represses the WEE1 gene 
in human cells (Quan et al., 2014). However, gene expression microarray analysis 
of neural progenitor cells, derived either from control mESCs or from mESCs 
depleted of CHD5, identified 512 genes that were preferentially activated during 
neurogenesis in control but not in CHD5-depleted cells. In contrast, only 119 genes 
were specifically activated in CHD5-depleted compared to control cells. Therefore, 
this data suggests that CHD5 acts more frequently to activate rather than repress 
transcription (Egan et al., 2013). Yet, a notable caveat is that it is impossible to 
distinguish genes that are directly regulated by CHD5 from those whose expression 
is only indirectly influenced by CHD5. Moreover, as this result reflects the function 
of CHD5 at a specific stage in neuronal development, it may not be indicative of the 
manner in which CHD5 regulates transcription under normal circumstances.  
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As suggested by its restricted expression pattern, CHD5 is involved in 
developmental processes. In the context of neural development, CHD5 upregulates 
neuronal genes, especially those encoding factors involved in late-stage neural 
development. Furthermore, depletion of CHD5 from the developing mouse 
neocortex prematurely curtails neuronal differentiation, as reflected in a surfeit of 
immature neural progenitor cells (Egan et al., 2013). Yet, CHD5 knockout mice 
display largely unremarkable neurological phenotypes, exhibiting only mild neuro-
behavioural defects (Zhuang et al., 2014). Considered together, it is probable that 
neuronal differentiation is regulated by multiple important, yet redundant 
mechanisms, of which CHD5 is but one. 
 
The dominant phenotype of CHD5 knockout mice is male infertility (Zhuang et al., 
2014). As befitting a regulator of sperm development, expression of CHD5 in the 
testis is temporally regulated relative to spermatogenesis, reaching a peak in post-
meiotic late round spermatids despite being virtually absent in pre-meiotic 
spermatogonia and spermatocytes (Bergs et al., 2014). Loss of CHD5 impairs 
spermiogeneis due to compromised chromatin integrity and compaction in sperm, 
which probably arise due to deregulation of the histone to protamine transition. 
Compared to wild-type mice, differentiated spermatids in CHD5-deficient mice 
retained higher levels of core histones for longer in spermiogenesis; moreover, 
CHD5 deficiency was also associated with perturbations in the expression of 
protamines and important regulators of the histone to protamine transition, such as 
Tnp1 and Tnp2. CHD5-deficient spermatids also exhibited reduced levels of 
histone H4 acetylation. Histone H4 hyperacetylation is a key molecular event for 
protamine incorporation as it induces histone eviction. This is probably achieved by 
a direct association between the acetylated histone tails and the testis-specific, 
bromodomain-containing protein, Brdt; it is further speculated that Brdt, in turn, 
recruits chromatin remodellers to eject histone octamers from nucleosomes. It is 
clear that CHD5 influences many processes integral to the histone to protamine 
replacement process; however, the roles of CHD5 in this process have yet to be 
precisely elucidated – it is unknown whether CHD5 acts indirectly by modulating 
gene expression or directly influences chromatin structure (Li et al., 2014). 
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CHD5 is not only associated with physiological development, but also with 
pathology – CHD5 has been identified to be the main tumour suppressor gene 
compromised by the 1p36 chromosomal deletion that has an incidence rate of 70-
80% in high-risk neuroblastomas (Bagchi et al., 2007, Fujita et al., 2008, Okawa et 
al., 2008). In this setting, the absence of CHD5 promotes cellular proliferation and 
inhibits further neuronal differentiation of malignant cells. Although the tumour-
suppressive function of CHD5 cannot be defined in mechanistic terms, it is 
dependent on the tandem PHD domains of CHD5, suggesting that proper genomic 
localization of this chromatin remodeller is essential for this process (Paul et al., 
2013). 
 
While it is clear that CHD5 is functionally distinct from its homologues, CHD3 and 
CHD4, it is unclear how similar the CHD5 complex composition is to that of either 
CHD3 or CHD4. However, given the relatively high sequence identity shared 
between CHD3, CHD4 and CHD5, it was predicted that the tissue-specific 
functions of CHD5 could be attributed to distinct complex subunits that either 
influenced the catalytic activity of CHD5 or regulated its genomic localization. Thus, 
the native CHD5 complex was purified from mouse brains and its subunit 
composition analysed by mass spectrometry, as described in Chapter 4. 
 
1.5 SMARCAD1 
1.5.1 Domain Architecture of SMARCAD1 – Comparisons with the Related 
SWR1 and INO80 Chromatin Remodellers 
Largely uncharacterized, SMARCAD1 is classified by multi-sequence alignment as 
an Swr1-like chromatin remodeller due to its split-ATPase domain organization 
(Figure 1.13) (Flaus et al., 2006). Due to a dearth of biochemical characterization of 
the SMARCAD1 protein, it is necessary to extrapolate from our understanding of 
the well-characterized SWR1 and INO80 chromatin remodelling complexes to 
obtain just the vaguest sense of the intrinsic capabilities of SMARCAD1. Yet, it 
must be emphasized that beyond a long insertion dividing their ATPase domains, 
SMARCAD1, Swr1 and Ino80 are not overly similar proteins – most apparently, the 
SWR1 and INO80 complex possess more than 15 subunits, while SMARCAD1 
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forms a complex with only KAP1 (Rowbotham et al., 2011, Nguyen et al., 2013, 
Tosi et al., 2013). 
 
 
Figure 1.13 – Domain Architecture of Human SMARCAD1 
This schematic of human SMARCAD1 illustrates its domain features. The long insertion 
between the ATPase domains characterizes SMARCAD1 as an Swr1-like remodeller. The 
abbreviation, NLS, refers to a nuclear localization signal. 
 
The defining shared characteristic of Swr1 and Ino80 is the long insertion dividing 
their ATPase domains. This insertion mediates an interaction with a hetero-
oligomer of Rvb1 and Rvb2, ATPases of the AAA+ family that are related to RuvB – 
a bacterial single-stranded DNA helicase that promotes strand migration for the 
resolution of Holliday junction structures that arise during DNA repair by 
homologous recombination. It is unclear whether human Rvb1/Rvb2 heterodimers 
possess helicase activity (Gerhold and Gasser, 2014). Nevertheless, mediated by 
the split insert domains of Swr1 and Ino80, the SWR1 complex incorporates a 
heterohexameric Rvb1/Rvb2 ring, while the INO80 complex stably associates with 
an Rvb1/Rvb2 heterododecamer, arranged in the form of two stacked hexameric 
rings (Nguyen et al., 2013, Tosi et al., 2013). Proteomic analysis, however, showed 
that neither Rvb1 nor Rvb2 is a specific interaction partner of SMARCAD1 
(Rowbotham et al., 2011). Though the ATPase domain insertion in SMARCAD1 is 
not directly comparable to those of Swr1 or Ino80, it may nevertheless, function an 
interaction surface for proteins other than Rvb1 and Rvb2. Also, without an HSA 
domain, SMARCAD1 does not interact with actin or actin-related proteins, in 
contrast to Swr1 and Ino80 (Rowbotham et al., 2011, Gerhold and Gasser, 2014). 
 
The structures of the SWR1 and INO80 chromatin remodelling complexes have 
recently been defined by cryo-EM (Nguyen et al., 2013, Tosi et al., 2013). 
Significantly, these studies have revealed that SWR1 and INO80 interact with 
nucleosomes in idiosyncratic manners that bear no resemblance to each other, or 
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to the way in which the RSC complex engulfs a nucleosome in its central cavity 
(Figure 1.14) (Chaban et al., 2008, Nguyen et al., 2013, Tosi et al., 2013). When a 
nucleosome is bound to the compact SWR1 complex, the nucleosome is 
peripherally located and occupies an interaction surface formed mainly by the 
catalytic Swr1 subunit, but also with a contribution from the Rvb1/Rvb2 
heterohexamer. Thus, in this structure, the majority of contacts between the SWR1 
complex and the nucleosome involve the Swr1 subunit (Nguyen et al., 2013). 
Biochemical data demonstrating the preference of the SWR1 complex for 
nucleosomes with long regions of extra-nucleosomal DNA has, however, revealed 
that a DNA-binding basic region in the N-terminus of the Swc2 subunit is the main 
determinant of the interaction (Ranjan et al., 2013). This discrepancy has prompted 
speculation that the SWR1 complex undergoes a conformation change to perform 
histone dimer exchange (Nguyen et al., 2013, Gerhold and Gasser, 2014). In 
contrast, the INO80 complex resembles an elongated embryo, which can be sub-
divided into head, neck, body and foot components. To bind a nucleosome, the 
INO80 grasps it with its head and foot modules, forming multiple nucleosome-
remodeller contacts with all INO80 modules (Tosi et al., 2013). The contrasting 
styles employed by the related SWR1 and INO80 complexes to interact with 
nucleosomes preclude an accurate, a priori prediction of the means by which 
SMARCAD1 may bind nucleosomes.  
 
 
Figure 1.14 – Nucleosome Binding by the INO80 & SWR1 Chromatin Remodellers 
A. The INO80 complex forms an elongated embryo structure, which can be sub-divided 
into head, neck, body and foot components. INO80 binds nucleosomes by grasping it 
with its head and foot modules. The image was taken from (Tosi et al., 2013). 
B. The nucleosome binds to a peripheral location on the compact SWR1 complex. The 
interaction interface on SWR1 is formed mainly by the catalytic Swr1 subunit, but with a 
contribution from the Rvb1/Rvb2 heterohexamer. The blue and yellow arrows illustrate 
the main conformational changes that accompany nucleosome binding to the SWR1 
complex. The image was adapted from (Nguyen et al., 2013). 
 
DNA-binding domains are crucial elements of chromatin remodellers. The 
importance of the SANT and SLIDE domains to ISWI-like (as part of a larger HSS 
motif) and Chd1-like chromatin remodellers has been previously described (in 
subsection 1.2.3) (Grune et al., 2003, Ryan et al., 2011). The SWR1 complex 
displays a clear in vivo preference for binding to promoter nucleosomes flanked by 
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at least 50bp of linker DNA. The basis for this can be directly attributed to the 
biochemical properties of SWR1, which forms contacts with both the 
extranucleosomal DNA and the adjacent nucleosome core particle. The DNA-
binding domain on the Swc2 subunit is the dominant contributor to SWR1-
nucleosome binding, though the catalytic Swr1 subunit is also capable of mediating 
an interaction with nucleosomes, albeit to a lesser extent (Ranjan et al., 2013). 
Apart from the ATPase domain, SMARCAD1 does not appear to possess any 
motifs that will confer DNA-binding ability. Therefore, SMARCAD1 either relies 
exclusively on the DNA-binding ability of its ATPase motor, or possesses a hitherto 
un-annotated DNA-binding domain, or has evolved a novel mechanism for 
stabilizing its presumed interaction with nucleosomes. 
 
Of especial relevance to the work in this thesis, a unique feature of SMARCAD1 is 
a pair of N-terminal tandem CUE (Coupling of ubiquitin conjugation to endoplasmic 
reticulum degradation) domains. CUE domains are ubiquitin-binding domains (and 
will be discussed in greater detail in section 1.7). The functions of the SMARCAD1 
CUE domains are unknown; however, the CUE domain of Fun30, the S. cerevisiae 
homologue of SMARCAD1, apparently does not recognize ubiquitylated histone 
tails (Awad et al., 2010). As the only domains annotated in SMARCAD1 besides 
the conserved ATPase, the hypothesis that the CUE domains regulate SMARCAD1 
function, perhaps by mediating protein-protein interactions, was investigated as 
described in Chapter 7. 
 
1.5.2 Functions of SMARCAD1 
The biochemical properties of SMARCAD1 remain unstudied. Its budding yeast 
homologue, Fun30, exhibits a limited ability to slide nucleosomes; however, this is 
exceeded by its ability to mediate histone H2A/H2B dimer exchange (Awad et al., 
2010). This activity is clearly reminiscent of the SWR1 and INO80 chromatin 
remodelling complexes – SWR1 incorporates free variant H2AZ/H2B dimers into 
nucleosomes that are originally composed of conventional H2A/H2B dimers, 
whereas INO80 catalyses the reverse reaction (Mizuguchi et al., 2004, 
Papamichos-Chronakis et al., 2011). Histone dimer exchange by SWR1 is the net 
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effect of at least two synergistic processes – the catalytic Swr1 subunit promotes 
the incorporation of H2AZ into nucleosomes, while the Swc2 subunit binds to H2AZ 
and acts as a lock, preventing its removal from nucleosomes (Watanabe et al., 
2013). It is suggested that SWR1 unwraps nucleosomal DNA from its entry/exit 
sites, thereby exposing the DNA-binding surface of the H2A/H2B dimer, and 
facilitating the intrinsic tendency of the histone octamer to dissociate into its 
constituent parts, namely H2A-H2B dimers and a (H3-H4)2 tetramer. With the 
histone octamer being in dynamic equilibrium, an Htz1-H2B dimer, brought into 
close proximity by the SWR1 complex, can compete for the binding site vacated by 
the H2A-H2B dimer. The structural incompatibility induced by the presence of two 
heterotypic dimers should subsequently promote SWR1-mediated exchange of the 
second H2A-H2B dimer (Mizuguchi et al., 2004). Histone dimer exchange appears 
to be conserved function for many chromatin remodellers classed as Swr1-like; 
consequently, SMARCAD1 may similarly possess histone dimer exchange activity. 
 
Depletion of SMARCAD1 from human cells resulted in a global increase in 
acetylation of histones H3 and H4 and in a decrease in the repressive H3K9me3 
mark, which is associated with constitutive heterochromatin. As SMARCAD1 co-
localized with sites of DNA replication, it was suggested that SMARCAD1 functions 
to maintain constitutive heterochromatin, for example at pericentric repeats, 
through replication (Rowbotham et al., 2011). It is unclear whether SMARCAD1 
achieves these functions by acting directly at the level of nucleosomes and 
chromatin structure, or indirectly through the regulation of gene expression. If it 
were the former, it is conceptually plausible that SMARCAD1 removes acetylated 
histones from replicated chromatin by promoting histone turnover through dimer 
exchange. 
 
The link between SMARCAD1 and heterochromatin might well be attributed to 
KAP1 (KRAB-associated protein 1), with which most cellular SMARCAD1 forms a 
stoichiometric complex in human cells (Rowbotham et al., 2011). (The Krüppel-
associated box (KRAB) domain is the defining feature of a family of ZNF 
transcription factors (Iyengar and Farnham, 2011).) By virtue of its HP1-box, the 
transcriptional co-repressor, KAP1 is capable of interacting with HP1 and thereby, 
indirectly with constitutive heterochromatin (Ryan et al., 1999). Consequently, it is 
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possible that KAP1 modulates the genomic localization of SMARCAD1 by 
recruiting it to constitutive heterochromatin, though such a hypothesis awaits 
empirical validation. 
 
Intriguingly, two independent genetic screens in yeast have implicated the 
SMARCAD1 homologue, Fun30, as a factor that promotes DNA end resection 
(Chen et al., 2012, Costelloe et al., 2012). End resection – the conversion the ends 
of DNA double-strand breaks (DSBs) into 3’ single-stranded DNA overhangs by 
5’3’ exonuclease cleavage – is a requisite for the repair of DSBs by the error-free 
homologous recombination pathway (Jasin and Rothstein, 2013). Fun30 is believed 
to directly regulate end resection as it is recruited to DSBs and spreads away 
bidirectionally from the DNA lesion over time (Chen et al., 2012, Costelloe et al., 
2012). Moreover, Fun30 interacts with canonical mediators of end resection in 
yeast, including the Exo1 exonuclease and RPA, a single-stranded DNA-binding 
protein. The mechanism by which Fun30 promotes end resection is unknown; 
however, it is unlikely to be achieved by regulating local nucleosome repositioning, 
as the absence of Fun30 fails to significantly alter nucleosome positions at DSBs 
(Chen et al., 2012). The observations have been extended to SMARCAD1, which is 
recruited to DSBs induced by laser micro-irradiation with similar kinetics to the 
Exo1. Additionally, in response to ionizing radiation, human fibroblasts depleted of 
SMARCAD1 form fewer RPA foci, which arise, in this situation, from the 
recruitment of RPA to the single-stranded DNA overhangs generated by end 
resection. Furthermore, depletion of SMARCAD1 sensitises human cells in culture 
to the genotoxin camptothecin (Costelloe et al., 2012). Based on these 
observations, SMARCAD1, like Fun30, is regarded as a positive regulator of end 
resection and thereby, of DSB repair by homologous recombination (Chen et al., 
2012, Costelloe et al., 2012). 
 
1.6 KAP1 
1.6.1 Domain Architecture of KAP1 
The SMARCAD1 interacting protein, KAP1, is a tripartite motif-containing (TRIM) 
protein, as reflected in its alternative name of TRIM28 (Friedman et al., 1996, Le 
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Douarin et al., 1996). (Yet another alias of KAP1 is transcription intermediary factor 
1 beta (TIF1β).) TRIM proteins are distinguished by their possession of an RBCC 
domain, which is a composite of RING, B-box and coiled-coil (RBCC) domains 
(Hatakeyama, 2011). Additionally, KAP1 has a centrally located HP1-box, through 
which it interacts with HP1, and a C-terminal PHD-bromodomain (Figure 1.15) 
(Friedman et al., 1996, Le Douarin et al., 1996). The closely related proteins, TIF1α 
(TRIM24) and TIF1γ (TRIM33), share the domain architecture of KAP1. Indeed, the 
RBCC domains and PHD-bromodomains of KAP1 and TIF1α share 40% and 34% 
sequence identity respectively; likewise, a similar level of homology occurs 
between KAP1 and TIF1γ (Iyengar and Farnham, 2011).  
 
 
Figure 1.15 – Domain Architecture of Human KAP1 
This schematic illustrates the main features of the human KAP1 protein. 
 
RING finger domains are zinc-finger domains that frequently possess E3 ubiquitin 
ligase activity, though a substantial minority are catalytically inactive (Deshaies and 
Joazeiro, 2009). No physiological ubiquitylation targets of KAP1’s RING finger 
domain have yet been identified; therefore, it remains unknown whether this KAP1 
domain functions as a bona fide E3 ubiquitin ligase. (Curiously, however, the KAP1 
PHD domain functions as an E3 small ubiquitin-like modifier (SUMO) ligase that 
promotes the sumoylation of the KAP1 bromodomain; this aspect of KAP1 biology 
will be elaborated upon later in this section (Ivanov et al., 2007).) 
 
Within the KAP1 RBCC domain are a pair of tandem B-boxes. The B-box domain is 
structurally related to the RING domain – a globular domain stabilized by two 
coordinating zinc ions (Massiah et al., 2006, Tao et al., 2008). Due to the structural 
similarity between B-boxes and RING domains, it has been suggested that B-boxes 
either possess of E3 ligase activity in their own right, or are capable of enhancing 
that of RING domains (Massiah et al., 2006). Neither function, however, can be 
definitively ascribed to B-boxes. 
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Figure 1.16 – Structure of the TRIM25 Coiled-Coil Domain 
A. The TRIM25 coiled-coil dimer is shown in orthogonal views. For clarity, one subunit is 
depicted in rainbow representation, beginning with violet at the N-terminus coloured and 
ending with red at the C-terminus. The other subunit is shown in white. The image was 
taken from (Sanchez et al., 2014). 
B. The coiled-coil domain may the main determinant of overall structural organization for 
TRIM-family proteins in general. The coiled-coil dimer acts as an extended interaction 
interface, with the RING and B-box domains at either end. The C-terminal part of the 
protein clusters in the middle, and on one side of the coiled-coil domain. This image is a 
recreation of one in (Sanchez et al., 2014). 
 
The coiled-coil domains of KAP1 mediate homo-trimerization of KAP1. Moreover, 
recent structural characterization of the TRIM25 coiled-coil homodimer has 
revealed how the coiled-coil domain can serve as the cornerstone that dictates the 
positions of the other domains of a TRIM-family protein (Figure 1.16). The construct 
of TRIM25 used for crystallization encompassed the coiled-coil domain and the first 
half of the ensuing linker region. Each TRIM25 molecule adopted a hairpin 
configuration; a short arm consisting of the linker region folded back onto a long 
arm, formed by the coiled-coil domain proper. The TRIM25 dimerized in an 
antiparallel orientation, with the coiled-coil domain functioning as an extended 
interaction interface. Intriguingly, the coiled-coil domain is comprised of heptad (7) 
and hendecad (11) amino acid repeats arranged in a palindromic 7-7-7-7-11-11-11-
11-7-7-7-7 pattern (where ‘7’ refers to a heptad repeat and ‘11’ a hendecad repeat). 
The heptad repeats at the ends form canonical left-handed supercoils that flank a 
central under-wound, right-handed coil arising from the hendecad repeats. Thus, 
the linker helices of the short arm can infiltrate the central portion of the coiled-coil 
domain, exploiting the under-winding to form an interdigitated four-helix bundle. 
The coiled-coil domain of TRIM25 thereby imposes the following positional 
constraints on the remaining domains – the C-terminal domains cluster in the 
middle, and on one side, of the coiled-coil domain, while the N-terminal RING and 
B-box domains cap the ends. Multiple sequence alignment confirms that the coiled-
coil domain of KAP1 is composed of a similar combination of heptad and hendecad 
repeats (Sanchez et al., 2014). Hence, it is plausible that KAP1 is organized 
structurally in a similar manner to TRIM25; however, in the absence of a substantial 
corpus of solved structures of TRIM proteins, it is unknown whether the structure of 
TRIM25 can be regarded as being representative of the TRIM family in general. 
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Located within the central region of the KAP1 protein, the HP1-box contains a 
hydrophobic pentapeptide PxVxL motif that mediates an interaction between KAP1 
and the chromo-shadow domain of all three isoforms of HP1 (Nielsen et al., 1999, 
Ryan et al., 1999, Lechner et al., 2000). Indeed, KAP1 co-localizes with HP1, 
particularly around nucleoli and in pericentric heterochromatin (Ryan et al., 1999). 
This interaction with HP1 is essential for the ability of KAP1 to repress transcription 
to be fully realized (Nielsen et al., 1999). Notably, enforced recruitment KAP1 to 
euchromatic gene loci is sufficient to mobilize HP1 to these sites, culminates in 
transcriptional silencing and chromatin compaction (Ayyanathan et al., 2003). The 
KAP1 HP1-box interacts with HP1 with a stoichiometry of one to two; furthermore, 
since KAP1 exists as a homotrimer, it may be associated with a cluster of six 
molecules of HP1. KAP1 may, therefore, nucleate multimerization of HP1 and 
promote the conversion of the local chromatin structure into a heterochromatic 
state (Lechner et al., 2000). Given its interaction with KAP1, it is particularly 
intriguing to speculate that SMARCAD1 may contribute to this process. Yet, as 
KAP1 is present in the cell at considerable excess compared to SMARCAD1, the 
SMARCAD1 may function entirely independently of KAP1-mediated transcriptional 
repression that involves HP1. 
 
PHD domains typically mediate interactions with histone tails, for example, 
enabling the specific recognition of the unmethylated H3K4me0 or tri-methylated 
H3K4me3 states (Patel and Wang, 2013). However, the PHD domain of KAP1 
possesses neither a conserved aspartic acid residue to form an ion pair with 
unmethylated lysine 4, nor an aromatic cage to stabilize an interaction with tri-
methylated lysine 4 through cation-π interactions (Chakravarty et al., 2009). 
Likewise, though most bromodomains enable interactions with acetylated histone 
tails, this is not true for the KAP1 bromodomain (Zeng et al., 2008, Filippakopoulos 
et al., 2012). One characteristic of canonical bromodomains is a hydrophobic 
pocket that can be occupied by acetylated histone tails; the KAP1 bromodomain, 
however, has a distorted pocket, thereby explaining its inability to undertake 
histone acetyl-lysine recognition (Zeng et al., 2008). 
 
Instead of histone mark recognition, the KAP1 PHD-bromodomain has evolved to 
interact with the histone methyl-transferase SETDB1, which deposits the repressive 
Chapter 1. Introduction 
67 
 
H3K9me3 modification, and CHD3, a catalytic subunit of the NuRD complex 
(Schultz et al., 2001, Schultz et al., 2002, Ivanov et al., 2007). These interactions 
are dependent on sumoylation of the KAP1 PHD-bromodomain as they involve 
SUMO-interacting motifs (SIMs) on SETDB1 and CHD3. Uniquely, the KAP1 PHD 
domain functions as an E3 SUMO ligase that promotes the sumoylation of KAP1’s 
bromodomain (Ivanov et al., 2007). The SUMO moiety is highly related to ubiquitin; 
indeed, the process of sumoylation is analogous to that of ubiquitylation (Flotho 
and Melchior, 2013). The PHD domain of KAP1 binds to Ubc9, the E2 conjugating 
enzyme, and presumably as a consequence, the E2~SUMO thioester is oriented in 
the optimal position to transfer the SUMO moiety to lysine residues of the 
bromodomain (Ivanov et al., 2007). The PHD and bromodomain of bromodomain 
form one structural domain that behaves as a single functional unit – compromising 
the PHD-bromodomain interface reduces the ability of KAP1 to repress 
transcription (Zeng et al., 2008). Similarly, the ability of KAP1 to function as a 
transcriptional co-repressor for KRAB ZNF transcription factors is also 
compromised under the following scenarios: by mutating the sumoylation sites on 
KAP1, by jeopardizing the integrity of the PHD domain, and by inhibiting the 
sumoylation machinery (Ivanov et al., 2007). Collectively, these data emphasize 
that recruitment of SETDB1 and CHD3 by the sumoylated PHD-bromodomain is an 
integral facet of KAP1-mediated transcriptional repression (Schultz et al., 2001, 
Schultz et al., 2002, Sripathy et al., 2006, Ivanov et al., 2007, Zeng et al., 2008). 
 
Despite its role in transcriptional repression and its association with chromatin, 
KAP1 does not itself contain a DNA-binding domain and is presumably recruited to 
chromatin by its interaction partners (Iyengar and Farnham, 2011). Nevertheless, 
approximately 7000 KAP1 binding sites were identified by chromatin 
immunoprecipitation-microarray chip (ChIP-chip) analysis (O'Geen et al., 2007). 
KAP1 genomic targets can be divided into two main categories. The first category 
consists of the 3’ ends of ZNF genes, to which KAP1 is recruited via KRAB ZNF 
transcription factors in a RBCC domain-dependent manner. Although the 
recruitment of KAP1 to ZNF genes by KRAB ZNF proteins would suggest an auto-
regulatory feedback loop, depletion of KAP1 does not affect the expression of the 
majority of these genes (Iyengar et al., 2011). Yet, a role in transcriptional 
regulation for KAP1 at these genes cannot be formally excluded as stable 
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inheritance of KAP1-induced heterochromatin has been observed, suggesting that 
it may be possible for direct KAP1-mediated transcriptional repression to be 
perpetuated in the transient absence of KAP1 (Ayyanathan et al., 2003). The 
second category represents targets that KAP1 binds in a KRAB ZNF protein-
independent manner; it includes the promoter regions of ZNF genes and non-ZNF 
genes. Therefore, factors other than ZNF transcription factors contribute to the 
recruitment of KAP1 to chromatin; for instance, the KAP1-HP1 interaction is 
necessary for the efficient tethering of KAP1 to its genomic targets (Iyengar et al., 
2011). Thus, to fully comprehend the biological functions of KAP1, exhaustively 
defining the co-factors that target KAP1 to DNA will inevitably be required. 
 
In the context of the SMARCAD1-KAP1 complex, the factors influencing its 
genomic localization remain undefined. Thus, it is unknown whether SMARCAD1 
can exploit the modular architecture of KAP1 to form ternary complexes specific for 
certain regions of the genome. For example, is it possible for the SMARCAD1-
KAP1 complex to be recruited to constitutive heterochromatin by forming a ternary 
complex with HP1?  
 
1.6.2 Functions of KAP1 
KAP1 is essential for physiological development (Iyengar and Farnham, 2011). 
Indeed, KAP1 knockout mice are embryonically lethal due to a failure to undergo 
gastrulation, the process through which the blastula is reorganized into a tri-laminar 
structure primed for subsequent organogenesis (Cammas et al., 2000). 
Correspondingly, KAP1 is implicated in the maintenance of pluripotency in mouse 
ESCs, and is essential for terminal differentiation of embryonal carcinoma cells 
along the endodermal lineage (Cammas et al., 2004, Hu et al., 2009). 
 
At a mechanistic level, KAP1 is best characterized as an obligatory co-repressor for 
KRAB ZNF transcription factors (Figure 1.17). Via its RBCC domain, KAP1 
interacts as a homotrimer with the KRAB repression domain of these transcription 
factors (Friedman et al., 1996, Moosmann et al., 1996, Peng et al., 2000). 
Targeting KAP1 to euchromatic gene loci results in their transcriptional silencing 
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and conversion into heterochromatin (Ayyanathan et al., 2003). KAP1-mediated 
transcriptional repression is dependent on the recruitment of additional chromatin-
associated factors including HP1, via the KAP1 HP1-box, and the H3K9 histone 
methyl-transferase SETDB1, which contains a SIM and interacts with the 
sumoylated PHD-bromodomain of KAP1 (Schultz et al., 2002, Sripathy et al., 2006, 
Ivanov et al., 2007). These processes are highly cooperative; for instance, 
sumoylation of the KAP1 bromodomain by the adjacent PHD domain is 
compromised in a KAP1 mutant that is unable to interact with HP1. Conversely, the 
sumoylated PHD-bromodomain stimulates the histone methyl-transferase activity of 
SETDB1 in vitro (Ivanov et al., 2007). The sumoylated PHD-bromodomain of KAP1 
also recruits the chromatin remodeller, CHD3, which promotes local chromatin 
compaction (Goodarzi et al., 2011). Furthermore, since HP1 recognizes the 
H3K9me3 mark, stable genomic localization of KAP1 and spreading of the 
H3K9me3 mark may be mediated by the HP1-KAP1 interaction (Jacobs and 
Khorasanizadeh, 2002). In summary, by exploiting its modular architecture, KAP1 
simultaneously recruits several effectors of chromatin structure to the same region 
of the genome. The amalgamation of the activities of these proteins is the 
conversion of the local chromatin structure into a form recapitulating the principal 
features of heterochromatin – highly compacted chromatin associated with HP1 
and H3K9me3 – thereby ensuring robust transcriptional repression (Ayyanathan et 
al., 2003, Sripathy et al., 2006, Ivanov et al., 2007, Goodarzi et al., 2011). 
 
 
Figure 1.17 – Model of KAP1-Mediated Transcriptional Repression 
Due to its modular architecture, KAP1 is able to use its HP1-box to recruit HP1 to 
chromatin, while simultaneously using its sumoylated bromodomain to interact with the 
NuRD complex and the H3K9 methyl-transferase, SETDB1. These interactions enable 
KAP1 to convert euchromatic gene loci into transcriptionally silent, compacted 
heterochromatin containing HP1 and bearing the repressive H3K9me3 modification. The 
figure was adapted from (Ivanov et al., 2007). 
 
Aside from transcriptional repression, KAP1 is essential for ataxia telangiectasia 
mutated (ATM) kinase-dependent repair of heterochromatic DSBs (Goodarzi et al., 
2008). In response to DNA damage, ATM phosphorylates KAP1 at serine 824 (Ziv 
et al., 2006). Phosphorylation of this residue disrupts the interaction between the 
sumoylated KAP1 bromodomain and a SIM on CHD3. Dissociation of the CHD3 
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chromatin remodeller results in relaxation of the local chromatin environment, 
which is reflected in an increase in micrococcal nuclease accessibility (Goodarzi et 
al., 2011). The reduction in chromatin compaction is presumably required to render 
the region permissive to the recruitment of the DNA repair machinery (Ziv et al., 
2006, Goodarzi et al., 2008, Goodarzi et al., 2011). 
 
It is curious that KAP1 interacts with multiple chromatin remodellers – CHD3 and 
SMARCAD1. However, it is unlikely that they are functionally redundant since they 
bear little similarity to one another in terms of domain architecture and complex 
composition. Indeed, it is entirely possible that CHD3 and SMARCAD1 function 
independently of each other – KAP1 is present in considerable excess in the cell 
relative to SMARCAD1, which consequently, would only be able to interact with a 
relatively small proportion of KAP1 molecules. Functional interactions between the 
two chromatin remodellers may, therefore, be limited in scope. On this basis, it is 
also possible that the canonical role for KAP1 in KRAB ZNF protein-mediated 
transcriptional repression may be irrelevant for its function with SMARCAD1. 
Virtually nothing is known about the SMARCAD1-KAP1 interaction, much less 
about the functional interplay between the two proteins. Thus, we felt that it was 
essential to investigate the effect of KAP1 on the catalytic activity of SMARCAD1 in 
vitro, and our findings are discussed in Chapter 6. 
 
1.7 CUE Domains 
The coupling of ubiquitin conjugation to endoplasmic reticulum degradation (CUE) 
domain earned its unusual epithet from the protein in which it as initially identified, 
the S. cerevisiae Cue1p protein, which recruits the ubiquitin E2 ligase, Ubc7p, to 
the endoplasmic reticulum membrane to promote proteasomal degradation 
(Biederer et al., 1997). A small protein motif of approximately 40 amino acids, the 
CUE domain is moderately well conserved across eukaryotes ranging from fungi to 
metazoans (Ponting, 2000). CUE domains adopt a globular configuration 
comprised of a bundle of three anti-parallel α-helices, and generally act as 
ubiquitin-binding domains (UBDs) (Shih et al., 2003, Hicke et al., 2005). 
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1.7.1 CUE Domains are Ubiquitin-Binding Domains 
Ubiquitin is a small, stable protein of 76 residues that displays high evolutionary 
conservation – aside for three conservative amino acid substitutions, its sequence 
is invariant between yeast and man (Komander and Rape, 2012). Ubiquitin 
assumes a compact β-grasp fold, consisting of a mixed five-strand β-sheet covered 
by an α-helix, with an exposed C-terminus (Vijay-Kumar et al., 1987). Ubiquitylation 
is a post-translational modification that involves the covalent linkage of the C-
terminus of ubiquitin to the ε-amino group of a lysine residue via an isopeptide 
linkage. Uniquely, conjugated ubiquitin moieties can themselves be modified, for 
example, by further ubiquitylation at any of its six lysine residues. While numerous 
arrangements of ubiquitin chains have been described, the two canonical forms 
involve either lysine 48 or lysine 63 linkages, with the former displaying a compact 
conformation and the latter an open one (Komander and Rape, 2012). Although 
ubiquitylation was initially regarded as the PTM that targets proteins for 
proteasomal degradation, it is now undisputable that ubiquitylation is also intimately 
implicated as a signalling device in a diverse range of biological processes, ranging 
from transcriptional regulation to immunity (Husnjak and Dikic, 2012). 
 
For ubiquitylation to regulate cellular processes, it is necessary that the ubiquitin 
moiety can be recognized. Indeed, cells have evolved a diverse set of UBDs, most 
of which bind to a large hydrophobic patch on the surface of the ubiquitin moiety, 
centred on the leucine 8, isoleucine 44 and valine 70 residues (Husnjak and Dikic, 
2012). This is true of CUE domains, which contact ubiquitin using an interface 
formed from two of its helices (α1 and α3). Specifically, the interaction interface of 
the CUE domain features a hydrophobic patch complementary to the L8-I44-V70 
hydrophobic patch of ubiquitin (Figure 1.18). The ubiquitin-CUE domain interaction 
is further stabilized by electrostatic contacts along the rim of the interaction 
interface (Kang et al., 2003, Prag et al., 2003, Liu et al., 2012). Multiple-sequence 
alignment of CUE domains defines two highly conserved elements – a methionine-
phenylalanine-proline (MFP) motif in the loop between α1 and α2 helices, and a di-
leucine repeat at the C-terminal end of the α3 helix (Ponting, 2000, Prag et al., 
2003). Many of these conserved residues contribute significantly to establishing the 
hydrophobic character of the CUE domain interaction interface, explaining the 
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correlation between their presence and high affinity ubiquitin binding (Kang et al., 
2003, Prag et al., 2003, Shih et al., 2003, Liu et al., 2012). The phenylalanine 
residue of the MFP motif also stabilizes the hydrophobic core of the CUE domain; 
therefore, substitution of phenylalanine with an alanine residue in the first CUE 
domain of the CUE2 protein or in the gp78 CUE domain disrupts protein folding 
(Kang et al., 2003, Liu et al., 2012). 
 
The interaction interface between the CUE domain and ubiquitin is limited, only 
spanning an area of approximately 400Å2. Consequently, even with fully intact MFP 
and LL motifs, CUE domains typically recognize ubiquitin with only modest affinity 
(Kang et al., 2003, Prag et al., 2003, Liu et al., 2012). Yet, CUE domains vary 
considerably in their affinity for ubiquitin, with dissociation constants ranging from 
approximately 20 to 160µM (Shih et al., 2003). Some of this variation could be 
explained by the ability of some CUE domains to function as a dimer to bind 
ubiquitin with higher affinity. For instance, as a dimer, the CUE domain of the yeast 
Vps9p protein is able to form additional contacts between ubiquitin and the typically 
unutilized α2 helix of the CUE domain (Prag et al., 2003). 
 
As indicated by the dissociation constants listed above, the ubiquitin-UBD 
interaction is typically weak. The biological significance of this phenomenon is 
unclear; however, it is speculated that the relatively low affinity is enables binding 
to be rapidly reversed, as befitting the role of ubiquitin as a broadly applicable 
regulatory mechanism. It is also plausible that ubiquitin-UBD interactions are weak 
to accommodate high cellular concentrations of free ubiquitin, which in mammalian 
cells, is estimated to be approximately 10µM. If free ubiquitin were to interact with 
UBDs with high affinity, UBDs may be irreversibly occupied by ubiquitin, precluding 
their interaction with ubiquitylated partner proteins (Hicke et al., 2005). Importantly, 
ubiquitin-binding domains also serve merely as secondary interaction domains 
ensuring specificity, strengthening an otherwise weak interaction between two 
proteins, so that the ubiquitylated version can be strongly selected for interaction. 
 
 
Figure 1.18 – Structure of the First CUE Domain of Cue2p Bound to Ubiquitin 
A. In this structure, ubiquitin is coloured in green and the first CUE domain of the Cue2p 
protein in violet. Two helices (α1 and α3) form a hydrophobic surface that packs against 
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the hydrophobic patch centred upon the L8-I44-V70 residues of ubiquitin. This structure 
was retrieved from the PDB as 1OTR. 
B. The interaction interface between the CUE domain and ubiquitin is shown here. The 
side chains of residues that contribute to the interaction are depicted here in stick 
representation, and important ubiquitin residues are labelled. This image was taken from 
(Kang et al., 2003). 
 
Aside for ubiquitin, the only other known ligand for CUE domains is the ubiquitin-
homology (UbH) domain. UbH domains are integral protein domains that adopt the 
β-grasp ubiquitin superfold conformation. As UbH domains bear structural 
resemblance to ubiquitin, they are frequently capable of interacting with UBDs, 
including CUE domains (Grabbe and Dikic, 2009). For example, Def1, a budding 
yeast protein that functions as a bridging factor, exploits a UbH-CUE domain 
interaction to recruit the Elongin-Cullin (Ela1-Elc1) E3 ubiquitin ligase complex to 
RNAPII via the Def1 CUE domain and an UbH domain in Ela1. While the UbH-CUE 
domain interaction probably involves the hydrophobic patches of both domains, 
specificity is probably conferred by additional contacts as only the Def1 CUE 
domain, but not several other UBDs tested, was able to enrich for the Elongin-
Cullin complex from yeast extracts (Wilson et al., 2013). 
 
1.8 Aims of this Thesis 
Although important roles in development have been described for CHD1 and CHD5, 
a cogent mechanistic explanation for these functions has yet to be offered. We 
hypothesized that like the BAF complex, CHD1 and CHD5 associate with hitherto 
unidentified tissue-specific complex subunits, which confer upon them the ability to 
regulate developmental processes. Thus, I sought to purify endogenous CHD1 
from mouse ESCs to identify complex subunits or interactors that are specific to the 
pluripotent cell state by mass spectrometry. Likewise, I aimed to purify the native 
CHD5 chromatin remodelling complex from mouse brains such as to determine its 
complex composition. Though no novel tissue-specific complex subunits were 
identified from detailed mass spectrometry analysis, the purification of CHD1 and 
CHD5 are described in Chapters 3 and 4 respectively.  
 
Due to the largely negative results associated with the characterization of these 
scarce CHD proteins, the remainder of this thesis focuses upon our biochemical 
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characterization of the poorly studied chromatin remodeller, SMARCAD1, which is 
implicated in the maintenance of heterochromatin and double-stranded DNA break 
repair. To better understand the regulation of this enzyme, we focussed upon the 
interplay between SMARCAD1 and KAP1, between which a constitutive 
stoichiometric protein complex is formed. First, we wanted to determine whether 
KAP1 affects the catalytic activity of SMARCAD1 in vitro. Following reconstitution 
of the SMARCAD1-KAP1 complex with purified recombinant proteins, we were able 
to demonstrate that KAP1 acts as a negative regulator of the nucleosome-
stimulated ATPase activity of SMARCAD1, as discussed in Chapter 6. Next, we 
sought to characterize the SMARCAD1-KAP1 interaction by identifying the regions 
of each protein involved, and by determining the nature of the interaction. Thus, 
Chapter 7 pertains to our findings that the interaction is a direct protein-protein 
interaction that involves the first SMARCAD1 CUE domain and the RBCC domain 
of KAP1, but does not require ubiquitylation of KAP1. As a ubiquitin-homology 
domain cannot be identified within KAP1, an attempt to determine the co-crystal 
structure of the SMARCAD1-KAP1 interaction interface is also described. 
 
Chapter 2. Materials and Methods 
 
75 
 
Chapter 2. Materials & Methods 
2.1 Buffers, Media and Solutions 
2.1.1 Bacterial Media 
2.1.1.1 Lysogeny Broth (LB), pH 7.0 
1% (w/v) bacto-tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
± 100µg/mL ampicillin (in 50% (v/v) ethanol) 
± 50µg/mL kanamycin 
± 50µg/mL spectinomycin 
± 100µg/mL streptomycin 
± 34µg/mL chloramphenicol (in ethanol) 
LB was prepared by the Media & Cell Services core facility (LRI). 
 
2.1.1.2 NZY Broth, pH 7.0 
10mg/mL yeast extract 
5mg/mL NaCl 
2mg/mL glucose 
16mg/mL NZ-Amine A 
 
2.1.1.3 SOC Media, pH 7.0 
2% (w/v) bacto-tryptone 
0.5% (w/v) yeast extract 
10mM NaCl 
2.5mM KCl 
10mM MgCl2 
10mM MgSO4 
20mM glucose 
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2.1.2 Mammalian Tissue Culture Media 
2.1.2.1 Dulbecco’s Modified Eagle’s Medium (DMEM) 
DMEM was obtained from Gibco® (Thermo Fisher Scientific) and supplemented 
with 10% (v/v) foetal bovine serum (labtech.com) and penicillin 
(20U/mL)/streptomycin (100µg/mL), supplied as a 100X stock solution (Sigma). 
 
2.1.2.2 ESC Medium 
DMEM supplemented with the following components: 
2.4mM L-glutamine 
15% (v/v) foetal bovine serum 
50µM β-mercaptoethanol (β-ME) 
10ng/mL leukaemia inhibitory factor (LIF) 
 
2.1.2.3 Freezing Medium 
DMEM supplemented with the following components: 
20% (v/v) foetal bovine serum 
10% (v/v) DMSO 
 
2.1.2.4 Opti-MEM Reduced Serum Medium 
Obtained from Gibco® (Thermo Fisher Scientific) 
 
2.1.2.5 Trypsin/EDTA Solution, pH 7.0-7.6 
0.5g/L trypsin 
0.2g/L EDTA 
Phenol red 
Obtained from Sigma-Aldrich 
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2.1.3 General Solutions 
2.1.3.1 1X SDS-PAGE Loading Buffer 
7.5% (v/v) glycerol 
70mM Tris pH 6.8 
0.25% (w/v) SDS 
0.125M Dithiothreitol (DTT) 
Bromophenol blue 
 
2.1.3.2 4-6X SDS-PAGE Loading Buffer 
30% (v/v) glycerol 
0.28M Tris pH 6.8 
1% (w/v) SDS 
0.5M DTT 
Bromophenol blue 
 
2.1.3.3 6X DNA Loading Buffer 
60% (v/v) glycerol 
10mM Tris pH 7.5 
60mM EDTA 
0.25% (w/v) Orange G 
 
2.1.3.4  100X Protease Inhibitor Cocktail (in Ethanol) 
28.4µg/ml leupeptin 
137µg/ml pepstatin A 
17mg/ml phenylmethylsulfonyl fluoride (PMSF) 
33mg/ml benzamindine 
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2.1.3.5 Lysozyme Reconstitution Buffer 
10mM Tris, pH 7.50 
10% (v/v) glycerol 
 
2.1.3.6  Phosphate Buffered Saline (PBS), pH 7.50 
137mM NaCl 
2.7mM KCl 
10mM Na2HPO4 
2mM NaH2PO4 
PBS was prepared by the Media & Cell Services core facility (LRI). 
 
2.1.3.7  PBS-Tween 
137mM NaCl 
2.7mM KCl 
10mM Na2HPO4 
2mM NaH2PO4 
0.05% (v/v) Tween 20 
 
2.1.3.8  SDS-PAGE Running Buffer 
SDS-PAGE running buffer was prepared by dilution of 20X XT MOPS or MES 
Running Buffer stock solutions (Bio-Rad). 
 
2.1.3.9 TBS-Tween 
20mM Tris pH7.50 at room temperature (RT) 
100mM NaCl 
0.1% (v/v) Tween 20 
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2.1.3.10  Tris-Borate-EDTA (TBE) Buffer 
89mM Tris-Cl 
89mM boric Acid 
2mM EDTA 
1X TBE was prepared by dilution of a 10X stock buffer. 
 
2.1.3.11 Trypsin Reconstitution Buffer 
50mM acetic acid 
10% (v/v) glycerol 
 
2.1.3.12  Transfer Buffer 
25mM Tris-base 
192mM glycine 
20% (v/v) methanol 
0.02% (v/v) SDS 
 
2.1.3.13  Triton Lysis Buffer, pH 7.50 
50mM Tris 
150mM NaCl 
1mM EDTA 
1% (v/v) Triton X-100 
 
2.1.4 Mammalian Purification Buffers 
2.1.4.1 WCE-150 Buffer, pH 7.90 at 4° 
20mM Hepes 
150mM NaCl 
1mM EDTA 
0.5% (v/v) NP-40 
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2.1.4.2 B-100 Buffer, pH 7.90 at 4°C 
10mM Hepes 
10mM sodium phosphate 
100mM NaCl 
 
2.1.4.3 R-150N Buffer, pH 7.80 at 4°C 
50mM Tris 
150mM NaCl 
1mM EDTA 
10µM ZnCl2 
RG-150N buffer also has 40% (v/v) propylene glycol 
 
2.1.4.4 R-500Am Buffer, pH 7.80 at 4°C 
50mM Tris 
500mM (NH)2SO4 
1mM EDTA 
10µM ZnCl2 
RG-150N buffer also has 40% (v/v) propylene glycol 
 
2.1.4.5 CHD-150 Buffer, pH 7.50 at 4°C 
50mM Tris 
150mM NaCl 
10% (v/v) glycerol 
10mM EDTA 
1mM DTT 
 
2.1.4.6 CHD-750 Buffer, pH 7.50 at 4°C 
50mM Tris 
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750mM NaCl 
10% (v/v) glycerol 
10mM EDTA 
1mM DTT 
 
2.1.4.7 CHD-50 Buffer, pH 7.50 at 4°C 
50mM Tris 
50mM NaCl 
10% (v/v) glycerol 
10mM EDTA 
1mM DTT 
 
2.1.4.8 TEV Buffer, pH 8.00 at 4°C 
50mM Tris 
100mM NaCl 
10% (v/v) glycerol 
1mM sodium citrate 
1mM DTT 
0.01% (v/v) NP-40 
 
2.1.4.9 CL-50 Buffer, pH7.9.0 at 4°C 
20mM Hepes 
50mM NaCl 
10% (v/v) glycerol 
2mM MgCl2 
1mM DTT 
0.01% (v/v) NP-40 
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2.1.4.10  C-100 Buffer, pH7.9.0 at 4°C 
50mM Hepes 
100mM NaCl 
10% (v/v) glycerol 
1mM DTT 
0.01% (v/v) NP-40 
C-100Ca also contains 2mM CaCl2 
 
2.1.4.11  C-750 Buffer, pH7.9.0 at 4°C 
50mM Hepes 
750mM NaCl 
10% (v/v) glycerol 
10mM EDTA 
1mM DTT 
0.01% (v/v) NP-40 
 
2.1.4.12  C-50 Buffer, pH7.9.0 at 4°C 
50mM Hepes 
50mM NaCl 
10% (v/v) glycerol 
10mM EDTA 
1mM DTT 
0.01% (v/v) NP-40 
 
2.1.4.13 C-2000 Buffer, pH7.9.0 at 4°C 
50mM Hepes 
2M NaCl 
10% (v/v) glycerol 
10mM EDTA 
Chapter 2. Materials and Methods 
 
83 
 
1mM DTT 
0.01% (v/v) NP-40 
 
2.1.5 Bacterial Purification Buffers 
2.1.5.1 HL-500 Buffer, pH 7.90 at 4°C 
20mM Tris 
500mM NaCl 
10mM imidazole 
10% (v/v) glycerol 
0.1% (v/v) NP-40 
5mM β-ME 
HL-500Zn also contains 50µM ZnSO4 
 
2.1.5.2 HW-750 Buffer, pH 7.90 at 4°C 
20mM Tris 
750mM NaCl 
10mM imidazole 
10% (v/v) glycerol 
5mM β-ME 
HW-750Zn also contains 50µM ZnSO4 
 
2.1.5.3 HW-100 Buffer, pH 7.90 at 4°C 
20mM Tris 
100mM NaCl 
10mM imidazole 
10% (v/v) glycerol 
5mM β-ME 
HW-100Zn also contains 50µM ZnSO4 
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2.1.5.4 HE-300 Buffer, pH 7.90 at 4°C 
20mM Tris 
100mM NaCl 
300mM imidazole 
10% (v/v) glycerol 
5mM β-ME 
HE-300Zn also contains 50µM ZnSO4 
 
2.1.5.5 P-50 Buffer, pH 7.50 at 4°C 
10mM sodium phosphate 
50mM NaCl 
10% (v/v) glycerol 
5mM β-ME 
 
2.1.5.6 P-100 Buffer, pH 7.50 at 4°C 
10mM sodium phosphate 
100mM NaCl 
10% (v/v) glycerol 
5mM β-ME 
P-100Zn also contains 50µM ZnSO4 
 
2.1.5.7 P-1000 Buffer, pH 7.50 at 4°C 
10mM sodium phosphate 
1M NaCl 
10% (v/v) glycerol 
5mM β-ME 
P-1000Zn also contains 50µM ZnSO4 
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2.1.5.8 Q-100 Buffer, pH 7.90 at 4°C 
10mM Tris 
100mM NaCl 
10% (v/v) glycerol 
5mM β-ME 
Q-100Zn also contains 50µM ZnSO4 
 
2.1.5.9 Q-1000 Buffer, pH 7.90 at 4°C 
10mM Tris 
1M NaCl 
10% (v/v) glycerol 
5mM β-ME 
Q-1000Zn also contains 50µM ZnSO4 
 
2.1.5.10  HL-200Zn Buffer, pH 7.90 at 4°C 
20mM Tris 
200mM NaCl 
10mM imidazole 
10% (v/v) glycerol 
0.1% (v/v) NP-40 
5mM β-ME 
50µM ZnSO4 
 
2.1.5.11  HW-200Zn Buffer, pH 7.90 at 4°C 
20mM Tris 
200mM NaCl 
10mM imidazole 
10% (v/v) glycerol 
5mM β-ME 
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50µM ZnSO4 
 
2.1.5.12 GF-150Zn Buffer, pH 7.90 at 4°C 
10mM Tris 
150mM NaCl 
50µM ZnSO4 
2mM DTT 
 
2.1.5.13 Ulp1 Lysis Buffer, pH 7.90 at 4°C 
20mM Tris 
500mM NaCl 
10mM imidazole 
5mM β-ME 
 
2.1.5.14  Ulp1 Wash Buffer 1, pH 7.90 at 4°C 
20mM Tris 
750mM NaCl 
20mM imidazole 
5mM β-ME 
 
2.1.5.15  Ulp1 Wash Buffer 2, pH 7.90 at 4°C 
20mM Tris 
500mM NaCl 
20mM imidazole 
5mM β-ME 
 
2.1.5.16  Ulp1 Elution Buffer, pH 7.90 at 4°C 
20mM Tris 
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500mM NaCl 
200mM imidazole 
5mM β-ME 
 
2.1.5.17  Ulp1 GF Buffer, pH 7.90 at 4°C 
25mM Tris 
500mM NaCl 
 
2.1.5.18  GST-L Buffer, pH 7.90 at 4°C 
20mM Tris 
100mM NaCl 
1mM EDTA 
10% (v/v) glycerol 
0.1% (v/v) NP-40 
 
2.1.5.19  GST-W500 Buffer, pH 7.90 at 4°C 
10mM Tris 
500mM NaCl 
10% (v/v) glycerol 
5mM β-ME 
 
2.1.5.20  GST-W50 Buffer, pH 7.90 at 4°C 
10mM Tris 
50mM NaCl 
10% (v/v) glycerol 
5mM β-ME 
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2.1.5.21  GST-100 Buffer, pH 7.90 at 4°C 
10mM Tris 
100mM NaCl 
10% (v/v) glycerol 
5mM β-ME 
 
2.1.5.22  STE Buffer 
10mM Tris, pH 8.0 
1mM EDTA 
100mM NaCl 
 
2.1.5.23  MD Wash Buffer 1 
1X PBS 
450mM NaCl 
10% (v/v) glycerol 
0.1mM EDTA 
0.1% (v/v) Triton™ X-100 
2mM DTT 
 
2.1.5.24  MD Wash Buffer 2 
50mM sodium phosphate 
50mM NaCl 
10% (v/v) glycerol 
1mM β-ME 
0.2% (v/v) Triton™ X-100 
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2.1.6 Biochemical Assay Buffers 
2.1.6.1 5X SK Reconstitution Buffer, pH7.50 at RT 
50mM sodium phosphate 
1M NaCl 
50% (v/v) glycerol 
0.5% (v/v) NP-40 
 
2.1.6.2 P-200 GF Buffer, pH7.50 at 4°C 
10mM sodium phosphate 
200mM NaCl 
2mM DTT 
 
2.1.6.3 5X ATPase Buffer 
50mM Tris pH7.90 
0.5mM MgCl2 
2.5mM DTT 
0.4mg/mL BSA 
 
2.1.6.4 TLC Running Buffer 
1M formic acid 
0.3M LiCl 
 
2.1.6.5 5X SK Binding Buffer 
50mM Tris, pH7.50 at RT 
750mM NaCl 
50% (v/v) glycerol 
0.05% (v/v) NP-40 
250µM ZnSO4 
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2.1.6.6 SK-200 Buffer 
10mM Tris, pH7.50 at RT 
200mM NaCl 
10% (v/v) glycerol 
0.01% (v/v) NP-40 
50µM ZnSO4 
 
2.1.6.7 GST-L-Zn Buffer, pH7.90 at 4°C 
20mM Tris 
100mM NaCl 
10% (v/v) glycerol 
0.1% (v/v) NP-40 
50µM ZnSO4 
5mM β-ME 
 
2.1.6.8 10X Trypsin Buffer 
200mM Tris, pH 7.40 
500mM NaCl 
10mM CaCl2 
20mM DTT 
 
2.2 DNA Techniques 
2.2.1 Plasmids 
Plasmid Description Cloning Sites 
Selection 
Markers Source 
p601 Widom 601 sequence in a pBluescript vector Unknown Amp DM 
pCDF-Duet1 Bacterial expression vector for coexpression of 2 ORFs N/A Strep/Spec Novagen 
pCDF-Duet1-
SUMO 
Smt3 (SUMO) cloned into pCDF-Duet1; 
enhances solubility of recombinant proteins; 
untagged 
NcoI & 
BamHI Strep/Spec PL 
pCDF-SUMO-
KAP1 S33-K434 
KAP1 S33-K434 cloned into pCDF-Duet1-
SUMO 
BamHI & 
KpnI Strep/Spec ML 
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pCDF-SUMO-
KAP1 D202-K434 
KAP1 D202-K434 cloned into pCDF-Duet1-
SUMO 
BamHI & 
KpnI Strep/Spec ML 
pcDNA4/TO 
Mammalian expression vector driven by the 
CMV promoter; for doxycycline inducible 
protein expression, using the T-REx system 
N/A Amp Invitrogen 
pSMARCAD1-
716R/TO 
SMARCAD1 cDNA with N-terminal FLAG tag 
cloned into pcDNA4/TO; resistant to shRNA 
knockdown by pGIPZ V2LHS-51716 
BamHI & 
XhoI Amp HW 
pSMARCAD1-
716R-
CUE1mt,2mt/TO 
Derivative of pSMARCAD1-716R/TO; both 
CUE domains are point mutated (F169A, 
P170A, L195A, L196A, F263A, P264A, 
L289A, K290A) 
BamHI & 
XhoI Amp HW 
pcDNA5/FRT 
Mammalian expression vector driven by the 
CMV promoter; allows establishment of stable 
cell lines with Flp-In system 
N/A Amp Invitrogen 
pcDNA5-FTH/FRT Derivative of pcDNA5/FRT that adds C-terminal FLAG-TEV-HA (FTH) tag 
Kpn1 & 
BamHI Amp ML 
pCHD1-FTH/FRT CHD1 cDNA cloned into pcDNA5-FTH/FRT; C-terminal FTH tag 
HindIII & 
KpnI Amp ML 
pCHD5-FTH/FRT CHD5 cDNA cloned into pcDNA5-FTH/FRT; C-terminal FTH tag 
HindIII & 
KpnI Amp ML 
pHTF-cDNA5/FRT Derivative of pcDNA5/FRT that adds N-terminal HA-TEV-FLAG (HTF) tag 
HindIII & 
KpnI Amp ML 
pHTF-CHD5/FRT CHD5 cDNA cloned into pHTF-cDNA5/FRT; N-terminal HTF tag KpnI & NotI Amp ML 
pKAP1-HA/FRT KAP1 cDNA with C-terminal HA tag cloned into pcDNA5/FRT 
NheI & 
HindIII Amp ML 
pKAP1-
10×UbMt/FRT 
Derivative of pKAP1-HA/FRT; 10 
ubiquitylation sites (lysines) mutated to 
arginine residues 
PasI & KasI Amp ML 
pF-
SMARCAD1/FRT 
SMARCAD1 cDNA with N-terminal FLAG tag 
cloned into pcDNA5/FRT 
BamHI & 
XhoI Amp HW 
pF-SMARCAD1-
CUE1mt,2/FRT 
Derivative of pSMARCAD1-F/FTH; 1st CUE 
domain is point mutated (F169A, P170A, 
L195A, L196A) 
BamHI & 
XhoI Amp HW 
pF-SMARCAD1-
CUE1,2mt/FRT 
Derivative of pSMARCAD1-F/FTH; 2nd CUE 
domain is point mutated (F263A, P264A, 
L289A, K290A) 
BamHI & 
XhoI Amp HW 
pF-SMARCAD1-
CUE1mt,2mt/FRT 
Derivative of pSMARCAD1-F/FTH; both CUE 
domains are point mutated (F169A, P170A, 
L195A, L196A, F263A, P264A, L289A, 
K290A) 
BamHI & 
XhoI Amp HW 
pIRES-puro Mammalian expression vector driven by the CMV promoter N/A Amp Clontech 
pMCS-IRES-puro Derivative of pIRES-puro with expanded multiple cloning site 
EcoRV & 
NotI Amp ML 
pCHD5F-IRES-
puro 
CHD5 cDNA with C-terminal FLAG tag cloned 
into pIRES-puro 
NotI & 
EcoRI Amp ML 
pKIAA1045HA-
IRES-puro 
KIAA1045 cDNA with C-terminal HA tag 
cloned into pIRES-puro 
NotI & 
EcoRI Amp ML 
pET21b Bacterial expression vector; C-terminal 6×His tag; NdeI (CATATG) in MCS  N/A Amp Novagen 
pET21b-KAP1 
S33-K434 
Untagged KAP1 S33-K434 cloned into 
pET21b 
NdeI & 
EcoRI Amp ML 
pET21b-KAP1 
D202-K434 
Untagged KAP1 D202-K434 cloned into 
pET21b 
NdeI & 
EcoRI Amp ML 
pET28a Bacterial expression vector; N-terminal 6×His tag N/A Kan Novagen 
pET28a-SUMO 
Smt3 (SUMO) cloned into pET28a; enhances 
solubility of recombinant proteins; N-terminal 
6×His tag 
NheI & 
BamHI Kan PC 
pET28a-SUMO-F-
Fun30 
Fun30 cDNA with N-terminal FLAG tag 
cloned into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
Fun30-CUEmt 
Derivative of pET28a-SUMO-F-Fun30; CUE 
domain is point mutated (F82A, P83A) 
BamHI & 
EcoRI Kan ML 
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pET28a-SUMO-
KAP1 KAP1 cDNA cloned into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
KAP1-HA 
KAP1 cDNA with C-terminal FLAG tag cloned 
into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
HA-KAP1 
KAP1 cDNA with N-terminal FLAG tag cloned 
into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
HA-KAP1 RBCC 
KAP1 1-388 with N-terminal HA tag cloned 
into pET28s-SUMO vector 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
HA-KAP1 ΔRBCC 
KAP1 389-835 with N-terminal HA tag cloned 
into pET28s-SUMO vector 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
HA-KAP1 PB 
KAP1 624-835 with N-terminal HA tag cloned 
into pET28s-SUMO vector 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
HA-KAP1 ΔPB 
KAP1 1-623 with N-terminal HA tag cloned 
into pET28s-SUMO vector 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
HA-KAP1 HP1 
KAP1 389-623 with N-terminal HA tag cloned 
into pET28s-SUMO vector 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
KAP1 S33-K434 
KAP1 S33-K434 cloned into pET28a-SUMO 
vector; soluble but purified protein sticks to 
spin concentrator 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
KAP1 D202-K434 
KAP1 D202-K434 cloned into pET28a-SUMO 
vector; insoluble 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
KAP1 L592-P835 
KAP1 L592-P835 (PHD-bromodomain) 
cloned into pET28a-SUMO vector 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
SMARCAD1 
SMARCAD1 cDNA cloned into pET28a-
SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
SMARCAD1-F 
SMARCAD1 cDNA with C-terminal FLAG tag 
cloned into pET28a-SUMO; FLAG tag 
inaccessible to M2 agarose 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
SMARCAD1 
SMARCAD1 cDNA with N-terminal FLAG tag 
cloned into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
SMARCAD1 
K528A 
Derivative of pET28a-SUMO-F-SMARCAD1; 
point mutation in Walker A motif (i.e. 'ATPase 
dead') 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
SMARCAD1-
CUE1mt,2 
Derivative of pET28a-SUMO-F-SMARCAD1; 
1st CUE domain is point mutated (F169A, 
P170A, L195A, L196A) 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
SMARCAD1-
CUE1,2mt 
Derivative of pET28a-SUMO-F-SMARCAD1; 
2nd CUE domain is point mutated (F263A, 
P264A, L289A, K290A) 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
SMARCAD1-
CUE1mt,2mt 
Derivative of pET28a-SUMO-F-SMARCAD1; 
both CUE domains are point mutated (F169A, 
P170A, L195A, L196A, F263A, P264A, 
L289A, K290A) 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
CUE1,2 (S95-
N347) 
S95-N347 (CUE domains) of SMARCAD1 
with N-terminal FLAG tag cloned into 
pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
CUE1mt,2 
Derivative of pET28a-SUMO-F-CUE1,2; 1st 
CUE domain is point mutated (F169A, P170A, 
L195A, L196A) 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
CUE1,2mt 
Derivative of pET28a-SUMO-F-CUE1,2; 2nd 
CUE domain is point mutated (F263A, P264A, 
L289A, K290A) 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
CUE1mt,2mt 
Derivative of pET28a-SUMO-F-CUE1,2; both 
CUE domains are point mutated (F169A, 
P170A, L195A, L196A, F263A, P264A, 
L289A, K290A) 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
CUE1,2 
Untagged CUE domains of SMARCAD1 
(S95-N347) cloned into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
CUE1 (S95-E237) 
S95-E237 (1st CUE domain) of SMARCAD1 
with N-terminal FLAG tag cloned into 
pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
CUE1mt 
Derivative of pET28a-SUMO-F-CUE1; 1st 
CUE domain is point mutatted (F169A, 
P170A, L195A, L196A) 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
CUE1 N142-R206 
N142-R206 of SMARCAD1 cloned into 
pET28a-SUMO; trypsin-resistant fragment of 
BamHI & 
EcoRI Kan ML 
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1st CUE domain 
pET28a-SUMO-
CUE1 N116-R206 
N116-R206 (1st CUE domain) of SMARCAD1 
cloned into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
CUE1 N142-E237 
N142-E237 (1st CUE domain) of SMARCAD1 
cloned into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-
CUE1 N116-E237 
N116-E237 (1st CUE domain) of SMARCAD1 
cloned into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
CUE2 (E238-
N347) 
E238-N347 (2nd CUE domain) of 
SMARCAD1 with N-terminal FLAG tag cloned 
into pET28a-SUMO 
BamHI & 
EcoRI Kan ML 
pET28a-SUMO-F-
CUE2mt 
Derivative of pET28a-SUMO-F-CUE2; 2nd 
CUE domain is point mutated (F263A, P264A, 
L289A, K290A) 
BamHI & 
EcoRI Kan ML 
pET42a Bacterial expression vector; N-terminal GST & 6×His tags; NdeI (CATATG) in MCS  N/A Kan Novagen 
pET42a-Ub Untagged Ubiquitin cDNA cloned into pET42a NdeI & EcoRI Kan ML 
pET42a-Ub I44A Derivative of pET42a-Ub; I44A mutation compromises binding 
NdeI & 
EcoRI Kan ML 
pGEX5X-TRIM28 KAP1 cDNA cloned into bacterial expression vector; N-terminal GST tag Unknown Amp 
(Liang et 
al., 2011) 
pGEX5X-TRIM28 
ΔBamHI 
Derivative of pGEX5X-TRIM28; BamHI site in 
KAP1 cDNA destroyed Unknown Amp ML 
pGEX6P1 Bacterial expression vector; N-terminal GST tag N/A Amp 
GE 
Healthcare 
pGEX6P1-KAP1 KAP1 cloned into pGEX6P1 BamHI & EcoRI Amp ML 
pGEX6P1-KAP1 
S33-K434 KAP1 S33-K434 cloned into pGEX6P1 
BamHI & 
EcoRI Amp ML 
pGEX6P1-KAP1 
D202-K434 KAP1 D202-K434 cloned into pGEX6P1 
BamHI & 
EcoRI Amp ML 
pGEX6P1-KAP1 
L592-P835 KAP1 L592-P835 cloned into pGEX6P1 
BamHI & 
EcoRI Amp ML 
pGEX6P1-
SUMO1GG 
Human SUMO1 cDNA (terminates at di-
glycine) cloned into pGEX6P1 
BamHI & 
NotI Amp ML 
pGEX6P1-
SUMO2GG 
Human SUMO2 cDNA (terminates at di-
glycine) cloned into pGEX6P1 
BamHI & 
EcoRI Amp ML 
pGEX6P1-
SUMO3GG 
Human SUMO3 cDNA (terminates at di-
glycine) cloned into pGEX6P1 
BamHI & 
EcoRI Amp ML 
pGIPZ-
SMARCAD1 
V2LHS-51716 
shRNA targeting human SMARCAD1 
(TAGTCTGGCCTACTCTATG) cloned into 
the pGIPZ lentiviral vector 
Unknown Amp Dharmacon 
pLKO shCHD5 
shRNA targeting human CHD5 
(CGTGTTCCTTTACTCCCTCTA) cloned into 
the pLKO lentiviral vector 
Unknown Amp (Egan et al., 2013) 
pLKO shCtrl A non-targeting shRNA sequence cloned into the pLKO lentiviral vector Unknown Amp 
(Egan et 
al., 2013) 
pOG44 Expresses Flp recombinase for use with Flp-In system N/A Amp Invitrogen 
pUlp1 Recombinant Ulp1 (SUMO protease) bacterial expression vector Unknown Amp PC 
pVP35 VP35 cDNA with N-terminal HA tag cloned into pcDNA3.1(-) Unknown Amp 
(Gantke et 
al., 2013) 
Table 2.1 – Plasmids Used in this Study 
In this table, thick borders demarcate groups of plasmids that share a common backbone. 
Several plasmids used in this study are commercially available, whereas others were 
generous gifts of others; the sources of all plasmids are clearly indicated. (DM = Daniel 
Maskell; HW = Hannah Williams; PC = Peter Cherepanov; PL = Paul Lesbats) 
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2.2.2 Polymerase Chain Reaction (PCR) 
For cloning, PCR was performed with the high fidelity KOD DNA polymerase in 
accordance with the manufacturer’s instructions (Toyobo). However, colony PCR 
reactions were performed using GoTaq® DNA polymerase (Promega). The primers 
were synthesized by Sigma-Aldrich. Each PCR reaction was optimized by including 
or excluding dimethyl sulfoxide (DMSO) in the reaction, and by varying the 
extension temperature using a gradient thermocycler. 
 
2.2.3 Agarose Gel Electrophoresis 
Gel electrophoresis was performed to resolve DNA by size using 0.8-2% (w/v) gels 
(depending on the expected size of the DNA fragments to be resolved), which 
contained 0.1µL/mL of SafeView (NBS Biologicals). 6X DNA loading buffer 
(2.1.3.3) was added to samples prior to electrophoresis. The gels were run in TBE 
at a constant voltage of 100V, typically for 30-45 minutes. 
 
2.2.4 DNA Purification 
DNA was purified from PCR reactions or following restriction digestion using the 
GeneJET™ PCR Purification kit (Thermo Fisher Scientific) as per the 
manufacturer’s instructions. Likewise, DNA was recovered after agarose gel 
electrophoresis using the GeneJET™ Gel Extraction kit (Thermo Fisher Scientific). 
 
2.2.5 Cloning 
Cloning was performed according to conventional protocols by ligating together 
fragments of DNA that had been previously digested with restriction enzymes. 
Typical restriction digest reactions were performed in CutSmart® buffer with High-
Fidelity® enzymes (New England Biolabs) for 3 hours at 37°C. Digested vectors 
were dephosphorylated by adding recombinant shrimp alkaline phosphatase 
(Roche) to the restriction digest reaction and incubating at 37°C for another hour. 
Digested DNA was then resolved by agarose gel electrophoresis and extracted 
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using the GeneJET™ Gel Extraction kit (Thermo Fisher Scientific). DNA ligase 
(Roche) was used to ligate the insert into the vector; the reaction was usually 
performed at room temperature for 1 hour, though it was occasionally incubated at 
16°C overnight for convenience. Ligation reactions were transformed into 
chemically competent E. coli cells and colonies were assessed by colony PCR. The 
inserts of all cloned plasmids were sequenced to confirm their identities. 
 
2.2.6 Site-Directed Mutagenesis 
For site-directed mutagenesis, PCR reactions using primers that encoded for the 
point mutations were performed. The primers were designed in such a way that the 
region of dissimilarity was flanked by regions of complementarity (of at least 10bp 
in length each). The 5’ ends of the forward and reverse primers abutted against 
each other, ensuring that the entire plasmid would be replicated, albeit in linear 
form. The PCR product was phosphorylated with T4 polynucleotide kinase (New 
England Biolabs), ligated into a circular plasmid using DNA ligase (Roche) and 
transformed into chemically competent E. coli cells. 
 
2.2.7 Sequencing 
Conventional Sanger sequencing was performed according to standard protocols 
by the Equipment Park core facility of the London Research Institute (LRI) latterly, 
The Francis Crick Institute. 
 
2.3 Protein Techniques 
2.3.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Criterion™ pre-cast 4-12% gradient polyacrylamide gels (Bio-Rad) gels were used 
to separate denatured proteins by size. Electrophoresis was conducted in 
Criterion™ gel tanks (Bio-Rad) in either MOPS or MES SDS-PAGE running buffer 
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(2.1.3.8), depending on the molecular weight range where maximal resolution was 
desired. 
 
2.3.2 InstantBlue Staining 
Following SDS-PAGE, polyacrylamide gels were immersed in InstantBlue™ 
solution (Expedion) and allowed to stain for at least 15 minutes, before being de-
stained in water, as per the manufacturer’s instructions. While InstantBlue™ stains 
proteins non-specifically, the staining intensity is nevertheless affected by the 
precise amino acid composition of a protein since the blue stain results from the 
Coomassie Brilliant Blue dye binding to basic amino acids (i.e. lysine, arginine and 
histidine) under acidic conditions. 
 
2.3.3 Silver Staining 
Silver staining of polyacrylamide gels was performed using the SilverQuest™ Silver 
Staining Kit (Invitrogen) according to the manufacturer’s instructions. Silver staining 
depends on silver ions binding to specific functional groups; thus, strong staining is 
associated with amino acids containing carboxylic acid groups (i.e. aspartic acid 
and glutamic acid), imidazoles (i.e. histidine), sulfhydryls (i.e. cysteine) and amines 
(i.e. lysine). Hence, while silver staining is extremely sensitive, it is nonetheless 
affected by amino acid composition. 
 
2.3.4 Western Blotting 
After SDS-PAGE, proteins were transferred from polyacrylamide gels to 
nitrocellulose membranes (either Hybond C or Amersham™ Protran Premium 
0.45µm nitrocellulose, GE Healthcare) using the Criterion™ Blotter apparatus (Bio-
Rad). The transfer cassette was assembled in the following arrangement: sponge, 
three pieces of Whatman® filter paper, nitrocellulose membrane, polyacrylamide 
gel, three pieces of Whatman® filter paper and sponge. The tank was filled with 
Transfer Buffer (2.1.3.12) before performing electrophoresis at a constant wattage 
of 500mAmps for 90 minutes. 
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The membrane was stained with Ponceau S solution (Sigma) to confirm efficient 
protein transfer, and to assess the equality of loading. An image of the Ponceau S-
stained membrane was acquired with a scanner. The membrane was then blocked 
in 5% (w/v) milk dissolved in PBS-Tween (2.1.3.7) for 30 minutes at room 
temperature. Proteins were detected by incubating the membranes with antibody 
solutions diluted in 5% (w/v) milk/PBS-Tween for either 1 hour at room temperature 
or overnight at 4°C. The antibody dilutions used in this study are listed in Table 2.2. 
Incubations were performed on a rocking platform to ensure that the antibody 
solution came into contact with the membrane in its entirety. Primary antibody 
solutions were reused several times; they were stored at 4°C between uses and 
were supplemented with 0.1% (w/v) sodium azide to prevent microbial 
contamination. The membrane was washed thrice in PBS-Tween, each time for 5 
minutes, before being incubated with secondary antibody, diluted 1:10000 in 5% 
(w/v) milk/PBS-Tween, for 1 hour at room temperature. The secondary antibodies 
used were as follows: sheep anti-mouse IgG HRP-linked F(ab’)2 fragments and 
donkey anti-rabbit IgG HRP-linked F(ab’)2 fragments (GE Healthcare). Following 
incubation with secondary antibody, the membranes were again washed thrice in 
PBS-Tween in 5 minutes cycles. 
 
To visualize the blots, the membrane was incubated with SuperSignal™ West 
Pico/Dura Chemiluminescent Substrate (Thermo Fisher Scientific) for 5 minutes. 
Luminescence was detected with Amersham™ Hyperfilm ECL (GE Healthcare). An 
Epson Perfection V700 Photo scanner was used to convert the data into a digital 
image, typically captured in 8-bit greyscale at a resolution of 600dpi. 
 
For quantitative comparison of Western blotting data, the Odyssey® infrared 
fluorescence system (LI-COR) was used. Thus, instead of HRP-conjugated 
secondary antibodies, secondary antibodies conjugated to dyes emitting in the 
near-infrared range were used. Specifically, the donkey anti-mouse IgG IRDye® 
680RD and goat anti-rabbit IgG IRDye® 800CW secondary antibodies (LI-COR) 
were used. Membranes were incubated with fluorescent secondary antibody 
solutions, diluted 1:5000 in 5% (w/v) milk/PBS-Tween for 1 hour at room 
temperature. After being washed thrice in PBS-Tween for 5 minutes each time, the 
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blots were visualized with an Odyssey® Infrared Imager (LI-COR). The signal from 
fluorescently labelled secondary antibodies is linear over a wider dynamic range as 
compared to standard Western blotting that relies upon a chemiluminescent 
enzymatic reaction. 
 
Epitope Clone/Product Number Supplier Antibody Type Dilution 
α-Tubulin B-5-1-2 Sigma Mouse monoclonal 1:3000 
α-Tubulin TAT-1 LRI Mouse monoclonal 1:10000 
CHD1 2F11H5 Millipore Rat monoclonal 1:100 
CHD5 ab66516 Abcam Rabbit polyclonal 1:1000 
FLAG M2, F1804 Sigma Mouse monoclonal 1:1000 
FLAG F7425 Sigma Rabbit polyclonal 1:1000 
Gata4 ab84593 Abcam Rabbit polyclonal 1:1000 
Gatad2a (p66α) ab87663 Abcam Rabbit polyclonal 1:1000 
Glyr1 ab124615 Abcam Rabbit polyclonal 1:1000 
HA 12CA5 LRI Mouse monoclonal 1:10000 
HA ab9110 Abcam Rabbit polyclonal 1:4000 
HDAC1 ab7028 Abcam Rabbit polyclonal 1:1000 
Histone H3 ab1791 Abcam Rabbit polyclonal 1:1000 
KAP1 4E1 Cell Signaling Mouse monoclonal 1:2000 
KAP1 ab10483 Abcam Rabbit polyclonal 1:1000 
KIAA1045 ab178954 Abcam Rabbit polyclonal 1:500 
MAP2 AP20, MAB3418 Millipore Mouse monoclonal 1:1000 
MTA1 ab71153 Abcam Rabbit polyclonal 1:1000 
MTA2 A300-395A Bethyl Rabbit polyclonal 1:1000 
Nanog ab80892 Abcam Rabbit polyclonal 1:1000 
NeuN A60, MAB377 Millipore Mouse monoclonal 1:1000 
Oct4 ab19857 Abcam Rabbit polyclonal 1:1000 
RBBP7 (RbAp46) ab3535 Abcam Rabbit polyclonal 1:500 
RPB1 4H8 LRI Mouse monoclonal 1:20000 
RPB1 8WG16 LRI Mouse monoclonal 1:10000 
Sbf1 ab177146 Abcam Rabbit monoclonal 1:1000 
SMARCAD1 A301-593A Bethyl Rabbit polyclonal 1:1000 
Spindlin1 ab118784 Abcam Rabbit polyclonal 1:1000 
SUMO N/A Helle Ulrich Rabbit polyclonal 1:10000 
TIF1α NB100-2596 Novus Rabbit polyclonal 1:1000 
Ubiquitin P4D1 Enzo Life Sciences Mouse monoclonal 1:1000 
Table 2.2 – Antibodies Used for Western Blotting 
The antibodies that were used in this study for Western blotting are listed here, along with 
the concentration at which they were used successfully. 
 
2.3.5 Measurement of Protein Concentration 
Protein concentrations were typically determined using the Bradford assay (Bio-
Rad Protein Assay). A defined amount of the protein sample was added to 1mL of 
Bradford assay reagent in a disposable spectrophotometer cuvette; the reaction 
was allowed to proceed for 5 minutes at room temperature. The absorbance at 
595nm was then measured with an Ultraspec™ 1100 pro spectrophotometer 
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(Amersham Biosciences). The protein concentration was then calculated based on 
a BSA standard curve. Two independent measurements were usually made for 
each sample and the average was adopted as the approximate protein 
concentration for the sample. The colorimetric change observed is the result of 
Coomassie Brilliant Blue G-250 dye binding to basic amino acid residues; thus, the 
protein concentration determined using the Bradford assay might be inaccurate, 
particularly for purified protein samples with unusual amino acid compositions.   
 
As a complementary technique, the concentration of a purified protein sample was 
also assessed by visual comparison of the sample to defined quantities of BSA on 
an InstantBlue™-stained polyacrylamide gel. Similarly, the concentration of a 
purified protein sample was sometimes also determined by measuring the 
absorbance at 280nm using a Nanodrop 2000c spectrophotometer (Thermo Fisher 
Scientific) and interpreting it with reference to the calculated extinction coefficient. 
 
2.3.6 Immunoprecipitation (IP) 
Cell extract containing 2.5mg of total protein was used for a typical 
immunoprecipitation reaction. As different samples usually had different protein 
concentrations, the reaction volumes were normalized with the addition of 
additional lysis buffer, usually to a final volume of 250-300µL. The IP reactions 
were frequently supplemented with benzonase/micrococcal nuclease and 
MgCl2/CaCl2 to final concentrations of 0.1U/µL and 2mM respectively; this step is 
designed to reduce proteins co-immunoprecipitating because of indirect 
interactions mediated by DNA. Primary antibody was then added to the extract and 
allowed to incubate at 4°C for 3 hours or overnight; typically, a ratio of 2µg of 
antibody to 1mg of total protein was used, though the efficiency with which 
individual antibodies immunoprecipitated their targets varied considerably. 15µL of 
Dynabeads® Protein A or G (Thermo Fisher Scientific), which had previously been 
equilibrated in the lysis buffer, was added to each IP reaction and allowed to 
incubate at 4°C for 1 hour. The unbound sample was then separated from the 
beads using a magnetic tube holder. The beads were then washed thrice; each 
wash step involved thorough resuspension of the beads in 500µL of lysis buffer, 
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before discarding the wash buffer with the aid of a magnetic tube holder. The 
beads were finally resuspended in 30µL of 2X SDS loading buffer and heated at 
100°C for 5 minutes to elute all bound proteins. 
 
FLAG-tagged proteins were immunoprecipitated with higher efficiency with the anti-
FLAG® M2 affinity gel (Sigma) than with free anti-FLAG antibodies. In these cases, 
15µL of pre-equilibrated M2 agarose beads per sample was added directly to the 
protein extract and allowed to incubate at 4°C for 3 hours. The beads were then 
subjected to a similarly rigorous series of wash steps; however, in this case, the 
liquid phase was separated from the beads using a Pierce™ spin column (Thermo 
Fisher Scientific). 
 
2.4 Bacterial Techniques 
2.4.1 Transformation of Chemically Competent E. coli Cells 
One Shot® Top10 competent cells (Invitrogen) were typically used for cloning and 
for plasmid propagation. XL-10 Gold ultra-competent cells (Stratagene) were used 
for cloning large plasmids. Transformations of plasmids into these cells were 
performed as per the manufacturers’ instructions. 
 
For bacterial expression of recombinant proteins, plasmids were transformed into 
either BL21-CodonPlus® (DE3)-RIL or BL21-CodonPlus® (DE3)-RP competent 
cells (Stratagene), depending on the amino acid composition of the protein to be 
expressed. Transformed cells were selected against both the resistance marker of 
the plasmid and chloramphenicol to ensure the retention of additional copies of rare 
tRNA genes. Co-expression of recombinant proteins in E. coli was achieved by 
transforming cells with two plasmids simultaneously. 
 
2.4.2 Purification of Plasmid DNA 
Plasmid DNA was generally purified from 5mL of overnight E. coli cultures using 
the GeneJET™ Plasmid Miniprep kit (Thermo Fisher Scientific) as per the 
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manufacturer’s instructions. Larger quantities of plasmid DNA were purified from 
400mL of overnight bacterial cultures using the Plasmid Maxi kit (Qiagen). 
 
2.4.3 Expression of Recombinant Proteins 
The optimal conditions for bacterial expression of each recombinant protein were 
determined empirically in small-scale induction trials comparing the induction 
temperature and duration (Table 2.3). Nevertheless, a general protocol is described 
here. Starter cultures of transformed BL21-CodonPlus® (DE3)-RIL or BL21-
CodonPlus® (DE3)-RP cells (Stratagene) were grown overnight at 37°C, in an 
incubator shaking at 180rpm, in LB (2.1.1.1) supplemented with the appropriate 
antibiotic for that plasmid and chloramphenicol. 1L cultures of LB were inoculated 
with 12mL of the overnight starter culture and cultured at 37°C, for approximately 2-
3 hours, until an optical density (OD600) of 0.6-0.8 was reached, to ensure that the 
cells were in mid-log phase. LB was supplemented with 50µM zinc sulphate for the 
expression of proteins with zinc fingers. Recombinant protein expression was 
induced by the additional of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 0.5mM. The cultures were then shifted to either 30°C or 16°C and 
cultured for an additional 3 or 6 hours respectively. The cells were harvested by 
centrifugation in a chilled centrifuge at 6000×g for 30 minutes, washed in PBS 
(2.1.3.6), and snap-frozen in liquid nitrogen. The E. coli pellets were stored at -
80°C until they were used for protein purification. In some cases, 30L cultures were 
grown in a fermenter with the assistance of the Fermentation core facility (LRI). 
 
Protein Plasmid E. coli Strain 
Induction Conditions 
[IPTG] Temperature Duration 
SMARCAD1 pET28a-SUMO-SMARCAD1 & tagged derivatives RIL 0.5mM 16°C 6 hours 
CUE1,2 
(S95-N347) 
pET28a-SUMO-CUE1,2 & 
tagged derivatives RIL 0.5mM 30°C 3 hours 
KAP1 pET28a-SUMO-KAP1 & tagged derivatives RP 0.5mM 30°C 6 hours 
KAP1 RBCC 
(S33-K434) 
pET28a-SUMO-KAP1 S33-
K434 RP 0.5mM 30°C 6 hours 
SMARCAD1 
S95-N347 + 
KAP1 S33-
K434 
pET28a-SUMO-CUE1,2 
(S95-N347) + pCDF-SUMO-
KAP1 S33-K434 
RP 0.5mM 30°C 6 hours 
Ulp1 pUlp1 RIL 0.1mM 30°C 4 hours 
Ubiquitin pGEX-Ub & derivatives; pET42a-Ub + derivatives RP 1mM 30°C 3 hours 
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Table 2.3 – Conditions Used for Bacterial Expression of Recombinant Proteins 
The conditions in this study used to express recombinant proteins in E. coli are listed in this 
table. Most of these conditions have been optimized empirically in small-scale induction 
trials comparing several induction temperatures and durations. In terms of E. coli strains, 
RIL and RP refer to BL21-CodonPlus(DE3)-RIL and BL21-CodonPlus(DE3)-RP cells 
(Stratagene) respectively. 
 
2.4.4 Preparation of Bacterial Whole Cell Lysates 
1mL of an E. coli culture was pelleted by centrifugation at 4000×g for 10 minutes. 
The supernatant was discarded and the pellet was washed once in 500µL of PBS. 
The cell pellet was then resuspended in 200µL of 1X SDS-PAGE loading buffer 
(2.1.3.1). The release of DNA from the cells results in a significant increase in 
sample viscosity. Thus, the sample was sonicated with a tip sonicator (Branson) for 
10 seconds at an amplitude of 10%, or until the viscosity of the sample was 
significantly reduced. The sample was then centrifuged at 14000rpm in a benchtop 
centrifuge (Eppendorf) for 10 minutes to obtain a denatured, bacterial whole cell 
lysate.  
 
2.5 Techniques for Mammalian Cells 
2.5.1 Standard Culturing of Mammalian Cells 
Cells were usually cultured in DMEM (2.1.2.1) as adherent monolayers in a 37°C 
incubator with 3% CO2 according to standard protocols. Cultures were split upon 
reaching approximately 80% confluency – cells were dissociated from the plate by 
brief incubation with a trypsin/EDTA solution (2.1.2.5) and a proportion of the cells 
was re-plated. To freeze cells, they were resuspended in freezing medium (2.1.2.3), 
transferred into cryogenic vials, and frozen using a freezing container that achieves 
a rate of cooling of -1°C/minute. 
 
2.5.2 Preparation of Irradiated MEF Feeder Cells 
Irradiated DR-4 MEFs were prepared by the Cell Services core facility (LRI). 12.5-
13.5 days post-coital mouse embryos were dissected from gravid females and 
washed in sterile PBS (2.1.3.6). The embryos were then cut into small pieces using 
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a sterile pair of scissors. The sample was then digested with a trypsin/EDTA 
(2.1.2.5) solution at 37°C until there were no more large pieces; this process 
usually took approximately 30 minutes, at which point foetal bovine serum was 
added to inhibit trypsin. The cells were then plated on 10cm plates – generally, 
each embryo was sufficient for 2 × 10cm plates – and cultured in DMEM (2.1.2.1) 
until confluency, upon which they were frozen (2.5.1). To support the growth of 
mouse ESCs as a layer of feeder cells, 3 × 106 MEFs were plated on a 10cm plate 
and mitotically inactivated with 4Gy of γ-irradiation. 
 
2.5.3 Culturing of Mouse ESCs 
Mouse ESCs were cultured on feeder layers of irradiated MEFs (2.5.2) in mouse 
ESC medium (2.1.2.2) in a 37°C incubator with 3% CO2. Due to the rapid 
proliferation rate of these cells, cultures were split (2.5.1) every other day. The 
culture medium was refreshed on days between splits. 
 
2.5.4 Differentiation of Mouse ESCs into Embryoid Bodies 
Mouse ESCs were induced to differentiate by switching them to suspension culture 
in the absence of leukaemia inhibitory factor (LIF). Mouse ESCs were dissociated 
from plates by incubation with a trypsin/EDTA solution (2.1.2.5). Re-plating the 
cells on fresh cell culture plates and collecting the culture medium 30 minutes later 
recovered a sample of ESCs largely depleted of MEFs, which adhere more readily 
to the plate. 1 × 107 ESCs were then transferred to each 10cm bacterial petri dish 
and cultured in ESC medium lacking LIF. The culture medium was refreshed every 
two days. As embryoid bodies are relatively delicate structures whose integrity can 
be compromised by centrifugation, the culture was transferred to a 15mL Falcon 
tube and incubated for at least 5 minutes to allow the embryoid bodies to sediment 
by gravity, permitting the medium to be removed using a pipette. Embryoid bodies 
were cultured for up to seven days; over that time period, they gradually 
transformed from cell aggregates into large cystic structures. 
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2.5.5 Neuronal Differentiation of SH-SY5Y Neuroblastoma Cells 
1 × 105 SH-SY5Y cells were seeded in each well of a 6-well plate coated with poly-
D-lysine. (To coat the plates, each well was incubated with 1.5mL of a 50mg/mL 
poly-D-lysine solution for 1 hour at room temperature, washed with 1.5mL of water 
twice, and allowed to dry for 1 hour.) The next day, the medium was replaced by 
DMEM (2.1.2.1) with only 0.5% (v/v) foetal bovine serum, but supplemented with 
1X N-2 Supplement (Gibco, Thermo Fisher Scientific) and 5µM retinoic acid 
(Sigma). As retinoic acid is a photosensitive compound, the plates were wrapped in 
aluminium foil.  The cells were allowed to differentiate for as long as 12 days, but 
features of neuronal differentiation could be observed 3 days after initiating 
differentiation.  
 
2.5.6 Calcium Phosphate Transfection 
For calcium phosphate transfection of a 15cm plate of 293T cells, 2.5mL of a 
solution containing 250mM CaCl2 and plasmids was prepared. The amount of each 
plasmid added varied; for example, optimal overexpression of CHD1 required 36µg 
of pCHD1-FTH/FRT and 18µg of pVP35, while CHD5 was overexpressed with 
36µg of pCHD5-FTH/FRT and 9µg of pVP35. The CaCl2-plasmid mixture was 
added to 2.5mL of 2X BES buffered saline (Sigma) in a drop-wise manner. While 
adding the CaCl2-plasmid mixture, bubbles were generated in the BES solution to 
promote the formation of calcium phosphate crystals. The mixture was then 
incubated at room temperature for 15 minutes, before it was added to a plate of 
293T cells that had been plated the day before. The culture medium was replaced 
the next morning to limit cell toxicity. The transfected cells were harvested 24 hours 
after transfection. This protocol can be scaled up or down depending on the 
number of plates and the size of plates to be transfected. 
 
2.5.7 Lipofectamine® 2000 Transfection 
Transfection with Lipofectamine® 2000 (Invitrogen, Thermo Fisher Scientific) was 
performed in accordance with the manufacturer’s instructions. For example, to 
transfect a 10cm plate of 293T cells, a total of 20µg o fplasmid DNA was diluted in 
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500µL of Opti-MEM® medium (2.1.2.4). Likewise, 70µL of Lipofectamine® 2000 
lipid reagent was diluted with 430µL of Opti-MEM® medium. The diluted DNA was 
added to the diluted lipid transfection reagent and the mixture was incubated at 
room temperature for 5 minutes. The mixture was then added to a 70-80% 
confluent plate of 293T cells. The culture medium was replaced the next day to 
minimize cell toxicity. 
 
2.5.8 Generation of Stable Cell Lines 
The mouse ESCs expressing tagged CHD proteins used in this study (Table 2.4) 
were generated by homologous recombination by our collaborator, Matthieu Gérard 
(IBITECS CEA Saclay, France). 
 
The Flp-In™ system (Invitrogen, Thermo Fisher Scientific) was used to generate 
293 cell lines (Table 2.4) that stably overexpressed specific proteins. Typically, a 
10cm plate of 293 Flp-In™ cells (i.e. 293 cells that contain FRT sites) were 
transfected with 18µg of pOG44, which encodes for the Flp-recombinase, and 2µg 
of a pcDNA5/FRT-derived plasmid encoding for the desired protein using the 
Lipofectamine® 2000 transfection method (2.5.7). The cells were subsequently 
selected for hygromycin resistance. Individual colonies were isolated using a 
cloning cylinder, detached from the plate using a trypsin/EDTA solution (2.1.2.5), 
and re-plated in a 48-well plate. The 293 Flp-In™ cells stably expressing either wild 
type SMARCAD1 or a version with point mutations in both CUE domains (F169A, 
P170A, L195A, L196A, F263A, P264A, L289A, K290A) were generated by Hannah 
Williams.  
 
A 293 T-REx™ cell line (Invitrogen, Thermo Fisher Scientific) that was depleted of 
endogenous SMARCAD1 by shRNA knockdown, but expressed exogenous FLAG-
tagged SMARCAD1 from a doxycycline inducible promoter was also established by 
Hannah Williams. This was achieved by transfecting 293 T-Rex cells with 
pSMARCAD1 716R/TO using Lipofectamine® 2000 (2.5.7) and selecting for 
Zeocin™ (Thermo Fisher Scientific) resistance. The pool of Zeocin™-resistant cells 
were then transduced with the V2LHS_51716 shRNA (Dharmacon) using the 
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pGIPZ™ lentiviral vector (Dharmacon), before being selected for puromycin 
resistance. Individual colonies were isolated as described above. A similar cell line 
that rescued the cells with exogenous SMARCAD1 bearing point mutations in both 
CUE domains was also generated. By titrating the doxycycline concentration, it was 
determined by quantitative Western blotting using the Odyssey® infrared 
fluorescence system (2.3.4) that exogenous SMARCAD1 was expressed at 
approximately endogenous level in the presence of 1ng/mL and 0.5ng/mL 
doxycycline in the 293 TREX F-SMARCAD1 716R and 293 TREX F-SMARCAD1 
CUE1mt,2mt 716R cell lines respectively. 
 
Cell Line Description Source 
CHD1-FTH mESCs Endogenous CHD1 locus in 46C mESCs engineered to 
contain C-terminal FLAG-TEV-HA (tag 
MG 
CHD2-FTH mESCs Endogenous CHD2 locus in 46C mESCs engineered to 
contain C-terminal FLAG-TEV-HA tag 
MG 
CHD3-FTH mESCs Endogenous CHD3 locus in 46C mESCs engineered to 
contain C-terminal FLAG-TEV-HA tag 
MG 
CHD4-FTH mESCs Endogenous CHD4 locus in 46C mESCs engineered to 
contain C-terminal FLAG-TEV-HA tag 
MG 
CHD5-FTH mESCs Endogenous CHD5 locus in 46C mESCs engineered to 
contain C-terminal FLAG-TEV-HA tag 
MG 
CHD6-FTH mESCs Endogenous CHD6 locus in 46C mESCs engineered to 
contain C-terminal FLAG-TEV-HA tag 
MG 
CHD8-FTH mESCs Endogenous CHD8 locus in 46C mESCs engineered to 
contain C-terminal FLAG-TEV-HA tag 
MG 
CHD9-FTH mESCs Endogenous CHD9 locus in 46C mESCs engineered to 
contain C-terminal FLAG-TEV-HA tag 
MG 
293 Flp-In F-SMARCAD1 C3 293 Flp-In cells stably overexpressing FLAG-tagged 
SMARCAD1; highest level of overexpression 
HW 
293 Flp-In F-SMARCAD1 C5 293 Flp-In cells stably overexpressing FLAG-tagged 
SMARCAD1 
HW 
293 Flp-In F-SMARCAD1 
CUE1mt,2mt C2 
293 Flp-In cells stably overexpressing FLAG-tagged 
SMARCAD1 that has point mutations (F169A, P170A, 
L195A, L196A, F263A, P264A, L289A, K290A) in both CUE 
domains; much lower expression that wild type cell lines 
HW 
293 Flp-In F-SMARCAD1 
CUE1mt,2mt C7 
293 Flp-In cells stably overexpressing FLAG-tagged 
SMARCAD1 that has point mutations F169A, P170A, 
L195A, L196A, F263A, P264A, L289A, K290A) in both CUE 
domains; lowest level of overexpression 
HW 
293 Flp-In HA-KAP1 293 Flp-In cells stably overexpressing HA-tagged KAP1 ML 
293 Flp-In HA-KAP1 10×Ub-mt 293 Flp-In cells stably overexpressing HA-tagged KAP1 
with K  R point mutations at 10 ubiquitylation sites 
ML 
293 T-REx F-SMARCAD1 716R 293 TREX cells depleted of endogenous SMARCAD1 
(due to stable knockdown by the V2LHS_51716 shRNA) 
that expresses FLAG-tagged SMARCAD1 from a 
doxycycline-inducible promoter 
HW 
293 T-REx F-SMARCAD1 664R 293 TREX cells depleted of endogenous SMARCAD1 
(due to stable knockdown by the V3LHS_343664 shRNA) 
that expresses FLAG-tagged SMARCAD1 from a 
doxycycline-inducible promoter 
HW 
293 T-REx F-SMARCAD1 
CUE1mt,2mt 716R 
293 TREX cells depleted of endogenous SMARCAD1 
(due to stable knockdown by the V2LHS_51716 shRNA) 
that expresses FLAG-tagged SMARCAD1 with point 
mutations in both CUE domains from a doxycycline-
ML 
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inducible promoter 
Table 2.4 – Cell Lines Generated or Used in this Study 
The cell lines used in this study are described in this table. Many of these cell lines were 
generous gifts of collaborators, most notably Matthieu Gérard (MG) and Hannah Williams 
(HW); the provenance of each cell line is clearly indicated. 
 
2.5.9 Preparation of Whole Cell Extracts 
Cell pellets were thoroughly resuspended in Triton lysis buffer (2.1.3.13) 
supplemented with 1X protease inhibitor cocktail (2.1.3.4) and allowed to incubated 
on ice for 30 minutes; a typical pellet from a 10cm plate was resuspended in 120µL 
of lysis buffer. The samples were then sonicated in a cold water bath using the 
Bioruptor® (Diagenode) for 3-5 minutes in 30s on/30s off cycles at high intensity. 
Some proteins, including CHD5, were adversely affected by sonication; hence 
when performing a Western blot for CHD5, the samples were not sonicated. The 
samples were then clarified by centrifugation at 14000rpm for 20 minutes at 4°C in 
an Eppendorf 5417R microcentrifuge. 
 
2.6 Protein Purification from Mammalian Tissues 
2.6.1 Preparation of Chromatin Extracts with Heparin 
Each mouse ESC pellet was resuspended in four times its volume of WCE-150 
buffer (2.1.4.1). Extensive cell lysis was achieved by processing the cell 
resuspension with loose and tight Dounce homogenizers, and then by passing it 
through a 21G needle thrice. The sample was then centrifuged at 45000rpm in a 
Type 45 Ti rotor (Beckman Coulter) for 1 hour. The supernatant was discarded, 
while the pellet was resuspended in B-100 buffer (2.1.4.2), using the same volume 
of B-100 buffer as WCE-150 buffer used initially. The pellet was effectively 
resuspended by sonication of the sample for 1.5 minutes in 15s on/30s off cycles at 
25% amplitude. Heparin was mixed into the sample, which was then incubated at 
4°C for 10 minutes. The amount of heparin added was based on an approximate 
DNA concentration of 2.5mg/mL extract. As extensive extraction of chromatin-
bound proteins (including CHD1) was observed with 2.5 times (w/w) the amount of 
heparin to DNA, this was the ratio typically used. Benzonase® (Millipore), RNase A 
and MgCl2 were then added to the sample to final concentrations of 200U/mL, 
Chapter 2. Materials and Methods 
 
108 
 
2mg/mL and 2mM respectively. The sample was incubated for 30 minutes before 
being spun at 45000rpm in a type 45 Ti rotor (Beckman Coulter). The supernatant 
of the second spin was the soluble chromatin extract. 
 
2.6.2 Purification of RNAPII from Mouse ESCs 
Approximately 4mL of chromatin extract (2.6.1) was mixed with 200µL of pre-
equilibrated 8WG16 beads – an equal mixture of Pierce™ Protein A and G agarose 
beads (Thermo Fisher Scientific) that was covalently coupled with the mouse 
monoclonal antibody, 8WG16, using the dimethyl pimelimidate technique – and 
incubated at 4°C for 3 hours. As a control, mouse IgG beads were similarly 
incubated with an equal amount of chromatin extract. To enhance the binding 
efficiency, the unbound samples from the initial batch-binding process were 
pumped over the resins at a flow rate of 1mL/minute. 
 
For the low stringency purification, the beads were washed twice, using 35mL of R-
150N buffer (2.1.4.3) supplemented with 0.01% (v/v) NP-40 per wash. Bound 
RNAPII was then eluted from the resin by incubation at 4°C for 30min with 200µL of 
1mg/mL CTD peptide (Peptide Chemistry core facility, LRI) dissolved in RG-150N 
buffer (2.1.4.3). This elution step was repeated 5 times in total; the final cycle was 
performed at 37°C to maximise protein elution. The high stringency purification was 
performed in a similar manner; however, the washes were performed with R-
500Am buffer (2.1.4.4) supplemented with 0.1% (v/v) NP-40, while the CTD peptide 
was dissolved in RG-500Am (2.1.4.4) buffer for elution.  
 
2.6.3 Purification of CHD1 from Mouse ESCs 
60mL of chromatin extract  (2.6.1) from (90 × 15cm plates of) mouse ESCs 
expressing C-terminally FLAG-tagged CHD1 was mixed with 500µL of pre-
equilibrated anti-FLAG® M2 affinity gel (Sigma) and incubated at 4°C for 3 hours. 
As a control, an equal amount of chromatin extract from parental 46C mouse ESCs 
was used for a parallel purification performed identically. The unbound samples 
were re-loaded over the resin by pumping at a flow rate of 1mL/minute. For the low 
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stringency purification, the columns were washed in 20mL (40CV) of CHD-150 
(2.1.4.5) buffer supplemented with 0.01% (v/v) NP-40 thrice. CHD1 was eluted 
from the resin by incubation for 30min at 4°C with 500µL of 1mg/mL FLAG peptide 
(Peptide Chemistry core facility, LRI) dissolved in CHD-150 buffer. This elution step 
was repeated 5 times in total; the final cycle was performed at 37°C to maximise 
protein elution. The fractions containing CHD1 were pooled, mixed with 60µL of 
pre-equilibrated anti-HA (3F10) affinity matrix (Roche) and allowed to incubate at 
4°C for 3 hours. The HA beads were washed in 1mL of CHD-150 buffer twice, 
before being equilibrated in TEV buffer (2.1.4.8). CHD1 was eluted from the HA 
resin by cleavage with TEV protease – the beads were incubated with 60µL of 
200µg/mL TEV protease diluted in TEV buffer for 1.5 hours at room temperature. 
The high stringency purification was performed in a comparable manner though 
different wash buffers were used – the beads were washed once with CHD-750 
buffer (2.1.4.6) supplemented with 0.01% (v/v) NP-40 and once with CHD-50 buffer 
(2.1.4.7) supplemented with 0.01% (v/v) NP-40. 
 
2.6.4 Purification of CHD5 Overexpressed in 293T Cells  
10 × 15cm plates of 293T cells were transfected using calcium phosphate with the 
pCHD5-FTH/FRT and pVP35 plasmids (2.5.6), resulting in transient 
overexpression of CHD5. As a control, CHD1 was transiently overexpressed in 
293T cells in parallel. The cell pellets were resuspended in 4X their volumes of CL-
50 buffer (2.1.4.9) supplemented with 1X protease inhibitor cocktail (2.1.3.4). The 
samples were sonicated using the tip sonicator (Branson) for 3 minutes in 15s 
on/30s off cycles at 30% amplitude, with the samples being kept cool in an ice bath 
of salt and ice during the process. Following addition of Benzonase® (Millipore) to 
a concentration of 0.1U/mL, the sample was incubated at 4°C for 30 minutes. The 
sodium chloride concentration of the sample was then raised to 750mM to extract 
proteins from chromatin. A soluble extract was then obtained by centrifugation at 
41000rpm in the SW 41 Ti rotor (Beckman Coulter) for 30 minutes at 4°C.  
 
To purify the CHD5 complex, the CHD5 extract was loaded onto a 250µL column of 
pre-equilibrated anti-FLAG® M2 affinity gel (Sigma) at a flow rate of 0.1mL/minute. 
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As a control, CHD1 was purified in parallel. The columns were washed with CHD-
750 (2.1.4.6), CHD-50 (2.1.4.7) and CHD-150 (2.1.4.5) buffers; for each wash, 
12.5mL (50CV) of buffer supplemented with 0.01% (v/v) NP-40 was pumped over 
the column at a flow rate of 2mL/minute. Elution was performed as previously 
described (2.6.3), though each elution cycle used 250µL of 1mg/mL FLAG peptide 
(Peptide Chemistry core facility, LRI) dissolved in CHD-150 buffer. 
 
2.6.5 Purification of CHD5 from Mouse Brains 
17 frozen CHD53FTH/3FTH mouse brains were ground into a fine powder using a 
ceramic mortar and pestle; to ensure that the sample remained frozen, the mortar 
was filled with liquid nitrogen during this process. The powdered brain sample was 
resuspended in C-100Ca buffer (2.1.4.10) supplemented with 1X protease inhibitor 
cocktail (2.1.3.4); 6µL of buffer was added per 1mg of mouse brains. 2000 gel units 
of micrococcal nuclease (NEB) was then added per mouse brain used; to promote 
digestion, the sample was incubated at room temperature for 30 minutes, while 
being mixed with a magnetic stir bar. The sodium chloride concentration of the 
sample was raised to 750mM, before micrococcal nuclease activity was inactivated 
by addition of EGTA to a concentration of 5mM. Soluble extract was obtained by 
centrifugation of the sample at 45000rpm in a Type 45 Ti rotor (Beckman Coulter) 
at 4°C for 30 minutes. 
 
The mouse brain extract was pumped over a 250µL column of pre-equilibrated anti-
FLAG® M2 affinity gel (Sigma) at a flow rate of 0.25mL/minute. The resin was 
washed with C-750 (2.1.4.11), C-50 (2.1.4.12) and C-100 (2.1.4.10) buffers; for 
each wash, 25mL (100CV) of buffer was pumped over the column at a flow rate of 
2mL/minute. CHD5 was eluted from the column by incubation with 300µL of 
500µg/mL FLAG peptide (Peptide Chemistry core facility, LRI) dissolved in C-100 
buffer for 30 minutes at 4°C. To maximise the elution, it was repeated again, 
though this time the sample was incubated at 37C for 30 minutes. 
 
The peak fraction was loaded onto an equilibrated Mini S™ PC 3.2/3 column 
(240µL) at a flow rate of 0.05mL/minute. The column was washed in 2CV of C-100 
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buffer, and CHD5 was eluted in a 4.8mL (20CV) salt gradient of 0-50% C-2000 
(2.1.4.13) at a flow rate of 0.2mL/minute. Alternatively, CHD5 could also be purified 
using the MAbPac SCX-10G column (Thermo Fisher Scientific). CHD5 was eluted 
from this column in a 4.8mL salt gradient of 0-100% C-2000 at a flow rate of 
0.2mL/minute. 
 
2.6.6 Tandem Liquid Chromatography-Mass Spectromety (LC-MS) Analysis 
LC-MS analysis was performed by the Protein Analysis and Proteomics core facility 
(LRI). Protein sample were submitted as gel slices, following which in-gel tryptic 
digestion and peptide extraction were performed according to standard protocols. 
Peptide mixtures were resuspended in 0.1% (v/v) TFA before separation by liquid 
chromatography. Hydrophilic protonated peptides were first concentrated on a 
trapping column before being separated on a 500mm × 75µm internal diameter 
Acclaim® Pepmap™ column (Thermo Fisher Scientific) and eluted directly onto an 
Orbitrap™ mass spectrometer (Thermo Fisher Scientific). Data-dependent 
acquisition was performed – the top 10 or 20 most abundant peptides were 
selected for MS/MS. Data analysis was subsequently performed using the 
MaxQuant bioinformatics suite. 
 
2.7 Purification of Bacterially-Expressed Recombinant 
Proteins 
2.7.1 Purification of SMARCAD1 
Expression of N-terminally FLAG-tagged SMARCAD1 was induced as previously 
described (2.4.3) in a 10L culture of E. coli transformed with the pET28a-SUMO-F-
SMARCAD1 plasmid or its derivatives. (While C-terminally FLAG-tagged 
SMARCAD1 is soluble, the C-terminal tag is inaccessible to M2 agarose.) The 
resulting cell pellet was resuspended in 60mL of HL-500 buffer (2.1.5.1) 
supplemented with 1X Protease Inhibitor cocktail (2.1.3.4). Thorough resuspension 
of such a large cell pellet by pipetting alone was frequently challenging; however, it 
was greatly assisted by the use of a loose Dounce homogenizer. The sample was 
Chapter 2. Materials and Methods 
 
112 
 
divided into three equal portions of approximately 30mL each; each portion 
sonicated using a tip sonicator with a large probe (Branson) for 2 minutes in 15s 
on/30s off cycles at 25% amplitude. During sonication, the samples were kept cool 
in an ice bath of salt and ice. The sonicated sample was subsequently spun at 
35,000 rpm in a Type 45 Ti rotor (Beckman Coulter) for 30 minutes. 
 
The supernatant was loaded through a 150mL Superloop™ (GE Healthcare) onto a 
5mL HisTrap™ HP column (GE Healthcare) at a flow rate of 1mL/minute. The 
column was washed in 10 column volumes (CV) of HW-750 buffer (2.1.5.2) at a 
flow rate of 2mL/minute. The column was then washed in HW-100 (2.1.5.3) until 
the conductivity measurement stabilized at the baseline. Elution was started with a 
30CV gradient from 0-30% of HE-300 buffer (2.1.5.4) at a flow rate of 1mL/minute 
and continued using 100% HE-300 until the A280 trace stabilized at the baseline; 
the elution was collected in 1mL fractions. SMARCAD1 tended to elute in 50mL 
across the entire gradient; however, limited resolution from contaminants was 
occasionally observed at the start of the elution, hence the use of an initial 
imidazole gradient. Fractions containing SMARCAD1 were pooled along with 5µL 
of Ulp1 (22mg/mL), before being dialyzed (12.4K MWCO) overnight at 4°C against 
2L of P-100 buffer (2.1.5.6). 
 
The dialyzed sample was loaded through a 50mL Superloop™ (GE Healthcare) 
onto a 5mL HiTrap™ Heparin HP column (GE Healthcare) at a flow rate of 
1mL/minute. A first cut with 25% P-1000 buffer at a flow rate of 1.5mL/minute until 
the A280 reading stabilized at the baseline removed a dominant contaminant 
roughly 55kDa in size. Full-length SMARCAD1 was eluted in a 10CV gradient from 
25-45% P-1000 buffer (2.1.5.7) at a flow rate of 0.8mL/minute; 1mL fractions were 
collected. The fractions were pooled conservatively since separation of the 
~100kDa contaminant from SMARCAD1 from full-length SMARCAD1 was 
inefficient. The pooled sample was dialyzed overnight at 4°C against 2L of Q-100 
buffer (2.1.5.8) for wild-type SMARCAD1 and the CUE1mt,2 mutant, and against 
2L of P-50 buffer (2.1.5.5) for the CUE1,2mt and CUE1mt,2mt mutants.  
 
While wild-type SMARCAD1 does not bind to ProSwift WCX-1S (Thermo Fisher 
Scientific), a weak cation exchange column, this is useful chromatographic step for 
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SMARCAD1 bearing point mutations in its second CUE domain, since full-length 
protein can be resolved from a ~100kDa contaminant. If applicable, sample was 
loaded through a 10mL Superloop™ (GE Healthcare) onto the ProSwift WCX-1S 
column at a flow rate of 0.5mL/minute. A 19mL elution gradient from 0-30% P-1000 
buffer at 0.5mL/minute separated full-length protein from the ~100kDa contaminant; 
500µL fractions were collected. Following conservative pooling, the sample was 
diluted in P-50 for a final NaCl concentration of approximately 100mM. 
 
The final column was ProSwift SAX-1S (Thermo Fisher Scientific), a strong anion 
exchange column, to which samples were loaded via a 10mL Superloop™ at a flow 
rate of 0.5mL/minute. A sharp, initial 2.5mL gradient of 0-10% Q-1000 buffer 
(2.1.5.9) helped removed a few contaminants; however, SMARCAD1 eluted within 
a 17.5mL gradient of 10-40% Q-1000 buffer. Pooled fractions were concentrated in 
and exchanged into P-100 buffer using a Microcon® spin concentrator (Millipore) 
with a 50K molecular weight cut-off (MWCO). 
 
2.7.2 Purification of SMARCAD1 CUE1,2 Fragment (S95-N347) 
The cell pellet from a 1L culture of E. coli expressing the CUE1,2 fragment (2.4.3) 
was resuspended in 20mL of HL-500 buffer (2.1.5.1) supplemented with 1X 
Protease Inhibitor cocktail (2.1.3.4). The sample was sonicated for 3 minutes in 15s 
on/30s off cycles, while being kept cool in an ice bath of salt and ice. To obtain a 
soluble extract, the sample was spun at 50000rpm for 30 minutes in the Type 70 Ti 
rotor (Beckman Coulter). The sample was loaded onto 3mL of pre-equilibrated Ni-
NTA agarose (Qiagen) at a flow rate of 0.5mL/minute. The column was first 
washed in 10CV of HW-750 buffer (2.1.5.2), then in 10CV of HW-100 (2.1.5.3) at a 
flow rate of 2mL/minute. The CUE domain fragment was eluted from the column 
with HE-300 buffer (2.1.5.4) into a sample volume of approximately 9mL, to which 
2.5µL of Ulp1 (56mg/mL) was added. The sample was dialyzed (12.4K MWCO) 
against 2L of Q-100 buffer (2.1.5.8) for 1.5 hours at 4°C, before the buffer was 
replaced with another 2L of Q-100 buffer and dialysis allowed to continue for 
another 1.5 hours. To deplete the SUMO tag, the dialyzed sample was loaded back 
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over the 3mL of Ni-NTA resin at a flow rate of 0.5mL/minute and the unbound flow-
through collected. 
 
The sample was then loaded using a 10mL Superloop™ (GE Healthcare) onto an 
equilibrated 1mL Mono Q® 5/50 GL column (GE Healthcare) at a flow rate of 
0.8mL/minute. The CUE domain fragment was eluted from the column within a 
30mL salt gradient of 0-30% Q-1000 (2.1.5.9), run at a flow rate of 0.8mL/min, and 
collected in 500µL fractions. The peak fractions were pooled and dialyzed overnight 
against 2L of Q-100 buffer at 4°C, before being concentrated into an approximate 
total volume of 600µL using an Amicon® Ultra-4 10K MWCO spin concentrators 
(Millipore). The protein concentration of the final sample was in the 5mg/mL range.  
 
2.7.3 Purification of KAP1 
Expression of KAP1 was induced as previously described (2.4.3) in an 8L culture of 
E. coli transformed with the pET28a-SUMO-KAP1 plasmid or a tagged version. The 
resulting cell pellet was resuspended in 60mL of HL-500Zn buffer (2.1.5.1) 
supplemented with 1X Protease Inhibitor cocktail (2.1.3.4). Soluble extract was 
prepared by sonication and centrifugation as previously described for the 
SMARCAD1 purification (2.7.1). The sample was loaded through a 150mL 
Superloop™ onto a 5mL HisTrap™ HP column at a flow rate of 1mL/minute. The 
column was washed in 10CV of HW-750Zn buffer (2.1.5.2) at a flow rate of 
2mL/minute. The column was then washed in HW-100Zn (2.1.5.3) until the 
conductivity measurement stabilized at the baseline. KAP1 was eluted from the 
column in 1mL fractions, using a 100mL imidazole gradient from 0-50% HE-300 
buffer (2.1.5.4) at a flow rate of 1mL/minute. Fractions containing KAP1 were 
pooled; following addition of 5µL of Ulp1 (22mg/mL), the sample was dialyzed 
(12.4K MWCO) overnight at 4°C against 2L of P-100Zn buffer. 
 
The dialyzed sample was loaded through a 50mL Superloop™ (GE Healthcare) 
onto a 5mL HiTrap™ Heparin HP column (GE Healthcare) at a flow rate of 
1mL/minute. KAP1 was eluted from the column with a 100mL salt gradient from 0-
50% P-1000Zn buffer (2.1.5.7), in 1mL fractions. Those containing KAP1 were 
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pooled and concentrated to a volume of approximately 4mL using an Amicon® 
Ultra-15 30K MWCO spin concentrator (Millipore). 
 
The sample was then loaded using a 10mL Superloop™ onto a 120mL HiPrep™ 
16/60 Sephacryl® S-400 HR gel filtration column (GE Healthcare) at a flow rate of 
0.3mL/minute. The column was eluted isocratically with GF-150Zn buffer (2.1.5.12) 
over 1.1CV at a flow rate of 0.3mL/minute in 1.2mL fractions. KAP1 eluted as a 
single peak, which was pooled and concentrated to approximately 1.4mL (i.e. 
9mg/mL) using an Amicon® Ultra-15 30K MWCO spin concentrator (Millipore). 
 
2.7.4 Purification of KAP1 RBCC S33-K434 
The cell pellet from a 1L culture of E. coli expressing the KAP1 S33-K434 (2.4.3) 
was resuspended in 20mL of HL-500Zn buffer (2.1.5.1) supplemented with 1X 
Protease Inhibitor cocktail (2.1.3.4). A soluble extract was prepared by sonication 
and centrifugation, as previously described for the CUE domain fragment (2.7.2). 
The sample was loaded onto 3mL of pre-equilibrated Ni-NTA agarose (Qiagen) at a 
flow rate of 0.25mL/minute. The column was first washed in 10CV of HW-750Zn 
buffer (2.1.5.2), then in 10CV of HW-100Zn (2.1.5.3) at a flow rate of 2mL/minute. 
KAP1 S33-K434 was eluted from the column with HE-300 buffer (2.1.5.4) into a 
sample volume of 9mL, to which 2.5µL of Ulp1 (56mg/mL) was added. The sample 
was dialyzed (12.4K MWCO) against 2L of Q-100Zn buffer (2.1.5.8) for 1.5 hours at 
4°C, before the buffer was replaced with another 2L of Q-100Zn buffer and dialysis 
allowed to continue for another 1.5 hours. To deplete the SUMO tag, the dialyzed 
sample was loaded back over the 3mL of Ni-NTA resin at a flow rate of 
0.25mL/minute and the unbound flow-through collected. 
 
The sample was then loaded using a 10mL Superloop™ (GE Healthcare) onto an 
equilibrated 1mL Mono Q® 5/50 GL column (GE Healthcare) at a flow rate of 
0.6mL/minute. The CUE domain fragment was eluted from the column within a 
50mL salt gradient of 0-50% Q-1000Zn (2.1.5.9), run at a flow rate of 0.5mL/min, 
and collected in 500µL fractions. The peak fractions were pooled and dialyzed 
overnight against 2L of Q-100 buffer at 4°C. The sample was not concentrated any 
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further as it sticks non-specifically to Amicon® Ultra-4 spin concentrators 
(Millipore); nevertheless, the concentration of the sample was 0.4mg/mL.  
 
2.7.5 Purification of SMARCAD1 CUE1,2 Fragment (S95-N347) in Complex 
with KAP1 S33-K434 
The cell pellet from an 8L culture of E. coli expressing SMARCAD1 S95-N347 and 
KAP1 S33-K434 (2.4.3) was resuspended in 50mL of HL-200Zn buffer (2.1.5.10) 
supplemented with 1X Protease Inhibitor cocktail (2.1.3.4). Soluble extract was 
prepared by sonication and centrifugation as previously described for the 
SMARCAD1 purification (2.7.1). The sample was loaded through a 150mL 
Superloop™ onto a 5mL HisTrap™ HP column at a flow rate of 0.8mL/minute. The 
column was first washed in 10CV of HW-200Zn buffer (2.1.5.11) at a flow rate of 
2mL/minute, then in HW-100Zn buffer until the conductivity trace stabilized at the 
baseline. The stable protein complex was eluted in a 100mL gradient of 0-100% 
HE-300Zn buffer (2.1.5.4) at a flow rate of 1mL/minute. The imidazole gradient 
separates the free CUE1,2 fragment from the complex, which elutes later in the 
gradient. The peak fractions were pooled, to which 10µL of Ulp1 (56mg/mL) was 
added. The sample was then dialyzed overnight at 4°C against 2L of Q-100Zn 
buffer (2.1.5.8). 
 
Although the sample frequently became cloudy after overnight dialysis, this was not 
because of precipitation of the complex. Nevertheless, the sample was centrifuged 
at 3900×g for 30minute and further clarified through a sterile Millex®-GP 0.22µm 
syringe filter unit. The sample was then loaded through a 50mL Superloop™ (GE 
Healthcare) onto an equilibrated 8mL Mono Q® HR 10/10 column at a flow rate of 
1mL/minute. The complex was eluted from the column in 1.5mL fractions using a 
160mL (20CV) gradient of 0-50% Q-1000Zn buffer (2.1.5.9) at a flow rate of 
1mL/minute. The peak fractions were pooled and concentrated to approximately 
4mL using an Amicon® Ultra-15 30K MWCO spin concentrator (Millipore). 
 
The sample was then loaded using a 10mL Superloop™ onto a 120mL HiLoad™ 
16/60 Superdex® 200 gel filtration column (GE Healthcare) at a flow rate of 
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0.3mL/minute. The column was eluted isocratically with GF-150Zn buffer (2.1.5.12) 
over 1.1CV at a flow rate of 0.3mL/minute in 1.2mL fractions. The stable complex 
eluted as a single peak and was separated from the free CUE1,2 fragment. The 
peak fractions were pooled and concentrated to approximately 500µL (i.e. 10-
16mg/mL) using an Amicon® Ultra-15 30K MWCO spin concentrator (Millipore). 
 
2.7.6 Purification of Ulp1 
The cell pellet from a 4L culture of E. coli expressing Ulp1 (2.4.3) was resuspended 
in 50mL of Ulp1 lysis buffer (2.1.5.13) supplemented with 1X Protease Inhibitor 
cocktail (2.1.3.4). Lysozyme (40mg/mL) dissolved in lysozyme reconstitution buffer 
was added to a final concentration of 1mg/mL. The sample became more viscous, 
suggesting cell lysis, following incubation at 4°C for 45 minutes. Soluble extract 
was prepared by sonication and centrifugation as previously described for the 
SMARCAD1 purification (2.7.1). The sample was loaded onto 5mL of pre-
equilibrated Ni-NTA agarose (Qiagen) at a flow rate of 1mL/minute. The column 
was first washed in 8CV of Ulp1 wash buffer 1 (2.1.5.14), then in 8CV of Ulp1 wash 
buffer 2 (2.1.5.15) at a flow rate of 1mL/minute. Proteins were eluted from the 
column with Ulp1 elution buffer (2.1.5.16); Ulp1 eluted in a sample volume of 
approximately 25mL. Fractions containing Ulp1 were concentrated into an 
approximate total volume of 4mL using two Amicon® Ultra-15 15K MWCO spin 
concentrators (Millipore). 
 
The sample was then loaded using a 10mL Superloop™ (GE Healthcare) onto an 
equilibrated 120mL HiLoad™ 16/60 Superdex® 200 gel filtration column (GE 
Healthcare) at a flow rate of 0.4mL/minute. The column was eluted isocratically 
with Ulp1 GF buffer (2.1.5.17) over 1.5CV at a flow rate of 0.25mL/minute in 1.5mL 
fractions. Fractions containing Ulp1 were concentrated into an approximate total 
volume of 1.6mL using two Amicon® Ultra-15 15K MWCO spin concentrators 
(Millipore). DTT and glycerol were added to final concentrations of 10mM and 10% 
(v/v) respectively. The protein concentration of the final sample was 56mg/mL.  
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2.7.7 Purification of GST-Ubiquitin Resin 
The cell pellet from a 1L culture of E. coli expressing GST-Ub (2.4.3) was 
resuspended in 20mL of GST-L buffer (2.1.5.18) supplemented with 1X Protease 
Inhibitor cocktail (2.1.3.4). Following addition of lysozyme (40mg/mL) to a final 
concentration of 1mg/mL to the sample, it was incubated at 4°C for 45 minutes, 
becoming significantly more viscous. Soluble extract was prepared by sonication 
and centrifugation as previously described for the CUE fragment purification (2.7.2). 
The sample was mixed with 3mL of pre-equilibrated Glutathione Sepharose™ 4B 
(GE Healthcare) and allowed to incubate at 4°C for at least 3 hours. The column 
was first washed in 10CV of GST-W500 buffer (2.1.5.19), then in 10CV of GST-
W50 buffer (2.1.5.20) at a flow rate of 2mL/minute. The column was finally washed 
in 10mL of GST-W100 buffer (2.1.5.21), in which it was stored at 4°C until used. 
 
2.7.8 Preparation of Multi-Dsk Resin 
Multi-Dsk resin was prepared as described in (Wilson et al., 2012). The cell pellet 
from a 1L culture of E. coli expressing GST-MultiDsk was resuspended in 40mL of 
STE buffer (2.1.5.22) supplemented with 1X Protease Inhibitor cocktail (2.1.3.4). 
Following addition of lysozyme (40mg/mL) to a final concentration of 1mg/mL to the 
sample, it was incubated at 4°C for 30 minutes. DTT and N-lauryl sarcosine were 
added to the sample to final concentrations of 5mM and 1.5% (v/v) respectively. 
The sample was kept on ice while being sonicated for 1 minute in 15s on/40s off 
cycles at 25% amplitude using a tip sonicator (Branson). The sample was spun at 
16000×g for 30 minutes; the supernatant was then further filtered through a few 
layers of gauze. After Triton™ X-100 was added to the sample to a final 
concentration of 1.5% (v/v), the sample was incubated on ice for 5 minutes. The 
sample was mixed with 2mL of pre-equilibrated Glutathione Sepharose™ 4B (GE 
Healthcare) and allowed to incubate at 4°C for 4 hours. The beads were then 
washed in batch in 80mL of MD wash buffer 1 (2.1.5.23) twice. Using a peristaltic 
pump flowing at a rate of 2mL/minute, the beads were further washed in 100CV of 
MD wash buffer 1, then in 50CV of MD wash buffer 2 (2.1.5.24), before being 
equilibrated in PBS, in which it was stored until use. 
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2.8 Biochemical Assays 
2.8.1 Reconstitution of the SMARCAD1-KAP1 Complex 
180µg of purified FLAG-SMARCAD1 was combined with 180µg of purified HA-
KAP1 in a 220µL binding reaction that also contained 1X SK reconstitution buffer 
(2.1.6.1) and 5mM β-ME. The binding reaction was then allowed to mix for 30 
minutes at 4°C, before being added to 300µL of pre-equilibrated anti-HA (3F10) 
affinity matrix (Roche) and allowed to incubate at 4°C for 12 hours. The resin was 
washed in 500µL of 1X SK reconstitution buffer thrice, before bound proteins were 
eluted by incubation at 37°C for 30 minutes with 300µL of 1mg/mL HA peptide 
(Peptide Chemistry core facility, LRI) prepared in 1X SK reconstitution buffer. HA 
peptide elution was repeated again, and the two fractions were pooled. The eluate 
was added to 300µL of pre-equilibrated anti-FLAG® M2 affinity gel (Sigma) and 
incubated at 4°C overnight. The FLAG resin was washed in 500µL of 1X SK 
reconstitution buffer thrice, before bound proteins were eluted by incubation at 
30°C for 30 minutes with 300µL of 500µg/mL FLAG peptide (Peptide Chemistry 
core facility, LRI) prepared in P-100 buffer (2.1.5.6). Although FLAG peptide elution 
was repeated one more time, the first fraction contained the majority of the 
reconstituted SMARCAD1-KAP1 complex. 
 
2.8.2 Analytical Gel Filtration Chromatography 
Analytical gel filtration chromatography was performed using a 4×300mm MAbPac 
SEC-1 column (Thermo Fisher Scientific) to compare the Stokes (hydrodynamic) 
radii of purified SMARCAD1, KAP1 and the reconstituted SMARCAD1-KAP1 
complex. The different proteins samples were adjusted to the same protein 
concentration by addition of buffer before 45µL (375ng) of each protein was 
injected onto the column and eluted in P-200 GF buffer (2.1.6.2) over a 1.5CV 
isocratic gradient in 60µL fractions. A gel filtration markers kit spanning the 29-
700kDa range (Sigma) was used to calibrate the column; likewise, the void volume 
was determined empirically using blue dextran (Sigma). 
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2.8.3 ATPase Assays 
ATPase assays were performed as 5µL reactions containing 1X ATPase buffer 
(2.1.6.3), enzyme (typically 120nM), co-factor (typically 80nM reconstituted 30-601-
30 nucleosome), and ATP (final concentration of 0.1mM). Variations to these 
typical values are explicitly described in relation to the specific experiment. As the 
purified protein samples were in P-100 buffer (2.1.5.6) that contains 100mM 
sodium chloride, in experiments where the enzyme concentration was titrated, the 
reactions were adjusted to the same sodium chloride concentration. ATP, as a 
mixture of cold ATP and 32P radiolabelled ATP, was typically the final component 
added to the reaction. The amount of radiolabelled ATP added to each sample 
varied according to the specific activity of the stock – for a 5µL ATPase reaction, 
the amount of 6000Ci/mmol EasyTide ATP [γ-32P] (PerkinElmer) added ranged 
from 0.05µL when used fresh, to 0.2µL after approximately 4 half-lives had elapsed. 
The co-factors tested in this study included single-stranded DNA (a 150-mer 
oligonucleotide), double-stranded DNA (annealed 150-mer oligonucleotides), and 
recombinant 30-601-30 human nucleosomes (generously gifted by Daniel Maskell) 
– recombinant human histone octamers positioned on the Widom 601 sequence 
and flanked by 30bp of DNA on either side. 
 
The ATPase reactions were incubated at 37°C; typically, ATP hydrolysis was 
measured at two time points – 20 and 60 minutes. To stop the reaction, 2µL of the 
reaction was transferred to microcentrifuge tubes containing 0.5µL of 500mM 
EDTA. For each reaction, 2µL of the resulting mixture was spotted on PEI-
impregnated cellulose TLC plates (Machery-Nagel), approximately 1cm from the 
bottom, and dried using a hairdryer. The plate was incubated in a TLC chamber 
filled with TLC running buffer (2.1.6.4), which travelled up the plate by capillary 
action, separating ATP from free inorganic phosphate in the process. The TLC 
plate was dried using a hairdryer before being exposed to a phosphorimager 
screen (GE Healthcare), which was processed into a digital image using a 
Typhoon™ Trio variable mode imager (GE Healthcare). ATP hydrolysis was 
quantified by densitometry using the ImageQuant™ TL software (GE Healthcare). 
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2.8.4 SMARCAD1-KAP1 Binding Assays 
To interrogate the SMARCAD1-KAP1 interaction with purified full-length 
recombinant proteins in vitro, 7µg of FLAG-SMARCAD1 was mixed with 7µg of HA-
KAP1 in a 280µL binding reaction containing 1X SK binding buffer (2.1.6.5), 
0.1mg/mL BSA, and 5mM β-ME. The final concentration of sodium chloride in each 
binding reaction was adjusted to 200mM. The binding reactions were mixed at 4°C 
for 1 hour before 20µL of pre-equilibrated anti-FLAG® M2 affinity gel (Sigma) was 
added to each reaction. The binding reaction was immunoprecipitated with FLAG 
beads overnight at 4°C before being washed in 500µL of SK-200 buffer (2.1.6.6) 
three times. 30µL of 2X SDS-PAGE loading buffer (2.1.3.1) was added to each 
sample and heated at 100°C for 5 minutes. The binding assay was evaluated by 
SDS-PAGE and InstantBlue staining. 
 
The binding assay involving purified fragments of SMARCAD1 and KAP1 was 
performed in a similar manner using the same set of buffers. However, 9.6µg of 
FLAG-CUE1,2 (S95-E347) was mixed with 9.6µg of KAP1 S33-K434 in a 240µL 
binding reaction containing 1X SK binding buffer, 0.1mg/mL BSA, and 5mM β-ME. 
The final concentration of sodium chloride in each binding reaction was also 
adjusted to 200mM. Following mixing of the binding reaction at 4°C for 1 hour, the 
FLAG-CUE1,2 fragment was immunoprecipitated using 20µL of pre-equilibrated 
anti-FLAG® M2 affinity gel (Sigma), which was incubated with the binding reaction 
at 4°C for 3 hours. The beads were then washed in 500µL of SK-200 buffer three 
times. Elution was achieved by resuspending beads in 30µL of 2X SDS-PAGE 
loading buffer (2.1.3.1) and heating the sample at 100°C for 5 minutes. The effect 
of ubiquitin on the SMARCAD1-KAP1 interaction was investigated by adding 
purified recombinant, monomeric ubiquitin (Boston Biochem) to the binding reaction. 
A molar ratio of ubiquitin to CUE1,2 fragment of 100:1 was readily accommodated 
within this assay. While it was technically feasible to test a molar ratio of 1000:1, at 
such high protein concentration, the sample was poorly resolved by SDS-PAGE. 
 
To identify the region of KAP1 recognized by the first CUE domain of SMARCAD1, 
an affinity resin comprised of immobilized SMARCAD1 CUE1,2 fragment was 
prepared.  180µg of CUE1,2 fragment was added to a 300µL binding reaction 
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containing 1X SK binding buffer and 5mM β-ME; as before, the final salt 
concentration was adjusted to 200mM. As the intention was to saturate the beads 
with the CUE1,2 fragment, the amount of protein added was three times the 
binding capacity of the M2 resin (approximately 12.2nmol protein/mL resin). The 
beads were incubated overnight at 4°C before being washed in 500µL of SK-200 
buffer twice. The beads were then equilibrated in 500µL of GST-L-Zn buffer. 
 
Expression of GST-tagged KAP1 fragments was induced with 1mM IPTG at 30°C 
for 3 hours in 50mL E. coli cultures. Extracts were prepared by resuspending each 
E. coli pellet in 1mL of GST-L-Zn buffer (2.1.6.7) supplemented with 1X protease 
inhibitor cocktail (2.1.3.4) and 1mM CaCl2. Following addition of lysozyme to a 
concentration of 2mg/mL, the samples were incubated at 4°C for 30 minutes. The 
viscous samples were then sonicated in the Bioruptor (Diagenode) for 6 minutes in 
15s on/30s off cycles at high amplitude, before being digested at 4°C for 30 
minutes with micrococcal nuclease (New England Biolabs), used at a concentration 
of 2000 gel units/mL. The extracts were clarified by centrifugation at 14000rpm for 
30 minutes in a 5417R microcentrifuge (Eppendorf). 20µL of CUE1,2-coupled resin 
was used for each IP reaction, to which E. coli extract (2.5mg of total protein per 
reaction) was added and incubated at 4°C for 3 hours. The beads were washed in 
500µL of SK-200 buffer thrice. Finally, the beads were resuspended in 30µL of 2X 
SDS-PAGE loading buffer (2.1.3.1) and heated at 100°C for 5 minutes to elute 
proteins bound to the CUE1,2-coupled resin. 
 
2.8.5 Limited Tryptic Proteolysis 
For limited tryptic digestion, a 60µL reaction containing 1X trypsin buffer (2.1.6.8) 
and 24µg of purified recombinant protein was set up. After a 10µL aliquot was 
collected as the “no trypsin” control, 20ng of trypsin dissolved in trypsin 
reconstitution buffer (2.1.3.11) was added to the reaction, which was incubated at 
20°C. 10µL aliquots were collected after 5, 20, 60 and 150 minutes and transferred 
to microcentrifuge tubes containing 4X SDS-PAGE loading buffer (2.1.3.2) 
supplemented with 4X protease inhibitor cocktail (2.1.3.4). 
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Two complementary techniques were used to map the fragments arising from the 
limited digestion: Edman degradation and intact molecular weight mass 
spectrometry. For Edman degradation, digested samples were resolved by SDS-
PAGE, transferred onto an Amersham® Hybond P 0.45 polyvinylidene fluoride 
(PVDF) membrane (GE Healthcare) that had been activated by incubation in 
methanol, and stained with Ponceau S (Sigma). After allowing the membranes to 
air-dry, the stained bands were excised. Edman degradation was performed by 
AltaBioscience; for each sample, 5 degradation cycles were performed. 
 
As the buffers of the purified protein samples contain β-ME, which covalently attach 
to cysteine thereby introducing sample heterogeneity, the digested samples were 
incubated with 50mM DTT on ice for 30 minutes to remove β-ME adducts. Tryptic 
peptides were then removed using an Ultrafree®-CL centrifugal filter unit with a 5K 
MWCO (Millipore). LC/MS grade formic acid (Fisher Scientific) was then added to 
the sample to a concentration of at least 0.2% (v/v) for a target of approximately 
pH3; the pH was tested by spotting a drop of the sample on pH indicator strips. The 
samples were frozen and stored at -80°C until intact molecular weight mass 
spectrometry analysis was performed by Steve Howell (Protein Analysis and 
Proteomics core facility, LRI). 
 
2.8.6 Peptide Arrays 
Peptide arrays were synthesized by the Peptide Chemistry core facility (LRI) using 
a Multipep peptide synthesizer (Intavis AG). Peptides were spotted onto a cellulose 
membrane. In this study, the peptide arrays were composed of peptides 20 amino 
acids in length and were designed to scan the primary sequence of a protein by 
moving along the sequence in 1bp steps. 
 
The dry peptide array membranes were reactivated by incubation in 50% (v/v) 
methanol for 10 minutes, rinsed in TBS-Tween (2.1.3.9) for 10 minutes, and then 
blocked in 4% (w/v) milk dissolved in TBS-Tween. The membranes were then 
rinsed in TBS-Tween for 10 minutes, before being incubated overnight at 4°C with 
purified protein diluted in 1% (w/v) milk; in this study, 80µg of either the wild type 
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CUE1,2 fragment or the version with point mutations within the first CUE domain 
was used. Unbound protein was washed off the membrane using TBS-Tween; 
three washes of 10 minutes each were performed. To determine whether the 
protein bound to any peptides on the array, the membrane was processed as if it 
were a regular Western blot. It was incubated with primary antibody diluted in 1% 
(w/v) milk at room temperature for 2 hours, washed for 10 minutes in TBS-Tween 
thrice, incubated at room temperature for 1 hour with a secondary antibody solution 
prepared in 1% (w/v) milk, before finally being washed in TBS-Tween three times in 
10 minute cycles. The arrays were then visualized using the SuperSignal™ West 
Pico/Dura Chemiluminescent Substrate (Thermo Fisher Scientific) and 
luminescence detected with Amersham™ Hyperfilm ECL (GE Healthcare). 
 
2.9 Crystallography Techniques 
2.9.1 Crystallization Screens 
The 14 commercial crystallization screens used to identify initial crystallization 
conditions are as follows: Natrix HT, Crystal Screen HT, Peg/Ion HT, Index HT 
(Hampton Research), PACT premier™, JCSG-plus™, ProPlex™, Midas™, 
Morpheus® (Molecular Dimensions), JBScreen Kinase, JBScreen Pentaerythritol, 
Cryo 1 & 2 (Jena Biosciences), Wizard 1 & 2 and Wizard 3 & 4 (Rigaku). These 
screens were performed in 96-well format, using the sitting drop vapour diffusion 
method. The Mosquito® Crystal robot (TTP Labtech) was used to mix 0.2µL of the 
protein solution (9-15mg/mL) with 0.2µL of the mother liquor on a platform within 
each enclosed well. The plates were incubated at 18°C and manually inspected for 
crystals using a Leica M205 C stereo microscope (Leica Microsystems) on 
alternate days in the first week after setting up the crystal trays, and subsequently, 
weekly or fortnightly for up to 2 months. 
 
2.9.2 Optimization of Crystallization Conditions 
The initial crystallization conditions identified from the screens were replicated 
using the hanging drop vapour diffusion method in 48-well or 24-well plates, for 
which 1µL of the protein solution was used per drop. The crystallization conditions 
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were also optimized in this format by iteratively varying each component of the 
mother liquor. Thus, variables that were tested included the pH, concentration of 
the precipitant and concentration of other ions in the mother liquor. It was also 
investigated whether the Additive Screen HT (Hampton Research) improved 
crystallization. While a 1:1 drop ratio of protein solution to mother liquor was used 
by default, drop ratios of 0.5:1 and 2:1 were also tested. For some conditions, 
microseeding was also tried. 
 
2.9.3 Mounting of Protein Crystals 
Crystals obtained in this studied were mounted by Valerie Pye. Each crystal was 
caught with a cryogenic loop (Hampton Research), immersed in solutions of the 
mother liquor with increasing concentrations of cryoprotectant, before being frozen 
and stored in  liquid nitrogen. Of the crystallization conditions in this study, one 
contained PEG 400; thus, crystals that formed in that condition were frozen in 
mother liquor supplemented with 30% (v/v) PEG 400. For each of the two other 
conditions, three different cryoprotectants – 30% (v/v) PEG 400, glycerol, or 
ethylene glycol – were used. 
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Chapter 3. Results I: Purification & Mass 
Spectrometry Analysis of Endogenous CHD1 from 
Murine Embryonic Stem Cells 
3.1 Aims 
CHD1 belongs to the Chd1 subfamily of chromatin remodelling ATPases, which is 
defined by the presence of chromodomains, a conserved helicase-like ATPase 
domain and a DNA-binding domain that is structurally similar to the ISWI SANT and 
SLIDE domains (Clapier and Cairns, 2009, Ryan et al., 2011, Sharma et al., 2011). 
CHD1 is highly conserved, with homologues in yeast to man. Nonetheless, it has 
acquired metazoan-specific functions – most notably, it is essential for ES cell 
proliferation and for the maintenance of pluripotency, as depletion of CHD1 
prevents mouse ESCs from differentiating into primitive endoderm (Gaspar-Maia et 
al., 2009). 
 
While the conserved SWI2/SNF2-like ATPase domain of certain chromatin 
remodellers, such as that of the monomeric Drosophila ISWI protein, may in itself 
be sufficient for recognizing and remodelling nucleosomal substrates (Mueller-
Planitz et al., 2013), accessory subunits frequently alter the affinity and specificity 
of chromatin remodellers for specific substrates (Chaban et al., 2008, Chen et al., 
2013, Nguyen et al., 2013, Tosi et al., 2013). Tissue-specific subunits may, 
therefore, confer upon ubiquitously expressed chromatin remodelling complexes 
the ability to regulate the expression of specific sets of genes. Indeed, changes in 
composition of the mammalian SWI/SNF (BAF) chromatin remodelling complex to 
incorporate tissue-specific subunits allow it to function as an important 
developmental regulator (Lessard et al., 2007, Ho et al., 2009a, Ho et al., 2009b, 
Ho et al., 2011). In contrast, Chd1 has been previously characterized to be 
principally monomeric in budding yeast and in Drosophila (Tran et al., 2000, Lusser 
et al., 2005, Ehrensberger and Kornberg, 2011). Hence, we hypothesized that the 
role of CHD1 in pluripotency was acquired late in evolution and is mediated by 
hitherto unknown complex subunits. To address this question, we sought to purify 
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the native CHD1 complex from mouse ESCs and to characterize its subunits by 
mass spectrometry analysis. 
3.2 Results 
3.2.1 Conventional Protocols Fail to Extract Chromatin-Bound CHD1 
To identify novel stem-cell specific subunits of the putative CHD1 complex, it was 
essential to purify the native, endogenous CHD1 complex from stem cells. 
Endogenous protein complexes have traditionally been isolated from native tissues 
by purification over an extensive series of columns while tracking a specific 
biochemical activity. However, this approach was judged to be impractical in this 
situation where the amount of source material – mouse ESCs – is limited. Instead, 
we decided to purify CHD1 from a mouse ESC line that expresses epitope-tagged 
CHD1. The comparatively high rate of homologous recombination in ESCs was 
exploited to recombine a FLAG-TEV-HA epitope tag into the 3’ end of the CHD1 
gene (Figure 3.1A), such that CHD1 with a C-terminal epitope tag was expressed 
from its native promoter at endogenous level. This minimises the probability of non-
specific interactions arising from an excess of overexpressed CHD and as such, it 
is highly likely the composition of the tagged CHD1 complex will retain its native 
stoichiometry. As these epitope tags are relatively small, it is unlikely that they 
interfere with protein-protein interactions involving CHD1; however, this possibility 
was not formally tested here. 
 
To assess the feasibility of purifying CHD1 from mouse ESCs, the relative 
expression level of CHD1 in mouse ESCs was compared to that of other CHD 
proteins. By a considerable margin, CHD4, the catalytic subunit of the NuRD 
complex, was the most abundant member of this protein family in mouse ESCs. 
After CHD4, however, CHD1 was probably the next most abundant of the CHD 
proteins. As expected, subcellular fractionation indicated that CHD1 localized 
primarily to the nucleus, as there was significant enrichment of CHD1 in the nuclear 
fraction (Figure 3.1B). On the basis of this data, we felt that the purification of 
CHD1 from mouse ESCs would be possible, albeit with limited yields. 
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Figure 3.1 – Comparison of the Expression Levels of the CHD Proteins in mESCs 
A. This schematic illustrates the modified CHD1 gene locus following homologous 
recombination. A 3FTH tag – comprised of three FLAG tags, an intervening TEV 
cleavage site and an HA tag – is introduced into the end of exon 36, the last exon of the 
CHD1 gene. 
B. These mouse ESCs express C-terminally tagged CHD proteins at endogenous levels. 
The expression levels of the different CHD proteins relative to each other were 
compared by a Western blot against the FLAG tag. After CHD4, CHD1 is one of the 
more abundant members of this protein family in mouse ESCs. Subcellular fractionation 
indicates that CHD1 is enriched in the nuclear fraction. 
 
To purify CHD1, we decided to apply a protocol previously optimized in our lab for 
the purification of novel interactors of RNA polymerase II (Aygun et al., 2008). 
Arguably the most important aspect of this protocol is that subcellular fractionation 
is performed prior to affinity purification, not only to reduce the sample complexity 
and to enrich for the protein-of-interest, but also to focus on interactions that occur 
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on chromatin, which have the highest likelihood of being of functional relevance. In 
brief, the subcellular fractionation protocol involves the isolation of nuclei by 
hypotonic lysis of mammalian cells, subsequently followed by preparation of a 
chromatin fraction by homogenization, sonication and centrifugation of the nuclei. 
Chromatin-bound proteins are then extracted from the chromatin pellet by digestion 
with benzonase, a promiscuous endonuclease that digests both RNA and DNA, 
into a buffer containing 150mM NaCl – roughly physiological ionic strength – to 
preserve as many protein-protein interactions as possible. 
 
CHD1 was recovered almost entirely in the chromatin pellet (Figure 3.2A). However, 
digestion of the chromatin pellet with typical concentrations of benzonase failed to 
render CHD1 soluble (Figure 3.2A). The inability of benzonase digestion to extract 
CHD1 from the chromatin pellet probably does not reflect insufficient enzyme being 
added to the sample since high concentrations of benzonase and micrococcal 
nuclease, a nuclease that preferentially cleaves the linker DNA between 
nucleosomes, were similarly ineffectual (Figure 3.2B). Benzonase was confirmed to 
be active under these conditions – agarose gel electrophoresis indicated that most 
of the DNA recovered from digested chromatin samples by phenol-chloroform 
extraction was in the form of fragments less than 500 base pairs in length. It is 
known that it can be particularly challenging to extract nuclear matrix components 
and chromatin-associated proteins, especially those associated with highly 
compacted heterochromatin (Torrente et al., 2011). In that regard, the particularly 
tight association with chromatin demonstrated by CHD1 was rather surprising since 
it has been reported to associated specifically with euchromatic promoters – 
regions of the genome that are less compacted (Gaspar-Maia et al., 2009). Due to 
the intractability of extracting CHD1 from chromatin by conventional methods, 
alterative approaches had to be explored.  
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Figure 3.2 – Benzonase Digestion Fails to Extract CHD1 from Chromatin 
A. Following subcellular fractionation, CHD1 is recovered almost entirely in the chromatin 
pellet. However, digestion of the chromatin sample with a typical concentration of 
benzonase, a promiscuous endonuclease, fails to release CHD1 into the soluble fraction. 
B. CHD1 is highly resistant to being extracted from chromatin by benzonase digestion, as 
even very high concentrations of nuclease are ineffective. 
 
3.2.2 Extraction of Chromatin-Bound Proteins by Heparin 
Heparin is a polyanionic polysaccharide; in the sense that it possesses a high 
density of negative charge, it is similar to DNA. Indeed, in some scenarios, for 
example as a chromatographic substrate, it can even be regarded as a DNA-
mimetic. In addition to its medical application as an anticoagulant, it has been 
previously used for biochemical purposes, including for the purification of nuclear 
membranes with minimal nucleic acid and protein contamination (Bornens, 1973, 
Bornens, 1977, Courvalin et al., 1982). In this context, heparin preferentially 
solubilizes non-histone, chromatin-bound proteins, with solubilization of chromatin 
occurring at higher heparin concentrations. Histones can even be induced to 
dissociate from chromatin if the quantity of heparin in the sample is greater than the 
amount of DNA (Courvalin et al., 1982). As DNA binds histones with high affinity, 
we reasoned that if histones could be solubilized in the presence of heparin, then it 
should similarly be possible to extract CHD1 from chromatin. 
 
Addition of heparin to the resuspended chromatin pellet perceptibly altered the 
macroscopic appearance of the sample, which became more clarified. As reported, 
solubilization of chromatin-bound proteins occurred upon addition of heparin 
(Figure 3.3). 
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Figure 3.3 – Extraction of CHD1 & CHD8 from Chromatin by Heparin 
A. Chromatin-bound proteins, including CHD1 and RPB1, are solubilized by heparin in a 
concentration-dependent manner (Ponceau S). At the highest heparin concentration 
tested, relatively few proteins apart from histones persist in the insoluble chromatin 
pellet. Interestingly, optimal extraction of RPB1 is achieved at a lower heparin 
concentration than that required for CHD1. 
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B. CHD8, another CHD protein that appears to associate tightly with chromatin, can also b 
extracted from the chromatin pellet by heparin in a concentration dependent manner. 
 
The amount of heparin required to extract a specific protein from chromatin varied 
from protein to protein. For example, extraction of CHD1 or CHD8 from chromatin 
requires higher heparin concentrations than RPB1, the largest subunit of the 
RNAPII complex. At a heparin to DNA ratio (by weight) of 2.5, the majority of CHD1 
and CHD8 are soluble (Figures 3.3A & B respectively). In contrast, a heparin to 
DNA ratio (w/w) of 0.75 sufficed for optimal extraction of RPB1, further increases in 
heparin concentration did not significantly increase the amount of RPB1 extracted 
from chromatin (Figure 3.3). Interestingly, the selective ability of the initiating, but 
not the elongating, form of RNAPII to bind to a heparin column has previously been 
noted (Gnatt et al., 1997). Thus, it is likely that the residual amount of chromatin-
bound RPB1 following heparin extraction represents RPB1 molecules incorporated 
into elongating RNAPII complexes.  
 
While heparin extracts proteins from chromatin in a concentration dependent 
manner, the key determinant is not the absolute heparin concentration of the 
sample. Instead, the amount of heparin relative to the amount of DNA in the 
sample determines the extent to which chromatin-bound proteins are solubilized 
(Figure 3.4A). Moreover, it was observed that the addition of herring sperm DNA to 
the resuspended chromatin pellet was sufficient to solubilize some chromatin-
bound proteins, including CHD1 (Figure 3.4B). Taken collectively, these data 
suggest that heparin exploits its chemical similarities to DNA to directly compete 
proteins off chromatin. Importantly, the relatively indiscriminate manner in which 
proteins are extracted from chromatin by heparin suggests that this technique is 
broadly applicable for the preparation of extracts of chromatin-associated proteins.  
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Figure 3.4 – Characterization of Heparin Extraction of Chromatin-Bound Proteins  
A. It is the ratio of the amount of heparin to DNA in the sample, rather than the absolute 
heparin concentration, that determines the extent of solubilisation of chromatin-bound 
proteins. Each condition tested contains equal amounts of a chromatin sample, and thus 
comparable starting amounts of DNA. As these samples were diluted with different 
amounts of buffer, when heparin was added to a final concentration of 2.5mg/mL, each 
condition had a different ratio of heparin to DNA. As the heparin:DNA ratio increases, 
the amount of total protein (Ponceau S) and CHD1 extracted increases. 
B. Herring sperm DNA is similarly capable of solubilizing chromatin-bound proteins and 
histones. Hence, it is probable that heparin relies upon its similarity to DNA to extract 
proteins from chromatin, possibly by direct competition.   
 
3.2.3 Purification of RNAPII & CHD1 from Mouse ESCs 
While the heparin extraction technique should be broadly applicable for the 
purification of most chromatin-bound proteins, it may be especially valuable when 
attempting to purify such proteins under low stringency conditions since heparin 
extraction remains efficient in buffers of low ionic strength designed to preserve 
weak or transient protein interactions. To confirm that heparin extraction is 
compatible with subsequent protein purification, we decided to purify the RNA 
polymerase II core complex and interactome from mouse ESC chromatin extract 
prepared with heparin.  
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RNAPII is essential in cells as it is responsible for the transcription of protein-
coding genes. The core RNAPII complex consists of 12 subunits and displays high 
evolutionary conservation. Nonetheless, Gdown1 has only relatively recently been 
identified to be a novel subunit of a proportion of mammalian RNAPII complexes 
(Hu et al., 2006). Thus, we also wanted to test the, admittedly unlikely, hypothesis 
that the RNAPII complex may possess stem cell-specific subunits.  
 
RNAPII was purified from mouse ESC chromatin extract by immunoaffinity 
chromatography using the 8WG16 monoclonal antibody, which was raised against 
the unphosphorylated RPB1 C-terminal domain (CTD) heptapeptide. Importantly, 
the 8WG16 antibody is a polyol-responsive antibody; thus, bound RNAPII can be 
induced to dissociate from the antibody column by a high polyol concentration 
(Thompson et al., 1990). Mammalian RNAPII has been noted to elute poorly from 
the 8WG16 antibody column; presumably, it binds to the column with high avidity 
due to the 52 heptapeptide repeats present in the CTD of mammalian RPB1. 
Hence, several elution conditions were tested, including elution with a CTD peptide 
and various buffers containing propylene glycol, a polyol. The best elution was 
observed with an excess (i.e. 1mg/mL) of CTD peptide, though 40% (v/v) propylene 
glycol in the presence of 500mM ammonium sulphate also succeeded in eluting 
some RNAPII (Figure 3.5A).  
 
Western blot analysis confirmed the presence of RPB1 and RPB2, two integral 
subunits of the RNAPII complex, in the eluates from the 8WG16 column, 
suggesting that RNAPII was successfully purified from mouse ESC chromatin 
extract (Figure 3.5B). Silver staining of the eluates revealed more than twelve 
bands, indiating that other interactors beyond the core RNAPII complex were 
recovered (Figure 3.5C). However, tandem liquid chromatography-mass 
spectrometry (LC-MS) analysis of the high stringency RNAPII purification failed to 
identify any novel stem cell-specific subunits. 
 
Chapter 3. Results I 
 
135 
 
 
Figure 3.5 – Purification of the RNAPII Interactome from Mouse ESCs 
A. Various strategies to elute the RNAPII from the 8WG16 antibody column were tested in 
a small-scale experiment. This Western blot against RPB1 (4H8) shows that an excess 
(1mg/mL) of CTD peptide is capable of competitively eluting a significant amount of 
RPB1 from the column. In the presence of 500mM ammonium sulphate, 40% (v/v) 
propylene glycol is also capable of eluting some RPB1 from the column. 
B. RNAPII was purified by 8WG16 affinity chromatography from mouse ESC chromatin 
extract, prepared using the heparin solubilization protocol described above. RPB1 and 
RPB2 were efficiently depleted from extract by the antibody column. The RNAPII 
complex was eluted from the column by a combination of CTD peptide and 40% (v/v) 
propylene glycol. High and low stringency purifications were performed in parallel to 
isolate the RNAPII core complex and interactome respectively. While the analysis 
displayed is derived from the high stringency purification, it is representative of both. 
The dotted line denotes cropping of the image to omit irrelevant lanes. 
C. The staining pattern of the eluates from the 8WG16 antibody column indicates that 
additional proteins were recovered in addition to the RNAPII complex. The intense 
smear at the bottom of the gel represents the CTD peptide used for elution. Less 
RNAPII is recovered from the low stringency purification than from the high stringency 
one due to reduced elution efficiency in a buffer of lower ionic strength.  
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A low stringency purification of RNAPII designed to preserve weaker interactions 
by omitting washes of high ionic strength was performed in parallel to define its 
interactome in mouse ESCs. The yields from the low stringency purification were, 
however, considerably less than that for the high stringency purification (Figure 
3.5C). This is due to the elution from the 8WG16 affinity column being less efficient 
for the low stringency purification than for its high stringency counterpart. Indeed, it 
was previously observed that elution by propylene glycol in the context of a low 
ionic strength buffer was significantly less effective than if a buffer of high ionic 
strength were used (Figure 3.5B). Nonetheless, the low stringency RNAPII 
purification was analysed by LC-MS, revealing relative conservation of the RNAPII 
interactome between ES cells and other differentiated cells. For example, well-
characterized interactors of RNAPII such as the FACT complex, Spt5 and RECQL5 
were detected.The co-purification of these interactors with RNAPII suggests that 
heparin does not disrupt protein- protein interactions in spite of its highly 
polyanionic nature. This data, therefore, validates the use of heparin extraction in 
conjunction with low stringency affinity purifications to define the interactome of 
specific chromatin-associated proteins. Thus, we proceeded to purify CHD1 under 
both high and low stringency conditions to identify any complex subunits, and to 
characterize its interactome respectively (Figure 3.6). 
 
For the high stringency purification, chromatin extract from mouse ESCs 
expressing epitope-tagged CHD1 was loaded sequentially onto FLAG and HA 
affinity columns (Figure 3.6A). A control ‘mock’ purification was performed in 
parallel using chromatin extract prepared from parental 46C mouse ESCs. 
Extensive high (750mM sodium chloride) and low (50mM sodium chloride) washes 
were performed to disrupt ionic and hydrophobic interactions respectively. The 
samples eluted off the HA columns by cleavage with the TEV protease were 
resolved resolved by SDS-PAGE and visualized by silver staining. 
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Figure 3.6 – High & Low Stringency Purifications of CHD1 from Mouse ESCs 
A. The endogenous CHD1 core complex was purified from mouse ESC chromatin extract 
by sequential FLAG and HA affinity chromatography. For the high stringency purification, 
washes of up to 750mM NaCl were used, such that only strong interactions would be 
retained. As a control, a parallel purification was performed using chromatin from 
parental 46C mouse ESCs, which did not express any tagged CHD protein. 
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B. The eluates from the high stringency purification are of a high purity, as assessed by 
silver staining. Similar to its budding yeast and Drosophila orthologues, mouse CHD1 
does not form a multi-subunit protein complex. The red asterisks indicate bands that 
probably correspond to CHD1. 
C. To define the interactome of CHD1, CHD1 was similarly purified as before, though the 
entire purification was performed under mild conditions to retain even weak interactions. 
D. Based on the control 46C purifications, it is clear that purification under mild conditions 
results in significant background contamination. It is impossible to clearly identify CHD1-
specific interactors by silver staining, though as before, the red asterisks indicate bands 
that probably correspond to CHD1. 
 
A unique band migrating near the 250kDa molecular weight marker is present only 
in the CHD1 but not the control sample almost certainly corresponds to CHD1 
(Figure 3.6B). However, there were no other bands of similar intensity specific to 
the tagged sample. Correspondingly, while LC-MS analysis readily identified CHD1 
in only the tagged sample, with over 350 assigned spectra, no other proteins in the 
same sample were detected with comparable frequency. Thus, CHD1 probably 
does not exist as part of a stable stoichiometric, multi-subunit protein complex in 
mouse ESCs. Indeed, the CHD1 orthologues in budding yeast and Drosophila are 
also monomeric, suggesting that the additional functions of mammalian CHD1 are 
unlikely to be because of the acquisition of novel complex subunits (Tran et al., 
2000, Lusser et al., 2005, Ehrensberger and Kornberg, 2011). 
 
We then proceeded to perform a low stringency purification of CHD1 to define its 
interactome, including lower affinity or transient protein interactors that may 
nevertheless be important regulators of CHD1. The tandem affinity purification was 
adapted to feature mild washes of physiological ionic strength (150mM sodium 
chloride) to preserve more protein-protein interactions (Figure 3.6C). The 
numerous bands observed by silver staining in the control 46C purification reveal 
that significant non-specific background contamination was associated with the low 
stringency purifications (Figure 3.6D). Consequently, it is difficult to confidently 
nominate a specific band to be CHD1, much less identify specific interaction 
partners. LC-MS analysis identified hundreds of proteins in both samples. The 
relative abundance of a protein was assessed by comparing the intensity-based 
label-free absolute-quantification (iBAQ) scores associated with a given protein for 
the tagged-CHD1 sample to that of the control sample. A list of proteins enriched in 
the CHD1 sample over background levels was compiled (Table 3.1). These CHD1-
enriched proteins were subjected to unbiased gene ontology analysis; amongst the 
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top ten most highly enriched terms, four terms relate to transcription or chromatin 
remodelling, suggesting that the proteins identified to be enriched in the CHD1 
sample over background may perhaps be of biological relevance (Table 3.2). 
Nevertheless, these data were interpreted with caution since CHD1 could not be 
efficiently purified from ESCs – the silver-stained gels lacked a clear and dominant 
CHD1 band (Figure 3.6D). Unsurprisingly, a low signal-to-noise ratio plagued the 
results of the mass spectrometry analysis (Table 3.1). 
 
Name Enrichment iBAQ Score Spectral Count PEP Value CHD1 Control CHD1 Control 
Gtf2i 2.98 20.3 6.8 10 0 9.61E-23 
Chd1 2.66 23.3 8.8 367 1 0 
COX2 2.62 17.8 6.8 4 0 1.02E-04 
Rab1;Rab1A 2.58 17.5 6.8 7 0 8.75E-15 
Ndufa13 2.52 17.1 6.8 2 0 5.74E-06 
L1Md-A1 2.51 17.0 6.8 4 1 4.80E-04 
Gnb2 2.47 16.8 6.8 3 0 1.31E-08 
Rab6a;Rab6b;Ra
b39;Rab39a 2.46 16.7 6.8 4 0 6.17E-11 
Atp5h 2.45 16.7 6.8 3 0 2.50E-15 
2700060E02Rik 2.45 16.6 6.8 4 0 1.85E-27 
Dimt1 2.45 16.6 6.8 5 0 5.66E-12 
Hat1 2.45 16.6 6.8 5 0 2.43E-31 
Sf3b14 2.44 16.6 6.8 2 0 7.29E-15 
Hsd17b10 2.44 16.6 6.8 4 0 6.23E-12 
Suclg1 2.42 16.4 6.8 3 0 1.75E-25 
Acat1 2.39 16.3 6.8 4 0 1.39E-09 
Cdh1 2.38 16.2 6.8 7 0 9.14E-18 
Rfc5 2.37 16.1 6.8 3 0 1.64E-08 
Fam98b 2.36 16.1 6.8 2 0 1.64E-10 
Cope 2.36 12.2 6.8 1 0 4.65E-03 
Rrp7a 2.36 16.0 6.8 2 0 1.51E-03 
Nup43 2.35 16.0 6.8 2 0 2.41E-06 
Timm13 2.35 16.0 6.8 1 0 3.67E-09 
Gnb1 2.35 15.9 6.8 1 0 4.07E-09 
Dnaja2 2.34 15.9 6.8 4 0 2.47E-11 
Acadm 2.34 15.9 6.8 4 0 8.33E-15 
Srrt 2.33 15.8 6.8 18 0 8.99E-39 
Lig1 2.32 15.8 6.8 12 0 5.15E-27 
Kif22 2.32 15.8 6.8 8 0 2.14E-20 
Aimp2 2.32 15.8 6.8 2 0 1.11E-11 
Pdk1 2.32 15.8 6.8 3 0 2.47E-06 
Exosc2 2.32 15.8 6.8 3 0 6.07E-08 
Sdhb 2.31 15.7 6.8 5 0 2.26E-08 
Txn1;Txn 2.31 15.7 6.8 1 0 2.65E-03 
Dnajb11 2.31 15.7 6.8 3 0 3.51E-22 
Ppp1ca 2.30 15.6 6.8 1 0 1.45E-07 
Dstn 2.30 15.6 6.8 2 0 9.32E-04 
Mrps30 2.30 15.6 6.8 5 0 9.90E-06 
Nup93 2.29 15.6 6.8 8 0 9.74E-20 
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Smarcd1 2.29 15.6 6.8 4 0 8.33E-32 
Bcas2 2.29 15.6 6.8 1 0 7.37E-07 
Armc10 2.29 15.5 6.8 2 0 1.50E-05 
Got2 2.28 15.5 6.8 5 0 1.50E-12 
Tcea3 2.28 15.5 6.8 2 0 1.95E-11 
Ass1 2.28 15.5 6.8 2 0 9.72E-06 
Hadhb 2.28 15.5 6.8 5 0 1.65E-09 
Uba1 2.28 15.5 6.8 12 0 7.39E-30 
Actr1a;Actr1b 2.27 15.5 6.8 1 0 1.77E-03 
Dpm1 2.27 15.4 6.8 2 0 6.77E-04 
Plk1 2.26 15.4 6.8 4 0 4.59E-26 
Trim24 1.50 14.1 9.4 7 1 1.63E-07 
Table 3.1 – The Most Highly-Enriched CHD1 Interactors 
The level of enrichment was calculated by normalizing the iBAQ score of a given protein for 
the tagged-CHD1 sample to that for the control sample. The fifty most highly enriched 
proteins are listed in this table. An iBAQ score of 6.8 (the score of the least abundant 
protein detected in this sample) was arbitrarily assigned to all proteins without detectable 
spectra. The iBAQ score takes into account the size of the protein; hence, they do not 
directly correlate with the spectral count. The lower the PEP value, the higher the likelihood 
of accurate identification of the protein. 
 
 
Gene Ontology Category Enrichment Factor P value 
Benjamini 
Hochberg 
FDR 
1. Holo TFIIH complex 220 1.04E-05 0.019302 
2. Photoreceptor outer segment 220 1.04E-05 0.019349 
3. mRNA cap binding complex 220 1.04E-05 0.01949 
4. Lamellipodium membrane 220 1.04E-05 0.019585 
5. Early endosome membrane 220 1.04E-05 0.019633 
6. Integrin complex 220 1.04E-05 0.019828 
7. Mitochondrial proton-transporting 
ATP synthase complex 
220 1.04E-05 0.019976 
8. Cdc73/Paf1 (transcription 
elongation factor) complex 
146.67 7.09E-08 0.00049429 
9. Heterotrimeric G-protein complex 110 2.84E-07 0.0014438 
10. SWI/SNF-type complex 110 2.84E-07 0.0014829 
Table 3.2 – Gene Ontology Enrichment Analysis of the CHD1 Interactome 
Gene ontology analysis was performed on the proteins enriched in the CHD1 sample over 
background levels using the Fisher exact test. The duplicated terms were either omitted or 
merged. The ten most highly enriched terms are listed in this table; of these four terms 
(highlighted) relate to transcription or chromatin remodelling suggesting that this data set is 
probably of biological relevance. 
 
Although 367 spectra were assigned to CHD1, most of the other proteins were 
identified from a few peptides (Table 3.2). Indeed, none of the hits was specifically 
identified in such a large quantity that they could be incontrovertibly be regarded as 
a genuine CHD1 interactor. Thus, additional selection criteria were introduced – for 
example, the list of CHD1-enriched hits was cross-referenced to lists of common 
mass spectrometry contaminants. Based on their known biological functions, the 
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hits were also subjectively evaluated for a plausible functional connection to CHD1. 
Unfortunately, none of the most highly enriched hits convincingly fulfilled all of 
these criteria. 
 
3.2.4 Validation of TIF1α (TRIM24) as an Interactor of CHD1 
Although TIF1α was not highly enriched (1.5 fold enrichment) in the CHD1 sample 
over background, it was the most interesting of the putative CHD1 interactors. 
TIF1α is a transcriptional co-regulator, encoded by the TRIM24 gene, that 
preferentially binds to histone H3 tails that are unmethylated at K4 and acetylated 
at residue K23 (H3K4me0K23ac) via its PHD-bromodomain (Tsai et al., 2010). 
Additionally, it is possible that its RING domain confers upon it E3 ubiquitin ligase 
activity. Incidentally, amongst the multiple nuclear receptors regulated by TIF1α is 
the retinoic acid receptor, RXRα, whose signalling can induce differentiation of 
ESCs (Fraser et al., 1998). 
 
To validate the possible CHD1-TIF1α interaction, it was investigated whether CHD1 
and TIF1α co-immunoprecipitate. Indeed, TIF1α was enriched over background 
levels when CHD1 was pulled down (Figure 3.7A). Conversely, some CHD1 was 
co-immunoprecipitated by TIF1α. As this interaction appears relatively weak, 
additional controls were performed to confirm its specificity – for example, the 
possibility of TIF1α binding non-specifically to the FLAG antibody was excluded 
(Figure 3.7B). Nevertheless, while this interaction is probably specific, it must be 
noted that it only involves a small proportion of the total population of CHD1 or 
TIF1α. Thus, the CHD1-TIF1α interaction represents a relatively minor 
subpopulation of the total population of either protein, possibly because the 
interaction is weak or occurs only transiently. 
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Figure 3.7 – CHD1 & TIF1α co-Immunoprecipitate 
A. Immunoprecipitation of epitope-tagged CHD1 by FLAG IP with Protein G Dynabeads® 
(Invitrogen) resulted in co-immunoprecipitation of TIF1α. The reciprocal result was also 
observed – TIF1α pull-down resulted in enrichment of CHD1 compared to the IgG 
control. While the co-immunoprecipitation is detectable, only a small proportion of the 
total amount of CHD1 or TIF1α is ever pulled down by its counterpart, indicating that the 
CHD1-TIF1α interaction represents a minority subpopulation. 
B. IP of tagged CHD1 with FLAG M2 agarose also achieved enrichement of TIF1α. 
However, co-IP of TIF1α does not occur when parental 46C ESC extract was used as 
the load, indicating that TIF1α does bind non-specifically to the FLAG antibody. 
 
CHD1 has been implicated in the maintenance of pluripotency. Indeed, CHD1 is 
preferentially expressed in mouse ESCs, with downregulation of CHD1 protein 
levels occurring upon differentiation of the ESCs into embryoid bodies, three-
dimensional cellular aggregates consisting of precursor cells of various lineages 
(Figure 3.8). If TIF1α is mechanistically linked to CHD1’s role in pluripotency, it 
might be expected that the expression of TIF1α is also influenced by pluripotency. 
In fact, TIF1α expression is rapidly and significantly downregulated upon induction 
of differentiation of ESCs, achieved by transferring ESCs into suspension culture in 
the absence of leukaemia inhibitor factor (LIF), a cytokine that inhibits 
differentiation (Figure 3.8B). Thus, while certainly not definitive evidence, this result 
suggests that TIF1α might have a functional role in the pluripotent cell state. 
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Figure 3.8 – Expression of CHD1 & TIF1α is Downregulated upon Differentiation 
A. This schematic illustrates the experimental procedure. Epitope tagged-CHD1 mouse 
ESCs were differentiated into embryoid bodies by shifting them into suspension culture 
in the absence of LIF. As can be observed in the image (right), after seven days, the 
embryoid bodies have become large fluid-filled cystic structures. 
B. Downregulation of Oct4 and Nanog, two master regulators of pluripotency, was 
observed by Western blot analysis, confirming successful differentiation of the ESCs. 
Likewise, induction of Gata4 expression, a marker of endoderm differentiation, was 
observed. Both CHD1 and TIF1α are preferentially expressed in ESCs, with 
downregulation occurring upon differentiation. 
 
Our preliminary characterization of TIF1α suggests that it is an interesting protein 
with potential roles in pluripotency. However, further characterization was hindered 
by inefficient depletion of TIF1α by interference with short hairpin RNA (shRNA). 
Moreover, the CHD1-TIF1α interaction appears to only represent a minor 
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subpopulation. Thus, a judgement call was made to cease further characterization 
of the CHD1-TIF1α interaction. 
 
3.3 Conclusions 
CHD1 is a chromatin remodeller implicated in the maintenance of pluripotency, 
though the mechanistic details about its role in this process have yet to be 
determined. To investigate this question, the native CHD1 stable core complex and 
interactome was purified from mouse ESCs, employing a novel heparin extraction 
method that is broadly applicable for the solubilization of chromatin-bound proteins. 
Like its budding yeast and Drosophila orthologues, mouse CHD1 probably does not 
assemble into a stable stoichiometric protein complex that withstands exposure to 
buffers of high ionic strength. 
 
The low-stringency CHD1 purification was limited by a high level of background 
contaminants – the silver-stained gels lacked a clear and dominant CHD1 band. 
Unsurprisingly, even proteins enriched in the CHD1 sample compared to the 
control had a low signal-to-noise ratio, making it difficult to easily identify specific 
CHD1 interactors. Nevertheless, one of the mass spectrometry hits, TIF1α, was 
validated to specifically interact with CHD1. However, the CHD1-TIF1α interaction 
represents a minor subpopulation of the two proteins. Preferential expression of 
CHD1 and TIF1α in mouse ESCs was nevertheless noted, suggesting roles in the 
pluripotent cell state. Although TIF1α deserves further characterization in its own 
right, the inability to demonstrate a functional connection between CHD1 and TIF1α 
meant that this project was deemed untenable. 
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Chapter 4. Results II: Purification of the 
Endogenous CHD5 Complex from Mouse Tissues 
4.1 Aims 
Another member of the CHD subfamily of SWI2/SNF2-like chromatin remodelling 
ATPases, CHD5 is characterized by its tissue-specific expression in neurons and 
the testis (Zhuang et al., 2014). Unsurprisingly, it is important for the neural 
development – depletion of CHD5 from the developing mouse neocortex blocks 
differentiation, resulting in the accumulation of immature neural progenitor cells 
(Egan et al., 2013). The main phenotype of CHD5 knockout mice is male infertility 
due to impaired spermiogenesis, reflecting a role of CHD5 in regulating histone to 
protamine transition (Li et al., 2014, Zhuang et al., 2014). CHD5 is also the tumour 
suppressor gene deleted by loss of chromosome 1p36, which occurs in 70-80% of 
high-risk neuroblastomas (Bagchi et al., 2007, Fujita et al., 2008). 
 
CHD5 is a homologue of CHD3 and CHD4, sharing 68% and 72% amino acid 
identity respectively. CHD4 and CHD3 are the catalytic subunits of the ubiquitous 
NuRD complex (Zhuang et al., 2014). It is suggested that CHD5 forms a neuronal 
NuRD-like complex as co-immunoprecipitation of CHD5 with other NuRD complex 
subunits, including HDAC2, RBBP7 and MTA3, has been detected in mouse brains 
(Potts et al., 2011). Yet, this hypothesis has not been conclusively substantiated by 
biochemical purification of a stable CHD5 complex. Thus, we decided to purify 
endogenous CHD5 from mouse brains to clarify the existence of a stable CHD5 
complex and its subunit composition. We expected this work to be informative in 
elucidating the biochemical function and regulation of CHD5, a developmentally 
important, tissue-specific chromatin remodeller. 
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4.2 Results 
4.2.1 Purification & Mass Spectrometry Analysis of CHD5 Transiently 
Overexpressed in 293T Cells 
As CHD5 is a tissue-specific chromatin remodeller, it is ultimately essential to purify 
it from an appropriate tissue source – in this case, brains or testes. However, as an 
initial proof-of-concept experiment, epitope-tagged CHD5 was purified following 
transient overexpression by calcium phosphate transfection in 293T cells. Despite 
expression being regulated by a strong CMV promoter, the level of overexpression 
achieved was initially limited. However, co-transfection with a plasmid expressing 
the Ebola virus protein, VP35, dramatically enhanced exogenous expression of 
CHD5 (Figure 4.1A). Co-transfection of mammalian cells with a VP35-encoding 
plasmid has been previously characterized as a general method of enhancing 
transient overexpression of target proteins (Gantke et al., 2013). The precise 
mechanism for this phenomenon remains unclear, but it is believed that the VP35 
protein reduces the extent to which double-stranded DNA plasmids activate PKR, a 
double-stranded RNA-dependent protein kinase that inhibits translation. A striking 
increase in the level of CHD5 overexpression is observed in the presence of only a 
small quantity of the VP35 plasmid (a quarter of the amount of CHD5 plasmid 
transfected) (Figure 4.1A). As a control, 293T cells were transiently co-transfected 
with plasmids encoding CHD1 and VP35. CHD1 is an appropriate negative control 
since it is a chromatin remodeller of comparable size and has been established to 
be monomeric (Figure 3.6B and (Tran et al., 2000, Lusser et al., 2005, 
Ehrensberger and Kornberg, 2011)). 
 
CHD5 was purified by FLAG affinity chromatography to levels detectable by silver 
staining (Figure 4.1B). Highly stringent conditions, including both high (750mM 
sodium chloride) and low (50mM sodium chloride) washes to disrupt ionic and 
hydrophobic interactions respectively, were used for the purification such that there 
would be enrichment for the most stable CHD5 interactors. Although some 
background contamination remained present (refer to the multiple bands visible by 
silver staining in the control CHD1 purification), the CHD5 purification was 
associated with unique bands. Thus, both the CHD5 and the control CHD1 
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puriifications were analysed by tandem LC-MS. The proteins that are most highly 
enriched in the CHD5 purification are listed in Table 4.1. Notably, this list is 
dominated by components of the NuRD complex, suggesting that CHD5 forms a 
NuRD-like complex.  
 
 
Figure 4.1 – Purification of CHD5 Overexpressed in 293T Cells 
A. Expression of CHD1 and CHD5 in 293T cells is dramatically enhanced by co-
transfection with a plasmid encoding the Ebola virus VP35 protein. 
B. CHD5 was purified by FLAG affinity chromatography under stringent conditions after 
transient overexpression in 293T cells. CHD1, which is known to be monomeric, was 
purified in parallel as a negative control. The samples were visualized by silver staining. 
Although these purifications are associated with some non-specific background 
contamination (as indicated by the multiple bands in the CHD1 sample), CHD5 appears 
to specifically enrich for several proteins. 
 
Name Enrichment 
iBAQ Score Spectral Count 
PEP Value CHD5 CHD1 Control CHD5 
CHD1 
Control 
GATAD2B 5.03 6.03 1 65 0 1.22E-128 
PATZ1 4.56 5.56 1 33 0 2.42E-132 
MBD3 4.56 5.56 1 13 0 5.52E-51 
C5orf55 4.33 5.33 1 3 0 1.49E-02 
CHD5 4.19 7.43 3.24 713 3 0 
ZKSCAN8 4.16 5.16 1 16 0 3.29E-27 
SMN 4.14 5.14 1 2 0 1.49E-04 
HOXD13 4.07 5.07 1 10 0 9.94E-26 
BAG2 4.01 5.01 1 6 0 9.72E-17 
HDAC1 3.96 4.96 1 7 0 1.94E-29 
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ZBTB5 3.87 4.87 1 9 0 1.20E-49 
CDK2AP1;CDK2
AP2;DOC-1R 3.84 4.84 1 2 0 4.41E-06 
NDUFA4 3.82 4.82 1 1 0 9.17E-08 
ADNP 3.80 4.80 1 29 0 2.33E-82 
BCL7A;BCL7B;B
CL7C 3.79 4.79 1 3 0 1.18E-07 
MLF2 3.74 4.74 1 2 0 1.45E-07 
MTA1 3.69 4.69 1 12 0 3.25E-52 
C3orf67 3.68 4.68 1 1 0 2.75E-04 
LTV1 3.67 4.67 1 7 0 1.27E-19 
MTA3 3.67 4.67 1 6 0 1.27E-26 
MAGED2 3.63 4.63 1 8 0 1.28E-29 
FAM101B 3.60 4.60 1 1 0 6.71E-03 
FAM207A 3.56 4.56 1 2 0 1.34E-06 
STAU2 3.55 4.55 1 7 0 3.38E-21 
ECT2 3.53 4.53 1 2 0 1.75E-04 
GPATCH4 3.53 4.53 1 3 0 6.40E-17 
VPS72 3.51 4.51 1 2 0 6.86E-05 
MBD2 3.48 4.48 1 4 0 4.85E-08 
AURKB 3.46 4.46 1 2 0 1.14E-07 
CBX8 3.44 4.44 1 6 0 1.34E-14 
Table 4.1 – The 30 Most Highly-Enriched Proteins by IP of Overexpressed CHD5 
The level of enrichment was calculated by normalizing the iBAQ score of a given protein for 
the CHD5 sample to that for the control CHD1 sample. The thirty most highly enriched 
proteins are listed in this table. An iBAQ score of 1 (the score of the least abundant protein 
detected in this sample) was arbitrarily assigned to all proteins without detectable spectra. 
Most of the NuRD complex subunits (highlighted in yellow) are present in this list of CHD5-
enriched proteins. 
 
A notable caveat of this experiment is that CHD5 was transiently overexpressed in 
a cell type from which it is usually not highly expressed. Hence, it is possible that 
while CHD5 may be capable of interacting with NuRD complex subunits, this 
interaction may not actually occur in native tissues because it because it usually 
interacts instead with an alternative ligand that is of much higher abundance or that 
has a greater avidity. Nevertheless, this experiment served its purpose as a proof-
of-concept study, since it indicates that CHD5 probably forms a stable, multi-
subunit protein complex with similarities to the NuRD complex. Consequently, we 
sought to purify the endogenous, native CHD5 complex from an appropriate tissue 
source to define its tissue-specific subunit composition. 
 
4.2.2 Purification of Endogenous CHD5 from Mouse Brains 
For subsequent purifications of CHD5, a mouse strain expressing epitope-tagged 
CHD5 mice (CHD53FTH/3FTH) from the native CHD5 gene locus, generated by our 
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collaborator, Matthieu Gérard, was used as the source of material. The architecture 
of the engineered CHD5 locus is analogous to that described for the epitope-
tagged CHD1 ESC line used earlier (Figure 3.1A). The CHD53FTH/3FTH mouse is 
indistinguishable from its wild-type counterparts, obtained at Mendelian ratios, and 
demonstrates no obvious phenotype (personal communication with Matthieu 
Gérard). Consequently, it is probable that the addition of a C-terminal epitope tag 
has not affected CHD5 function in this mouse. This mouse is the ideal tissue 
source for purifications as it combines the unique specificity of an affinity tag with 
expression of CHD5 at endogenous levels, thereby preserving the native 
stoichiometries of its interactions. Specifically, brains were used as CHD5 is 
preferentially expressed in the brain and to a lesser extent, in the testis. 
 
It was noted that the integrity of soluble CHD5 was adversely affected by numerous 
factors including sonication (Figure 4.2A). For example, when preparing whole cell 
extracts of SH-SY5Y neuroblastoma cells, sonication significantly reduced the 
amount of full-length CHD5 in the soluble fraction despite not appearing to affect 
the vast majority of proteins. Thus, various approaches including nuclease 
digestion techniques were tested to optimise the extraction of soluble CHD5 in 
mouse brain extracts. The optimal condition was to combine grinding of snap-
frozen mouse brains in liquid nitrogen using a pre-chilled mortar and pestle with 
high salt (i.e. 750mM sodium chloride) extraction (Figure 4.2B). 
 
A purification protocol featuring affinity and conventional chromatography was 
developed – purification on an M2 FLAG column with competitive elution using an 
excess of FLAG peptide was followed by cation exchange chromatography with 
elution over a salt gradient (Figure 4.3A). The salt elution gradient is particularly 
useful in identifying bona fide subunits of a protein complex since a protein 
complex should behave as a single molecular entity and consequently, 
demonstrate perfect co-elution of all of its subunits. Successful enrichment of 
CHD5 was accomplished by FLAG purification as near-complete depletion of 
CHD5 from brain extract following passage over the affinity resin was accompanied 
by efficient peptide elution (Figure 4.3B). Affinity purified CHD5 resolves by SDS-
PAGE analysis as several different bands; however, it remains unknown whether 
these represent distinct isoforms or post-translational modifications. 
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Figure 4.2 – Optimization of Extract Preparation for CHD5 Solubility 
A. It was noted that CHD5 is susceptible to sonication-induced degradation. In this 
experiment, whole cell extracts were prepared from SH-SY5Y neuroblastoma cells with 
or without sonication. Though sonication did not affect the majority of proteins (Ponceau 
S), it significantly reduced the level of full-length CHD5 in the soluble cell extract. 
B. The level of CHD5 in mouse brain extracts was also adversely affected by sonication 
(compare lane 1 to 3). Optimal solubilisation of full-length CHD5 was achieved by 
grinding frozen mouse brains in liquid nitrogen, followed by high-salt extraction. 
 
Significant purification of CHD5 was achieved by cation exchange chromatography 
since many contaminants are unable to bind to the resin (Figre 4.3C). While CHD5 
was purified to a sufficient concentration to be visualized by silver staining, the 
presence of co-eluting subunits present in stoichiometric amounts was not 
immediately apparent (Figure 4.3C). Nevertheless, the purification was assessed to 
be of sufficient quality to warrant tandem LC-MS analysis. 
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Figure 4.3 – Purification of CHD5 from Mouse Brains 
A. CHD5 was purified from mouse brain extracts by sequential FLAG affinity 
chromatography with competitive elution by FLAG peptide and cation exchange 
chromatography (Mini S PC 3.2/3). Importantly, the mouse brain extracts have to be 
prepared by grinding frozen mouse brains with a mortar and pestle followed by high salt 
extraction. 
B. CHD5 is efficiently purified by FLAG affinity chromatography. 
C. CHD5 binds efficiently to a cation exchange resin. Some separation of a modified form 
of CHD5 is achieved in this sharp salt gradient. 
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Three sets of samples representing different portions of the elution gradient from 
the ion exchange column were analysed by mass spectrometry. While sample 1 
(fractions 87-89) represents the peak fractions of CHD5, sample 2 (fractions 81-83) 
is effectively a ‘negative control’ since CHD5 is only present in small quantities in 
those fractions.  Finally, sample 3 (fractions 92-94), comprised of fractions from the 
tail of the peak, contains intermediate amounts of CHD5 (Figure 4.3C). Each of the 
three samples were injected on the mass spectrometer three times, allowing for the 
identification of putative CHD5 subunits by statistical analysis. This was required 
because of the miniscule amounts of total protein available, and because the CHD5 
complex was far from fully purified. 
 
Samples 1 and 2 were directly compared to identify proteins that were specifically 
enriched in the peak fractions (Table 4.2A). The list of enriched proteins was 
manually curated to eliminate common non-specific contaminants detected by 
mass spectrometry. Strikingly, many known subunits of the NuRD complex were 
identified as being enriched in the peak CHD5 fractions, suggesting that the native 
CHD5 complex present in mouse brains is similar in composition to the canonical 
NuRD complex containing CHD3 or CHD4. Nevertheless, several other proteins 
(highlighted in green) were plausible candidates for being subunits of the CHD5 
complex and deserved further validation (Table 4.2A). 
 
The tail of the CHD5 peak can be resolved over a shallower salt gradient as a 
separate sub-population of CHD5 (Figure 4.5). This separate species of CHD5 
roughly corresponds to sample 3 of the initial purification. Comparison of samples 3 
and 2 only revealed one protein to be specifically enriched in the second CHD5 
peak – KIAA1045 (Table 4.2B). 
 
A. Enriched in Sample 1 vs. Sample 2 
Name Test Score 
Label-Free Quantification (LFQ) Intensity 
PEP 
Value Sample 1 (87-89) Sample 2 (81-83) Sample 3 (92-94) 
1 2 3 1 2 3 1 2 3 
Spin1 8.76 
4.66E
+06 
3.90E
+06 
3.07E
+06 0 0 0 0 
9.46E
+05 
7.90E
+05 
8.60E-
14 
Pura 8.16 
1.25E
+06 
1.27E
+06 
1.28E
+06 0 0 0 
1.18E
+06 
1.16E
+06 
1.18E
+06 
1.64E-
06 
Mta1 7.40 
2.06E
+06 
1.89E
+06 
1.44E
+06 0 0 0 
3.15E
+06 
2.22E
+06 
1.46E
+06 
5.58E-
15 
Khsrp 6.83 
1.69E
+06 
2.00E
+06 
1.70E
+06 
3.64E
+05 0 
4.17E
+05 
3.92E
+06 
3.33E
+06 
3.86E
+06 
1.26E-
25 
Csde1 6.53 9.35E 1.23E 1.32E 0 0 0 9.75E 9.54E 1.31E 1.96E-
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+05 +06 +06 +05 +05 +06 10 
Elavl2;El
avl4 5.87 
8.69E
+05 
9.33E
+05 
9.82E
+05 
2.13E
+05 0 0 
7.34E
+05 
6.92E
+05 
7.07E
+05 
3.12E-
14 
Sbf1 5.85 
2.86E
+07 
2.66E
+07 
3.02E
+07 
5.44E
+06 
7.07E
+06 
5.99E
+06 
5.74E
+06 
7.09E
+06 
5.55E
+06 
1.04E-
76 
Chd5 5.26 
9.12E
+08 
8.55E
+08 
8.43E
+08 
4.27E
+07 
5.57E
+07 
5.47E
+07 
5.16E
+08 
4.93E
+08 
3.91E
+08 0 
Glyr1 4.94 
1.12E
+06 
1.71E
+06 
1.60E
+06 0 0 0 
4.40E
+05 
1.35E
+06 
1.09E
+06 
3.74E-
82 
Gatad2b 4.91 
1.79E
+07 
2.20E
+07 
2.27E
+07 
3.30E
+06 
2.87E
+06 
2.48E
+06 
1.05E
+07 
7.81E
+06 
1.05E
+07 
2.70E-
52 
Naca 4.87 
1.27E
+06 
1.95E
+06 
1.70E
+06 0 0 0 
2.23E
+05 
3.85E
+05 
2.71E
+05 
1.78E-
53 
Mta3 4.71 
4.59E
+05 
7.77E
+05 
5.84E
+05 0 0 0 
8.86E
+05 
6.67E
+05 0 
1.44E-
12 
Hdgfrp3 4.46 
2.70E
+05 
4.61E
+05 
3.21E
+05 0 0 0 
3.84E
+05 
4.04E
+05 
5.85E
+05 
4.71E-
03 
Gatad2a 4.30 
3.41E
+06 
3.46E
+06 
2.66E
+06 
7.62E
+05 0 0 
1.53E
+06 
1.32E
+06 
2.02E
+06 
1.16E-
37 
Hdac2 4.28 
1.71E
+06 
1.47E
+06 
6.02E
+05 
1.31E
+05 0 0 
1.33E
+06 0 0 
4.09E-
18 
Dhx57 3.95 
3.03E
+07 
3.07E
+07 
2.96E
+07 
1.49E
+07 
1.50E
+07 
1.51E
+07 
5.31E
+07 
4.47E
+07 
2.50E
+07 
3.71E-
107 
Api5 3.73 
1.22E
+05 
2.70E
+05 
2.70E
+05 0 0 0 0 0 0 
1.10E-
06 
Rbbp4;R
bbp7 3.45 
2.93E
+06 
4.25E
+06 
4.04E
+06 
5.27E
+05 
4.59E
+05 0 
5.59E
+06 
4.49E
+06 0 
2.31E-
57 
Mtmr1 3.01 
1.62E
+06 
1.39E
+06 
1.32E
+06 
5.14E
+05 
5.31E
+05 
4.96E
+05 0 
4.03E
+05 0 
9.04E-
15 
Ddx5 2.78 
3.11E
+06 
4.73E
+06 
4.88E
+06 
2.49E
+06 
2.33E
+06 
3.07E
+06 
2.37E
+06 
2.38E
+06 0 
1.83E-
54 
Cdk2ap1;
Cdk2ap2 2.62 
5.49E
+06 
4.40E
+06 
4.99E
+06 
1.39E
+06 
1.00E
+06 0 
2.41E
+06 
2.41E
+06 
2.40E
+06 
1.41E-
23 
Phxr5 2.49 
1.19E
+06 
4.51E
+05 
4.54E
+05 
2.92E
+05 0 0 
1.43E
+05 0 0 
1.83E-
03 
Myef2 2.30 
2.07E
+05 
2.99E
+05 
1.50E
+05 
9.09E
+04 0 0 
7.73E
+05 
5.98E
+05 0 
1.92E-
09 
B. Enriched in Sample 3 vs. Sample 2 
Name Test Score 
Sample 1 (87-89) Sample 2 (81-83) Sample 3 (92-94) PEP 
Value 1 2 3 1 2 3 1 2 3 
Kiaa1045 3.87 0 0 
1.55E
+05 0 0 0 
2.83E
+06 
3.24E
+06 
4.59E
+06 
7.06E-
27 
Table 4.2 – Proteins Enriched by Purification of CHD5 from Mouse Brains 
A. Each of the three main peaks from the Mini S PC 3.2/3 was injected onto the mass 
spectrometer three times. Proteins enriched in sample 1 (first CHD5 peak; middle of the 
gradient) compared to sample 2 (low CHD5; start of the gradient) are listed here, though 
the data has been manually curated to omit common contaminants. CHD5 is highlighted 
in blue, whereas the NuRD subunits are coloured yellow. The most interesting of the 
putative subunits are highlighted in green. 
B. This table lists the proteins enriched in sample 3 (second CHD5 peak; end of the 
gradient) compared to sample 2 (low CHD5, start of the gradient), though the data has 
been manually curated to omit common contaminants. 
 
The abundance of each protein across the various samples and replicate injections 
can be clearly visualized in profile plots (Figure 4.4). Hence, it enables assessment 
of how closely a putative CHD5 subunit recapitulates the elution pattern of CHD5. 
Unsurprisingly, the NuRD complex subunits behave similarly to CHD5, being 
detected in fairly high levels in both CHD5 sub-populations (Figure 4.4A). Curiously, 
the putative CHD5 complex subunits appear to be specific to either one of the two 
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subsets – Spindlin1, Pura, Sbf1 and Glyr1 are specifically enriched in sample 1, 
whereas KIAA1045 is enriched in only sample 2 (Figure 4.4B). 
 
 
Figure 4.4 – LFQ Intensity Profile Plots of Proteins Identified by Mass Spectrometry 
from the CHD5 Purification 
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A. Each grey line represents the LFQ intensities of one protein from the CHD5 purification 
across the various samples and replicate injections. The CHD5 profile plot is shown in 
blue, while the NuRD complex subunits are indicated in red. The NuRD complex 
subunits behave similarly to CHD5 in this purification, being present in relatively high 
quantities in both CHD sub-populations 
B. The profile plots of the putative CHD5 subunits are highlighted here. (KIAA1045 is 
shown in green, Sbf1 in pink, Pura in orange, Glyr1 in brown and Spindlin in brown.) 
This diagram illustrates the specificity of these novel factors for one or the other subset 
of CHD5. 
 
The NuRD complex may undergo combinatorial subunit assembly, particularly in 
terms of its MBD2/MBD3 and MTA1/MTA2/MTA3 subunits. Thus, the mass 
spectrometry data was analysed to assess whether the CHD5-NuRD complex 
differs in composition from the canonical NuRD complex. Both MBD2 and MBD3 
are canonical NuRD complex subunits, though their presence in a single complex 
is mutually exclusive (Le Guezennec et al., 2006). Neither protein was enriched in 
the CHD5 purification from mouse brains (Table 4.2), though both were associated 
with over-expressed CHD5 in 293T cells (Table 4.1). Nevertheless, CHD5 has 
been reported to physically interact with both MBD2 and MBD3 (Potts et al., 2011, 
Quan et al., 2014, Kolla et al., 2015). This is consistent with the observation that 
most cell types, apart from ESCs, express both MBD2 and MBD3 (Kaji et al., 2006, 
Gunther et al., 2013). 
 
MTA1 and MTA3 were identified as being enriched in both the CHD5 purifications 
from mouse brains and 293T cells (Tables 4.1 and 4.2A). However, MTA2 was not 
identified to associate with CHD5 in either purification. This is in contrast to 
previous reports that observed an interaction between CHD5 and MTA2 (Quan et 
al., 2014, Kolla et al., 2015). Nevertheless, since CHD5 was not purified from 
mouse brains in sufficient quantities for its stoichiometric complex subunits to be 
identified conclusively, it is impossible to conclude definitively that MTA2 is absent 
from the CHD5-NuRD complex in mouse brains. Nevertheless, this observation is 
certainly intriguing and worthy of further exploration, though the functional 
significance of a NuRD complex lacking MTA2 is unclear. 
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4.2.3 Characterization of Putative CHD5 Complex Subunits 
Genuine subunits of a stable multi-subunit protein complex should precisely co-
elute with each other from a column. Thus, CHD5 was purified again as described 
earlier (Figure 4.3A), though a shallower salt gradient was used to fully resolve the 
two CHD5 sub-populations (Figure 4.5). In agreement with the mass spectrometry 
analysis, MTA1, a subunit of the NuRD complex, is associated with both CHD5 
subsets. In addition, out of the five putative subunits identified, Sbf1 and KIAA1045 
were also seen to precisely co-elute with CHD5 by Western blotting. Moreover, 
confirming the mass spectrometry analysis, Sbf1 and KIAA1045 exclusively interact 
with only one each of the two sub-populations of CHD5 (Figure 4.5).  
 
 
Figure 4.5 – Co-elution of MTA1, Sbf1 & KIAA1045 with CHD5 
The CHD5 purification from mouse brains was repeated again, though a shallower salt 
gradient was used to elute proteins off the Mini S PC 3.2/3 column. This allows the bi-
phasic nature of CHD5 elution to be clearly visualized. The NuRD complex subunits, such 
as MTA1 shown here, appear to co-elute with both subsets of CHD5. However, Sbf1 
precisely co-elutes with the earlier-eluting CHD5 peak, whereas KIAA1045 only co-elutes 
with the second peak. This result may suggest the concomitant existence of multiple CHD5 
complexes defined by unique subunits that are exclusively present in one or the other. 
 
Although the purified samples appear fairly clean, it remains possible that Sbf1 and 
KIAA1045 are non-specific contaminants of the purification. Traditionally, co-elution 
over multiple columns is required to conclusively identify novel subunits of a stable 
protein complex (Svejstrup et al., 1995, Zhang et al., 1998). However, such 
extensive purification of CHD5 is precluded by the inevitable losses associated with 
each purification step, the limited supply of CHD53FTH/3FTH mouse brains, and the 
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low yields of CHD5 due to its relatively low expression levels. Hence, orthogonal 
approaches were required to validate Sbf1 and KIAA1045. As CHD5 is required for 
neurogenesis, its expression changes during differentiation of SH-SY5Y 
neuroblastoma cells. Thus, the changes in expression of CHD5 during neural 
differentiation was compared to those of Sbf1 and KIAA1045 (Figure 4.6) 
 
 
Figure 4.6 – Changes in Expression of Putative CHD5 Subunits upon Differentiation 
of SH-SY5Y Cells 
A. This schematic illustrates the SH-SY5Y differentiation protocol. SH-SY5Y cells seeded 
in poly-D-lysine-coated dishes were induced to differentiate by 10µM all-trans retinoic 
acid. Differentiated cells are characterized by the presence of long neurites. 
B. Successful neuronal differentiation is indicated by the upregulation of MAP2, a 
microtubule-associated protein enriched in dendrites. CHD5 levels increased 
significantly early in the differentiation process before returning to baseline levels. In 
contrast, Sbf1 levels increased progressively throughout differentiation, while KIAA1045 
levels experienced a gradual reduction. Thus, there is no direct correlation between the 
expression patterns of CHD5, Sbf1 and KIAA1045. As a negative control, a plate of SH-
SY5Y cells was also cultured for twelve days, but in the absence of retinoic acid. 
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The SH-SY5Y neuroblastoma cell line is a well-defined model system for studying 
neuronal differentiation as it differentiation can be reproducibly achieved by retinoic 
acid (Korecka et al., 2013, Wang et al., 2014b). Moreover, neuronal differentiation 
can be monitored by reliable molecular markers such as an up-regulation of the 
microtubule-associated protein, MAP2, which is enriched in dendrites (Figure 4.6B). 
In contrast, SH-SY5Y cells cultured for the same duration in the absence of retinoic 
acid failed to up-regulate MAP2, implying that the changes observed in protein 
expression were specific to neuronal differentiation and not an artefact of a 
protracted duration in culture. 
 
CHD5 is expressed at relatively low levels in wild type SH-SY5Y neuroblastoma 
cells. It is, however, rapidly upregulated early in neuronal differentiation; for 
example, in this experiment, the highest CHD5 levels were observed three days 
after inducing differentiation with retinoic acid (Figure 4.6B). While the expression 
of Sbf1 also increased during neuronal differentiation, it did so with different 
kinetics to CHD5 – the amount of Sbf1 protein increased progressively over the 
entire twelve-day differentiation protocol. While KIAA1045 is annotated as being 
preferentially expressed in brains and in the testis (Genecards), its expression in 
SH-SY5Y cells changed only subtly upon differentiation, with a slight reduction in 
its expression being observed (Figure 4.6B). Thus, neither of the two proteins 
demonstrated to precisely co-elute with CHD5 from the Mini S PC 3.2/3 column 
displays regulated fluctuations in expression level during differentiation that are 
similar to that of CHD5. While this result per se did not disprove the hypothesis that 
Sbf1 and KIAA1045 are stoichiometric subunits of stable CHD5 complexes, it was 
discouraging and indicated that the biochemical data needed to be incontrovertible. 
4.2.4 An Alternative CHD5 Purification Strategy from Mouse Brains 
In theory, purification over an ion exchange column results in an increase in the 
concentration of the sample. However, in the case of CHD5, the increase in sample 
concentration did not materialize, as CHD5 eluted across multiple fractions and 
was consequently diluted into a relatively large sample volume (Figure 4.5). 
Nevertheless, it is important to recognize that the considerable width of the CHD5 
peak does not reflect a poorly performing column since it is observed reproducibly 
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with different columns; instead, it suggests that differentially spliced or post-
translationally-modified forms of CHD5 are sufficiently distinct from each other in 
surface charge to be resolved into separate peaks. Regardless of the biological 
significance of the result, however, subsequent purification of the sample by 
chromatography is challenging, as there is only a small volume of each CHD5 sub-
population. Coupled with the very low protein concentration of the sample and the 
inevitable losses associated with sample manipulation, additional purification by 
chromatography would, in all likelihood, reduce the concentration to below the 
detection threshold. However, we rationalized that ion exchange columns 
formulated with different resin chemistries would bind non-specifically to different 
groups of contaminants. Thus, we decided to validate the putative CHD5 complex 
subunits by assessing whether they co-eluted with CHD5 from a different column. 
 
Consequently, an alternative purification strategy was developed to isolate CHD5 
from mouse brains (Figure 4.7A). As before, initial purification by FLAG affinity 
chromatography successfully enriched for CHD5 from mouse brain extract (Figure 
4.7B). A MAbPac SCX-10G cation exchange column (Thermo-Fisher Scientific) 
was used for the subsequent purification step. While the sulphonic acid functional 
group of the MAbPac SCX-10G column is similar to that of the Mini S PC 3.2/3 
column used previously, it is coupled to a proprietary pellicular substrate that is 
purported to eliminate hydrophobic interactions due to a hydrophilic surface coating. 
While elution of CHD5 from the MAbPac SCX-10G was once again in a broad peak, 
the column appears to separate on the basis of the concomitant presence of a 
slower-migrating band that is probably indicative of a post-translational modification. 
Crucially, neither Sbf1, nor KIAA1045, nor any of the other putative subunits 
previously short-listed, was identified to co-purify with CHD5 by either Western 
blotting or mass spectrometry analysis (Table 4.3). 
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Figure 4.7 – An Alternative Purification Strategy for CHD5 from Mouse Brains 
A. CHD5 was purified from mouse brains by sequential FLAG affinity and cation exchange 
chromatography as before. However, a MAbPAc SCX-10G column was used instead. 
While the sulphonic acid functional group responsible for binding is similar for both 
columns, the underlying resin substrate is different. The MAbPac SCX-10G column is 
supposed to eliminate non-specific hydrophobic interactions and support high efficient 
separations due to faster mass transfer. 
B. As previously observed, CHD5 was efficiently enriched from chromatin extract by FLAG 
purification. 
C. CHD5 elutes across the majority of the salt gradient. However, this column appears to 
separate CHD5 into predominantly modified or unmodified sub-populations. This is best 
appreciated on the silver-stained gel. 
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For the best chance of identifying factors that specifically co-purify with CHD5, all 
twenty-one fractions from the MAbPac SCX-10G column seen in Figure 4.7C were 
analysed by tandem LC-MS (Figure 4.8). The fifty proteins that behaved most 
similarly to CHD5 over all the fractions, using Euclidean distance from the CHD5 
reference plot as the ranking criterion, were short-listed (Figure 4.8B). This list of 
proteins was then manually curated to exclude common contaminants of mass 
spectrometry experiments (Table 4.3). Strikingly, with the notable exception of 
NuRD complex subunits (Figure 4.8A), this list is largely free from overlap with the 
proteins previously identified to co-purify with CHD5 (compare Tables 4.2 and 4.3). 
 
Name Δ iBAQ Scores of Fractions PEP Value 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
Chd5 0 4.0 4.2 4.9 4.6 4.5 4.5 4.4 4.7 4.5 4.6 4.0 4.6 4.5 4.2 4.6 4.4 5.3 4.4 4.1 4.8 4.7 0 
Zc3h3 5.2 3.4 3.4 2.8 3.5 3.5 3.2 3.3 3.4 3.6 3.5 3.4 3.3 3.2 3.8 3.4 3.3 4.0 3.1 4.0 3.4 3.8 2.15E-03 
Jup 5.2 4.2 3.6 4.0 3.4 3.9 3.7 4.2 3.1 4.3 3.7 2.1 4.2 2.3 2.4 4.1 4.2 3.3 4.0 3.1 3.2 3.9 
3.13E-
216 
Mtap1b 5.7 3.9 4.3 4.6 4.3 4.4 4.1 3.8 4.1 3.9 3.7 3.8 3.4 3.4 3.1 3.3 3.0 2.8 2.7 1.3 2.9 3.1 
8.94E-
288 
Clasp2 6.3 3.4 4.1 5.1 4.8 5.0 4.7 4.3 4.5 4.2 3.9 4.1 3.9 3.7 3.3 3.1 2.9 3.1 1.3 1.3 2.1 3.2 
3.06E-
273 
Anxa2 7.1 3.2 2.8 3.5 3.7 3.6 3.7 3.8 3.4 3.9 3.9 2.5 4.1 3.5 3.2 3.9 3.8 1.3 1.3 1.3 3.4 4.0 3.65E-51 
Gatad2b 7.5 3.1 3.8 4.2 4.1 4.2 3.2 3.4 4.0 3.9 3.3 3.5 2.4 2.6 1.3 2.8 1.3 3.7 1.3 2.7 3.0 3.2 1.52E-46 
Dsp 7.6 3.7 3.2 2.4 2.6 3.5 3.5 3.9 2.4 4.0 3.4 1.3 3.8 1.6 1.6 3.7 3.7 2.9 3.6 2.3 3.2 3.8 
1.95E-
197 
Hist1h4a 7.8 4.6 3.7 3.6 3.2 3.1 1.3 4.4 3.4 3.7 1.3 3.6 4.6 3.1 1.3 3.4 1.3 4.7 3.9 1.3 4.1 3.9 5.53E-37 
Sprr2h 8.0 2.9 3.5 3.5 3.3 3.9 4.1 3.0 3.1 3.9 3.5 1.3 4.3 1.3 1.3 3.4 3.6 3.8 3.9 1.3 1.3 3.5 5.32E-05 
Ubc 8.6 3.1 2.7 3.2 2.9 2.5 2.7 2.6 2.5 3.1 2.7 1.3 2.8 1.3 2.0 2.7 3.0 3.2 3.0 2.8 3.0 3.4 6.29E-06 
Mbp 8.9 3.2 3.9 4.3 4.2 4.8 3.9 3.8 4.6 4.5 3.7 4.0 1.3 3.3 1.3 2.9 1.3 3.5 1.3 1.3 1.3 1.3 1.98E-70 
Aldh1l1 9.7 5.4 6.0 5.7 4.5 4.8 4.6 2.8 4.0 4.2 2.5 3.8 2.7 2.4 1.3 1.3 1.3 1.3 1.3 1.3 2.2 2.4 0 
Dsg1b 9.8 2.9 2.9 1.3 2.8 2.8 2.7 2.6 1.3 3.3 1.3 1.3 3.1 1.3 1.3 2.7 3.0 2.9 3.1 3.5 3.6 3.9 3.35E-08 
Cacna1d 10.0 2.9 3.0 2.7 3.2 3.0 3.2 3.2 3.2 3.2 3.0 3.3 1.3 3.0 2.9 2.8 2.5 1.3 1.3 1.3 1.3 1.3 2.17E-04 
Eef1a1 10.2 3.2 1.3 2.7 2.9 3.0 2.4 3.7 3.1 2.9 1.3 1.3 3.9 1.3 1.3 3.3 3.3 1.3 1.3 1.3 3.6 3.5 5.94E-20 
Prdx2 10.3 3.7 3.2 3.2 3.1 3.3 1.3 3.2 2.7 3.6 3.0 2.7 3.7 1.3 1.3 3.6 3.4 1.3 1.3 1.3 1.3 1.3 2.54E-03 
Pkp1 10.8 2.7 2.3 1.3 2.3 3.1 2.2 4.2 1.3 3.2 3.1 1.3 3.6 1.3 1.3 3.3 3.0 1.3 1.3 1.3 2.6 3.1 1.59E-56 
Tada2b 11.0 3.0 3.2 1.3 3.5 3.0 3.5 1.3 1.3 3.2 3.4 1.3 3.1 1.3 1.3 3.2 3.3 1.3 1.3 1.3 1.3 3.4 2.67E-05 
Atp6v0a1 11.4 4.3 4.4 4.8 4.1 4.7 4.1 1.3 3.8 3.9 1.3 3.1 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 4.37E-85 
Stk38 11.6 2.3 3.9 5.1 3.6 4.7 3.2 1.3 3.9 3.4 2.7 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 
2.33E-
105 
Atp6v0d1 11.7 4.0 4.1 4.0 3.6 4.0 1.3 1.3 3.7 3.5 2.6 2.7 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.00E-11 
Tnrc6b 11.8 2.6 3.4 4.0 3.5 3.6 3.5 2.5 2.2 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 3.3 1.3 1.3 1.3 1.3 0 
Dhx57 11.8 1.3 1.3 1.3 1.7 1.9 2.3 2.8 3.2 3.0 3.2 3.2 3.0 2.8 2.1 2.4 1.3 1.3 1.3 1.3 1.3 1.3 3.23E-26 
Mta1 11.9 1.3 3.2 3.7 3.3 3.6 3.1 1.3 3.1 3.5 1.3 3.0 1.3 2.2 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.28E-20 
Sprr1b 11.9 1.3 1.3 1.3 1.3 3.8 3.5 1.3 1.3 3.7 3.2 1.3 4.2 1.3 1.3 3.1 3.2 1.3 1.3 1.3 1.3 3.3 4.59E-04 
Rbbp4 11.9 3.1 3.6 3.5 2.9 3.4 2.5 1.3 3.5 3.5 1.3 3.0 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.16E-07 
Hdac2 12.0 1.3 3.5 3.9 2.6 3.6 1.3 1.3 3.4 3.7 1.3 2.5 1.3 1.3 1.3 1.3 1.3 3.2 1.3 1.3 1.3 1.3 1.76E-12 
Cdk2ap1 12.1 3.3 4.1 4.5 4.3 4.2 1.3 1.3 4.0 3.9 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.24E-05 
Table 4.3 – Proteins Enriched by Purification of CHD5 Using the MAbPac SCX-10G 
Column that Behave most Similarly to CHD5 
Fractions from the MAbPac SCX-10G gradient were analysed by LC-MS. The elution 
pattern of each protein across the gradient was compared to that of CHD5 on the basis of 
Euclidean distance (the Δ column in this table). Proteins that were undetected in are 
sample were arbitrarily assigned the iBAQ score of 1.3, which is the score of the least 
abundant protein detected in the sample. The 50 proteins that behaved most similarly to 
CHD5 (indicated in blue) are listed in this table, though the dataset was manually curated 
to exclude well-known contaminants. This list of proteins is highly enriched in NuRD 
complex components (highlighted in yellow). None of the other proteins identified can be 
convincingly described as CHD5 complex subunits. 
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Figure 4.8 – Profile Plots of Proteins Identified from the MAbPac SCX-10G Column 
Fractions Containing CHD5 
A. The abundance (iBAQ values) of CHD5 in these selected fractions from the MAbPac 
SCX-10G column is illustrated graphically in blue. Each pink line corresponds to a 
unique NuRD complex subunit. The overall similarity in elution pattern of CHD5 and the 
NuRD complex subunits can be appreciated. 
B. The fifty proteins that behaved most similarly to CHD5, using Euclidean distance from 
the CHD5 reference plot as the ranking criterion, are indicated in red.  
 
The failure to observe co-purification of Sbf1 and KIAA1045 with CHD5 over the 
MAbPac SCX-10G column strongly argues against them being genuine subunits a 
CHD5 complex. Considering all the results holistically, the only strong conclusion 
that can be drawn is that CHD5 forms a NuRD-like complex in mouse brains. 
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However, the precise composition of the complex cannot be determined from these 
data since CHD5 could not be purified from mouse brains in sufficient quantities for 
all of its stoichiometric subunits to be clearly visualized by silver staining (Figure 
4.3C and 4.7C). Unfortunately, this study was unable to identify novel subunits of 
the CHD5 complex. The lack of overlap between the lists of proteins identified to 
co-purify with CHD5 using the two complementary purification protocols argues 
against the existence of such subunits. Given the relatively small quantities of 
CHD5 and correspondingly, its subunits, that could be purified, it is possible that 
some subunits were below the detection limit of mass spectrometry. As each tryptic 
peptide has a certain probability of failing to give rise to detectable spectra, failure 
of detection by mass spectrometry is more of an issue for small proteins that are 
inherently limited in the number of peptides that they can generate. Yet, the 
unparalleled sensitivity of modern mass spectrometers suggests that this is an 
unlikely possibility, though one that cannot be formally excluded. 
 
4.3 Conclusions 
CHD5 is a tissue-specific chromatin remodeller that is specifically expressed in the 
central nervous system and in the testis. While CHD5 has been previously 
described to interact with components of the NuRD complex, we anticipated that its 
complex would contain unique subunits that confer upon it the ability to regulate 
developmental processes. To address this question, we sought to isolate the native 
CHD5 complex from mouse brains, a tissue in which CHD5 is preferentially 
expressed. While an efficient purification strategy combining the specificity of FLAG 
affinity chromatography and the resolution of ion exchange chromatography was 
developed, the yields remained modest due to the low expression of CHD5. 
Although extensive mass spectrometry analysis was performed to thoroughly 
identify proteins co-purifying with CHD5, no novel complex subunits could be 
reliably identified for CHD5. However, NuRD complex subunits were consistently 
enriched in these CHD5 purifications, thereby reinforcing the paradigm of a NuRD-
like CHD5 complex. 
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Yet, the question of how CHD5 achieves its tissue-specific functions, for which 
CHD3 and CHD4 cannot compensate via functional redundancy, remains an 
unresolved matter (Egan et al., 2013). Indeed, the failure to identify novel complex 
subunits specific to CHD5 suggests that the CHD5 protein autonomously confers 
these unique functions upon itself. Yet, CHD5 shares significant sequence 
similarity with CHD3 and CHD4, and lacks additional annotated protein domains 
that might affect its genomic localization or substrate specificity. Thus, additional 
biochemical and structural studies characterizing the CHD5 protein are required to 
establish a framework through which its roles in development can be understood 
mechanistically. 
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Chapter 5. Discussion I: Insights from the 
Purification of Endogenous CHD1 and CHD5 from 
Native Tissues 
CHD1 and CHD5 are chromatin remodelling SWI2/SNF2-like ATPases that have 
important functions in the development of higher eukaryotes. Yet, these enzymes 
remain poorly characterized at a mechanistic level. Here, the purification of 
endogenous CHD1 and CHD5 from appropriate tissue sources has been described. 
However, no novel complex subunits were conclusively identified for either protein. 
Similar to its budding yeast and fruit fly orthologues, mouse CHD1 does not stably 
interact with any other co-factor as part of a stoichiometric complex. In contrast, 
CHD5 appears to assemble into a canonical NuRD complex without any additional 
unique subunits. 
 
5.1 Combinatorial Subunit Assembly of Chromatin 
Remodelling Complexes 
Chromatin remodellers regulate a diverse range of biological processes; at an 
organismal level, their functions include the regulation of specific developmental 
transitions and the maintenance of cellular identity (Lickert et al., 2004, Lessard et 
al., 2007, Wu et al., 2007, Gaspar-Maia et al., 2009, Ho et al., 2009b). This 
functional diversity is accomplished through the varied spectrum of specific 
activities displayed by individual chromatin remodellers, but also through the 
combinatorial assembly of chromatin remodelling complexes. In general, the core 
catalytic subunit is shared between the different complexes, while the unique 
subunits modify its genomic localization or its interaction partners. This represents 
an elegant, yet general biological mechanism that offers specificity of function 
without requiring cells to evolve a multitude of specialized chromatin remodelling 
paralogues. The BAF complex, the mammalian orthologue of the yeast SWI/SNF 
complex, is undoubtedly the most prolific chromatin remodeller at exploiting 
combinatorial subunit assembly. For example, unique BAF complexes specific to 
ESCs, neural progenitor cells, post-mitotic neurons and myocytes are essential for 
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the maintenance of pluripotency, self-renewal of neural progenitors, dendrite 
growth, and cardiac development respectively (Lickert et al., 2004, Lessard et al., 
2007, Wu et al., 2007, Ho et al., 2009b). In fact, combinatorial subunit assembly 
has even been exploited in a subset of synovial sarcomas to facilitate 
carcinogenesis – the SS18-SSX fusion protein, which arises from a specific 
chromosomal translocation, competitively assembles into the BAF complex, before 
mediating transcriptional de-repression of the proto-oncogene, Sox2 (Kadoch and 
Crabtree, 2013).  
 
Cell type-specific functions have been ascribed to both CHD1 and CHD5. 
Specifically, CHD1 is essential for maintaining the defining traits of self-renewal 
and pluripotency of ESCs, whereas CHD5 is a tissue-specific chromatin remodeller 
that is required for the terminal differentiation of neurons (Gaspar-Maia et al., 2009, 
Egan et al., 2013). Consequently, we speculated that the parallels between the 
BAF complexes and these CHD proteins extended beyond possessing similar 
biological functions, to also being organized in a combinatorial manner. However, 
CHD1 does not exist as part of a stable, multi-subunit protein complex. CHD5 
appears to be assembled into the canonical NuRD complex; neither definite 
preferences for specific MBD or MTA proteins, nor novel complex subunits was 
identified. Thus, these CHD chromatin remodellers must have acquired functional 
diversity through a means other than by combinatorial assembly; although the 
precise mechanistic details remain uncertain, it is possible to construe speculative, 
yet plausible models for their activities, as discussed below. 
 
5.2 CHD1 Functions as a Monomer 
Monomeric chromatin remodellers are not unprecedented. Indeed, the budding 
yeast and fruit fly orthologues of CHD1 are characterized to be principally 
monomeric enzymes that can nonetheless regulate transcription termination and 
pre-mRNA splicing, or mediate the removal of a promoter nucleosome in a gene 
activator-dependent manner (Alen et al., 2002, Sims et al., 2007, Ehrensberger and 
Kornberg, 2011). In fact, it is entirely believable that CHD1 acts principally as a 
monomer since it possesses DNA-binding ability through its C-terminal SANT and 
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SLIDE domains. Moreover, its general specificity for DNA may be conferred by the 
ability of its tandem chromodomains to recognize histone tails tri-methylated at 
lysine 4 (H3K4me3), an active mark (Flanagan et al., 2005, Sims et al., 2005). 
(Although the binding specificity for the H3K4me3 mark was demonstrated for the 
chromodomains of human CHD1, the mouse CHD1 chromodomains are virtually 
identical, except for a few unconserved residues that are substituted with amino 
acids of the same charge characteristics.) Correspondingly, ChIP-seq of CHD1 in 
MEFs indicates that it binds just downstream of the transcription start site of genes 
that are also occupied by RNAPII, thereby allowing it to evict the promoter 
nucleosome of actively-transcribed genes at a genome-wide level (Skene et al., 
2014). This association with active genes is evolutionarily conserved since CHD1 
localizes to the de-condensed interband and puff regions of polytene chromsomes 
(Kelley et al., 1999). 
 
It may be possible that the main functions of CHD1 in ESCs are the same ones it 
plays in other cells – to maintain the overall nucleosome organization and to 
globally facilitate transcription by ejecting the promoter proximal nucleosome that 
would serves as a physical impediment to transcription (Gkikopoulos et al., 2011, 
Skene et al., 2014). This model may be able to explain the preferential expression 
of CHD1 in ESCs observed in this study since higher levels of CHD1 may be 
required to regulate the greater transcriptional activity observed across the entire 
genome of ESCs (Efroni et al., 2008). 
 
However, it remains impossible to exclude the possibility that CHD1 may acquire 
functional specificity from transient protein interactions. Indeed, our failure to 
definitively identify any interaction partners of CHD1 that contribute to its role in 
pluripotency probably reflects a technical limitation of our study. As compared to 
stable complex subunits, transient protein interactions are generally weaker and do 
not interact with every molecule of the protein of interest. Thus, coupled to the 
relatively low expression of CHD1, the signal-to-noise ratio of CHD1 interactors 
was low, compromising identification of genuine hits. These technical limitations 
could be surmounted through quantitative proteomics, for example by the stable 
isotope labeling by amino acids in culture (SILAC) technique, since the differences 
in abundance of a protein between samples could then be measured quantitatively 
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rather than approximated. Future characterization of the CHD1 interactome in 
ESCs should also introduce differentiated CHD1-tagged cells as an additional 
control to distinguish between interaction partners of CHD1 that occur specifically 
in ESCs and those that bind regardless of cell state.  
 
5.3 The CHD5-NuRD Complex 
Unlike combinatorial subunit assembly in BAF complexes, where the catalytic 
subunit remains constant but accessory subunits are swapped to reflect the 
specific cell type, the NuRD complex appears to substitute its catalytic subunit to 
reflect the cellular context. CHD5 was observed to associate reliably with canonical 
subunits of the NuRD complex. Indeed, using different model systems, several 
groups have now independently reported that CHD5 is incorporated into canonical 
NuRD complexes (Kolla et al., 2014, Quan et al., 2014). However, while it is clear 
that CHD5 has the ability to associate with the fully assembled NuRD complex, it 
remains uncertain whether or not diversification through the formation of partial 
sub-complexes that only consist of a few of the NuRD complex subunits along with 
CHD5 occurs simultaneously. 
 
The possibility that the CHD5-NuRD complex might have strong preferences for 
specific MBD (i.e. MBD2 or MBD3) or MTA (i.e. MTA1, MTA2 or MTA3) subunits 
was also considered. Although neither MBD2 nor MBD3 was enriched in the CHD5 
purification from mouse brains, both were associated with over-expressed CHD5 in 
293T cells. The literature also suggests that CHD5 can physically interact with both 
MBD2 and MBD3 (Potts et al., 2011, Quan et al., 2014, Kolla et al., 2015). This is 
consistent with the observation that most cell types, apart from ESCs, express both 
MBD2 and MBD3 (Kaji et al., 2006, Gunther et al., 2013). 
 
MTA1 and MTA3 were identified as being enriched in both the CHD5 purifications 
from mouse brains and 293T cells (Tables 4.1 and 4.2A). However, MTA2 was not 
identified to associate with CHD5 in either purification. This is in contrast to 
previous reports that observed an interaction between CHD5 and MTA2 (Quan et 
al., 2014, Kolla et al., 2015). Nevertheless, since CHD5 was not purified from 
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mouse brains in sufficient quantities for its stoichiometric complex subunits to be 
identified conclusively, it is impossible to conclude definitively that MTA2 is absent 
from the CHD5-NuRD complex in mouse brains. Nevertheless, this observation is 
certainly intriguing and worthy of further exploration, though the functional 
significance of a NuRD complex lacking MTA2 is unclear. Although all three MTA 
homologues biochemically co-purify with the NuRD complex, there are indications 
that they may mediate subtly different biological effects {Xue, 1998 #215;Zhang, 
1998 #59;Zhang, 1999 #295;Fujita, 2003 #297;Yao, 2003 #296;Le Guezennec, 
2006 #238}. For example, though both MTA1 and MTA2 are potent transcriptional 
repressors, MTA3 performs this role less efficiently (Yao and Yang, 2003). In vitro 
data also suggests that MTA2 enhances the histone deacetylase activity of the 
NuRD complex; its homologues, MTA1 and MTA3, however, have not been 
assessed for this capability (Zhang et al., 1999). Finally, in breast glandular 
epithelium, MTA3, whose expression is dependent on oestrogen signalling, 
appears to have a specific role in promoting the expression of the epithelial cell-
adhesion molecule, E-cadherin. In breast cancer cells, the absence of MTA3 is 
associated with E-cadherin down-regulation and epithelial-to-mesenchymal cell 
transition, which promotes tumour invasion. This is because MTA3 acts, probably 
directly, as a transcriptional repressor of the transcriptional factor, Snail, which 
inhibits E-cadherin expression (Fujita et al., 2003).  
 
BAF complexes do not readily exchange free subunit molecules for those already 
incorporated into existing complexes (Lessard et al., 2007, Wu et al., 2007, Kadoch 
and Crabtree, 2013). Tissue-specific BAF complexes probably arise because cell 
type-specific subunits are present at comparatively high concentrations and 
consequently, are favoured for incorporation into BAF complexes over canonical 
subunits. Thus, the subunit composition of BAF complexes reflects the relative 
expression level of cell-type specific subunits. For example, coincident with 
terminal differentiation of neural progenitor cells into post-mitotic neurons, the 
expression of the progenitor-specific subunits, BAF45a and BAF53a, are 
dramatically suppressed, with a corresponding induction of the post-mitotic-specific 
BAF45b and BAF53b subunits. This abrupt volte-face reversal in expression 
establishes a defined transition in the composition and function of the BAF complex, 
commensurate with the requirements of the cell at either differentiation state 
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(Lessard et al., 2007). It is possible that the BAF complex represents an anomaly 
due to its extreme chemical stability – the complex remains stable in a urea 
concentration of up to two molar (Kadoch and Crabtree, 2013). However, it could 
also be suggested that the NuRD complex is regulated in a similar fashion since 
the expression of CHD5 during spermatogenesis anti-correlates with that of CHD3 
and CHD4. CHD5 expression is undetectable in germ cells and during early 
spermatogenesis, but is readily detectable in post-meiotic late round spermatids. 
Conversely, CHD3 and CHD4 expression is highest in immature germ cells (i.e. in 
spermatogonia and spermatocytes), but is considerably diminished later in 
spermatogenesis (Bergs et al., 2014). However, this formal confirmation of this 
hypothesis awaits further characterization in vitro with purified components.  
 
The main implication of this study is, however, that the functional differences 
between CHD3/CHD4 and CHD5 can probably be attributed to the catalytic 
subunits themselves. Yet, CHD5 shares a considerable degree of sequence 
similarity with CHD3 and CHD4, especially in terms of its histone mark reading and 
ATPase domains. These paralogues differ most considerably in the C-termini, 
which do not contain any known functional domains. Small protein domains that 
auto-regulate the catalytic activity of the helicase-like ATPase domain have been 
identified in other chromatin remodellers; hence, it is possible that comparable 
regulatory motifs distinguish CHD5 from CHD3 and CHD4, though extensive 
biochemical characterization of CHD5 will be necessary to investigate the veracity 
of that prediction (Clapier and Cairns, 2012, Wang et al., 2014a). Additionally, while 
CHD5 and CHD4 are both able to increase the accessibility of a chromatin 
template to restriction enzymes, this is achieved by different catalytic activities –
CHD4 slides nucleosomes, whereas CHD5 stably unwraps nucleosomal DNA 
approximately 40-50 base pairs from the end without disrupting the nucleosome 
(Watson et al., 2012, Quan and Yusufzai, 2014). Nonetheless, additional 
biochemical and structural studies are required to fully characterize the differences 
in specific activities between CHD5 and the canonical NuRD complex catalytic 
subunits, CHD3 and CHD4, and the mechanisms underpinning these differences. 
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5.4 Limitations of Proteomic Screens 
Mass spectrometry has long superseded Edman degradation as the method of 
choice for the identification of unknown polypeptides. The main limitation of Edman 
degradation is limited sensitivity. The main limitation of mass spectrometry is that 
not all peptides ‘fly’ equally well; correspondingly, not all proteins are easily 
detected by this approach. On the whole, however, mass spectrometry benefits 
from remarkable sensitivity, though this introduces a challenge in that many 
background contaminants are also identified; consequently, specific hits must be 
distinguished from non-specific ones. The difficulty of identifying bona fide co-
purifying interaction partners by mass spectrometry is exacerbated when they are 
only present in the sample at a low abundance, resulting in a low signal to noise 
ratio. Unfortunately, the proteomic characterizations of the CHD1 interactome and 
the CHD5 complex were blighted by this issue, which resulted primarily from the 
small amounts of CHD1 and CHD5 that could be purified from native tissues. 
Logistical and practical constraints made scaling up the purifications unfeasible. 
 
The selectivity of proteomic screens can be improved considerably by quantitative 
proteomics, most notably with the SILAC approach. With conventional mass 
spectrometry, the failure to detect a given protein in a sample does not prove its 
absence. With SILAC, if the test sample is labelled with a light isotope and the 
control a heavy isotope or vice versa, the difference in abundance of a specific 
protein between the test and control samples can be quantified more accurately – 
since the difference in mass between the light and heavy isotopes is known, it is 
possible to accurately predict the spectral position of a heavy isotope-labelled 
peptide based on the spectrum of the same peptide that is differentially light 
isotope-labelled. Thus, if a protein is detected in the test sample, the absence of 
that same protein from the control sample can be conclusively determined in the 
context of SILAC-mass spectrometry. While such a technique does not necessarily 
improve the signal to noise ratio, it allows the relative abundance of proteins to be 
compared between samples with greater accuracy. Moreover, it is now possible to 
label whole organisms, including mice, in vivo with stable isotopes, thereby making 
quantitative proteomics feasible even for studies such as that of CHD5, where 
mouse brains were used as the source material for purification (Zanivan et al., 
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2012). Alternatively, the signal to noise ratio could be improved by increasing the 
yield of protein from the purification. While this simple strategy is undoubtedly 
effective, it is frequently challenging to purify large quantities of proteins that are 
endogenously expressed at low levels in native tissues.  
 
A typical immunoprecipitation-mass spectrometry (IP-MS) proteomic screen 
identified hundreds to thousands of proteins that appear to be specifically enriched 
over the control. While common contaminants can be discounted, the selection of 
hits for further characterization is frequently a biased and arbitrary process. Thus, 
orthogonal functional screens should ideally complement proteomic screens. For 
example, simultaneously performing a forward genetic screen by RNA interference 
along with IP-MS would allow the identification of hits that not only interact with the 
protein-of-interest, but also regulate the same biological pathway. While validation 
of selected hits with functional assays is typical of IP-MS experiments – and 
pursued to a certain extent in this work – it is inherently limited by selection bias in 
terms of the proteins chosen for further validation. In contrast, combining unbiased 
proteomic and genetic screens grants the greatest opportunity for the identification 
of novel factors for any given biological process. Indeed, other members of the 
Svejstrup Lab have successfully applied this “multi-omics” approach to discovering 
hitherto uncharacterized factors involved in the transcription-related cellular 
response to DNA damage (personal communication with Stefan Boeing and Laura 
Williamson). 
 
Given the largely negative nature of the results described in the previous chapters, 
it was decided to abandon further investigation of the very scarce CHD proteins, 
and instead to focus on a different project, described below. 
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Chapter 6. Results III: Comparison of the Enzymatic 
Activities of SMARCAD1 and the SMARCAD1-KAP1 
Complex 
6.1 Aims 
SMARCAD1 is a predicted chromatin remodelling enzyme on the basis of its 
conserved SWI2/SNF2-like ATPase domain. It promotes the maintenance of a 
repressive chromatin environment by antagonizing histone acetylation and by 
promoting deposition of the H3K9me3 histone mark (Rowbotham et al., 2011). 
Furthermore, as SMARCAD1 stimulates DNA end resection, it also promotes the 
repair of DNA double-strand breaks by homologous recombination (Costelloe et al., 
2012). Despite these important cellular functions, SMARCAD1 remains 
uncharacterized mechanistically. Indeed, it has yet to be demonstrated that 
SMARCAD1 is enzymatically active. Therefore, we wanted to purify recombinant 
SMARCAD1 to assess some of its enzymatic properties in vitro, including its 
substrate preference. 
  
SMARCAD1 has been demonstrated to form a constitutive, stoichiometric 
interaction with KAP1, a transcription repressor that is typically associated with 
heterochromatin (Rowbotham et al., 2011). Chromatin remodellers often feature as 
integral components of multi-subunit protein complexes – the accessory subunits 
often either specify additional specificity in the genomic targets of the enzyme or 
modulate the remodeller’s enzymatic activity. Thus, we also wanted to investigate 
the effect of KAP1 on the enzymatic activity of SMARCAD1. 
 
6.2 Results 
6.2.1 Purification of Recombinant SMARCAD1 & KAP1 
Prior biochemical characterization of SMARCAD1 has relied upon 
immunoprecipitation of tagged protein following overexpression in mammalian cells 
(Rowbotham et al., 2011). While such an approach has allowed the stoichiometric 
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interaction between SMARCAD1 and KAP1 to be identified, the yields of purified 
protein that can be obtained from mammalian cells are, inevitably, limited 
(preliminary data obtained by Hannah Williams). As detailed biochemical 
characterization of the enzymatic properties of SMARCAD1 would be most feasible 
with an abundance of purified protein, we investigated the prospect of expressing it 
recombinantly in E. coli. While an ideal expression system in many regards, 
obtaining soluble, full-length protein is a frequent challenge when expressing large 
proteins such as SMARCAD1 in E. coli.  
 
To maximise the chances of obtaining soluble, full-length protein, the human 
SMARCAD1 cDNA was cloned into the pET28a-SUMO vector, allowing 
SMARCAD1 to be expressed as a fusion protein with an N-terminal hexa-histidine 
tag and SUMO moiety (Figure 6.1). Compared to other conventional tags, the 
SUMO tag has been demonstrated to be the most effective at enhancing the 
solubility of exogenous proteins expressed in E. coli (Marblestone et al., 2006). 
Additionally, the yeast SUMO (Smt3) protease, Ulp1, which can be purified in large 
quantities, can then be used to cleave the fusion protein immediately after the 
tandem glycine residues of the SUMO moiety, resulting in recombinant protein with 
a native N-terminus.  
 
 
Figure 6.1– The pET28a-SUMO Expression System 
A. A schematic depicting the pET28a-SUMO vector used to express most of the 
recombinant proteins in this study. The hexa-histidine tag at the N-terminus of the 
fusion protein allows affinity purification by Ni-NTA chromatography, while the SUMO 
moiety enhances the solubility of many recombinant proteins expressed in E. coli. 
B. The SUMO-fusion protein expressed from the pET28a-SUMO vector can be converted 
into its native form by cleavage with the yeast SUMO (Smt3) protease, Ulp1, which cuts 
specifically after the di-glycine residues at the C-terminus of the SUMO moiety.  
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Figure 6.2 – Purification of Recombinant SMARCAD1 
A. This diagram outlines the chromatographic steps required to obtain pure recombinant 
SMARCAD1 expressed in E. coli.  
B. These gels, stained by InstantBlue, from a representative SMARCAD1 purification 
illustrate the progressive increase in purity over the purification protocol. The red 
asterisks indicate full-length SMARCAD1. The green bars above each gel indicate the 
fractions that were pooled and loaded onto the next column. The key chromatographic 
step is HiTrap Heparin chromatography (second gel from the top), which allows the 
separation of full-length SMARCAD1 from lower molecular weight SMARCAD1 
fragments. 
 
Expression trials revealed that SMARCAD1 expression was maximal when cultured 
at 16°C for six hours following IPTG induction. Pure, recombinant SMARCAD1 was 
obtained after extensive purification over four columns (Figure 6.2). The most 
important step was the HiTrap Heparin chromatography as it allowed separation of 
full-length SMARCAD1 from lower molecular weight SMARCAD1 fragments. Since 
SMARCAD1 was first purified via an N-terminal hexa-histidine tag, the shorter 
fragments probably arise from prematurely terminated transcripts or by degradation 
of the C-terminus. In contrast, the third ProSwift WCX-1S column only achieved 
marginal improvements in purity and its omission only resulted in slightly more 
contamination that could be overcome by greater selectivity in pooling fractions. 
 
In contrast to SMARCAD1, KAP1 has been previously purified following expression 
in E. coli (Liang et al., 2011). Indeed, recombinant KAP1 was soluble and could be 
purified to a high level of purity by a combination of affinity and conventional 
chromatographic techniques (Figure 6.3). While the main constituent of the purified 
sample was full-length KAP1, a small quantity of lower molecular weight KAP1 
fragments persists. Interestingly, these KAP1 fragments could not be separated 
from the full-length protein by either anion exchange or size exclusion 
chromatography (Figure 6.3B respectively). KAP1 has previously been reported to 
trimerize due to its coiled-coil domain (Peng et al., 2000). Thus, it is possible that a 
truncated KAP1 molecule that nevertheless retains its N-terminal RBCC domain 
may form a stable heterotrimer with full-length KAP1. This KAP1 heterotrimer may 
not differ significantly from a KAP1 homotrimer in terms of surface charge or 
hydrodynamic radius, potentially explaining the persistence of lower molecular 
weight KAP1 fragments even after multiple chromatographic steps. The yields of 
purified recombinant KAP1 from E. coli were sufficiently high to permit screening in 
crystallization trials, though no crystals were ultimately obtained. 
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Figure 6.3 – Purification of Recombinant KAP1 
A. This diagram outlines the chromatographic steps required to obtain pure recombinant 
KAP1 following expression in E. coli. The final gel filtration chromatography step can be 
replaced with anion exchange chromatography (e.g. Mono Q 5/50 GL) without affecting 
either the purity or yield.  
B. These gels, stained by InstantBlue, from a representative KAP1 purification illustrate the 
progressive increase in purity over the purification. The red asterisks indicate full-length 
KAP1; the blue asterisks denote the cleaved SUMO tag. The green bars above each gel 
indicate the fractions that were pooled and loaded onto the next column. The lower 
molecular weight KAP1 fragments cannot be separated from full-length KAP1 by either 
gel filtration chromatography, probably because these fragments possess an intact 
coiled-coil domain, thereby retaining the ability to oligomerize with the full-length protein. 
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6.2.2 Reconstitution of the SMARCAD1-KAP1 Complex 
Having devised a protocol to purify recombinant SMARCAD1 and KAP1, the next 
goal was to reconstitute the SMARCAD1-KAP1 complex in vitro. A simple strategy 
of sequential FLAG and HA affinity purifications on a mixture of FLAG-tagged 
SMARCAD1 and HA-tagged KAP1 proteins was used (Figure 6.4). However, the 
recovery of protein following the reconstitution process was poor because of low 
efficiency binding to the HA column. Further losses were incurred from incomplete 
elution of the bound complex from the affinity resins by competition with FLAG or 
HA peptide. Correspondingly, the concentration of the SMARCAD1-KAP1 complex 
was significantly lower than that of either of the individual components. 
Nonetheless, the reconstituted SMARCAD1-KAP1 complex was pure and 
appeared to contain stoichiometric quantities of both SMARCAD1 and KAP1. 
 
 
Figure 6.4 – Reconstitution of the SMARCAD1-KAP1 Complex 
A. This diagram depicts the sequential affinity purifications performed to reconstitute the 
SMARCAD1-KAP1 complex in vitro. 
B. This SyproRuby-stained gel from a representative SMARCAD1-KAP1 reconstitution 
illustrates the losses incurred at various stages of the tandem affinity purification 
protocol. Notably, recovery of protein following peptide elution from the two affinity 
resins was particularly poor. Nonetheless, the final reconstituted SMARCAD1-KAP1 is 
pure and is comprised of stoichiometric quantities of each protein. 
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To confirm that the reconstituted SMARCAD1-KAP1 complex behaved as a single 
molecular species, it was analysed by gel filtration chromatography, along with 
purified recombinant SMARCAD1 and KAP1 (Figure 6.5). All three samples tested 
(i.e. SMARCAD1, KAP1 and the SMARCAD1-KAP1 complex) eluted as single 
peaks from the MAbPac SEC-1 gel filtration column, suggesting mono-dispersity. 
Crucially, both components of the reconstituted complex precisely co-eluted with 
each other. Additionally, the complex eluted earlier in the gradient than either 
SMARCAD1 or KAP1 alone, indicating that the hydrodynamic radius of the 
complex is larger than that of either of its constituent parts (Figure 6.5B). Taken 
together, this data suggests that a bona fide SMARCAD1-KAP1 complex can be 
reconstituted in vitro from purified components. 
 
 
Figure 6.5 – Evaluation of the Reconstituted SMARCAD1-KAP1 Complex by Gel 
Filtration Chromatography 
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A. This silver-stained gel compares the samples analysed by gel filtration chromatography; 
three times the amount of protein present on the gel was actually loaded onto the 
MAbPac SEC-1 column. 
B. Pure SMARCAD1 and KAP1 elute as single peaks from the size exclusion column after 
the void volumne, suggesting monodispersity of the samples. When the SMARCAD1-
KAP1 complex is resolved by gel filtration chromatography, both SMARCAD1 and KAP1 
precisely co-elute as assessed by both Western blotting and silver staining, suggesting 
the formation of a bona fide complex. Importantly, the components of the complex elute 
earlier in the gradient than their individual components (compare the blots in section 3 to 
those in sections 1 and 2), suggesting that the complex has a larger hydrodynamic 
radius than either of its constituent parts. 
 
6.2.3 Substrate Preferences of SMARCAD1 
Although the enzymatic properties of SMARCAD1 have yet to be described, a 
reasonable prediction is that it would behave similarly to other chromatin 
remodellers – displaying ATPase activity that is preferentially stimulated by 
nucleosomes (Corona et al., 1999). This hypothesis was directly tested in an 
ATPase assay, where a defined concentration of SMARCAD1 (120nM) was 
stimulated with limiting concentrations (either 40nM or 80nM) of single-stranded 
DNA, double-stranded DNA (dsDNA), or reconstituted Xenopus nucleosomes 
(Figure 6.6). (Although the ATPase assays shown here are representative 
examples, the results were obtained reproducibly.) SMARCAD1 displayed a clear 
substrate preference for nucleosomes though dsDNA elicited some ATP hydrolysis 
(Figure 6.6A & B). 
 
Akin to SMARCAD1, the SMARCAD1-KAP1 complex displayed greater ATP 
hydrolysis when stimulated by nucleosomes as compared to either ssDNA or 
dsDNA (Figure 6.6A & B). Notably, however, when stimulated with the same 
concentration of nucleosome, the SMARCAD1-KAP1 complex hydrolysed 
considerably less ATP than SMARCAD1, suggesting that KAP1 acts to inhibit the 
enzymatic activity of SMARCAD1. As a control, equal amounts of the samples of 
SMARCAD1 and the SMARCAD1-KAP1 complex used in this experiment were 
resolved by SDS-PAGE and silver-stained, confirming that the concentration of the 
samples were comparable (Figure 6.6C). Thus, while this possibility cannot be 
formally discounted, it is unlikely that these differences in activity can be attributed 
to vastly different concentrations of enzyme being used in these reactions. 
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Figure 6.6 – Substrate Preferences of SMARCAD1 & the SMARCAD1-KAP1 Complex 
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A. In this ATPase assay, the substrate preferences of SMARCAD1 and the SMARCAD1-
KAP1 complex were compared by mixing limiting concentrations (40nM or 80nM) of 
ssDNA, dsDNA, or reconstituted Xenopus nucleosomes with a constant concentration of 
enzyme (120nM) along with an excess of ATP. Thin layer chromatography allowed free 
phosphate to be resolved from unhydrolysed ATP; since some radiolabelled ATP [γ-32P] 
was included in the reaction, the extent of ATP hydrolysis could be determined. 
SMARCAD1 displays a clear preference for nucleosomes, though double-stranded DNA 
elicits some ATP hydrolysis. Notably, as shown in this representative experiment, the 
nucleosome-stimulated ATPase activity of the SMARCAD1-KAP1 complex was 
considerably lower than that of the SMARCAD1 enzyme by itself. Though this image 
illustrates the result from a 20-minute reaction, a longer reaction (i.e. 60 minutes) 
produces a comparable result. 
B. The percentage of ATP hydrolysis observed under each condition is plotted in this graph. 
The red lines relate to reactions with SMARCAD1, while the blue lines relate to 
reactions with the SMARCAD1-KAP1 complex. The different shapes indicate the 
substrate added to the reaction. This graph, once again, illustrates the preference of 
SMARCAD1 for nucleosomes. 
C. As assessed in this silver-stained gel, comparable concentrations of SMARCAD1 
protein and the SMARCAD1-KAP1 complex were used for these ATPase reactions. 
 
The silver-stained gels (Figures 6.6C, 6.8C, 6.9C & 6.10C) comparing the 
SMARCAD1 and SMARCAD1-KAP1 samples used in the ATPase assays give the 
impression that BSA was only added to the SMARCAD1 reactions. In fact, an 
excess of BSA was present in all ATPase reactions as it was a major constituent of 
the reaction buffer (2.1.6.3). Prior to use in the ATPase assay reactions, the 
purified SMARCAD1 protein was diluted to a similar concentration as the 
SMARCAD1-KAP1 complex. BSA was added to the SMARCAD1 sample when it 
was diluted since in its absence, considerable losses of SMARCAD1 were 
associated with low sample concentration – it is plausible that the microcentrifuge 
tubes used have a certain capacity for binding non-specifically to SMARCAD1 
molecules that translates into a noticeable problem when the sample concentration 
is low. While the presence of BSA in the SMARCAD1 sample increased the 
concentration of BSA in the reaction, the increase was slight in relation to the 
amount of BSA added to all reactions through the reaction buffer. Moreover, it was 
also empirically determined the slight differences in BSA concentration caused by 
the presence of BSA in the SMARCAD1 sample do not affect the ATP hydrolysis 
activity of either SMARCAD1 or the SMARCAD1-KAP1 complex. 
 
As this is the first instance in which an enzymatic activity can be directly attributed 
to SMARCAD1, a series of ATPase reactions were set up to determine the optimal 
conditions for its activity. The two main variables tested were the concentrations of 
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sodium chloride (NaCl) and magnesium chloride (MgCl2) in the reactions (Figure 
6.7). It is clear that the ATPase activity of SMARCAD1 is exquisitely sensitive to the 
concentration of NaCl – increasing it beyond an optimal concentration of 40mM 
results in dramatic reductions in activity. In contrast, the magnesium concentration 
does not appear to drastically affect activity though SMARCAD1 probably has a 
slight preference for a concentration of 0.1mM MgCl2 (Figure 6.7A & B). On the 
basis of this knowledge, the salt concentration of all subsequent series of reactions 
was kept strictly controlled; indeed, to ensure that the concentration of NaCl was 
minimised and in the optimal range, the only source of salt in these reactions was 
from the purified protein samples. While it is known that some chromatin 
remodellers (e.g. RSC) are salt-sensitive and display a preference for potassium 
acetate compared to sodium chloride, this was not a hypothesis that could be 
easily tested here, as it required all the enzymes used in this study to be re-purified 
under different conditions. 
 
Finally, to exclude the possibility that the nucleosome-stimulated ATPase activity 
observed with SMARCAD1 or the SMARCAD1-KAP1 complex was actually due to 
a minor contaminant, the ‘ATPase-dead’ K528A SMARCAD1 mutant was 
expressed, purified in the same fashion, and tested in an ATPase reaction. 
Importantly, no ATP hydrolysis over background levels was associated with the 
K528A mutant, as would be expected for a protein incapable or binding ATP due to 
a point mutation in the conserved lysine residue of its ATP-binding, Walker A motif 
(Figure 6.9A & Figure 6.10A). This data strongly argues against the possibility of an 
unidentified contaminant in the purified protein samples as being the source of the 
ATPase activity. Furthermore, the ATPase activity of SMARCAD1 is dependent on 
the presence of nucleosome (Figure 6.8A &B). Likewise, by itself, KAP1 is 
incapable of ATP hydrolysis, even when stimulated with nucleosomes. Taken 
collectively, the data strongly suggests that the nucleosome-stimulated ATPase 
activity is a specific activity of the SMARCAD1 enzyme.  
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Figure 6.7 – Optimal Conditions for the ATPase Activity of SMARCAD1 
A. This series of ATPase reactions aims to determine the optimal concentrations of salt 
and magnesium for SMARCAD1 activity. Overall, it is evident that the nucleosome-
stimulated ATPase activity of SMARCAD1 is exquisitely sensitive to the concentration of 
NaCl – increasing the NaCl concentration beyond an optimal of 40mM results in 
dramatically reduced enzymatic activity. 
B. This graph plots the percentage of ATP hydrolysis observed for each condition. The red 
line relates to reactions containing 0.1mM MgCl2, the green line indicates reactions with 
0.2mM MgCl2, while the blue line represents reactions with 0.5mM MgCl2. The optimal 
concentration of NaCl is approximately 40mM; however, further increases in NaCl 
concentration result in a marked reduction in the ATPase activity of SMARCAD1. In 
contrast, the magnesium concentration does not have a major effect on the ATPase 
activity of SMARCAD1, though slightly more ATP hydrolysis is observed with 0.1mM 
MgCl2 as compared to the other concentrations tested.  
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6.2.4 Comparison of the Nucleosome-Stimulated ATPase Activities of 
SMARCAD1 and the SMARCAD1-KAP1 Complex 
To further validate the observation that KAP1 down-regulates the nucleosome-
stimulated ATPase activity of SMARCAD1, the progress of the ATPase reaction 
with SMARCAD1 and the SMARCAD1-KAP1 was compared over time in a time 
course experiment (Figure 6.8). For both enzymes, there was increasing 
accumulation of the reaction product – in this case, hydrolysed inorganic phosphate 
– over time, though the amount of product appears to be reaching a plateau after 
two hours (Figure 6.8B). The amount of ATP hydrolysis observed with SMARCAD1 
alone was higher than that for the SMARCAD1-KAP1 complex at all timepoints 
tested, indicating that the antagonism caused by KAP1 on the enzymatic activity of 
SMARCAD1 is reproducible. 
 
The percentage of ATP hydrolysed under each condition was also quantified and 
plotted graphically to display the relationship between enzymatic activity and 
reaction duration for each of the enzymes (Figure 6.8B). The main distinction 
between the curves associated with SMARCAD1 and the SMARCAD1-KAP1 
complex is the initial rate – the extent of ATP hydrolysis increases dramatically at 
the start of the reaction in the presence of SMARCAD1, whereas ATP hydrolysis by 
SMARCAD1-KAP1 proceeds much more sedately. In the latter stages of the 
reaction, however, the reaction rates appear largely comparable (Figure 6.8B). The 
slower reaction rate with increasing reaction duration, associated particularly with 
SMARCAD1 alone, may reflect either depletion of substrate – in this context, ATP – 
or enzymatic activity ‘dying’ over the course of the experiment, perhaps by protein 
denaturation. The former scenario may be possible since after two hours, the 
amount of un-hydrolysed ATP left in the reaction is approximately 25% of the 
original (Figure 6.8B). Nevertheless, Michaelis-Menten analysis, whereby the 
reaction rate is determined at different substrate concentrations, is necessary to 
distinguish between these two possibilities. 
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Figure 6.8 – Time Course Comparison of SMARCAD1 & the SMARCAD1-KAP1 
Complex 
A. The progress of the nucleosome-stimulated ATPase reaction by SMARCAD1 and the 
SMARCAD1-KAP1 complex was tracked over time here. Increasing levels of free 
hydrolysed γ-phosphate accumulated over time. At all timepoints, however, SMARCAD1 
displayed higher levels of ATPase activity than the complex. As noted above, minimal 
ATP hydrolysis was observed in the absence of nucleosome (lower image). 
B. This graph plots the percentage of ATP hydrolysis observed at each timepoint for each 
condition. The red lines relate to reactions with SMARCAD1, while the blue lines relate 
to reactions with the SMARCAD1-KAP1 complex; likewise, the open diamonds reflect 
reactions performed in the absence of nucleosome, while the closed diamonds indicate 
the presence of nucleosome. Both reactions appear to be approaching a plateau by two 
hours. The two curves differ most prominently in the initial stages of the reaction as the 
initial reaction rate for SMARCAD1 is considerably higher than that for the SMARCAD1-
KAP1 complex. In contrast, the rate at which hydrolysed ATP accumulates in the 
second-half of the reaction is comparable for both enzymes. 
C. As assessed in this silver-stained gel, comparable concentrations of SMARCAD1 and 
the SMARCAD1-KAP1 complex were used for these reactions, suggesting that 
differences in activity cannot be attributed to differences in enzyme concentration. 
 
Another implication of this time course experiment is that comparisons in enzymatic 
activity should be performed at a relatively early time point, as the considerable 
differences in initial rates between SMARCAD1 and the SMARCAD1-KAP1 
complex would accentuate any differences in ATPase activity. Consequently, all 
further experiments featuring this assay focus upon the 20-minute timepoint. It is, 
nevertheless, important to emphasize that allowing these reactions to progress for 
60 minutes did not materially alter the results or conclusions in any way (Figures 
7.9B, 7.10B). 
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To further characterize the ATPase activities of SMARCAD1 and the SMARCAD1-
KAP1 complex, a series of ATPase reactions were performed where increasing 
concentrations of enzyme were mixed with a constant concentration of recombinant 
nucleosome (Figure 6.9). For both SMARCAD1 and the SMARCAD1-KAP1 
complex, as the enzyme concentration increased, the level of ATPase activity 
increased, though it appeared to be approaching a plateau at the highest enzyme 
concentrations tested (Figure 6.9B). Crucially, however, for any given enzyme 
concentration, the level of nucleosome-stimulated ATPase activity observed for the 
SMARCAD1-KAP1 complex was consistently lower than that of SMARCAD1 alone 
(Figure 6.9A & B). The inhibitory effect associated with KAP1 is not insignificant 
since the SMARCAD1-KAP1 complex generally exhibits three- to four-fold less 
nucleosome-stimulated ATPase activity compared to SMARCAD1 (Figure 6.9B).  
 
Although the substrate in the ATPase assay is ATP, the ability of nucleosomes to 
stimulate SMARCAD1-mediated ATPase activity implies that SMARCAD1 acts on 
the nucleosome, which is a co-factor in the context of the ATPase assay. Thus, it 
might be expected that an increase in nucleosome concentration would result in a 
corresponding increase in ATP hydrolysis. Curiously, however, the relationship 
between nucleosome concentration and ATPase activities of SMARCAD1 and the 
SMARCAD1-KAP1 complex is biphasic (Figure 6.10A & B). At lower nucleosome 
concentrations, increases in cofactor concentration result in increased activity. As 
the nucleosome concentration approaches the enzyme concentration, however, 
further increases in cofactor concentration do not elicit additional increases in 
activity. Indeed, a large excess of nucleosome compared to the amount of 
SMARCAD1 or SMARCAD1-KAP1 complex may even be inhibitory. 
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Figure 6.9 – Effect of Enzyme Concentration on the Nucleosome-Stimulated ATPase 
Activities of SMARCAD1 & the SMARCAD1-KAP1 Complex 
A. In this series of ATPase reactions, increasing concentrations of enzyme (either 
SMARCAD1 or the SMARCAD1-KAP1 complex) were combined with a constant amount 
of nucleosome (80nm). For both enzymes, increasing the concentration increased the 
amount of ATP hydrolysis observed. However, the SMARCAD1-KAP1 complex was 
consistently less active than SMARCAD1 alone at all concentrations tested. Moreover, 
the nucleosome-stimulated ATPase activity observed with these enzymes is specific as 
the ‘ATPase-dead’, K528A SMARCAD1 mutant displays no ATP hydrolysis even when 
stimulated with nucleosomes. 
B. The percentage of ATP hydrolysis observed under each condition is plotted in this graph. 
The red lines relate to reactions with SMARCAD1, while the blue lines relate to 
reactions with the SMARCAD1-KAP1 complex; likewise, the open circles reflect 20-
minute reactions, while the closed circles reflect 60-minute reactions. This graph shows 
that SMARCAD1 is more active than the reconstituted complex for any given enzyme 
concentration. 
C. As assessed in this silver-stained gel, comparable concentrations of SMARCAD1, 
‘ATPase-dead’ K528A SMARCAD1 mutant and the SMARCAD1-KAP1 complex were 
used for these reactions. 
 
This behaviour is theoretically atypical since, by definition, enzymes should be able 
to catalyse reactions while remaining unaltered. However, one possible explanation 
is that the SMARCAD1 and SMARCAD1-KAP1 proteins gradually degrade over the 
course of the reaction; indeed, this possibility may be supported by the reduced 
reaction rates observed at late timepoints in a timecourse experiment as compared 
to that at early timepoints (Figure 6.8A & B). A second possibility is that the 
samples of purified SMARCAD1 and SMARCAD1-KAP1 complex contain only a 
small proportion of active enzyme. Thus, even the lower nucleosome 
concentrations tested would represent an excess to the amount of active enzyme 
present in the reactions. Yet, this explanation still fails to explain the inhibitory 
effect of a large excess of nucleosome. Moreover, a heparin column is a key step 
in the purification of SMARCAD1; as heparin is a DNA-mimetic, purification on the 
basis of affinity for heparin (and thus, indirectly, DNA) should be a reasonable 
means of enriching for active molecules. A third possibility is that the reconstituted 
nucleosome sample contains an inhibitory contaminant activity; at high nucleosome 
concentrations, the effect of this inhibitory contaminant outweighs that of the 
stimulatory activity, resulting in a net decrease in ATP hydrolysis. 
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Figure 6.10 – Effect of Nucleosome Concentration on the ATPase Activities of 
SMARCAD1 & the SMARCAD1-KAP1 Complex 
A. In this series of ATPase reactions, increasing concentrations of recombinant 
nucleosomes were combined with a constant concentration of enzyme (120nM). 
Virtually no ATPase activity is observed when SMARCAD1 is not stimulated with 
nucleosome. At low nucleosome concentrations, further increases result in greater 
activity. However, as the nucleosome concentration approximates the SMARCAD1 
concentration, further increases are not accompanied by additional increases in activity; 
indeed, an excess of nucleosome may even be inhibitory. Nonetheless, SMARCAD1 is 
consistently more active than the SMARCAD1-KAP1 complex. 
B. The percentage of ATP hydrolysis observed under each condition is plotted in this graph. 
The red lines relate to reactions with SMARCAD1, while the blue lines relate to 
reactions with the SMARCAD1-KAP1 complex; likewise, the open circles reflect 20-
minute reactions, while the closed circles reflect 60-minute reactions. This graph 
emphasizes the biphasic effect of nucleosome concentration on the ATPase activities of 
SMARCAD1 and the SMARCAD1-KAP1 complex. At low nucleosome concentrations, 
further increases in substrate result in more activity; above a point, however, additional 
nucleosomes in the reaction may even be inhibitory. 
C. As assessed in this silver-stained gel, comparable concentrations of SMARCAD1, the 
‘ATPase-dead’ K528A SMARCAD1 mutant, and the SMARCAD1-KAP1 complex were 
used for these reactions. 
 
In spite of the curious relationship between nucleosome concentration and ATPase 
activities of SMARCAD1 and the SMARCAD1-KAP1 complex, all the data 
presented here are, nonetheless, unanimous in showing that KAP1 acts to inhibit or 
down-regulate the enzymatic activity of SMARCAD1.  
 
Finally, it was observed that KAP1 added directly to an ATPase reaction with 
SMARCAD1 did not exert an inhibitory effect. This is likely to be an experimental 
artefact reflecting the relatively slow rate of complex formation; indeed, we note 
that the efficiency of reconstituting the SMARCAD1-KAP1 complex is low, unless 
long incubation periods are allowed for the affinity purification steps.   
 
6.3 Conclusions 
In this part of the study, we have described protocols to purify recombinant 
SMARCAD1 and KAP1 expressed in E. coli to a high level of purity. Moreover, it 
has been possible to reconstitute the SMARCAD1-KAP1 complex by way of 
sequential affinity purification steps. Importantly, the reconstituted SMARCAD1-
KAP1 complex behaves as a bona fide protein complex – when analysed by gel 
filtration chromatography, SMARCAD1 and KAP1 precisely co-elute with each 
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other. Furthermore, the complex elutes earlier in the size exclusion gradient than 
each individual component, as would be expected for a larger molecule. 
 
We have also shown, for the first time, that the SMARCAD1 protein is capable of 
ATP hydrolysis, particularly in the presence of nucleosomes. Fittingly, a substrate 
preference for nucleosomes is characteristic of many chromatin remodellers. While 
the SMARCAD1-KAP1 complex is also optimally stimulated by nucleosomes, we 
show in several experiments that it is consistently less active at ATP hydrolysis 
than SMARCAD1 by itself. The inhibitory effect of KAP1 is not insignificant – in 
general, it results in a three- to four-fold reduction in nucleosome-stimulated ATP 
hydrolysis. Yet, this data cannot definitively indicate the mechanism by which KAP1 
antagonises the ATPase activity of SMARCAD1. It is, however, likely that the 
reduction in initial reaction rate observed in the presence of KAP1 significantly 
contributes to this antagonism. Nevertheless, since ATP hydrolysis is a surrogate 
measure for a complex, probably multi-step, enzymatic reaction, it is impossible to 
distinguish between a reduced affinity for nucleosomes or a reduction in 
processivity amongst other possibilities. It would be extremely useful for the 
preliminary characterization of the SMARCAD1 and SMARCAD1-KAP1 enzymes 
were to be extended by Michaelis-Menten analysis; for example, such analysis 
should help distinguish between depletion of substrate and protein degradation as 
the reason for the plateauing ATP hydrolysis observed at late timepoints. Also, the 
use of a malachite green ATPase assay, where phosphate release is measured, 
might be more suitable in subsequent experiments since it allows ATP hydrolysis to 
be quantified more accurately and is amenable to being performed in high-
throughput formats. Further experiments such as electromobility shift assays to 
determine the dissociation constant between SMARCAD1 or the SMARCAD1-
KAP1 complex and nucleosome, or nucleosome sliding assays will be required to 
further elucidate upon the mechanism by which KAP1 acts as an inhibitory factor. 
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Chapter 7. Results IV: Characterization of the 
Interaction between SMARCAD1 & KAP1 
7.1 Aims 
In addition to the conserved helicase-like ATPase domain, chromatin remodellers 
often possess other accessory domains that either enhance or confer specificity to 
the basal enzymatic activity of the protein. These domains are generally, though 
not universally, histone-mark readers. With regards to the SMARCAD1 protein, 
however, the only other annotated domains are a pair of tandem CUE domains in 
its C-terminus. As CUE domains are ubiquitin-binding domains, the rationale for 
their presence in a chromatin remodeller is not immediately apparent. Thus, an 
important question that we wanted to address was the role of the SMARCAD1 CUE 
domains. 
 
Although SMARCAD1 and KAP1 exist constitutively as a stable complex, based on 
their annotated protein domains, there is no prima facie indication for the means by 
which this interaction is mediated. However, as previously discussed, we were able 
to reconstitute the interaction with purified, recombinant proteins. To gain further 
insight into the nature of the SMARCAD1-KAP1 interaction and the means by 
which it could be regulated, we wanted to biochemically characterize this 
interaction and to define the regions of the two proteins that mediate it. 
  
7.2 Results 
7.2.1 Mutation of the CUE Domains of SMARCAD1 Abrogates the 
SMARCAD1-KAP1 Interaction in Cells 
Our initial approach to investigate the function of the CUE domains of SMARCAD1 
involved a T-Rex™ 293 cell line that was depleted of endogenous SMARCAD by 
shRNA knockdown, but inducibly expressed exogenous SMARCAD1 under the 
control of a doxycycline regulated promoter. (This cell line was generated by 
Hannah Williams.) By titration of the doxycycline concentration, SMARCAD1 was 
expressed to approximately endogenous levels (Figure 7.1A). A comparable cell 
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line rescued with exogenous SMARCAD1 bearing four point mutations in each of 
its tandem CUE domains was also established. As these alanine substitutions 
target the MFP and LL motifs, this SMARCAD1 mutant should be rendered entirely 
incapable of binding to ubiquitin. 
 
 
Figure 7.1 – Mutation of the CUE Domains of SMARCAD1 Abrogates the SMARCAD1-
KAP1 Interaction in Cells 
A. Endogenous SMARCAD1 was extensively depleted (see ‘-‘ doxycycline samples) from 
parental T-REx™ 293 cells (Invitrogen) by shRNA. These cells were then 
complemented with either wild-type (T-REx SMARCAD1) or CUE domain mutant 
SMARCAD1 (T-REx SMARCAD1 CUE1mt,2mt). As a doxycycline-regulated promoter 
controlled expression of exogenous SMARCAD1, it was possible to rescue these cells 
with approximately endogenous levels of SMARCAD1. The CUE domain mutant 
possesses four point mutations in each of its two CUE domains, which consequently, 
should be functionally inactive. 
B. Relatively equal levels of wild-type SMARCAD1 or the double CUE domain mutant were 
pulled down by immunoprecipitation with FLAG M2 agarose from the cell lines described 
above. While KAP1 co-immunoprecipitated with SMARCAD1, this interaction was 
completely abrogated by mutation of the tandem CUE domains of SMARCAD1. 
 
To determine whether mutation of the CUE domains of SMARCAD1 affects its 
interaction partners, both wild-type SMARCAD1 and the double CUE domain 
mutant were pulled down from the aforementioned cell lines by 
immunoprecipitation with M2 agarose. As expected, wild type SMARCAD1 co-
immunoprecipitated with KAP1. Notably, this interaction was abrogated in the CUE 
domain mutant (Figure 7.1B). (This observation was initially made by Hannah 
Williams, but the data presented here was reproduced in my hands.) Importantly, 
both cell lines expressed comparable levels of KAP1, indicating that the inability of 
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the SMARCAD1 CUE domain mutant to co-immunoprecipitate with KAP1 was not 
because of dramatic differences in KAP1 expression. 
 
 
Figure 7.2 – KAP1 is Not Constitutively Ubiquitylated in Human Cells 
A. Multi-Dsk, an affinity resin with a high avidity for ubiquitin, was used to enrich for 
ubiquitylated proteins from 293T cell extract. The enrichment for ubiquitylated proteins 
by the Multi-Dsk resin over non-specific interactions with the control glutathione 
sepharose beads can be visualized by Ponceau S staining. 
B. A Western blot against ubiquitin also demonstrates the specific enrichment for 
ubiquitylated proteins by the Multi-Dsk resin. 
C. There is some KAP1 binding to the Multi-Dsk resin; however, the absence of higher 
molecular weight forms of KAP1 suggests that KAP1 is not constitutively ubiquitylated in 
human 293T cells.  
 
As SMARCAD1 interacts constitutively with KAP1, and as CUE domains are 
ubiquitin-binding domains, it was hypothesized that KAP1 would be constitutively 
ubiquitylated. Taking advantage of the high avidity for ubiquitin of the Multi-Dsk 
resin, a fusion protein consisting of five repeats of the UBA ubiquitin-binding 
domain of Dsk2 (Wilson et al., 2012), ubiquitylated proteins were enriched from 
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293T human cell extract (Figure 7.2A & B). By Western blotting, it was identified 
that some KAP1 bound to the Multi-Dsk resin, though there were no KAP1 bands of 
a higher molecular weight, as would be expected for ubiquitylation (Figure 7.2C). 
This data strongly argues against the existence of constitutive KAP1 ubiquitylation. 
The apparent discrepancy of KAP1 binding to the Multi-Dsk resin in the absence of 
ubiquitin might reflect, for example, the indirect binding via an intermediary, 
ubiquitylated protein; this explanation would be consistent with the mild stringency 
of this immunoprecipitation experiment. 
 
7.2.2 SMARCAD1-KAP1 Interaction Depends on the First CUE Domain of 
SMARCAD1 and the RBCC Domain of KAP1 In Vitro 
As described above, the SMARCAD1-KAP1 interaction can be reconstituted in vitro 
with purified, recombinant proteins (Figure 6.4). Thus, to further investigate whether 
the reconstituted interaction truly recapitulates that observed in cells, three 
additional SMARCAD1 mutants were purified to assess whether the same 
dependence on the CUE domains for the interaction exists in vitro. These N-
terminally FLAG-tagged SMARCAD1 mutants had point mutations in individual or 
both CUE domains and consequently, have compromised ubiquitin-binding ability 
in one or both of its CUE domains (Figure 7.3A). The ability of the SMARCAD1 
CUE domain mutants to bind to KAP1 in vitro was compared to that of wild type 
SMARCAD1 in a binding assay (Figure 7.3B). Following overnight incubation of the 
recombinant proteins, pulling down wild type SMARCAD1 resulted in co-
immunoprecipitation of stoichiometric levels of KAP1. In contrast, however, the 
mutant with point mutations in the first CUE domain was severely compromised in 
its ability to bind KAP1. Predictably, the double mutant behaved similarly, thereby 
recapitulating the phenotype observed in cells. Nevertheless, mutation of the 
second CUE domain did not perceptibly affect the ability of SMARCAD1 to bind 
KAP1. Hence, this data indicates that the SMARCAD1-KAP1 interaction is strictly 
mediated via the first CUE domain of SMARCAD1 and that the tandem CUE 
domains of SMARCAD1 are not functionally redundant (Figure 7.3B). 
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Figure 7.3 – The SMARCAD1-KAP1 Interaction Depends on the First CUE Domain of 
SMARCAD In Vitro 
A. As assessed by InstantBlue staining, the purified, recombinant protein samples used to 
reconstitute the SMARCAD1-KAP1 interaction are of a high purity. In addition to wild 
type full-length SMARCAD1, three additional mutants, which had point mutations in 
individual or both CUE domains, were purified. 
B. Purified, recombinant wild type and mutant FLAG-tagged SMARCAD1 proteins were 
mixed with purified, recombinant KAP1 along with BSA. The different versions of 
SMARCAD1 were immunoprecipitated by FLAG M2 agarose to determine whether or 
not they possessed the ability to bind to KAP1. The SMARCAD1-KAP1 interaction was 
once again observed. Mutation of the first CUE domain severely compromised the ability 
of SMARCAD1 to bind to KAP1, while mutation of the second CUE domain did not 
perturb binding.  
 
To determine the region of KAP1 responsible for binding to SMARCAD1, truncated 
fragments of KAP1 were assessed for retention of the ability to specifically interact 
with the first CUE domain of SMARCAD1. The initial KAP1 fragments truncated the 
protein along annotated protein domains; however, they did not offer much insight 
apart from demonstrating that the C-terminal PHD-bromodomain was dispensable 
for the interaction with SMARCAD1. Thus, limited tryptic digestion was used to 
identify KAP1 fragments that reflect the actual structure of the protein. By 
incubating SMARCAD1 with a limiting concentration of trypsin for a relatively short 
period of time, three fragments of KAP1 that displayed a comparatively higher 
resistance to trypsin were identified (Figure 7.4A). These trypsin-resistant KAP1 
fragments probably represent ordered regions of the protein and consequently, are 
more likely to contain the interaction interface with SMARCAD1. To map these 
fragments, the sequences of their N-termini were determined by Edman 
degradation, while their mass were measured to a high level of accuracy by intact 
molecular weight mass spectrometry. Interpreted in line with the knowledge that 
trypsin cleaves primarily after lysine or arginine residues, the largest KAP1 
fragment (S33-K434, 45kDa) was identified to span the RBCC domain of KAP1 
(Figure 7.4B). Further cleavage yields the second fragment, which encompasses 
the second B-box and the coiled-coil domain (S200/D202-K434, 27kDa). The final 
fragment (L592-P835) covers the C-terminal PHD-bromodomain. 
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Figure 7.4 – The Trypsin-Resistant KAP1 S33-K434 Fragment Binds Specifically to 
the First CUE Domain of SMARCAD1 
A. Pure recombinant KAP1 was incubated with a limiting concentration of trypsin to identify 
fragments that were resistant to tryptic digestion. Three relatively stable fragments are 
obtained after 2.5 hours of digestion at 20°C. These fragments probably represent 
ordered regions of the KAP1 protein.  
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B. The three trypsin-resistant KAP1 fragments were mapped by a combination of Edman 
degradation and intact molecular weight mass spectrometry. These complementary 
techniques reveal the sequences of the N-termini of the fragments and their precise 
mass respectively. The largest fragment, S33-K434, spans the entire RBCC domain of 
KAP1. It can be further digested into a small fragment, S200/D202-K434, which 
encompasses the second B-box and the coiled-coil domain. The C-terminal PHD-
bromodomain forms the final fragment, L592-P835. 
C. The SMARCAD1 CUE domain fragment, S95-N347, is illustrated in this schematic of the 
SMARCAD1 protein. 
D. Together with full-length KAP1, the three trypsin-resistant fragments were expressed in 
E. coli as GST fusion proteins. Bacterial protein extracts containing these GST fusion 
proteins were then incubated with beads immobilised with a CUE domain fragment of 
SMARCAD1. The CUE domain SMARCAD1 fragment strongly enriched for full-length 
KAP1 and the S33-K434 RBCC fragment. This interaction was specific as the control 
CUE1mt,2 fragment, which contains a mutated first CUE domain, failed to bind either 
full-length protein or KAP1 S33-K434. Some enrichment of D202-K434 was also 
observed, slbeit to a lesser extent. 
 
Along with full-length KAP1, the three trypsin-resistant fragments were expressed 
in E. coli as GST fusion proteins. Bacterial protein extracts containing these GST 
fusion proteins were then incubated with beads immobilised with a CUE domain 
fragment of SMARCAD1 (Figure 7.4C). The CUE domain SMARCAD1 fragment 
strongly enriched for full-length KAP1 and the S33-K434 RBCC fragment (Figure 
7.4D). Crucially, this interaction depended on the integrity of the first CUE domain 
of SMARCAD1; mutation completely abrogated binding. Enrichment to a lesser 
extent was also observed for the D202-K434 fragment; the apparent reduction in 
affinity may, in fact, simply reflect lower abundance in extract due to significantly 
poorer solubility. Strikingly, although the RBCC domain is present in its entirety, the 
M1-E388 fragment does not bind to the SMARCAD1 CUE domain fragment, 
indicating that the forty-seven amino acids immediately after the RBCC domain are 
required for KAP1 to retain the ability to interact with SMARCAD1. It is, however, 
unclear whether those forty-seven residues directly contact the SMARCAD1 CUE 
domain, or contribute to proper folding of the protein. 
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Figure 7.5 – Reconstitution of the Minimal SMARCAD1-KAP1 Interaction 
A. InstantBlue staining was used to assess the purity of purified, recombinant wild type and 
mutant SMARCAD1 CUE domain fragments. Pure KAP1 S33-K434 is also shown in this 
figure. 
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B. Purified KAP1 S33-K434 binds specifically to the SMARCAD1 CUE domain fragment 
but not fragments with mutations in the first CUE domain. This suggests that the 
interaction between the minimal soluble fragment of KAP1, S33-K434, and the CUE 
domain fragment of SMARCAD1 is representative of the SMARCAD1-KAP1 interaction. 
 
To further confirm that KAP1 S33-K434 is responsible for the interaction with 
SMARCAD1, we sought to repeat it with purified components.  The GST-KAP1 
S33-K434 fusion protein suffers from poor solubility and cannot be purified. 
However, its solubility is enhanced considerably when expressed using the 
pET28a-SUMO expression system, and can be purified by a combination of Ni-
NTA affinity chromatography and anion exchange chromatography (Figure 7.5A). It 
is worth noting that despite several rounds of optimization, the D202-K434 
fragment remains largely insoluble and intractable to purification. Hence, we regard 
the S33-K434 fragment as the minimal soluble fragment of KAP1 capable of 
interacting with SMARCAD1. In addition to the aforementioned SMARCAD1 CUE 
domain fragment (Figure 7.4C), three additional mutants – with mutations in 
individual or both CUE domains – were purified (Figure 7.5A). 
 
The KAP1 S33-K434 fragment was incubated briefly with the wild type SMARCAD1 
CUE domain fragment or the various mutants before the CUE domain fragments 
were immunoprecipitated with FLAG M2 agarose. Stoichiometric quantities of 
KAP1 S33-K434 bound to the wild-type CUE domain fragment. Moreover, the 
KAP1 S33-K434 was completely incapable of interacting with either the CUE1mt,2 
mutant, which has point mutations in the first CUE domain, or the CUE1mt,2mt 
double mutant. KAP1 S33-K434 bound just as efficiently to the CUE1,2mt mutant 
that possesses a mutated second CUE domain, as to the wild type CUE fragment, 
recapitulating the strict requirement for the first CUE domain of SMARCAD1 
observed with full-length proteins (Figure 7.5B). Considered holistically, the data 
strongly suggests that the SMARCAD1-KAP1 interaction occurs at the level of a 
direct protein-protein interaction between the first CUE domain of SMARCAD1 
directly and the N-terminal, S33-K434 portion of KAP1 encompassing the RBCC 
domain. The only caveat, however, is that the interaction observed between the 
protein fragments occurs with faster kinetics than that between full-length 
SMARCAD1 and KAP1 – strong enrichment of the KAP1 S33-K434 fragment by 
the SMARCAD1 CUE domain was observed after incubation for an hour, while 
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efficient reconstitution of the SMARCAD1-KAP1 complex was only seen after 
overnight incubation. 
 
The poor solubility of KAP1 fragments involving the RBCC domain (e.g. the D202-
K434 fragment which appears to retain some ability to bind to SMARCAD1) 
imposes significant limitations on any attempt to more precisely map the interaction 
interface used by KAP1 to bind SMARCAD1 by truncation analysis. Consequently, 
a peptide array spanning the KAP1 sequence was used to determine whether the 
SMARCAD1 CUE domain fragment recognises a specific KAP1 peptide. Since the 
array is composed of peptides twenty residues in length that progress along the 
KAP1 sequence in increments of a single amino acid, only linear epitopes are 
represented. 
 
 
Figure 7.6 – KAP1 Peptide Arrays Cannot Conclusively Reveal the Peptides 
Recognized by the SMARCAD1 CUE Domain 
These peptide arrays array are composed of peptides twenty residues in length that 
progress along the KAP1 sequence in increments of a single amino acid. Two stretches of 
peptides interact specifically with the wild type SMARCAD1 CUE domain fragment, but not 
the CUE1mt,2 fragment, which has a mutated first CUE domain. Both of these clusters of 
peptides mapped to the RING domain of KAP1. 
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Two stretches of peptides are recognized specifically by the wild type SMARCAD1 
CUE domain fragment, but not the CUE1mt,2 mutant, which has mutations 
targeting its first CUE domain (Figure 7.6). Both of these areas map to the RING 
domain of KAP1. It would be judicious to interpret this result with caution since the 
D202-K434 fragment, which lacks the RING domain, retains some ability to bind 
the SMARCAD1 CUE domain fragment (Figure 7.4D). Moreover, most RING 
domains are E3 ubiquitin ligases and the presence of an intrinsic ubiquitin-
homology domain within a RING domain has hitherto never been reported 
(Deshaies and Joazeiro, 2009). In light of the conflicting data, ultimately, it will be 
necessary to evaluate RING domain KAP1 mutants for the ability to bind 
SMARCAD1. Additionally, it is possible that the surface of KAP1 recognized by the 
SMARCAD1 CUE domain is formed by discontiguous amino acids that brought into 
close proximity upon folding of the protein. Indeed, since conformational epitopes 
are unrepresented on a peptide array, it is entirely possible that this technique will 
never reveal the surface with which the SMARCAD1 CUE domain interacts. 
 
7.2.3 Inconclusive Support for a Ubiquitin-Homology Domain in KAP1 
The data unanimously indicate that the SMARCAD1-KAP1 interaction strictly 
depends on the first CUE domain of SMARCAD1. CUE domains are ubiquitin-
binding domains with no known ligands apart from ubiquitin and ubiquitin-homology 
domains. Yet, the interaction between SMARCAD1 and KAP1 can be reconstituted 
with purified, recombinant proteins that, due to the absence of a functional 
ubiquitylation system in E. coli, are definitely not ubiquitylated, indicating that the 
residues recognized by the SMARCAD1 CUE domain can intrinsically be located 
amidst the primary structure of KAP1 (Figure 7.3B). Thus, it was necessary to 
consider the hypothesis that KAP1 possesses a ubiquitin-homology domain.  
 
If the first CUE domain of SMARCAD1 recognizes a ubiquitin-homology domain 
within KAP1, it would be expected that an excess of ubiquitin would be able to 
interfere with the SMARCAD1-KAP1 interaction. However, a hundred fold molar 
excess of ubiquitin did not affect the ability of the SMARCAD1 CUE domain 
fragment to interact with KAP1 S33-K434 (Figure 7.7). Thus far, only monomeric 
Chapter 7. Results IV 
 
206 
 
ubiquitin has been tested in this assay; thus, further experiments are required to 
exclude the possibility that poly-ubiquitin chains are capable of interfering with the 
SMARCAD1-KAP1 interaction. It is clear, nonetheless, that physiological 
concentrations of monomeric ubiquitin will not affect the SMARCAD1-KAP1 
interaction. Moreover, the inability of ubiquitin to affect the SMARCAD1-KAP1 
interaction suggests two hypotheses: 1) the CUE domain of SMARCAD1 may 
theoretically be able to bind ubiquitin; however, its affinity for ubiquitin significantly 
lower than that for KAP1, or 2) the first CUE domain of SMARCAD1 recognizes a 
ligand that is structurally distinct from ubiquitin. For the first scenario to occur, the 
interaction surface on KAP1 must fill the same hydrophobic groove of the CUE 
domain in a way that improves binding affinity by more than a hundred fold. This 
may be possible since the ubiquitin-CUE domain interaction is typically weak, with 
dissociation constants commonly in the range of a few hundred micromolar. 
 
 
Figure 7.7 – The Interaction between the SMARCAD1 CUE Domain Fragment & KAP1 
S33-K434 is Unaffected by an Excess of Ubiquitin 
The SMARCAD1 CUE domain fragment was incubated briefly with KAP1 S33-K434 and up 
to a hundred fold molar excess of ubiquitin. Immunoprecipitation of the CUE domain 
fragment with FLAG M2 agarose revealed that the excess of ubiquitin did not affect the 
extent to which the CUE fragment interacted with KAP1 S33-K434. 
 
In silico approaches were then applied to investigate whether any part of KAP1 
bore a resemblance to ubiquitin. Comparison of the sequences of ubiquitin and 
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KAP1 S33-K434 did not reveal any regions of significant homology (Figure 7.8A). 
Some ubiquitin-homology domains, such as that present in the yeast Ela1 protein, 
do not possess striking sequence homology to ubiquitin, yet are recognized by a 
wide range of ubiquitin-binding domains. Despite the limited homology, key 
ubiquitin residues tend to be conserved or substituted conservatively in bona fide 
ubiquitin-homology domains; for example, in Ela1, the crucial isoleucine 44 residue 
of ubiquitin was substituted for leucine (Wilson et al., 2013). In contrast, however, 
key ubiquitin residues were not conserved in the region of KAP1 that bore the 
greatest sequence similarity to ubiquitin, suggesting that even if a ubiquitin-
homology domain were present in KAP1, it is probably not encoded in the primary 
structure  (Figure 7.8A). 
 
It is possible that a ubiquitin-homology domain is created from the higher order 
folding of the KAP1 polypeptide. Due to the lack of a reported structure of KAP1, 
the predicted structure of KAP1 generated by the Phyre2 algorithm was analysed 
for structural similarity to ubiquitin (Kelley et al., 2015). In this model, 567 residues 
(68% of the entire sequence) were modelled with accuracy greater than 90%. In 
fact, specifically considering the RBCC domain, which was of particular interest, 
83% of the sequence (333 residues) was modelled with accuracy greater than 90%. 
Predictably, structures used to construct the model included the coiled-coil domain 
of TRIM69, and the RING domains of TRIM30 and TRIM5. Additionally, the model 
was also built upon structures of the human homologue of Ariadne (HHARI), an E3 
ubiquitin ligase, and Roquin-1, an RNA-binding zinc-finger protein, as they were 
also considered to have a high probability of being homologous to KAP1. The 
predicted KAP1 structure does not bear any similarity to the compact globular 
ubiquitin fold consisting of a mixture of five β-sheets and an α-helix (Figure 7.8B). 
Although Phyre2 also performs secondary structure prediction independent of 
parental structures, this approach similarly failed to identify a region of the RBCC 
domain with a similar secondary structure configuration to ubiquitin. A priori 
structural prediction is notoriously inaccurate, especially in the absence of 
structures of multiple homologues. Thus, while suggestive, it certainly cannot be 
concluded that KAP1 S33-K434 lacks a ubiquitin-homology domain. 
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Figure 7.8 – Lack of Sequence or Structural Homology between Ubiquitin and KAP1 
S33-K434 
A. As assessed by the Clustal Omega algorithm, KAP1 S33-K434 does not contain any 
regions bearing significant sequence homology to ubiquitin. 
B. The predicted structure of KAP1 (Phyre2) is shown above. For comparison, the 
structure of ubiquitin (PDB: 1UBQ) is shown below. Based on this model, KAP1 does 
not bear any similarity to the compact globular fold of ubiquitin. 
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As CUE domains are regarded exclusively as ubiquitin-binding domains, it has 
been assumed that the CUE domains of SMARCAD1 recognize ligands that 
structurally resemble ubiquitin. However, beads immobilized with a GST-ubiquitin 
fusion protein enriched for neither full-length SMARCAD1 nor the SMARCAD1 
CUE domain fragment. To favour the interaction between ubiquitin and the 
SMARCAD1 CUE domains, a high concentration of the purified CUE domain 
fragment was added to the binding reaction. This was to no avail since the CUE 
domain fragment did not bind to the GST-ubiquitin fusion protein over background 
levels, as assessed by the level of non-specific interaction between the CUE 
domain fragment and the GST-ubiquitin I44A mutant that should suffer from 
compromised binding.  
 
Empirically, the data suggest that the CUE domains of SMARCAD1 do not 
recognize ubiquitin. However, it remains formally possible that sub-optimal 
conditions were used in the in vitro binding assay, reducing the interaction between 
the CUE domains and ubiquitin to below the threshold for detection. Yet, in silico 
approaches indicate a lack of sequence or structural homology between KAP1 and 
ubiquitin. Therefore, on the balance of probabilities, while unprecedented, the first 
CUE domain of SMARCAD1 most likely recognizes a region of KAP1 that is 
structurally distinct from ubiquitin. 
 
7.2.4 Co-Crystallization of the Minimal SMARCAD1-KAP1 Complex 
Despite the varied approaches used to characterize the SMARCAD1-KAP1 
interaction, its true nature remains inconclusive. This uncertainty can be reduced to 
one main question – does the region of KAP1 bound by the first CUE domain of 
SMARCAD1 resemble ubiquitin in terms of its structure? To address this question 
comprehensively, I am currently attempting to solve the co-crystal structure of the 
minimal SMARCAD1-KAP1 complex by X-ray crystallography in collaboration with 
Peter Cherepanov. 
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Figure 7.9 – Purification of the Minimal SMARCAD1-KAP1 Complex 
A. This schematic outlines the chromatographic steps required to purify the minimal 
SMARCAD1-KAP1 complex recombinantly co-expressed in E. coli. 
B. These gels, stained by InstantBlue, from a representative purification of the minimal 
SMARCAD1-KAP1 complex illustrate the progressive increase in purity over the 
purification. The green bars above each gel indicate the fractions that were pooled and 
loaded onto the next column. The red asterisk indicates the KAP1 S33-K434 fragment, 
while the blue asterisk denotes the SMARCAD1 S95-N346 CUE domain fragment. 
Interestingly, free CUE domain fragments can be separated from the complex as the 
latter elutes from the HisTrap column later in the imidazole gradient, suggesting that 
complex is actually a hetero-multimer with at least two copies of the CUE domain 
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subunit. The selected fractions from the gel filtration column were pooled and 
concentrated in spin concentrators to a protein concentration of approximately 15mg/mL. 
C. 1µL of the purified minimal SMARCAD1-KAP1 following concentration was resolved by 
SDS-PAGE and stained with InstantBlue. 
D. This schematic illustrates the portions of SMARCAD1 and KAP1 that were co-expressed 
in E. coli.  
 
For this purpose, the minimal SMARCAD1-KAP1 complex was reconstituted by co-
expression of the His-tagged, SUMO-CUE domain fragment and untagged SUMO-
KAP1 S33-K434 in E. coli. It was then purified by sequential affinity, anion 
exchange and size exclusion chromatography (Figure 7.9A). Interestingly, elution 
off the initial HisTrap column with an imidazole gradient allows separation of free 
CUE domain fragments from the minimal SMARCAD1-KAP1 complex, as the latter 
requires higher imidazole concentrations for elution (Figure 7.9B, top). This 
suggests that the minimal SMARCAD1-KAP1 complex is actually a hetero-multimer 
with at least two copies of the CUE domain subunit (since the His tag is only found 
on the CUE domain fragment). The KAP1 S33-K434 fragment probably dictates 
oligomerization since its coiled-coil domain is reported to mediate trimerization 
(Peng et al., 2000). The formal possibility that the enhanced avidity of the complex 
for nickel is due to a cluster of exposed histidine residues in KAP1 S33-K434 is 
unlikely since binding of free KAP1 S33-K434 to the nickel column is not observed. 
 
Both the CUE domain fragment and KAP1 S33-K434 co-elute precisely with each 
other after anion exchange and gel filtration chromatography, indicating that the 
minimal SMARCAD1-KAP1 complex behaves as a single molecular species, as 
would be expected for a genuine, stable protein complex (Figure 7.9B, middle & 
bottom). The minimal SMARCAD1-KAP1 complex is soluble and readily tolerates 
being concentrated up to 16mg/L with a spin concentrator. 
 
Screening for crystallization conditions for the minimal SMARCAD1-KAP1 complex 
was performed in 96-well plate format. Fourteen commercial screens were used, 
allowing 1344 conditions to be tested, though not all the conditions were entirely 
unique. Small crystals of the SMARCAD1-KAP1 complex were obtained from four 
conditions (Table 7.1 & Figure 7.10A, C & E). Of the four conditions, three were 
replicated and could be optimized by further screening to yield larger crystals 
(Figure 7.10B, D & F). Unfortunately, these crystals diffracted to a resolution of only 
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~9Å at best, precluding structure determination. Nonetheless, additional constructs 
are in the process of being tested. 
 
Screen: Initial (Screen) Condition: Optimized Condition: 
Midas HT-96 (G10) 20% (v/v) Sokalan CP-42 
0.1M Lithium acetate 
0.1M Bis-Tris NaOH pH 6 
19.5% (v/v) Sokalan CP-42 
0.1M Lithium acetate 
0.1M Bis-Tris NaOH pH5.7 
N.B. Drop ratio of 2:1 mother 
liquor to protein 
Natrix HT (A3) 10% (v/v) PEG 400 
0.2M Potassium chloride 
0.01M Magnesium sulphate 
heptahydrate 
0.05M MES NaOH pH 5.6 
7.5% (v/v) PEG 400 
0.2M Potassium chloride 
0.01M Magnesium sulphate 
heptahydrate 
0.05M MES NaOH pH 5.7 
JBScreen Kinase 
HTS (B8) 
1M Potassium/Sodium 
Tartrate 
0.1M MES NaOH pH 6.5 
1M Potassium/Sodium 
Tartrate 
0.1M MES NaOH pH 6.5 
Table 7.1 – Crystallization Conditions for the Minimal SMARCAD1-KAP1 Complex 
The conditions used to crystallize the minimal SMARCAD1-KAP1 complex are listed in the 
table. Unless otherwise stated, drop ratios of 1:1 mother liquor to protein (approximately 
15mg/mL) were used. The trays were incubated in a 18°C incubator. 
 
7.3 Conclusions 
SMARCAD1 exists in cells as part of a constitutive, stable protein complex with 
KAP1. Nonetheless, this interaction can be abrogated in cells by point mutations 
targeting the tandem CUE domains of SMARCAD1. This interaction does not 
require ubiquitylation of KAP1 since the complex can be reconstituted in vitro with 
purified recombinant proteins that are definitely not ubiquitylated. Mutation and 
truncation analyses reveal that the interaction occurs between the first CUE domain 
of SMARCAD1 and KAP1 S33-K434, an N-terminal fragment that spans the entire 
RBCC domain. The precise nature of the SMARCAD1-KAP1 interaction interface at 
a structural level remains unclear; on the balance of probabilities, however, the first 
CUE domain of SMARCAD1 probably recognises a region of KAP1 that lacks 
structural resemblance of ubiquitin. This is both surprising and interesting. We hope 
to conclusively address this question by determining the co-crystal structure of a 
SMARCAD1-KAP1 complex. In addition to clarifying the nature of the SMARCAD1-
KAP1 interaction, this structure may offer insights that are generally applicable to 
our understanding of chromatin and ubiquitin biology. 
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Figure 7.10 – Crystals of the Minimal SMARCAD1-KAP1 Complex 
These micrographs depict crystals of the minimal SMARCAD1-KAP1 complex. The crystals 
on the left (A, C & E) were obtained from conditions represented in commercial 
crystallization screens. These micrographs were captured under 18.4X magnification, 
except for E, which was magnified 12.8X, though all images were scaled to 15% of their 
original size. Optimization around the initial conditions in the screens yielded larger crystals, 
as shown on the right (B, D & F). The magnification of these micrographs is 16X, except for 
F, which was magnified 5.12X; all the images were scaled to 15% of their original sizes. 
 
As discussed in the previous chapter, KAP1 exerts an inhibitory effect on the 
nucleosome-stimulated ATPase activity of SMARCAD1, implying that the 
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SMARCAD1-KAP1 interaction is functionally important. Since the SMARCAD1-
KAP1 interaction is absolutely dependent on the first CUE domain of SMARCAD1 
and the RBCC domain of KAP1, it would be expected that cells expressing only 
SMARCAD1 bearing point mutations in its first CUE domain would display cellular 
phenotypes arising from deregulation in SMARCAD1 activity. It is further predicted 
that the phenotypes observed in these cells would, at least partially, phenocopy 
those of cells depleted of KAP1. While important, these hypotheses have, however, 
yet to be tested empirically, and represent an important direction of this project in 
the future. 
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Chapter 8. Discussion II: Characterization of the 
SMARCAD1-KAP1 Chromatin Remodelling Complex 
SMARCAD1 is a largely uncharacterized member of the SWI2/SNF2 subfamily of 
ATPases. Based on sequence homology, it is regarded to be a putative chromatin 
remodeller. It has been described to exist constitutively as part of a stable protein 
complex with the heterochromatin-associated protein, KAP1. Functionally, 
SMARCAD1 promotes the establishment of a repressive chromatin environment, 
by antagonizing histone hyperacetylation and promoting deposition of the inhibitory 
H3K9me3 histone mark (Rowbotham et al., 2011). Nevertheless, the SMARCAD1-
KAP1 complex has not been characterized at a mechanistic level. 
 
Data presented in this thesis demonstrates for the first time that the SMARCAD1 
protein is capable of ATP hydrolysis, especially when stimulated with nucleosomes. 
Notably, however, the SMARCAD1-KAP1 complex is comparatively less active 
than the SMARCAD1 ATPase by itself, implicating KAP1 as an inhibitory factor in 
this context. It is also shown that the interaction between SMARCAD1-KAP1 strictly 
requires the first CUE domain of SMARCAD1 and KAP1 S33-K434, a region of the 
KAP1 protein that encompasses its RBCC domain. This interaction does not 
require ubiquitylation of KAP1 and can be reconstituted in vitro with purified, 
recombinant proteins. Moreover, the data suggests, albeit not definitively, that the 
first CUE domain recognizes a region of KAP1 that is structurally distinct from 
ubiquitin. This may, therefore, represent the first report of a novel CUE domain 
ligand that is unrelated to ubiquitin, though this finding needs to be confirmed by 
structural studies.  
 
8.1 SMARCAD1 is a Swr1-like Chromatin Remodeller 
Members of the Snf2 family of helicase-related proteins can be classified by 
multiple sequence analysis into twenty-four subfamilies that can be divided into six 
groups (Flaus et al., 2006). The most well characterized members of the Swr1-like 
group are Ino80 and Swr1, the catalytic subunits of their eponymous multi-subunit 
complexes. These proteins are defined by the presence of a long insert between 
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the two RecA-like lobes of the conserved ATPase domain (Flaus et al., 2006, 
Clapier and Cairns, 2009). The long inserts are of considerable functional 
relevance since they serve as an interaction interface through which regulatory 
subunits associate the catalytic subunit (Wu et al., 2005, Nguyen et al., 2013, Tosi 
et al., 2013). For example, the inserts of both Swr1 and Ino80 are required for the 
SWR1 and INO80 chromatin remodelling complexes to associate with their 
Rvb1/Rvb2 subunits, which themselves, possess helicase activitites. Yet, the 
structural basis for the interaction differs, not least because SWR1 contains a 
heterohexameric Rvb1/Rvb2 ring in contrast to the heterododacemeric, stacked 
Rvb1/Rvb2 component of the INO80 complex (Nguyen et al., 2013, Tosi et al., 
2013). 
 
Although SMARCAD1 shares the same overall “split-ATPase” topology as the other 
members of the Swr1-like family, its insert domain is not as extensive as that of 
either Swr1 or Ino80. Moreover, SMARCAD1 interacts with neither Rvb1 nor Rvb2 
(Rowbotham et al., 2011). It is, nonetheless, important to emphasize that the insert 
domains mediate stable interactions with other polypeptides other than Rvb1/Rvb2 
hetero-oligomers (Wu et al., 2005). Yet, since the only known subunit of the 
SMARCAD1 chromatin remodelling complex is KAP1, which interacts 
independently of the insert domain, the significance of the “split-ATPase” topology 
in SMARCAD1 is unclear. One possibility, albeit entirely speculative, is that the 
long insert domain of SMARCAD1 mediates transient protein interactions rather 
than constitutive associations with stable complex subunits.  
 
Recent cryo-EM studies of the SWR1 and INO80 complexes bound to 
nucleosomes have elucidated the structural basis of nucleosome binding for these 
two chromatin remodelling complexes (Nguyen et al., 2013, Tosi et al., 2013). In 
contrast to RSC, another large, multi-subunit chromatin remodelling complex, 
which accommodates a nucleosome in its central cavity, both SWR1 and INO80 
form relatively few contacts with the nucleosome (Chaban et al., 2008, Nguyen et 
al., 2013, Tosi et al., 2013). Surprisingly, however, the SWR1 and INO80 
complexes do not bear much resemblance to each other at a structural level; 
correspondingly, the basis for their interactions with nucleosomes are entirely 
idiosyncratic. For example, the nucleosome binds to a depression on the surface of 
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the SWR1 complex created at an interface between the peripherally located Swr1 
subunit and the Rvb1/Rvb2 heterohexamer (Nguyen et al., 2013). In contrast, 
INO80 forms an elongated, embryo-like structure that cradles a nucleosome by 
contorting its head-neck-body-foot architecture around it (Tosi et al., 2013). Hence, 
the dissimilarity in nucleosome binding mechanisms between SWR1 and INO80 
prevents extrapolation to predict the structural means by which SMARCAD1 binds 
to nucleosomes.  
 
A notable difference between SMARCAD1 and other Swr1-like chromatin 
remodellers is the relative paucity of subunits possessed by SMARCAD1, 
compared, for instance, to the fourteen and fifteen in the SWR1 and INO80 
respectively. Thus, from a structural perspective, it is possible that SMARCAD1 
would more closely resemble either the monomeric CHD1 or the heterodimeric 
ISW1a enzymes. Despite being classified into separate families, both CHD1 and 
ISWIa possess structurally – though not sequence – conserved SANT and SLIDE 
DNA binding domains that dramatically enhance the affinity of the enzyme for DNA 
over the intrinsic binding ability of the ATPase domain (Grune et al., 2003, Ryan et 
al., 2011). Comparable DNA-binding domains have not been described in either 
SMARCAD1 or KAP1, suggesting that careful biochemical analysis of the un-
annotated regions of SMARCAD1 in search of additional motifs conferring affinity 
for DNA may represent a profitable line of investigation. 
 
A distinctive feature of SWR1 and the INO80 chromatin remodellers is their ability 
to catalyse histone exchange (Morrison and Shen, 2009). SWR1 specifically 
deposits free variant H2AZ/H2B dimers in nucleosomal arrays in place of 
conventional H2A/H2B dimers (Mizuguchi et al., 2004). INO80 does the exact 
opposite, substituting incorporated H2AZ/H2B dimers with free H2A/H2B dimers 
(Papamichos-Chronakis et al., 2011). Interestingly, histone dimer exchange ability 
has been reported for the yeast homologue of SMARCAD1, Fun30, suggesting that 
SMARCAD1 may also contribute to histone turnover (Awad et al., 2010). Curiously, 
depletion of SMARCAD1 results in histone H3 hyperacetylation, a finding that is 
reminiscent, though the opposite, of the decrease in overall levels of acetylated 
histone H2AZ in the context of Ino80 deletion (Papamichos-Chronakis et al., 2011, 
Rowbotham et al., 2011). Taken collectively, it is possible to extend the model 
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proposed by Rowbotham et al., by speculating that SMARCAD1 is mechanistically 
linked to the removal of acetylated histone marks from replicated chromatin by 
promoting histone turnover through dimer exchange. 
 
8.2 Regulation of the SMARCAD1-KAP1 Complex 
Although the precise biochemical activities of SMARCAD1 remain to be fully 
elucidated, its nucleosome-stimulated ATPase activity strongly indicates that it is 
an active enzyme. More significantly, however, when assembled into a stable 
complex with SMARCAD1, KAP1 acts as a negative regulator of the ATPase 
activity of SMARCAD1. KAP1 interacts stoichiometrically with SMARCAD1, 
suggesting that the majority of SMARCAD1 molecules are kept less active than is 
within their potential by their constitutive association with KAP1 (Figure 8.1). 
 
 
Figure 8.1 – KAP1 is a Negative Regulator of the ATPase Activity of SMARCAD1 
By itself, SMARCAD1 displays robust nucleosome-stimulated ATPase activity (left). When 
in complex with KAP1, however, the nucleosome-stimulated ATPase activity associated 
with SMARCAD1 is significantly reduced (right). As the main enzymatic activity associated 
with SMARCAD1 awaits clarification, creative license was adopted to depict SMARCAD1 
sliding nucleosomes in this schematic. An important function of KAP may be to maintain 
the SMARCAD1 ATPase in an inactive state until triggered by a context-specific signal to 
relieve inhibition, thereby allowing the intrinsically active ATPase domain to act unimpeded. 
 
Maintaining chromatin remodellers in an inactive state by default may be a general 
regulatory mechanism for cells for several reasons. First, as the human genome 
encodes for thirty-three proteins that possess a SWI2/SNF2-like helicase domain, it 
is likely that they are specialized for specific biological processes, with the majority 
not normally being required. Thus, maintaining a reserve of inactive chromatin 
remodellers that can be rapidly converted into an active conformation is a simple 
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yet effective means by which cells can dynamically modify their chromatin structure 
in response to stimuli. Additionally, unregulated promiscuous ATPase activity from 
all of the many chromatin remodellers present in each cell may unnecessarily 
deplete cellular pools of ATP or disrupt normal chromatin structure (Flaus et al., 
2006, Narlikar et al., 2013). Indeed, overexpression of the Rhp26 chromatin 
remodeller in Schizosacchromyces pombe resulted in severe cellular toxicity in the 
absence of exogenous cellular stress. Strikingly, this phenotype was more severe 
when a hyperactive mutant was overexpressed, suggesting a casual correlation 
between ATPase hyperactivity and cellular toxicity (Wang et al., 2014a).  
 
There is considerable precedent for chromatin remodellers being maintained in an 
inactive state. Most notably, the CHD1 ATPase is usually maintained in an open 
conformation not amenable to ATP hydrolysis. Together with two intervening 
helices, the two chromodomains form a wedge-like structure – dubbed the ‘chromo-
wedge’ – that occupies the central cleft separating the two recA lobes of the 
ATPase domain. Moreover, the ‘chromo-wedge’ physically impedes the second 
ATPase lobe from rotating the fifty-two degrees required to adopt the closed 
conformation that is permissible for ATP hydrolysis. In addition, due to the 
presence of multiple acidic residues, the ‘chromo-wedge’ is highly negatively 
charged, allowing it to occupy the DNA-binding surface of the CHD1 ATPase 
domain (Hauk et al., 2010). It is possible that upon recognition of H3K4me3 by the 
chromodomains or upon nucleosome binding, the ‘chromo-wedge’ shifts in position, 
enabling the CHD1 ATPase lobes to adopt the closed, active conformation. 
 
Similarly, though the ISWI ATPase domain is intrinsically active, it is kept inactive 
via auto-inhibition by the AutoN regulatory region, which bears sequence similarity 
with the basic patch of histone H4. It is believed that the AutoN region binds to the 
ISWI ATPase domains to coerce it to adopt an inactive conformation, in a manner 
analogous to the CHD1 chromodomains. The histone H4 tail probably competitively 
displaces AutoN from this interaction surface, thereby allowing ATPase activity and 
also explaining the requirement for histone H4 for ISWI activity (Clapier and Cairns, 
2012). Likewise, the ATPase activity of Rhp26, the S. pombe homologue of 
ERCC6/CSB, is auto-inhibited by a leucine latch motif that binds directly to the 
ATPase motor, presumably to lock it in an inactive state (Wang et al., 2014a).  
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Given the ubiquity of auto-inhibition as a regulatory mechanism for chromatin 
remodellers, it is unsurprising that the SMARCAD1-KAP1 complex is negatively 
regulated by KAP1. An additional, as yet unknown, stimulatory factor may be 
required for the complex to become fully active. Though possibilities abound about 
the identity of this speculative stimulatory factor, one conceptually pleasing 
hypothesis is that post-translational modification of KAP1 causes a conformational 
change in the complex that renders the SMARCAD1 ATPase motor fully active. 
Indeed, KAP1 is not only modified by phosphorylation in an ATM-dependent 
manner, but also by sumoylation (Ziv et al., 2006, Ivanov et al., 2007, Goodarzi et 
al., 2011). In this manner, KAP1 may, for instance, act as a signal transformer to 
specifically activate the SMARCAD1-KAP1 complex following activation of the DNA 
damage response. 
 
While it is possible to construe a model whereby activation of the SMARCAD1 
ATPase occurs when an ubiquitylated substrate competitively displaces KAP1 from 
the SMARCAD1 CUE domains, such a hypothesis seems quite unlikely. Our data 
demonstrates that the minimal SMARCAD1-KAP1 complex forms unabated in the 
presence of a large molar excess of free ubiquitin. Since CUE domains use a 
shared mechanism for recognizing mono-ubiquitin moieties and poly-ubiquitin 
chains, those that interact with the former with poor affinity, likewise bind poorly to 
the latter (Shih et al., 2003, Liu et al., 2012). Hence, while the effect of poly-
ubiquitin chains on SMARCAD1-KAP1 complex formation has not been formally 
tested, it is likely that it too will be similarly inconsequential.  
 
It is also possible that the relatively low activity associated with the SMARCAD1-
KAP1 complex is the result of it being stimulated by the wrong substrate. In our 
assays, we have worked upon the assumption that SMARCAD1 behaves like a 
typical chromatin remodeller, whose ATPase activity is stimulated by DNA or 
nucleosomes. It is, therefore, possible that the SMARCAD1-KAP1 is highly active if 
stimulated with the correct – as yet unknown and untested – substrate. In summary, 
although it is probably fair to assume that the activity of the SMARCAD1-KAP1 
chromatin remodelling complex is tightly regulated by the cell, these regulatory 
principles await clarification. 
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8.3 CUE Domains Mediate Protein Interactions 
CUE domains are ubiquitin-binding domains that are conserved from yeast to 
humans (Hicke et al., 2005). Structural studies indicate that each CUE domain is a 
globular structure comprised of a bundle of three α-helices. Two helices of the CUE 
domain (α1 and α3), which include the conserved MFP and LL motifs, come into 
contact with a hydrophobic patch present within the ubiquitin moiety; the interaction 
is further stabilized by electrostatic contacts along the rim of the interaction 
interface. Reflecting a relatively limited area of approximately 400Å2 of 
intermolecular contacts on each protein, CUE domains typically recognize ubiquitin 
with only modest affinity (Kang et al., 2003, Prag et al., 2003, Liu et al., 2012). 
Nevertheless, the dissociation constants for specific CUE domains span a range of 
approximately 20-160µM (Shih et al., 2003). It has been shown that some CUE 
domains, such as that of the yeast Vps9p protein, can function either in a 
monomeric globular state mediating weak binding or as a dimer allowing strong 
binding – as a dimer, additional contacts are formed between ubiquitin and the 
typically disengaged, third helix (α2) of the CUE domain (Prag et al., 2003). 
 
Based on sequence conservation, the CUE domains of SMARCAD1 should be 
capable of binding ubiquitin, though our data, however, suggests otherwise. Yet, 
the SMARCAD1-KAP1 interaction is abrogated by mutation of the MFP and LL 
motifs within the first CUE domain of SMARCAD1. The three published structures 
of CUE domains in complex with ubiquitin demonstrate that while some of these 
residues form direct hydrophobic interactions with ubiquitin, alanine substitution of 
the conserved phenylalanine or of the first leucine of the di-leucine repeat motif 
disrupts proper folding of the CUE domain (Kang et al., 2003, Prag et al., 2003, Liu 
et al., 2012). On this basis, it is difficult to predict the physical characteristics of the 
ligand recognized by the first CUE domain, though it is nonetheless likely that the 
interaction interface is a hydrophobic patch. 
 
The concept of CUE domains mediating protein-protein interactions with non-
ubiquitylated ligands is not unprecedented. For example, functioning as a bridging 
factor, the yeast Def1 protein recruits the Elongin-Cullin (Ela1-Elc1) E3 ubiquitin 
ligase complex to RNAPII via its CUE domain and a ubiquitin-homology domain in 
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Ela1. While the ligand in this case was a bona fide ubiquitin-homology domain –
various ubiquitin-binding domains are capable of interacting with recombinant Ela1-
Elc1 – only the Def1 CUE domain was able to enrich for the Elongin-Cullin complex 
from yeast extracts (Wilson et al., 2013). This observation, therefore, suggests that 
though the conserved MFP and LL motifs are essential for mediating the interaction 
interface, CUE domains are also governed by an additional, still unknown, motif 
that confers ligand specificity. Indeed, the specific enrichment of KAP1 from extract 
by the SMARCAD1 CUE domains is in accord with this model. Due to this ability for 
their basal ubiquitin-recognition capability to be tailored for bespoke ligand 
specificity, CUE domains should be recognized for their capabilities as an interface 
for protein-protein interactions, rather than as simple ubiquitin-binding domains.  
 
8.4 The KAP1 RBCC Domain as an Interaction Interface 
The KAP1 RBCC domain has been previously implicated as a protein interaction 
surface (Iyengar and Farnham, 2011). Acting as a homotrimer, it interacts with the 
KRAB repression domain of KRAB domain-containing zinc finger proteins to 
repress transcription. All three components – the RING domain, tandem B-boxes 
and coiled-coil domain – are indispensable for the interaction (Friedman et al., 
1996, Moosmann et al., 1996, Peng et al., 2000). There is, however, no structural 
data elucidating the mechanism for this interaction. Undoubtedly a contributing 
factor is the general resistance to purification presented by fragments of the RBCC 
domain; for example, extremely low recoveries of the S33-K434 fragment from 
centrifugal concentrators preclude concentration in that manner. Furthermore, 
smaller fragments that further truncate the RBCC domain are extremely insoluble. 
 
The recently elucidated structure of the TRIM25 coiled-coil homodimer has offered 
significant insight into the overall architecture of members of the TRIM family of 
proteins. Each subunit forms a hairpin structure composed of a short arm – 
comprised of residues from the linker region that succeeds the coiled-coil domain – 
that folds back onto a long arm, formed by the coiled-coil domain (Figure 1.16). 
Dimerization is mediated by the coiled-coil domain and occurs in an antiparallel 
direction. Uniquely, the coiled-coil domain consists of a combination of heptad (7) 
Chapter 8. Discussion II 
 
223 
 
and hendecad (11) amino acid repeats arranged in a symmetrical 7-7-7-7-11-11-
11-11-7-7-7-7 pattern, where ‘7’ and ‘11’ refer to a heptad and hendecad repeats 
respectively. Therefore, a canonical left-handed supercoil is formed by the heptad 
repeats at either end, whereas the central hendecad repeats generate an under-
wound, right-handed coil in the middle. As a consequence of the under-winding, 
helices from the short arm of the hairpin can interdigitate to pack into a four-helix 
bundle. Consequently, the domains at the C-terminus of TRIM proteins are 
centrally positioned on one side of this elongated structure, while the N-terminal 
RING and B-box domains are located on the apices (Sanchez et al., 2014). It is 
evident that dimerization and higher order assembly is intrinsic to TRIM proteins. 
Hence, TRIM proteins probably achieve protein-protein interactions in a bimodal 
fashion. One category of interactions exploits the modular assembly of TRIM 
proteins, which enables individual domains to function as discrete structural units 
that can mediate protein-protein interactions autonomously. The other group of 
interactions probably involves exposed surfaces created by oligomerization, such 
as along the coiled-coil domain or the central four-helix bundle. 
 
It was noted that the CUE domain fragment of SMARCAD1 is also able to interact 
with the D202-K434 KAP1 fragment – which includes only the second B-box and 
coiled-coil domains – though to a lesser extent than with the entire RBCC domain 
(S33-K434). This difference in binding is believed to reflect the extremely poor 
solubility of the D202-K434 fragment. This data suggests, though certainly not 
conclusively, that the RING and the first B-box domains are redundant for the 
SMARCAD1-KAP1 interaction. Also, it was noted that a RBCC fragment that 
excludes the additional linker region (M1-E388) failed to recognize the SMARCAD1 
CUE domain fragment, indicating that the short arm of the hairpin is essential for 
the interaction. KAP1 is probably organized along a similar blueprint to that of 
TRIM25, since it also conforms to the aforementioned pattern of heptad-hendecad 
repeats (Sanchez et al., 2014). Taken together, the most likely surface recognized 
by the SMARCAD1 CUE domain is the four-helix bundle at the centre of the coil. 
 
Our attempts to determine the co-crystal structure of the SMARCAD1 CUE 
domains in complex with KAP1 S33-K434 by X-ray crystallography are in progress. 
If obtained, such a structure would undoubtedly be able to definitively clarify our 
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speculative inferences about the nature of the SMARCAD1-KAP1 interaction. 
Importantly, it should also offer insights into the biology of KAP1, a pleiotropic 
chromatin regulator, and also of TRIM proteins in general. 
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